data_2mz0_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2mz0 _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_exo . . . . . 0 N--CA 1.495 1.61 0 N-CA-C 111.406 -0.267 . . . . 0.0 111.406 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 2.9 tt -116.68 118.66 33.18 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-O 120.626 0.25 . . . . 0.0 110.493 -179.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.4 tt -90.08 131.18 36.09 Favored 'General case' 0 N--CA 1.464 0.275 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 178.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.482 ' CD1' ' SG ' ' A' ' 47' ' ' CYS . 1.9 pt -108.67 -45.17 6.85 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 120.964 0.412 . . . . 0.0 110.415 -178.669 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -163.68 -176.38 35.55 Favored Glycine 0 N--CA 1.45 -0.421 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.54 ' C ' ' H ' ' A' ' 15' ' ' ILE . 13.6 m -86.65 137.3 32.58 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 8.7 t -46.93 -12.29 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 120.832 -0.347 . . . . 0.0 110.794 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.54 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.6 mt -69.86 -44.3 78.95 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.287 0 CA-C-O 121.364 0.602 . . . . 0.0 110.487 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -88.09 -29.69 20.44 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-N 115.223 -0.899 . . . . 0.0 110.514 -179.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 53.0 m-85 -124.85 84.05 58.84 Favored Pre-proline 0 N--CA 1.465 0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.815 179.564 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -53.08 -177.0 0.03 OUTLIER 'Trans proline' 0 N--CA 1.498 1.743 0 C-N-CA 122.959 2.44 . . . . 0.0 111.609 179.26 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.454 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 97.8 m -58.22 -49.71 76.12 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 112.547 0.573 . . . . 0.0 112.547 -178.275 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.534 ' CG ' ' H ' ' A' ' 21' ' ' LYS . 9.0 pt-20 -56.14 -58.18 9.04 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 111.767 0.284 . . . . 0.0 111.767 -178.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.534 ' H ' ' CG ' ' A' ' 20' ' ' GLU . 15.4 mtmt -64.11 -44.72 91.39 Favored 'General case' 0 CA--C 1.51 -0.569 0 CA-C-O 121.221 0.534 . . . . 0.0 111.522 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 28.9 t -44.7 -57.67 3.54 Favored 'General case' 0 C--N 1.312 -1.058 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.757 -177.778 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.693 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.7 p-10 -64.22 -50.73 66.89 Favored 'General case' 0 C--O 1.218 -0.587 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.375 -179.559 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.693 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 70.7 mttt -50.18 -42.12 50.66 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 -179.656 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 15.5 m -64.51 -39.16 93.26 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.645 0.736 . . . . 0.0 109.607 179.115 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.438 ' O ' ' OG ' ' A' ' 29' ' ' SER . 73.0 m -68.76 -31.51 70.6 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.149 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.404 HG12 ' O ' ' A' ' 23' ' ' ASN . 3.0 mm -64.39 -47.03 91.25 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.506 0 CA-C-O 121.087 0.47 . . . . 0.0 110.914 -179.512 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -70.14 -22.25 63.01 Favored 'General case' 0 N--CA 1.447 -0.622 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.872 -179.246 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.438 ' OG ' ' O ' ' A' ' 26' ' ' CYS . 59.8 p -74.81 -2.07 25.0 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 179.55 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 77.66 27.92 0.58 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.168 -0.923 . . . . 0.0 110.725 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.582 ' C ' ' H ' ' A' ' 33' ' ' GLY . 5.5 m-85 -110.96 162.32 14.95 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.74 -179.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.65 32.85 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.664 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.582 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 81.43 -173.96 54.24 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 -179.743 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -153.65 177.25 31.28 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 -179.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 17.0 ptpt -154.06 177.65 10.84 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.942 0.401 . . . . 0.0 110.784 -179.352 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 67.3 m -104.69 117.76 34.9 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.011 179.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 27.1 m -136.31 159.5 38.37 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-O 120.902 0.382 . . . . 0.0 110.865 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.685 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 0.1 OUTLIER -91.07 157.76 17.05 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.47 179.626 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 39.2 mm -105.85 126.92 61.23 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.18 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.451 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 41.02 -98.47 0.01 OUTLIER Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 179.651 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 40.3 tt0 -135.83 21.49 3.3 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 120.986 0.422 . . . . 0.0 109.957 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 58.1 m -79.65 -8.71 59.38 Favored 'General case' 0 CA--C 1.515 -0.397 0 CA-C-O 121.127 0.489 . . . . 0.0 110.418 179.564 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' LEU . . . . . 0.405 ' CD2' ' O ' ' A' ' 43' ' ' LEU . 0.9 OUTLIER 47.12 29.62 1.17 Allowed 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.246 -179.651 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -102.79 119.54 39.02 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 178.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -81.13 132.77 35.38 Favored 'General case' 0 CA--C 1.517 -0.326 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 -179.349 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 35.2 m -134.96 152.39 32.71 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.404 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.547 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.482 ' SG ' ' CD1' ' A' ' 11' ' ' ILE . 41.0 t -94.34 113.76 25.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.626 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.1 p -126.05 137.9 56.28 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.19 0 CA-C-O 121.001 0.429 . . . . 0.0 110.604 -179.388 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 8.3 m -97.44 165.05 12.19 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.784 -179.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 42.5 m-85 -117.39 145.79 36.92 Favored Pre-proline 0 N--CA 1.47 0.537 0 CA-C-N 116.742 -0.208 . . . . 0.0 111.256 -179.11 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo . . . . . 0 N--CA 1.496 1.658 0 C-N-CA 122.57 2.18 . . . . 0.0 112.077 179.553 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo . . . . . 0 N--CA 1.491 1.354 0 CA-C-O 120.964 0.318 . . . . 0.0 111.691 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.6 tt -121.53 119.68 32.67 Favored 'General case' 0 N--CA 1.474 0.748 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.562 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.8 tt -92.29 125.54 36.99 Favored 'General case' 0 N--CA 1.464 0.269 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 178.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.512 ' CD1' ' SG ' ' A' ' 47' ' ' CYS . 2.6 pt -102.54 -48.3 10.86 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.667 -179.056 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.417 ' H ' HG13 ' A' ' 11' ' ' ILE . . . -167.72 -138.29 2.42 Favored Glycine 0 N--CA 1.45 -0.398 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.525 ' C ' ' H ' ' A' ' 15' ' ' ILE . 43.1 p -132.62 159.01 40.79 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.085 0.469 . . . . 0.0 110.847 -179.697 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -56.12 -5.56 0.19 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.051 179.786 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.525 ' H ' ' C ' ' A' ' 13' ' ' THR . 84.6 mt -75.94 -26.5 17.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.883 0.373 . . . . 0.0 110.723 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -124.47 -27.69 3.71 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.063 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -122.62 80.57 47.75 Favored Pre-proline 0 C--O 1.233 0.187 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.335 179.206 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_exo -53.0 179.33 0.04 OUTLIER 'Trans proline' 0 N--CA 1.495 1.563 0 C-N-CA 122.787 2.325 . . . . 0.0 111.141 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.467 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 30.5 p -53.74 -61.28 2.4 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 121.074 0.464 . . . . 0.0 111.995 -179.802 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.457 ' HG3' ' H ' ' A' ' 21' ' ' LYS . 5.4 pt-20 -43.8 -59.41 2.25 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.387 -178.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.457 ' H ' ' HG3' ' A' ' 20' ' ' GLU . 19.8 mtmt -64.43 -46.15 84.42 Favored 'General case' 0 CA--C 1.509 -0.608 0 CA-C-O 121.201 0.524 . . . . 0.0 111.269 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 41.2 t -45.07 -60.56 2.03 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-N 115.549 -0.75 . . . . 0.0 111.124 -178.475 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.693 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 2.1 p-10 -65.63 -54.86 21.8 Favored 'General case' 0 C--O 1.22 -0.466 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.517 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.693 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 80.3 mttt -44.91 -44.5 9.75 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 120.691 -0.403 . . . . 0.0 110.575 -179.602 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 17.5 m -63.64 -39.9 95.52 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.164 0.506 . . . . 0.0 110.02 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 51.4 m -66.46 -31.4 72.12 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.573 -0.74 . . . . 0.0 111.042 -179.882 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.4 mm -63.94 -41.33 92.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-O 121.323 0.582 . . . . 0.0 110.141 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.457 ' C ' ' H ' ' A' ' 30' ' ' ASN . 52.9 mm-40 -67.06 -37.7 84.49 Favored 'General case' 0 N--CA 1.445 -0.725 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.527 -178.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 33.7 m -69.07 5.8 1.1 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.029 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.457 ' H ' ' C ' ' A' ' 28' ' ' GLU . 48.4 t30 71.47 50.89 0.26 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.067 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.609 ' C ' ' H ' ' A' ' 33' ' ' GLY . 57.0 m-85 -133.81 162.78 31.08 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.733 179.887 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.434 ' N ' ' O ' ' A' ' 50' ' ' PHE . . . -69.17 23.06 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.053 -0.522 . . . . 0.0 110.719 -179.81 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.609 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 89.78 -175.8 42.22 Favored Glycine 0 CA--C 1.52 0.374 0 N-CA-C 110.533 -1.027 . . . . 0.0 110.533 -179.893 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -147.83 174.01 27.7 Favored Glycine 0 CA--C 1.522 0.482 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 -179.379 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 13.2 ptmt -155.44 178.57 10.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.885 0.374 . . . . 0.0 110.578 -179.377 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 1.8 m -105.17 128.07 53.21 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.144 179.227 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 19.3 m -134.47 158.62 41.93 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.047 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.625 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 0.9 OUTLIER -101.36 156.41 17.47 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.023 179.943 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 35.9 mm -112.67 127.27 70.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.98 -179.755 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.495 ' O ' ' NE2' ' A' ' 41' ' ' GLN . . . 40.11 -97.82 0.01 OUTLIER Glycine 0 CA--C 1.527 0.795 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.495 ' NE2' ' O ' ' A' ' 40' ' ' GLY . 99.2 mm-40 -137.45 28.38 2.75 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.838 0.351 . . . . 0.0 110.477 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' SER . . . . . 0.543 ' O ' ' N ' ' A' ' 44' ' ' ASP . 73.5 m -87.29 4.73 41.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.917 179.883 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' LEU . . . . . 0.42 ' CD2' ' C ' ' A' ' 42' ' ' SER . 1.2 pt? 34.65 27.99 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.27 0 O-C-N 123.788 0.68 . . . . 0.0 111.496 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . 0.543 ' N ' ' O ' ' A' ' 42' ' ' SER . 43.4 t0 -99.98 121.1 40.84 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.572 -179.466 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -87.65 117.75 26.68 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.087 0.47 . . . . 0.0 109.963 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 30.6 m -111.86 136.05 49.24 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.255 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.116 -179.623 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.512 ' SG ' ' CD1' ' A' ' 11' ' ' ILE . 14.0 t -93.39 115.84 28.39 Favored 'General case' 0 CA--C 1.518 -0.286 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.628 -179.575 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.8 p -131.89 152.03 36.19 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.507 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.762 -179.036 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 6.4 m -97.47 172.51 7.7 Favored 'General case' 0 CA--C 1.515 -0.376 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.636 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.434 ' O ' ' N ' ' A' ' 32' ' ' ALA . 56.4 m-85 -138.23 142.57 35.8 Favored Pre-proline 0 C--N 1.331 -0.225 0 C-N-CA 120.882 -0.327 . . . . 0.0 111.359 -179.487 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo . . . . . 0 N--CA 1.494 1.547 0 C-N-CA 122.408 2.072 . . . . 0.0 112.297 178.516 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_exo . . . . . 0 N--CA 1.494 1.51 0 CA-C-O 120.647 0.186 . . . . 0.0 111.876 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -125.7 128.97 48.61 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-O 121.154 0.502 . . . . 0.0 110.708 179.895 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.1 tt -90.97 136.63 32.94 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.396 178.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -105.88 -47.47 8.93 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.262 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.125 -179.667 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -172.63 -124.74 0.79 Allowed Glycine 0 CA--C 1.519 0.307 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.564 ' C ' ' H ' ' A' ' 15' ' ' ILE . 66.3 p -127.81 150.36 49.86 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.912 0.387 . . . . 0.0 110.264 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 7.4 t -63.63 4.66 0.24 Allowed 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.353 179.714 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.564 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.2 mt -88.48 -40.75 13.69 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.181 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -99.6 -11.9 20.56 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.752 179.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -124.99 81.06 63.12 Favored Pre-proline 0 N--CA 1.464 0.275 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.028 179.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -53.44 168.03 0.75 Allowed 'Trans proline' 0 N--CA 1.5 1.9 0 C-N-CA 123.146 2.564 . . . . 0.0 111.507 178.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.447 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 39.9 p -45.71 -60.01 2.45 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 112.003 0.371 . . . . 0.0 112.003 -178.837 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.457 ' HG3' ' H ' ' A' ' 21' ' ' LYS . 6.6 pt-20 -46.37 -61.16 1.92 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.05 -179.27 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.457 ' H ' ' HG3' ' A' ' 20' ' ' GLU . 20.0 mtmt -63.11 -45.77 90.49 Favored 'General case' 0 CA--C 1.508 -0.644 0 CA-C-O 121.292 0.568 . . . . 0.0 111.629 -179.595 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 22.2 t -43.62 -59.35 2.22 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.024 -178.427 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.722 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 2.2 p-10 -67.3 -57.86 5.87 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.578 179.635 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.722 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 72.0 mttt -43.37 -43.62 5.2 Favored 'General case' 0 C--O 1.222 -0.358 0 CA-C-O 120.852 0.358 . . . . 0.0 110.51 -178.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 19.6 m -64.09 -40.61 96.61 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.177 0.513 . . . . 0.0 110.178 179.66 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.421 ' N ' ' O ' ' A' ' 23' ' ' ASN . 25.5 m -66.71 -30.73 71.04 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.795 -179.895 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.8 mm -64.87 -41.28 91.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-O 121.292 0.568 . . . . 0.0 110.009 -179.705 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.462 ' C ' ' H ' ' A' ' 30' ' ' ASN . 31.2 mm-40 -65.84 -38.07 87.89 Favored 'General case' 0 N--CA 1.447 -0.612 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.379 -178.705 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 26.8 m -69.49 5.15 1.46 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.639 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.462 ' H ' ' C ' ' A' ' 28' ' ' GLU . 44.6 t30 70.86 54.85 0.25 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.006 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.593 ' C ' ' H ' ' A' ' 33' ' ' GLY . 60.4 m-85 -137.76 161.98 35.13 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.592 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.47 28.28 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.981 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.593 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 85.07 -175.26 49.98 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 110.7 -0.96 . . . . 0.0 110.7 -179.784 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -148.63 174.0 28.42 Favored Glycine 0 CA--C 1.522 0.483 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 -179.403 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 4.7 ptmm? -155.86 -178.12 7.07 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.592 0.234 . . . . 0.0 110.384 -179.247 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 31.1 m -104.45 129.69 52.42 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.414 179.228 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 28.5 m -137.78 161.85 32.63 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.261 179.696 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 3.5 p80 -109.06 157.62 18.53 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.217 -0.447 . . . . 0.0 109.998 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 83.6 mt -122.21 125.98 73.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.339 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 42.03 -128.51 4.37 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.891 -0.883 . . . . 0.0 110.891 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 29.0 pt20 -106.82 31.7 5.1 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 120.694 0.283 . . . . 0.0 110.413 179.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 20.1 m -84.39 -9.77 58.13 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 120.983 0.42 . . . . 0.0 110.598 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 40.02 29.41 0.05 Allowed 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.635 -0.712 . . . . 0.0 110.872 -179.144 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -107.55 126.45 52.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.222 179.691 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -90.65 124.55 35.16 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.638 -0.505 . . . . 0.0 109.638 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 30.5 m -120.47 138.07 52.19 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 CA-C-N 116.068 -0.514 . . . . 0.0 109.997 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -94.31 119.22 32.75 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.1 p -134.18 153.18 35.4 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.448 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.588 -179.069 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 5.9 m -97.28 172.23 7.92 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.898 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 56.4 m-85 -132.6 148.07 68.11 Favored Pre-proline 0 CA--C 1.531 0.214 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.939 -179.163 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo . . . . . 0 N--CA 1.494 1.52 0 C-N-CA 122.74 2.293 . . . . 0.0 112.308 179.356 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 21.3 Cg_exo . . . . . 0 N--CA 1.487 1.129 0 N-CA-C 111.363 -0.284 . . . . 0.0 111.363 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.412 ' C ' ' CD2' ' A' ' 9' ' ' LEU . 3.8 tt -126.43 116.65 21.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.598 179.858 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.2 tt -91.71 129.11 37.73 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 179.009 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.472 ' CD1' ' SG ' ' A' ' 47' ' ' CYS . 1.4 pt -105.61 -50.07 8.65 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-O 120.837 0.351 . . . . 0.0 110.921 -178.496 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -160.43 -164.61 15.75 Favored Glycine 0 N--CA 1.451 -0.308 0 N-CA-C 110.694 -0.963 . . . . 0.0 110.694 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.485 ' C ' ' H ' ' A' ' 15' ' ' ILE . 6.5 m -89.33 158.29 17.86 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.843 0.354 . . . . 0.0 110.423 -179.385 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 9.5 t -69.35 6.6 0.98 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.207 179.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.485 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.5 mt -91.44 -45.62 14.52 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.148 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -90.92 -11.37 39.33 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.925 179.649 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 54.1 m-85 -142.78 82.02 12.7 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.684 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.42 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 15.9 Cg_exo -65.95 -172.72 0.28 Allowed 'Trans proline' 0 N--CA 1.493 1.479 0 C-N-CA 122.904 2.403 . . . . 0.0 111.83 179.279 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.512 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 26.2 p -48.07 -56.68 7.19 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 120.826 -0.35 . . . . 0.0 111.698 -179.054 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.602 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 0.0 OUTLIER -47.91 -72.2 0.06 Allowed 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.121 0.486 . . . . 0.0 111.736 -178.719 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 52.0 mtmt -60.49 -42.94 97.36 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.683 -178.273 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.42 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 44.7 t -44.94 -59.77 2.4 Favored 'General case' 0 C--N 1.313 -1.013 0 C-N-CA 120.215 -0.594 . . . . 0.0 111.089 -178.547 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.746 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.5 p-10 -64.58 -55.64 19.09 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.546 -179.468 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.746 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 69.1 mttt -47.14 -42.79 20.07 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 120.788 -0.365 . . . . 0.0 110.584 -178.742 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 11.4 m -65.8 -37.75 87.13 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.242 179.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 37.9 m -67.64 -33.63 75.34 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.877 -0.602 . . . . 0.0 110.287 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.6 mm -61.5 -46.35 96.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.564 -179.536 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -66.34 -31.07 71.64 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.494 -179.035 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 27.1 m -72.87 1.5 8.57 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.405 -179.12 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.3 m-80 74.51 52.98 0.09 Allowed 'General case' 0 C--N 1.329 -0.312 0 O-C-N 123.559 0.537 . . . . 0.0 111.032 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.59 ' C ' ' H ' ' A' ' 33' ' ' GLY . 68.6 m-85 -138.61 162.02 35.66 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.688 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.79 30.24 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.57 179.626 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.59 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 83.6 -176.87 52.53 Favored Glycine 0 CA--C 1.521 0.442 0 N-CA-C 110.568 -1.013 . . . . 0.0 110.568 -179.653 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -147.3 178.04 25.18 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 -179.595 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 14.7 ptmt -156.87 -176.79 6.17 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 110.237 -0.283 . . . . 0.0 110.237 -179.625 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 66.7 m -108.44 122.2 46.53 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.519 179.573 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 2.8 m -137.89 163.46 29.98 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.837 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.404 ' CD2' ' H ' ' A' ' 38' ' ' HIS . 2.4 p80 -92.97 157.61 16.24 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.341 179.714 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.437 ' O ' ' N ' ' A' ' 41' ' ' GLN . 34.1 mm -110.18 123.44 66.08 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 CA-C-O 121.086 0.47 . . . . 0.0 110.679 -179.741 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 43.99 20.74 0.17 Allowed Glycine 0 C--O 1.227 -0.307 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.575 179.629 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.437 ' N ' ' O ' ' A' ' 39' ' ' ILE . 37.3 tt0 72.61 36.18 1.01 Allowed 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.846 0.355 . . . . 0.0 110.721 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' SER . . . . . 0.422 ' N ' ' O ' ' A' ' 39' ' ' ILE . 41.0 m -85.61 -2.66 58.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.206 0.527 . . . . 0.0 110.885 -179.785 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 69.96 26.4 4.66 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.672 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 35.2 t70 -111.78 117.36 32.62 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 178.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -89.36 129.33 35.9 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 27.2 m -133.38 154.6 39.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.387 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.472 ' SG ' ' CD1' ' A' ' 11' ' ' ILE . 37.9 t -95.26 118.42 31.99 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 115.877 -0.601 . . . . 0.0 109.971 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.0 p -130.21 144.14 38.88 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 CA-C-O 120.87 0.366 . . . . 0.0 110.361 -179.466 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 4.9 m -97.93 167.52 10.86 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.889 -179.739 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 46.4 m-85 -122.18 143.05 38.14 Favored Pre-proline 0 CA--C 1.532 0.275 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.668 -179.428 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo . . . . . 0 N--CA 1.495 1.609 0 C-N-CA 122.544 2.163 . . . . 0.0 111.735 179.579 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_exo . . . . . 0 N--CA 1.494 1.554 0 N-CA-C 110.84 -0.485 . . . . 0.0 110.84 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.5 tt -129.77 116.89 19.4 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 179.607 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.4 tt -89.27 124.81 34.75 Favored 'General case' 0 N--CA 1.465 0.321 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.519 ' CD1' ' SG ' ' A' ' 47' ' ' CYS . 3.2 pt -102.59 -46.97 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.842 -179.009 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -164.49 -138.45 2.41 Favored Glycine 0 CA--C 1.519 0.306 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.446 ' C ' ' H ' ' A' ' 15' ' ' ILE . 65.5 p -136.22 159.5 41.56 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.149 -0.526 . . . . 0.0 110.249 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -53.38 -12.27 0.41 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.05 179.54 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.446 ' H ' ' C ' ' A' ' 13' ' ' THR . 78.0 mt -71.78 -43.75 69.25 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.396 0 CA-C-O 121.353 0.597 . . . . 0.0 110.425 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 3.0 pt-20 -100.91 -34.3 9.85 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.094 -179.297 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 9.3 m-85 -116.93 85.0 16.85 Favored Pre-proline 0 N--CA 1.468 0.473 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.572 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -49.64 -178.63 0.01 OUTLIER 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 122.462 2.108 . . . . 0.0 111.508 -179.565 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.436 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 96.9 m -59.14 -51.41 70.12 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.629 -0.428 . . . . 0.0 111.443 -178.818 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.477 ' CG ' ' N ' ' A' ' 21' ' ' LYS . 11.1 pt-20 -60.62 -50.17 74.61 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 112.052 0.389 . . . . 0.0 112.052 -179.706 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.477 ' N ' ' CG ' ' A' ' 20' ' ' GLU . 2.5 ttpp -64.8 -45.9 84.32 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.232 0.539 . . . . 0.0 110.225 -178.327 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 43.3 t -45.7 -61.47 1.7 Allowed 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.25 -0.886 . . . . 0.0 111.433 -179.57 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.685 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.7 p-10 -64.65 -49.31 71.51 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.697 -179.42 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.685 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 82.3 mttt -48.11 -42.56 29.41 Favored 'General case' 0 C--O 1.218 -0.555 0 C-N-CA 120.544 -0.462 . . . . 0.0 109.852 -179.926 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 20.1 m -61.86 -42.4 99.0 Favored 'General case' 0 C--N 1.311 -1.073 0 C-N-CA 120.016 -0.674 . . . . 0.0 110.748 -179.586 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.495 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 10.2 t -65.51 -34.19 77.68 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.743 0.783 . . . . 0.0 109.229 179.363 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.6 mm -65.99 -41.29 89.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 115.008 -0.996 . . . . 0.0 110.289 -179.768 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.437 ' C ' ' H ' ' A' ' 30' ' ' ASN . 54.4 mm-40 -64.23 -34.38 77.97 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.502 -179.555 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.448 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 36.1 m -67.87 -0.15 3.98 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.994 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.448 ' CB ' ' O ' ' A' ' 29' ' ' SER . 4.3 t-20 80.9 14.81 0.66 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.483 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.556 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 4.0 m-85 -94.89 -168.3 1.79 Allowed 'General case' 0 CA--C 1.533 0.298 0 CA-C-O 120.781 0.324 . . . . 0.0 110.261 -179.671 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -76.59 -51.26 11.96 Favored 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 -178.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.495 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 163.3 -179.24 38.56 Favored Glycine 0 CA--C 1.519 0.318 0 N-CA-C 109.734 -1.347 . . . . 0.0 109.734 -178.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -142.96 170.35 25.31 Favored Glycine 0 N--CA 1.462 0.405 0 N-CA-C 111.36 -0.696 . . . . 0.0 111.36 -179.115 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 23.3 pttt -156.9 178.43 10.37 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.071 0.462 . . . . 0.0 110.891 -179.663 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 3.2 m -104.56 128.4 52.53 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.053 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 35.1 m -136.23 163.38 34.15 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.573 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 2.8 p80 -108.75 156.61 19.41 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.129 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 95.9 mt -122.82 130.07 74.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.606 -179.391 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 48.02 -107.99 0.31 Allowed Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -136.38 32.29 2.83 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 120.596 0.236 . . . . 0.0 110.48 -179.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 8.7 m -82.64 -12.03 57.95 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 121.134 0.492 . . . . 0.0 110.282 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 49.56 29.17 2.84 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.224 179.657 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -105.62 132.71 51.42 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.344 179.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -93.5 117.53 30.2 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-O 120.965 0.412 . . . . 0.0 109.95 179.823 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 16.3 m -111.0 137.16 44.65 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.41 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.007 -179.6 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.519 ' SG ' ' CD1' ' A' ' 11' ' ' ILE . 16.1 t -93.05 118.79 31.59 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.734 -179.837 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.9 p -128.05 150.91 34.22 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.093 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.84 -179.319 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' CYS . . . . . 0.556 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 28.9 t -96.88 165.4 12.12 Favored 'General case' 0 N--CA 1.467 0.419 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.508 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 25.3 m-85 -127.95 124.17 23.07 Favored Pre-proline 0 CA--C 1.544 0.731 0 C-N-CA 121.114 -0.234 . . . . 0.0 111.236 -178.444 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_exo . . . . . 0 N--CA 1.499 1.818 0 C-N-CA 121.999 1.8 . . . . 0.0 113.018 179.092 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo . . . . . 0 N--CA 1.497 1.693 0 CA-C-O 120.745 0.227 . . . . 0.0 111.984 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.8 tt -131.63 120.91 23.48 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.42 -179.272 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 4.4 tt -89.94 128.43 36.23 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 178.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 6.4 pt -101.72 -43.03 9.71 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-O 120.786 0.327 . . . . 0.0 110.865 -178.536 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -173.54 -143.29 4.22 Favored Glycine 0 N--CA 1.451 -0.307 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.744 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.421 ' C ' ' H ' ' A' ' 15' ' ' ILE . 7.7 p -99.46 163.66 12.42 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.824 0.345 . . . . 0.0 110.275 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 43.4 t -74.1 7.55 2.64 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.331 179.6 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.421 ' H ' ' C ' ' A' ' 13' ' ' THR . 97.1 mt -93.15 -43.68 13.63 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.12 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.523 -179.814 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -88.37 -11.71 45.43 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.652 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 53.6 m-85 -122.84 81.22 49.58 Favored Pre-proline 0 N--CA 1.463 0.214 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.853 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_exo -48.88 165.99 0.17 Allowed 'Trans proline' 0 N--CA 1.495 1.599 0 C-N-CA 122.714 2.276 . . . . 0.0 111.33 179.065 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.424 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 17.0 m -48.39 -52.58 21.22 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.85 -0.34 . . . . 0.0 111.627 -178.036 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.541 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 1.3 pm0 -61.92 -55.44 29.58 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.551 -0.295 . . . . 0.0 111.651 -179.722 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.417 ' O ' ' OG1' ' A' ' 25' ' ' THR . 0.5 OUTLIER -57.57 -45.82 84.71 Favored 'General case' 0 CA--C 1.518 -0.255 0 CA-C-O 121.302 0.572 . . . . 0.0 110.94 -178.208 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 12.7 t -48.02 -65.12 0.62 Allowed 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.402 -178.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.667 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.6 p-10 -63.71 -48.37 77.37 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.755 -179.597 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.667 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 89.5 mttt -47.27 -42.02 19.88 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 120.543 -0.463 . . . . 0.0 110.05 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' THR . . . . . 0.417 ' OG1' ' O ' ' A' ' 21' ' ' LYS . 18.6 m -61.57 -43.68 98.41 Favored 'General case' 0 C--N 1.314 -0.978 0 C-N-CA 120.456 -0.498 . . . . 0.0 110.909 -179.453 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.503 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 10.7 t -66.2 -32.51 73.99 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.525 0.679 . . . . 0.0 109.745 179.562 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.6 mm -66.54 -39.34 83.68 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.442 -179.623 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.462 ' C ' ' H ' ' A' ' 30' ' ' ASN . 54.9 mm-40 -64.34 -35.72 81.8 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.299 -179.356 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.401 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 58.6 m -67.86 1.65 2.47 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.268 179.797 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.462 ' H ' ' C ' ' A' ' 28' ' ' GLU . 43.8 t30 77.78 18.25 1.27 Allowed 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.705 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.553 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 4.1 m-85 -96.34 -167.83 1.64 Allowed 'General case' 0 CA--C 1.532 0.288 0 CA-C-O 120.945 0.402 . . . . 0.0 110.406 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -75.71 -51.51 12.55 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 115.893 -0.594 . . . . 0.0 112.076 -179.079 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.503 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 162.56 -178.06 38.46 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 -179.025 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -142.95 169.02 25.82 Favored Glycine 0 N--CA 1.462 0.375 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.136 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 11.4 ptmt -158.48 -176.25 5.78 Favored 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 120.681 -0.408 . . . . 0.0 110.716 -179.3 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 66.2 m -103.73 119.86 39.76 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.932 179.509 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 18.9 m -133.32 163.93 36.41 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.204 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.6 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 0.3 OUTLIER -132.83 157.67 44.44 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 121.02 0.438 . . . . 0.0 110.394 179.879 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.528 ' O ' ' N ' ' A' ' 41' ' ' GLN . 20.2 mm -99.38 135.84 32.99 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.569 179.673 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -61.84 65.1 0.02 OUTLIER Glycine 0 N--CA 1.461 0.346 0 N-CA-C 111.543 -0.623 . . . . 0.0 111.543 -179.418 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.528 ' N ' ' O ' ' A' ' 39' ' ' ILE . 59.7 tp60 -174.63 -57.49 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.884 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 73.4 m -90.88 -13.84 32.88 Favored 'General case' 0 CA--C 1.505 -0.755 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.588 179.719 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' LEU . . . . . 0.535 ' N ' ' CD1' ' A' ' 43' ' ' LEU . 8.3 mp 46.88 28.28 0.82 Allowed 'General case' 0 N--CA 1.436 -1.171 0 C-N-CA 119.697 -0.801 . . . . 0.0 111.378 178.934 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 54.4 t0 -96.36 136.63 36.59 Favored 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.571 ' CE1' ' CD2' ' A' ' 38' ' ' HIS . 64.6 m-85 -86.35 124.75 33.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.998 0.428 . . . . 0.0 110.0 -179.596 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 27.8 m -126.13 150.59 31.76 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.377 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.111 -179.713 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -98.55 125.96 43.96 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.582 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.1 p -136.77 155.0 32.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.188 -179.339 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' CYS . . . . . 0.553 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 17.7 t -97.07 164.65 12.42 Favored 'General case' 0 C--O 1.233 0.215 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.538 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 30.7 m-85 -133.98 126.59 18.78 Favored Pre-proline 0 C--N 1.33 -0.24 0 C-N-CA 121.031 -0.268 . . . . 0.0 110.856 -178.363 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 N--CA 1.491 1.339 0 C-N-CA 121.712 1.608 . . . . 0.0 112.218 179.97 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo . . . . . 0 N--CA 1.498 1.78 0 CA-C-O 120.641 0.184 . . . . 0.0 111.929 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.5 tt -129.65 120.61 25.5 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.126 -178.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.2 tt -92.49 125.66 37.23 Favored 'General case' 0 N--CA 1.468 0.438 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 178.494 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.527 ' CD1' ' SG ' ' A' ' 47' ' ' CYS . 2.9 pt -103.56 -47.45 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-O 120.752 0.31 . . . . 0.0 111.0 -179.188 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -165.14 -135.73 1.88 Allowed Glycine 0 CA--C 1.519 0.311 0 C-N-CA 120.705 -0.76 . . . . 0.0 111.307 -179.649 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.417 ' C ' ' H ' ' A' ' 15' ' ' ILE . 71.3 p -136.89 159.6 41.38 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 114.99 -0.605 . . . . 0.0 110.163 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -56.72 -11.07 1.2 Allowed 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.026 179.636 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.417 ' H ' ' C ' ' A' ' 13' ' ' THR . 97.3 mt -69.41 -43.24 81.05 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.329 0 CA-C-O 121.454 0.645 . . . . 0.0 109.782 179.71 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -104.34 -31.11 9.7 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 114.9 -1.045 . . . . 0.0 111.648 -178.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.427 ' O ' ' O ' ' A' ' 18' ' ' PRO . 12.0 m-85 -119.06 82.99 22.75 Favored Pre-proline 0 N--CA 1.471 0.612 0 N-CA-C 110.103 -0.332 . . . . 0.0 110.103 179.473 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.427 ' O ' ' O ' ' A' ' 17' ' ' PHE . 77.5 Cg_exo -47.61 179.87 0.01 OUTLIER 'Trans proline' 0 N--CA 1.495 1.57 0 C-N-CA 122.645 2.23 . . . . 0.0 111.701 -179.79 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.449 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 99.0 m -59.0 -50.71 73.06 Favored 'General case' 0 C--N 1.326 -0.428 0 C-N-CA 120.89 -0.324 . . . . 0.0 111.845 -178.513 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.546 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 1.1 pm0 -60.03 -52.59 64.73 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.161 -179.688 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.13 -47.29 85.24 Favored 'General case' 0 CA--C 1.519 -0.235 0 CA-C-O 121.297 0.57 . . . . 0.0 110.691 -179.212 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 38.5 t -45.12 -60.38 2.13 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 115.312 -0.858 . . . . 0.0 111.259 -178.792 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.666 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.9 p-10 -64.71 -51.69 61.07 Favored 'General case' 0 C--O 1.221 -0.411 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.734 -179.593 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.666 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 81.2 mttt -47.97 -42.86 28.77 Favored 'General case' 0 C--N 1.323 -0.554 0 C-N-CA 120.405 -0.518 . . . . 0.0 110.584 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 55.5 m -66.35 -33.3 75.41 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.163 0.506 . . . . 0.0 110.085 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 56.9 m -72.0 -34.04 68.56 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.876 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.3 mm -62.07 -48.51 88.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.727 -179.251 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.495 ' C ' ' H ' ' A' ' 30' ' ' ASN . 6.0 pt-20 -70.47 -30.81 67.71 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.799 -179.303 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 39.5 m -68.96 7.15 0.74 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.706 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.495 ' H ' ' C ' ' A' ' 28' ' ' GLU . 49.8 t30 72.73 47.86 0.22 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.366 179.487 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.577 ' C ' ' H ' ' A' ' 33' ' ' GLY . 73.9 m-85 -137.23 160.8 37.97 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.759 179.424 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.32 23.3 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.168 -179.66 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.577 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 91.92 -179.88 41.4 Favored Glycine 0 CA--C 1.519 0.338 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 -179.683 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -148.92 174.45 28.54 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 8.8 pttm -154.12 -179.08 7.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.035 0.445 . . . . 0.0 110.788 -179.781 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 3.9 m -105.03 124.46 49.56 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 115.718 -0.673 . . . . 0.0 110.308 179.658 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 35.7 m -136.67 165.91 27.38 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.75 -179.679 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 3.3 p80 -106.92 155.85 19.34 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-O 121.025 0.44 . . . . 0.0 110.66 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 96.0 mt -128.96 126.49 64.74 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.217 -179.481 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 61.46 22.48 61.41 Favored Glycine 0 CA--C 1.52 0.387 0 N-CA-C 111.555 -0.618 . . . . 0.0 111.555 178.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 26.7 mt-30 57.3 37.37 28.11 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.026 0.441 . . . . 0.0 110.03 -179.466 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 20.7 m -81.49 -11.09 59.33 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.181 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' LEU . . . . . 0.41 ' CD2' ' O ' ' A' ' 43' ' ' LEU . 0.9 OUTLIER 70.69 28.63 3.43 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.493 0.663 . . . . 0.0 109.659 -179.783 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -110.97 121.34 45.1 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.665 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 64.5 m-85 -90.63 117.1 29.03 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-O 121.163 0.506 . . . . 0.0 110.007 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.5 m -110.97 137.65 42.55 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.33 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.715 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.527 ' SG ' ' CD1' ' A' ' 11' ' ' ILE . 13.5 t -93.02 113.95 26.36 Favored 'General case' 0 CA--C 1.512 -0.481 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 -179.862 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 8.8 p -130.39 147.78 33.16 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.308 0 CA-C-O 121.143 0.497 . . . . 0.0 111.62 -178.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 4.8 m -97.43 170.82 8.79 Favored 'General case' 0 CA--C 1.518 -0.257 0 CA-C-N 115.258 -0.883 . . . . 0.0 109.793 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -130.15 143.29 48.57 Favored Pre-proline 0 CA--C 1.542 0.644 0 CA-C-N 116.512 -0.313 . . . . 0.0 111.266 -178.804 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_exo . . . . . 0 N--CA 1.498 1.736 0 C-N-CA 122.37 2.047 . . . . 0.0 112.011 177.676 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo . . . . . 0 N--CA 1.495 1.571 0 N-CA-C 111.187 -0.351 . . . . 0.0 111.187 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -111.32 126.69 55.18 Favored 'General case' 0 N--CA 1.468 0.472 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.685 -179.006 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -92.05 128.5 37.91 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 178.336 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -108.06 -40.09 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -178.63 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -177.94 -140.59 3.84 Favored Glycine 0 CA--C 1.52 0.404 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 179.698 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.526 ' C ' ' H ' ' A' ' 15' ' ' ILE . 80.6 p -135.63 161.08 36.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.017 0.437 . . . . 0.0 111.045 -179.534 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -58.17 -2.96 0.21 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.26 179.54 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.526 ' H ' ' C ' ' A' ' 13' ' ' THR . 23.8 mm -73.45 -22.65 19.18 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 CA-C-O 121.092 0.473 . . . . 0.0 109.948 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . 0.477 ' OE1' ' CZ ' ' A' ' 17' ' ' PHE . 9.5 pt-20 -134.51 -30.76 1.11 Allowed 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.154 -179.515 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.477 ' CZ ' ' OE1' ' A' ' 16' ' ' GLU . 9.9 m-85 -114.88 93.4 34.01 Favored Pre-proline 0 N--CA 1.468 0.426 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.537 -179.619 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.45 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 56.5 Cg_endo -79.25 -179.08 5.1 Favored 'Trans proline' 0 N--CA 1.489 1.235 0 C-N-CA 122.489 2.126 . . . . 0.0 111.23 -179.543 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.411 ' OG1' ' OE2' ' A' ' 20' ' ' GLU . 23.4 p -45.4 -48.68 13.52 Favored 'General case' 0 C--N 1.32 -0.687 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.116 -178.74 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.443 ' CD ' ' N ' ' A' ' 20' ' ' GLU . 0.3 OUTLIER -52.55 -70.72 0.08 Allowed 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.614 -179.316 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 16.2 ttmt -64.59 -47.36 78.95 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-O 121.443 0.64 . . . . 0.0 111.304 -178.008 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.45 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 51.8 t -41.78 -59.8 1.56 Allowed 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.205 -0.907 . . . . 0.0 111.039 -178.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.688 ' ND2' ' H ' ' A' ' 24' ' ' LYS . 0.0 OUTLIER -66.89 -55.13 16.01 Favored 'General case' 0 C--O 1.218 -0.577 0 C-N-CA 120.205 -0.598 . . . . 0.0 110.421 -179.634 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.688 ' H ' ' ND2' ' A' ' 23' ' ' ASN . 71.7 mttt -44.53 -42.6 7.34 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.871 0.367 . . . . 0.0 110.71 -179.231 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' THR . . . . . 0.454 ' O ' ' OE2' ' A' ' 28' ' ' GLU . 8.8 m -65.12 -37.14 86.49 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.416 0.627 . . . . 0.0 109.558 179.408 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.463 ' N ' ' O ' ' A' ' 23' ' ' ASN . 67.9 m -72.08 -35.27 69.19 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.162 179.728 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.9 mm -62.67 -48.34 88.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.386 -179.192 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.454 ' OE2' ' O ' ' A' ' 25' ' ' THR . 2.6 pp20? -70.57 -31.09 67.97 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.601 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.434 ' N ' ' CD ' ' A' ' 28' ' ' GLU . 68.6 m -67.57 2.36 1.86 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.934 -179.688 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.44 ' H ' ' C ' ' A' ' 28' ' ' GLU . 41.6 t30 75.14 43.32 0.21 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.983 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.582 ' C ' ' H ' ' A' ' 33' ' ' GLY . 63.0 m-85 -131.92 160.99 34.13 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.459 179.463 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.48 31.19 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.96 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.582 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 84.11 -176.96 51.92 Favored Glycine 0 CA--C 1.52 0.4 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -150.58 172.13 30.35 Favored Glycine 0 CA--C 1.52 0.36 0 N-CA-C 110.715 -0.954 . . . . 0.0 110.715 -179.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 25.2 pttt -155.25 -179.02 7.68 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 120.935 0.398 . . . . 0.0 110.563 -179.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 3.3 m -103.94 127.08 51.48 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 115.866 -0.607 . . . . 0.0 110.172 179.384 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 34.5 m -136.77 159.81 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.419 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.492 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 2.9 p80 -104.6 156.94 17.53 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-O 121.072 0.463 . . . . 0.0 110.086 179.753 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.478 ' O ' ' N ' ' A' ' 41' ' ' GLN . 34.4 mm -109.21 125.13 66.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.243 -179.765 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 42.5 -92.42 0.01 OUTLIER Glycine 0 CA--C 1.526 0.75 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.484 ' CD ' ' N ' ' A' ' 41' ' ' GLN . 2.0 pm0 -143.9 30.44 1.31 Allowed 'General case' 0 N--CA 1.463 0.197 0 CA-C-O 120.702 0.287 . . . . 0.0 110.531 -179.64 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 66.3 m -84.43 -5.4 59.28 Favored 'General case' 0 CA--C 1.52 -0.188 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.689 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 45.14 28.37 0.4 Allowed 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.677 179.813 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -103.04 119.8 39.51 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.396 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 70.8 m-85 -87.75 117.8 26.83 Favored 'General case' 0 C--N 1.332 -0.191 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.725 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 33.4 m -112.82 137.09 47.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.331 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 25.2 t -92.25 108.2 19.77 Favored 'General case' 0 CA--C 1.513 -0.445 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 179.838 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.2 p -124.36 150.23 28.96 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.229 0 CA-C-O 120.941 0.4 . . . . 0.0 110.634 -178.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 10.6 m -97.26 163.13 13.03 Favored 'General case' 0 CA--C 1.515 -0.386 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 -179.696 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 -119.33 143.29 34.05 Favored Pre-proline 0 CA--C 1.531 0.249 0 C-N-CA 121.141 -0.224 . . . . 0.0 111.227 -178.879 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo . . . . . 0 N--CA 1.494 1.522 0 C-N-CA 122.221 1.947 . . . . 0.0 111.989 178.81 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo . . . . . 0 N--CA 1.486 1.051 0 N-CA-C 110.993 -0.426 . . . . 0.0 110.993 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.419 ' C ' ' CD2' ' A' ' 9' ' ' LEU . 3.5 tt -117.0 114.79 24.29 Favored 'General case' 0 CA--C 1.511 -0.523 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 -179.777 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.427 ' CD1' ' C ' ' A' ' 10' ' ' LEU . 3.0 tm? -93.27 124.5 37.29 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.37 -0.532 . . . . 0.0 109.881 179.266 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.5 ' CD1' ' SG ' ' A' ' 47' ' ' CYS . 5.7 pt -103.37 -41.91 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-O 121.052 0.453 . . . . 0.0 110.588 -179.342 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -174.8 -139.5 3.03 Favored Glycine 0 CA--C 1.521 0.418 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.471 ' C ' ' H ' ' A' ' 15' ' ' ILE . 72.7 p -134.06 165.99 23.78 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.914 0.388 . . . . 0.0 110.924 -179.524 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -58.6 -5.6 0.58 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.206 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.471 ' H ' ' C ' ' A' ' 13' ' ' THR . 24.0 mm -74.5 -24.48 18.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.538 -179.292 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -128.33 -29.92 2.43 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.84 -179.592 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -117.34 91.96 38.84 Favored Pre-proline 0 CA--C 1.536 0.411 0 CA-C-N 116.486 -0.324 . . . . 0.0 110.474 179.759 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.463 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 52.9 Cg_endo -71.56 -177.33 2.4 Favored 'Trans proline' 0 N--CA 1.498 1.736 0 C-N-CA 123.12 2.547 . . . . 0.0 111.853 -179.25 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.473 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 31.0 m -46.73 -70.61 0.09 Allowed 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 120.568 -0.453 . . . . 0.0 111.358 -179.275 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.575 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 1.3 pm0 -41.39 -70.13 0.11 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.395 -178.865 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 5.3 ttmt -54.44 -53.88 48.23 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.021 0.439 . . . . 0.0 111.499 -177.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.463 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 43.0 t -41.41 -59.44 1.57 Allowed 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.071 -178.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.745 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 0.9 OUTLIER -65.82 -52.1 53.41 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.848 179.611 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.745 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 69.7 mttt -48.42 -42.61 32.65 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 120.839 0.352 . . . . 0.0 110.674 -178.539 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 20.0 m -63.93 -41.08 97.73 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-O 121.331 0.586 . . . . 0.0 109.995 179.789 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 57.5 m -65.23 -31.06 72.03 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.574 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 mm -65.37 -38.83 83.48 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.427 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 30.2 mm-40 -65.74 -33.06 75.0 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.551 -0.749 . . . . 0.0 110.626 -178.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 46.2 m -73.27 -2.66 22.8 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.307 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 1.9 m120 77.84 34.5 0.32 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.958 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.603 ' C ' ' H ' ' A' ' 33' ' ' GLY . 8.2 m-85 -110.34 164.7 12.42 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.049 179.892 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.19 21.29 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.57 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.603 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 90.32 -178.7 43.25 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.371 -1.091 . . . . 0.0 110.371 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -147.01 170.33 27.93 Favored Glycine 0 CA--C 1.52 0.406 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 -179.344 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 10.7 ptmt -156.36 -177.0 6.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.619 0.247 . . . . 0.0 110.601 -179.576 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 1.7 m -104.02 125.76 50.62 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.131 179.489 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 34.0 m -133.92 162.57 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.297 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 3.1 p80 -109.12 157.42 18.76 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.867 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 92.1 mt -123.27 131.59 72.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.716 -179.485 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 49.55 -103.98 0.09 OUTLIER Glycine 0 CA--C 1.519 0.307 0 N-CA-C 110.812 -0.915 . . . . 0.0 110.812 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 41.2 tp60 -141.44 30.98 1.71 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.876 0.37 . . . . 0.0 110.396 -179.757 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 58.2 m -85.93 -5.7 59.19 Favored 'General case' 0 CA--C 1.518 -0.252 0 CA-C-O 120.967 0.413 . . . . 0.0 110.91 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' LEU . . . . . 0.403 ' CD2' ' O ' ' A' ' 43' ' ' LEU . 0.9 OUTLIER 44.42 29.95 0.43 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.398 -179.499 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -99.8 124.88 45.53 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.073 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -89.7 118.01 28.99 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 109.692 -0.485 . . . . 0.0 109.692 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 29.8 m -112.84 136.21 49.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.102 -179.52 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' CD1' ' A' ' 11' ' ' ILE . 22.1 t -92.94 105.98 18.01 Favored 'General case' 0 CA--C 1.513 -0.464 0 N-CA-C 109.373 -0.602 . . . . 0.0 109.373 179.901 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 4.7 p -125.54 154.97 34.6 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.375 0 CA-C-O 120.94 0.4 . . . . 0.0 110.573 -178.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 8.1 m -99.31 173.36 6.81 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.168 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 64.3 m-85 -133.6 117.95 14.44 Favored Pre-proline 0 CA--C 1.536 0.43 0 CA-C-N 116.269 -0.423 . . . . 0.0 109.999 179.224 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo . . . . . 0 N--CA 1.499 1.826 0 C-N-CA 122.186 1.924 . . . . 0.0 112.328 179.666 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo . . . . . 0 N--CA 1.502 1.986 0 CA-C-O 120.8 0.25 . . . . 0.0 112.303 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.6 tt -128.42 120.79 27.59 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.755 -179.215 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.6 tt -89.05 133.9 34.19 Favored 'General case' 0 N--CA 1.468 0.46 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 178.128 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 12.8 pt -109.04 -37.02 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-O 120.869 0.366 . . . . 0.0 111.068 -178.775 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 175.32 -153.72 16.09 Favored Glycine 0 N--CA 1.452 -0.255 0 N-CA-C 110.913 -0.875 . . . . 0.0 110.913 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.409 ' HG1' ' HB ' ' A' ' 15' ' ' ILE . 6.7 p -90.03 164.85 14.35 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 179.764 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 10.4 t -76.07 7.35 4.19 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.214 179.601 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.409 ' HB ' ' HG1' ' A' ' 13' ' ' THR . 96.5 mt -91.46 -42.32 13.65 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.221 0 CA-C-O 121.149 0.499 . . . . 0.0 109.808 179.727 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -87.91 -12.63 44.15 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.361 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -124.81 81.2 61.81 Favored Pre-proline 0 N--CA 1.463 0.217 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.954 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -48.64 163.23 0.29 Allowed 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.05 1.833 . . . . 0.0 110.719 178.731 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.406 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 25.5 p -46.5 -53.24 11.63 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.919 0.39 . . . . 0.0 111.721 -177.837 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.573 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 0.0 OUTLIER -59.72 -55.4 34.78 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.573 -179.429 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -58.96 -44.79 91.53 Favored 'General case' 0 CA--C 1.516 -0.336 0 CA-C-O 121.332 0.587 . . . . 0.0 110.388 -178.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 14.7 t -48.28 -65.46 0.56 Allowed 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 115.265 -0.88 . . . . 0.0 111.427 -178.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.659 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.6 p-10 -64.97 -46.97 79.26 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.011 -179.438 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.659 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 92.9 mttt -50.59 -37.55 40.53 Favored 'General case' 0 CA--C 1.5 -0.952 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.23 179.592 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 86.8 m -63.93 -42.79 97.26 Favored 'General case' 0 C--N 1.319 -0.751 0 O-C-N 124.012 0.82 . . . . 0.0 110.468 -179.342 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.497 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 33.8 t -72.58 -33.4 66.74 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.106 179.68 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.2 mm -66.08 -46.7 87.19 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.616 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.112 -179.192 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.546 ' C ' ' H ' ' A' ' 30' ' ' ASN . 19.0 pt-20 -69.64 -30.46 68.17 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 115.349 -0.841 . . . . 0.0 110.151 -179.698 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.416 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 68.3 m -65.49 1.78 1.09 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.75 179.845 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.546 ' H ' ' C ' ' A' ' 28' ' ' GLU . 16.9 t-20 79.82 12.56 1.1 Allowed 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.966 179.546 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.562 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 4.5 m-85 -98.07 -167.81 1.57 Allowed 'General case' 0 CA--C 1.533 0.322 0 CA-C-O 120.706 0.289 . . . . 0.0 110.27 -179.842 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -75.79 -53.97 7.65 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.582 0.586 . . . . 0.0 112.582 -178.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.497 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 166.5 178.9 39.45 Favored Glycine 0 CA--C 1.519 0.321 0 N-CA-C 110.068 -1.213 . . . . 0.0 110.068 -178.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -137.26 160.98 25.19 Favored Glycine 0 C--N 1.331 0.299 0 N-CA-C 111.579 -0.609 . . . . 0.0 111.579 -179.383 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 14.2 ptpt -153.45 170.23 21.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.29 -0.455 . . . . 0.0 110.779 -178.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 56.5 m -104.86 117.7 34.7 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.891 179.493 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 4.8 m -139.65 -178.5 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-O 120.873 0.368 . . . . 0.0 111.129 -179.427 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.619 ' ND1' ' N ' ' A' ' 44' ' ' ASP . 95.3 m-70 -114.0 147.98 37.72 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.802 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 95.6 mt -124.06 127.8 73.7 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.849 -179.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 68.74 21.78 75.09 Favored Glycine 0 CA--C 1.52 0.35 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 179.374 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 57.79 30.8 19.55 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.196 0.522 . . . . 0.0 109.794 -179.215 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 50.6 m -72.22 -10.92 60.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.443 -0.798 . . . . 0.0 110.511 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' LEU . . . . . 0.445 ' C ' ' ND1' ' A' ' 38' ' ' HIS . 0.9 OUTLIER 63.14 29.33 16.14 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.649 -179.636 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . 0.619 ' N ' ' ND1' ' A' ' 38' ' ' HIS . 67.2 t0 -111.05 138.69 47.16 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.714 179.499 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.489 ' N ' ' OD1' ' A' ' 44' ' ' ASP . 50.2 m-85 -92.95 117.38 29.98 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.645 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 25.9 m -124.29 136.81 59.29 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.328 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.052 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -94.46 122.59 37.19 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.352 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.0 p -135.52 152.52 31.71 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.318 0 C-N-CA 120.655 -0.418 . . . . 0.0 111.319 -179.393 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' CYS . . . . . 0.562 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 23.9 t -96.01 164.18 12.81 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.078 -179.937 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.494 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 37.7 m-85 -130.75 136.55 29.11 Favored Pre-proline 0 N--CA 1.476 0.849 0 C-N-CA 120.788 -0.365 . . . . 0.0 111.352 -178.427 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo . . . . . 0 N--CA 1.491 1.355 0 C-N-CA 121.865 1.71 . . . . 0.0 112.207 179.888 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo . . . . . 0 N--CA 1.501 1.934 0 CA-C-O 120.561 0.15 . . . . 0.0 111.797 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.5 tt -128.33 119.5 25.2 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.6 tt -88.65 126.58 35.36 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 108.839 -0.801 . . . . 0.0 108.839 179.199 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.505 ' CD1' ' SG ' ' A' ' 47' ' ' CYS . 2.2 pt -105.36 -48.12 9.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-O 120.983 0.421 . . . . 0.0 110.852 -178.549 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -159.87 -144.22 3.9 Favored Glycine 0 CA--C 1.52 0.369 0 N-CA-C 110.771 -0.931 . . . . 0.0 110.771 -179.802 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.5 ' C ' ' H ' ' A' ' 15' ' ' ILE . 55.2 p -138.89 161.22 37.83 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.994 0.426 . . . . 0.0 110.809 -179.826 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -59.81 -1.28 0.26 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.221 179.652 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.5 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.2 mt -77.9 -23.65 13.98 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.406 0 CA-C-O 121.164 0.506 . . . . 0.0 109.806 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 2.7 pt-20 -134.24 -34.17 0.98 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.589 -0.732 . . . . 0.0 111.197 -179.381 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.478 ' CE1' ' NZ ' ' A' ' 21' ' ' LYS . 6.4 m-85 -106.82 88.85 3.84 Favored Pre-proline 0 CA--C 1.538 0.5 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.416 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 19.0 Cg_endo -63.43 -173.6 0.18 Allowed 'Trans proline' 0 N--CA 1.499 1.799 0 C-N-CA 121.832 1.688 . . . . 0.0 112.461 -178.789 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 70.5 m -58.11 -49.81 75.66 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.021 -179.227 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.484 ' CG ' ' H ' ' A' ' 21' ' ' LYS . 8.9 pt-20 -59.06 -56.66 19.42 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.806 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.484 ' H ' ' CG ' ' A' ' 20' ' ' GLU . 0.6 OUTLIER -64.51 -47.22 79.68 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-O 121.235 0.541 . . . . 0.0 111.087 -177.989 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.416 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 32.4 t -45.4 -63.18 1.0 Allowed 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.375 -0.83 . . . . 0.0 111.682 -179.149 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.625 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 0.0 OUTLIER -63.45 -49.6 73.03 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.008 -179.276 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.625 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 47.5 mttp -45.1 -42.37 8.72 Favored 'General case' 0 C--O 1.218 -0.563 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.087 -179.7 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 17.8 m -62.34 -43.49 98.7 Favored 'General case' 0 C--N 1.311 -1.094 0 C-N-CA 119.98 -0.688 . . . . 0.0 110.366 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.492 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 11.4 t -66.99 -32.65 74.03 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 121.574 0.702 . . . . 0.0 109.788 179.615 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.5 mm -65.9 -41.76 90.63 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.213 -179.445 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.484 ' C ' ' H ' ' A' ' 30' ' ' ASN . 25.6 mm-40 -65.43 -34.87 79.31 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.146 -0.933 . . . . 0.0 110.371 -179.477 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.412 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 27.3 m -66.76 2.38 1.41 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.189 -179.742 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.484 ' H ' ' C ' ' A' ' 28' ' ' GLU . 17.5 t-20 78.24 15.28 1.38 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.59 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.553 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 4.1 m-85 -95.79 -168.62 1.8 Allowed 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 120.898 0.38 . . . . 0.0 110.343 -179.764 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -76.05 -50.13 15.62 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.987 -178.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.492 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 160.39 -176.17 37.08 Favored Glycine 0 C--O 1.226 -0.402 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 -179.148 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -146.02 168.14 27.66 Favored Glycine 0 CA--C 1.519 0.331 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 -179.41 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 14.6 ptpt -155.76 178.65 10.02 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.003 0.43 . . . . 0.0 110.81 -179.126 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 4.6 m -103.59 123.52 47.11 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.077 179.506 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 27.6 m -136.4 161.16 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.45 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.54 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 2.1 p80 -109.34 157.09 19.22 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.074 179.818 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.457 ' O ' ' N ' ' A' ' 41' ' ' GLN . 34.5 mm -107.83 125.74 64.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.174 -179.655 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 41.72 -94.4 0.01 OUTLIER Glycine 0 CA--C 1.527 0.782 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 179.694 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.457 ' N ' ' O ' ' A' ' 39' ' ' ILE . 16.6 mp0 -139.67 35.63 2.01 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.796 0.332 . . . . 0.0 110.348 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' SER . . . . . 0.529 ' O ' ' N ' ' A' ' 44' ' ' ASP . 63.7 m -87.02 2.22 50.29 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.951 -179.875 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' LEU . . . . . 0.409 ' CD2' ' C ' ' A' ' 42' ' ' SER . 1.3 pt? 34.64 28.06 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 O-C-N 123.756 0.66 . . . . 0.0 111.618 -179.583 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 42' ' ' SER . 52.5 t0 -107.78 120.42 42.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.478 -179.843 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 -88.79 117.66 27.93 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 32.5 m -115.12 142.85 26.43 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.269 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.177 -179.431 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.505 ' SG ' ' CD1' ' A' ' 11' ' ' ILE . 17.0 t -94.03 119.15 32.51 Favored 'General case' 0 CA--C 1.515 -0.396 0 CA-C-N 115.894 -0.594 . . . . 0.0 109.462 179.749 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.4 p -126.39 152.46 33.94 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.204 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.398 -179.512 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' CYS . . . . . 0.553 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 33.0 t -96.41 163.31 13.11 Favored 'General case' 0 N--CA 1.466 0.341 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 -179.771 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.484 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 19.0 m-85 -129.86 125.47 22.15 Favored Pre-proline 0 N--CA 1.469 0.497 0 C-N-CA 121.147 -0.221 . . . . 0.0 110.73 -178.738 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_endo . . . . . 0 N--CA 1.488 1.168 0 C-N-CA 121.812 1.674 . . . . 0.0 112.188 179.789 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.435 ' CB ' ' O ' ' A' ' 49' ' ' CYS . 74.2 Cg_endo . . . . . 0 N--CA 1.493 1.494 0 CA-C-O 120.548 0.145 . . . . 0.0 111.909 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.4 tt -135.55 119.68 17.66 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-O 120.764 0.316 . . . . 0.0 110.725 -179.312 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.3 tt -88.97 133.43 34.32 Favored 'General case' 0 N--CA 1.464 0.255 0 N-CA-C 109.584 -0.525 . . . . 0.0 109.584 178.238 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.477 ' CD1' ' SG ' ' A' ' 47' ' ' CYS . 2.3 pt -109.62 -46.17 6.68 Favored 'Isoleucine or valine' 0 C--O 1.231 0.11 0 CA-C-O 120.835 0.35 . . . . 0.0 110.232 -178.716 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 179.46 -159.74 24.59 Favored Glycine 0 N--CA 1.452 -0.26 0 N-CA-C 111.276 -0.73 . . . . 0.0 111.276 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 68.7 p -100.99 164.09 11.98 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.193 -0.503 . . . . 0.0 110.245 179.755 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -59.12 -11.46 3.73 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.455 179.448 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 97.0 mt -70.35 -43.73 78.08 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 CA-C-O 121.159 0.505 . . . . 0.0 110.296 -179.693 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -98.05 -31.2 12.26 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.954 -179.402 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.433 ' O ' ' O ' ' A' ' 18' ' ' PRO . 13.9 m-85 -121.11 80.47 35.33 Favored Pre-proline 0 N--CA 1.469 0.52 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 178.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.433 ' O ' ' O ' ' A' ' 17' ' ' PHE . 75.3 Cg_exo -47.05 -178.9 0.0 OUTLIER 'Trans proline' 0 N--CA 1.495 1.583 0 C-N-CA 122.794 2.329 . . . . 0.0 111.747 -179.667 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 37.4 p -58.77 -54.71 44.04 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.418 0.628 . . . . 0.0 111.536 -179.278 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.404 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 8.9 pt-20 -55.74 -52.24 64.62 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.01 -0.996 . . . . 0.0 111.216 -179.685 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -63.64 -47.36 81.67 Favored 'General case' 0 CA--C 1.519 -0.215 0 CA-C-O 121.312 0.577 . . . . 0.0 110.534 -179.623 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 36.8 t -45.44 -63.18 1.01 Allowed 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 115.12 -0.945 . . . . 0.0 111.229 -179.233 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.609 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 0.0 OUTLIER -64.36 -47.9 77.58 Favored 'General case' 0 C--O 1.221 -0.424 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.867 -178.953 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.609 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 83.4 mttt -48.73 -39.51 25.1 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.22 -179.675 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' THR . . . . . 0.434 ' O ' ' OG ' ' A' ' 29' ' ' SER . 16.7 m -64.9 -40.66 95.44 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.207 0.527 . . . . 0.0 110.112 -179.714 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.508 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 41.2 t -72.58 -36.3 68.13 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.409 0.623 . . . . 0.0 110.492 179.54 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.2 mm -64.62 -47.61 88.23 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.928 -179.097 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.446 ' C ' ' H ' ' A' ' 30' ' ' ASN . 2.9 pp20? -70.95 -27.52 63.8 Favored 'General case' 0 N--CA 1.446 -0.645 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.638 -179.504 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.477 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 72.8 m -67.17 0.66 2.55 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.611 -179.639 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.477 ' CB ' ' O ' ' A' ' 29' ' ' SER . 14.6 t-20 85.59 3.42 0.59 Allowed 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.534 179.781 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.578 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 47.5 m-85 -91.47 -167.79 1.88 Allowed 'General case' 0 N--CA 1.456 -0.169 0 CA-C-O 120.871 0.367 . . . . 0.0 110.525 179.608 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -78.34 -59.12 2.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.35 0.595 . . . . 0.0 111.756 -178.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.508 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 175.18 177.64 44.42 Favored Glycine 0 N--CA 1.449 -0.47 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -178.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -135.27 157.84 23.33 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -179.538 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 17.6 ptpt -149.62 166.96 27.71 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.915 0.388 . . . . 0.0 110.814 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 1.8 m -103.78 122.91 46.08 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.037 179.577 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 33.4 m -136.98 169.57 19.58 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.601 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.514 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 1.8 m-70 -97.45 154.04 17.74 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.116 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.464 ' O ' ' N ' ' A' ' 41' ' ' GLN . 42.2 mm -115.03 128.69 72.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 42.32 -94.41 0.01 OUTLIER Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.933 -0.867 . . . . 0.0 110.933 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.464 ' N ' ' O ' ' A' ' 39' ' ' ILE . 88.4 mt-30 -140.72 27.5 2.03 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.654 0.264 . . . . 0.0 110.672 -179.768 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 58.8 m -80.2 -9.99 59.74 Favored 'General case' 0 CA--C 1.518 -0.254 0 CA-C-O 121.012 0.434 . . . . 0.0 110.665 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' LEU . . . . . 0.403 ' O ' ' CD2' ' A' ' 43' ' ' LEU . 0.9 OUTLIER 41.92 30.85 0.19 Allowed 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.38 -179.355 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' A' ' 45' ' ' PHE . 66.2 t0 -110.24 141.17 43.57 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.139 179.877 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.521 ' N ' ' OD1' ' A' ' 44' ' ' ASP . 56.8 m-85 -88.59 116.43 26.82 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.045 0.45 . . . . 0.0 110.312 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 19.8 m -114.62 133.53 60.45 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.307 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.28 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.477 ' SG ' ' CD1' ' A' ' 11' ' ' ILE . 27.9 t -93.58 114.67 27.07 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.317 179.859 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.8 p -125.03 139.83 49.93 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.229 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.029 -178.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' CYS . . . . . 0.578 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 39.2 t -97.27 157.33 16.01 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 115.517 -0.765 . . . . 0.0 109.716 -179.687 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.431 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 0.2 OUTLIER -149.93 151.62 32.65 Favored Pre-proline 0 N--CA 1.473 0.688 0 C-N-CA 120.593 -0.443 . . . . 0.0 110.933 179.775 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_endo . . . . . 0 C--N 1.309 -1.514 0 C-N-CA 122.686 2.257 . . . . 0.0 111.956 178.851 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo . . . . . 0 N--CA 1.489 1.246 0 CA-C-O 120.757 0.232 . . . . 0.0 111.647 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.0 tt -133.74 119.75 19.69 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 120.78 0.324 . . . . 0.0 110.524 -179.751 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.8 tt -91.03 130.75 36.91 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.978 0.418 . . . . 0.0 109.947 178.326 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.514 ' CD1' ' SG ' ' A' ' 47' ' ' CYS . 5.8 pt -106.37 -44.59 7.75 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.632 -179.624 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -176.12 -133.74 1.83 Allowed Glycine 0 CA--C 1.519 0.305 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 -179.593 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.463 ' C ' ' H ' ' A' ' 15' ' ' ILE . 80.7 p -131.56 166.19 21.94 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.925 0.393 . . . . 0.0 111.034 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -61.66 -3.85 1.22 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.974 179.5 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.463 ' H ' ' C ' ' A' ' 13' ' ' THR . 34.2 mm -70.85 -42.73 77.36 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 CA-C-O 121.224 0.535 . . . . 0.0 109.92 -179.562 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -108.24 -23.07 12.09 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.628 -0.715 . . . . 0.0 111.072 -179.568 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 44.7 m-85 -124.67 79.17 63.15 Favored Pre-proline 0 C--O 1.223 -0.292 0 CA-C-N 116.577 -0.283 . . . . 0.0 110.553 179.687 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 71.4 Cg_exo -49.05 -179.01 0.01 OUTLIER 'Trans proline' 0 N--CA 1.501 1.93 0 C-N-CA 123.137 2.558 . . . . 0.0 111.733 179.457 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.454 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 96.2 m -58.22 -50.38 73.75 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 112.321 0.489 . . . . 0.0 112.321 -178.795 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.524 ' CG ' ' H ' ' A' ' 21' ' ' LYS . 6.6 pt-20 -56.57 -57.21 13.34 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.771 0.32 . . . . 0.0 111.257 -179.137 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.524 ' H ' ' CG ' ' A' ' 20' ' ' GLU . 18.7 mtmt -62.91 -44.99 94.58 Favored 'General case' 0 CA--C 1.509 -0.604 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.377 -179.718 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.409 ' O ' ' SG ' ' A' ' 26' ' ' CYS . 53.2 t -47.64 -46.43 28.81 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-O 121.233 0.54 . . . . 0.0 111.235 -178.292 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.734 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.6 p-10 -78.92 -53.11 7.39 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 120.483 -0.487 . . . . 0.0 110.39 179.305 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.734 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 29.7 mttp -50.71 -45.04 58.28 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.646 -0.422 . . . . 0.0 110.734 -178.004 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' THR . . . . . 0.403 HG21 ' O ' ' A' ' 22' ' ' CYS . 11.6 t -64.81 -37.86 89.04 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 121.391 0.615 . . . . 0.0 109.845 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.409 ' SG ' ' O ' ' A' ' 22' ' ' CYS . 54.8 m -63.61 -33.75 76.3 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.32 179.299 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.418 HG12 ' O ' ' A' ' 23' ' ' ASN . 3.3 mm -63.26 -36.86 77.75 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.054 179.728 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 29.0 mt-10 -66.1 -34.6 78.42 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.809 -178.639 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.411 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 7.1 m -72.59 -2.37 19.66 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.446 -179.173 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.411 ' CB ' ' O ' ' A' ' 29' ' ' SER . 4.5 m-80 78.31 33.68 0.3 Allowed 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.732 -179.88 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.608 ' C ' ' H ' ' A' ' 33' ' ' GLY . 8.0 m-85 -109.35 162.34 14.42 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.114 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.63 26.75 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.745 179.619 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.608 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 87.0 -174.92 46.23 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 110.739 -0.944 . . . . 0.0 110.739 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -151.67 172.04 31.12 Favored Glycine 0 CA--C 1.52 0.348 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 -179.313 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 20.0 pttt -156.27 -179.28 8.01 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.037 0.446 . . . . 0.0 110.63 -179.535 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 4.0 m -107.76 125.71 51.73 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.12 179.158 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 20.2 m -141.13 174.19 7.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.325 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.64 ' NE2' ' CE1' ' A' ' 45' ' ' PHE . 38.2 m80 -105.67 152.42 23.16 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.477 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 96.7 mt -129.8 125.58 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.477 179.497 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 66.46 21.66 70.74 Favored Glycine 0 CA--C 1.52 0.39 0 N-CA-C 111.339 -0.705 . . . . 0.0 111.339 179.126 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 58.24 38.08 26.14 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.933 0.396 . . . . 0.0 110.586 -179.818 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 44.1 m -82.26 -11.23 58.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.015 -179.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' LEU . . . . . 0.409 ' CD2' ' O ' ' A' ' 43' ' ' LEU . 0.8 OUTLIER 68.24 27.99 6.52 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.258 -179.607 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -111.7 135.49 52.23 Favored 'General case' 0 N--CA 1.463 0.188 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 179.262 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.64 ' CE1' ' NE2' ' A' ' 38' ' ' HIS . 52.6 m-85 -91.71 116.15 28.64 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 13.2 m -112.9 133.7 57.88 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.272 0 CA-C-N 115.964 -0.562 . . . . 0.0 109.807 -179.824 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.514 ' SG ' ' CD1' ' A' ' 11' ' ' ILE . 34.6 t -92.48 115.35 28.02 Favored 'General case' 0 CA--C 1.511 -0.536 0 CA-C-N 116.167 -0.47 . . . . 0.0 109.842 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.2 p -134.36 148.58 29.75 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.412 0 CA-C-O 121.118 0.485 . . . . 0.0 110.861 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 6.6 m -97.59 161.66 13.66 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.505 179.729 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 53.0 m-85 -116.84 147.96 41.09 Favored Pre-proline 0 N--CA 1.464 0.259 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.028 -179.326 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo . . . . . 0 N--CA 1.492 1.42 0 C-N-CA 122.405 2.07 . . . . 0.0 111.895 179.298 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo . . . . . 0 N--CA 1.493 1.492 0 CA-C-O 121.023 0.343 . . . . 0.0 111.947 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.41 ' C ' ' CD2' ' A' ' 9' ' ' LEU . 3.9 tt -136.67 117.31 13.91 Favored 'General case' 0 CA--C 1.52 -0.196 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.543 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.8 tt -92.8 131.95 37.4 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 179.21 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 10.2 pt -104.18 -36.9 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.281 -179.285 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -177.31 -127.62 1.07 Allowed Glycine 0 CA--C 1.517 0.163 0 N-CA-C 110.674 -0.971 . . . . 0.0 110.674 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.528 ' C ' ' H ' ' A' ' 15' ' ' ILE . 71.5 p -127.77 154.42 45.4 Favored 'General case' 0 CA--C 1.52 -0.189 0 CA-C-O 120.861 0.363 . . . . 0.0 110.479 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 6.6 t -66.3 6.67 0.39 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.521 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.528 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.7 mt -86.58 -40.97 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.138 0 CA-C-O 120.86 0.362 . . . . 0.0 110.143 -179.858 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -102.41 -5.48 24.07 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.978 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 51.2 m-85 -123.5 79.87 54.38 Favored Pre-proline 0 N--CA 1.465 0.293 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.847 179.57 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -47.77 168.01 0.09 OUTLIER 'Trans proline' 0 N--CA 1.495 1.572 0 C-N-CA 122.963 2.442 . . . . 0.0 111.866 179.164 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.436 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 10.0 m -49.78 -52.85 28.93 Favored 'General case' 0 C--N 1.326 -0.425 0 C-N-CA 120.642 -0.423 . . . . 0.0 111.62 -178.806 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.566 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 1.3 pm0 -61.91 -56.96 13.85 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.081 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -56.6 -45.13 81.6 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 121.046 0.451 . . . . 0.0 110.69 -178.201 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 12.4 t -47.75 -65.46 0.56 Allowed 'General case' 0 C--N 1.314 -0.978 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.011 -178.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.656 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 2.4 p-10 -62.51 -54.43 40.09 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.339 -179.756 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.656 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 43.8 mtpt -44.53 -43.91 8.31 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 120.546 -0.462 . . . . 0.0 110.853 -179.698 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 99.3 m -64.13 -39.62 94.42 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-O 121.495 0.664 . . . . 0.0 109.875 -179.651 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 58.5 m -67.42 -32.59 73.58 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.698 -179.681 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.3 mm -63.14 -43.63 98.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.518 -179.396 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -65.31 -35.63 81.59 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.42 -178.888 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.445 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 84.0 p -67.12 -3.41 7.43 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.459 -179.325 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.445 ' CB ' ' O ' ' A' ' 29' ' ' SER . 3.2 t-20 80.52 37.14 0.1 Allowed 'General case' 0 N--CA 1.466 0.358 0 O-C-N 123.478 0.486 . . . . 0.0 110.783 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.609 ' C ' ' H ' ' A' ' 33' ' ' GLY . 13.9 m-85 -119.54 160.7 21.91 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 120.993 0.425 . . . . 0.0 110.084 -179.843 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.428 ' N ' ' O ' ' A' ' 50' ' ' PHE . . . -68.96 27.99 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.584 -179.86 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.609 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 87.06 -172.92 44.24 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 179.829 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -154.04 174.48 32.52 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.731 -0.947 . . . . 0.0 110.731 -179.437 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 11.6 ptmt -155.89 -178.7 7.49 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.806 0.336 . . . . 0.0 110.507 -179.459 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 69.0 m -105.28 127.72 53.09 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.23 179.359 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 32.5 m -135.59 161.34 39.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.101 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 3.3 p80 -108.9 157.23 18.82 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.295 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.414 ' O ' ' N ' ' A' ' 41' ' ' GLN . 32.8 mm -104.59 122.42 57.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.328 -179.748 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 40.56 -96.47 0.01 OUTLIER Glycine 0 CA--C 1.524 0.634 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.414 ' N ' ' O ' ' A' ' 39' ' ' ILE . 97.5 mt-30 -139.65 30.47 2.1 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 120.675 0.274 . . . . 0.0 110.525 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 16.8 m -80.78 -6.22 58.21 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.138 0.494 . . . . 0.0 110.738 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 50.07 28.57 3.05 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.549 -179.702 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 38.7 t0 -109.43 120.79 43.59 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.112 179.594 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 70.6 m-85 -88.74 129.03 35.63 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-O 120.962 0.41 . . . . 0.0 109.919 -179.771 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 33.1 m -124.06 142.31 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.42 -179.359 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -95.25 119.84 34.45 Favored 'General case' 0 CA--C 1.518 -0.27 0 N-CA-C 109.211 -0.662 . . . . 0.0 109.211 -179.803 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.1 p -134.38 149.46 29.98 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.358 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.715 -179.195 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 14.1 m -98.69 177.97 5.14 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.79 179.741 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.428 ' O ' ' N ' ' A' ' 32' ' ' ALA . 45.7 m-85 -137.28 121.12 11.95 Favored Pre-proline 0 CA--C 1.537 0.461 0 C-N-CA 120.82 -0.352 . . . . 0.0 111.035 179.828 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo . . . . . 0 N--CA 1.495 1.61 0 C-N-CA 122.626 2.217 . . . . 0.0 111.916 -179.744 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo . . . . . 0 N--CA 1.491 1.325 0 N-CA-C 111.642 -0.176 . . . . 0.0 111.642 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.472 ' CD1' ' O ' ' A' ' 10' ' ' LEU . 0.4 OUTLIER -125.05 122.78 38.23 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-O 121.258 0.551 . . . . 0.0 110.798 179.781 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.472 ' O ' ' CD1' ' A' ' 9' ' ' LEU . 5.9 tt -86.01 147.7 26.09 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.45 178.371 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -126.74 -58.96 1.58 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.569 -178.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -160.2 -140.1 2.82 Favored Glycine 0 CA--C 1.519 0.294 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.35 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.471 ' C ' ' H ' ' A' ' 15' ' ' ILE . 43.5 p -131.5 160.12 36.15 Favored 'General case' 0 CA--C 1.518 -0.261 0 CA-C-O 121.006 0.431 . . . . 0.0 110.857 -179.79 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -52.63 -11.2 0.19 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.066 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.471 ' H ' ' C ' ' A' ' 13' ' ' THR . 39.0 mm -72.3 -43.12 65.45 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 CA-C-O 121.158 0.504 . . . . 0.0 110.288 -179.398 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 1.9 pt-20 -102.27 -31.36 10.58 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.39 -0.823 . . . . 0.0 110.945 -179.531 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 15.6 m-85 -120.94 82.78 36.44 Favored Pre-proline 0 N--CA 1.466 0.339 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.128 179.73 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo -48.46 -179.14 0.01 OUTLIER 'Trans proline' 0 N--CA 1.493 1.487 0 C-N-CA 122.807 2.338 . . . . 0.0 111.965 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.431 ' OG1' ' OE2' ' A' ' 20' ' ' GLU . 28.6 p -57.27 -52.31 65.84 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 120.942 0.401 . . . . 0.0 111.557 -179.336 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.572 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 0.2 OUTLIER -58.94 -57.84 11.3 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.474 -179.88 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -59.14 -43.94 92.05 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.736 -178.505 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.1 t -48.11 -60.97 2.22 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.881 -179.271 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.73 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.3 p-10 -62.59 -51.56 66.85 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.453 -179.631 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.73 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 31.7 mttp -47.36 -41.21 19.18 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.873 0.368 . . . . 0.0 110.168 -179.403 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 20.1 m -62.11 -43.9 97.81 Favored 'General case' 0 C--N 1.314 -0.939 0 C-N-CA 120.294 -0.563 . . . . 0.0 110.104 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 5.1 t -65.23 -32.68 74.48 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 179.645 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.5 mm -68.27 -31.71 52.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.538 -179.468 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.429 ' C ' ' H ' ' A' ' 30' ' ' ASN . 30.7 mm-40 -67.92 -34.99 77.68 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.762 -179.504 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.417 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 31.2 m -70.73 1.25 5.6 Favored 'General case' 0 CA--C 1.514 -0.408 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.944 -179.647 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.429 ' H ' ' C ' ' A' ' 28' ' ' GLU . 4.1 m-20 78.19 25.95 0.59 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.618 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.554 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 5.4 m-85 -103.29 -168.68 1.54 Allowed 'General case' 0 N--CA 1.452 -0.326 0 CA-C-O 120.952 0.406 . . . . 0.0 110.226 -179.744 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -76.2 -49.3 17.54 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.586 -179.596 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.496 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 160.54 -175.25 37.29 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 -179.478 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -148.03 170.4 28.67 Favored Glycine 0 C--O 1.226 -0.374 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -179.05 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 11.2 ptmt -158.68 -179.97 8.56 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.775 0.321 . . . . 0.0 110.525 -179.575 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 23.3 m -105.31 127.65 53.06 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.502 179.139 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 17.7 m -137.58 164.55 28.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.499 179.672 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.592 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 2.4 p80 -103.64 155.84 18.25 Favored 'General case' 0 N--CA 1.462 0.153 0 CA-C-O 121.002 0.429 . . . . 0.0 110.223 179.775 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.408 HD13 HG21 ' A' ' 39' ' ' ILE . 97.0 mt -131.37 128.59 61.51 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.627 -179.809 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 60.4 23.36 60.15 Favored Glycine 0 CA--C 1.52 0.35 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 179.343 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 87.5 mt-30 56.43 30.9 17.82 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 120.881 0.372 . . . . 0.0 110.573 -179.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 4.0 m -78.64 -7.2 57.41 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.767 -179.701 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 68.92 27.84 5.43 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.559 -179.641 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 40.3 t0 -107.44 118.49 36.86 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.091 179.65 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 3.3 m-30 -91.07 115.89 28.37 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-O 121.225 0.536 . . . . 0.0 109.705 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 28.3 m -113.95 142.34 26.89 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.301 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.097 -179.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 24.2 t -94.33 119.0 32.45 Favored 'General case' 0 CA--C 1.516 -0.333 0 CA-C-N 116.024 -0.535 . . . . 0.0 109.771 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 10.7 p -128.81 151.33 35.44 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.409 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.392 -179.423 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' CYS . . . . . 0.557 ' SG ' ' N ' ' A' ' 50' ' ' PHE . 33.0 t -96.52 164.83 12.45 Favored 'General case' 0 CA--C 1.514 -0.435 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 -179.634 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.557 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 37.2 m-85 -132.25 131.93 22.67 Favored Pre-proline 0 N--CA 1.465 0.284 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.136 -179.068 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo . . . . . 0 N--CA 1.489 1.237 0 C-N-CA 122.068 1.845 . . . . 0.0 112.122 179.541 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_exo . . . . . 0 N--CA 1.496 1.655 0 N-CA-C 111.783 -0.122 . . . . 0.0 111.783 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.7 tt -122.87 117.17 24.99 Favored 'General case' 0 N--CA 1.476 0.874 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.294 179.41 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.6 tt -95.11 127.48 41.19 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 179.187 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.443 HG13 ' H ' ' A' ' 12' ' ' GLY . 1.3 pt -103.51 -51.42 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-O 120.779 0.323 . . . . 0.0 110.831 -179.014 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.443 ' H ' HG13 ' A' ' 11' ' ' ILE . . . -160.27 -136.45 2.02 Favored Glycine 0 N--CA 1.451 -0.316 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -179.879 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.5 p -132.1 170.96 14.24 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.1 0.476 . . . . 0.0 110.415 -179.416 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -67.9 -1.86 6.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.332 -179.326 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 2.4 pp -78.2 -20.99 13.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.236 -179.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -131.91 -28.94 1.72 Allowed 'General case' 0 C--O 1.233 0.214 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.621 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 42.3 m-85 -116.3 81.77 11.06 Favored Pre-proline 0 CA--C 1.534 0.331 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.367 179.239 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.436 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 16.8 Cg_endo -59.35 -176.41 0.11 Allowed 'Trans proline' 0 N--CA 1.5 1.861 0 C-N-CA 122.449 2.099 . . . . 0.0 112.17 -179.644 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.444 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 83.3 m -58.89 -49.55 77.36 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.678 -0.409 . . . . 0.0 111.299 -179.347 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.533 ' CG ' ' H ' ' A' ' 21' ' ' LYS . 8.0 pt-20 -55.57 -59.59 4.62 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.616 -179.516 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.533 ' H ' ' CG ' ' A' ' 20' ' ' GLU . 17.3 mtpp -64.68 -48.39 74.92 Favored 'General case' 0 CA--C 1.512 -0.501 0 CA-C-O 121.084 0.468 . . . . 0.0 111.818 -179.43 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.436 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 34.8 t -43.02 -52.51 5.24 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.106 -177.641 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.721 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 0.8 OUTLIER -65.05 -44.51 88.78 Favored 'General case' 0 C--O 1.22 -0.474 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.783 -179.955 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.721 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 89.1 mttt -50.72 -40.79 55.15 Favored 'General case' 0 CA--C 1.509 -0.609 0 C-N-CA 120.294 -0.562 . . . . 0.0 110.321 -179.575 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' THR . . . . . 0.604 ' HG1' ' N ' ' A' ' 26' ' ' CYS . 70.0 p -63.2 -41.53 99.18 Favored 'General case' 0 C--N 1.313 -1.0 0 C-N-CA 119.179 -1.008 . . . . 0.0 110.376 -179.079 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.604 ' N ' ' HG1' ' A' ' 25' ' ' THR . 19.5 t -68.09 -34.1 75.76 Favored 'General case' 0 C--N 1.322 -0.587 0 C-N-CA 120.176 -0.61 . . . . 0.0 109.896 179.733 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.3 mm -66.3 -41.55 89.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.72 -179.258 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.46 ' C ' ' H ' ' A' ' 30' ' ' ASN . 40.2 mm-40 -64.13 -34.97 79.27 Favored 'General case' 0 N--CA 1.444 -0.746 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.654 -179.409 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.414 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 78.1 p -68.44 1.92 2.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.221 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.46 ' H ' ' C ' ' A' ' 28' ' ' GLU . 16.4 t-20 78.05 19.67 1.04 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.623 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.552 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 4.5 m-85 -98.32 -168.23 1.62 Allowed 'General case' 0 CA--C 1.53 0.191 0 CA-C-O 120.938 0.399 . . . . 0.0 110.351 -179.833 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -74.93 -53.26 9.32 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.791 -179.01 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.524 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 165.42 -178.51 40.3 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.151 -1.179 . . . . 0.0 110.151 -179.251 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.405 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -141.07 167.85 25.54 Favored Glycine 0 CA--C 1.519 0.293 0 N-CA-C 111.274 -0.73 . . . . 0.0 111.274 -179.219 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 15.0 ptpt -158.09 178.06 10.62 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.095 0.474 . . . . 0.0 110.401 -179.311 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 3.2 m -105.39 120.3 41.24 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.866 179.159 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 33.0 m -132.17 161.22 41.75 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.102 -179.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.496 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 3.2 p80 -107.07 157.14 18.06 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.184 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.512 ' O ' ' N ' ' A' ' 41' ' ' GLN . 33.2 mm -106.46 124.79 62.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.049 -179.549 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 43.34 -91.12 0.01 OUTLIER Glycine 0 C--N 1.33 0.205 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.512 ' N ' ' O ' ' A' ' 39' ' ' ILE . 42.0 tp60 -148.46 37.66 0.84 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.812 0.339 . . . . 0.0 110.436 -179.577 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 71.0 m -87.98 -2.39 58.58 Favored 'General case' 0 CA--C 1.519 -0.235 0 CA-C-O 121.042 0.449 . . . . 0.0 110.613 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 45.81 28.99 0.64 Allowed 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.551 179.522 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 68.3 t0 -108.88 119.32 39.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.919 179.455 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 81.3 m-85 -88.56 118.45 28.22 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.721 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 31.1 m -114.88 143.05 25.46 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.35 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.259 -179.406 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.414 ' SG ' ' CD1' ' A' ' 11' ' ' ILE . 18.4 t -94.07 117.88 30.73 Favored 'General case' 0 CA--C 1.513 -0.455 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.459 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.7 p -129.07 152.96 37.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-O 120.708 0.29 . . . . 0.0 110.306 -179.689 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' CYS . . . . . 0.552 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 17.2 t -96.83 164.94 12.34 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.547 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 38.1 m-85 -132.34 136.31 27.82 Favored Pre-proline 0 N--CA 1.468 0.474 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.842 -179.319 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo . . . . . 0 N--CA 1.495 1.571 0 C-N-CA 121.945 1.763 . . . . 0.0 112.391 179.903 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo . . . . . 0 N--CA 1.494 1.539 0 CA-C-O 120.699 0.208 . . . . 0.0 111.885 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.404 ' CD2' ' C ' ' A' ' 9' ' ' LEU . 3.8 tt -138.3 118.02 13.14 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.273 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.8 tt -92.68 130.87 38.18 Favored 'General case' 0 N--CA 1.465 0.305 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 178.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.474 ' CD1' ' SG ' ' A' ' 47' ' ' CYS . 1.5 pt -107.09 -50.18 7.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-O 120.917 0.389 . . . . 0.0 110.294 -178.78 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.402 ' H ' HG13 ' A' ' 11' ' ' ILE . . . -163.35 -162.99 15.04 Favored Glycine 0 N--CA 1.449 -0.491 0 N-CA-C 110.754 -0.938 . . . . 0.0 110.754 179.689 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.403 ' C ' ' H ' ' A' ' 15' ' ' ILE . 7.5 p -83.93 163.07 20.24 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.829 0.347 . . . . 0.0 110.12 -179.792 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 48.3 t -71.2 2.79 4.18 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.331 179.703 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.403 ' H ' ' C ' ' A' ' 13' ' ' THR . 86.8 mt -91.08 -52.48 10.26 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.217 0 CA-C-N 116.234 -0.439 . . . . 0.0 109.826 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . 0.464 ' OE1' ' CE2' ' A' ' 17' ' ' PHE . 7.5 pt-20 -70.82 -35.45 72.5 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.16 179.113 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.464 ' CE2' ' OE1' ' A' ' 16' ' ' GLU . 59.9 m-85 -114.96 104.61 53.94 Favored Pre-proline 0 CA--C 1.544 0.738 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.44 179.92 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.457 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 56.9 Cg_endo -74.23 -179.8 5.08 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 C-N-CA 123.043 2.495 . . . . 0.0 111.752 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 70.8 m -57.38 -49.12 77.18 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.576 -179.613 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.49 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 6.7 pt-20 -54.63 -58.24 8.27 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.574 -0.285 . . . . 0.0 111.592 -179.477 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.414 ' H ' ' CG ' ' A' ' 20' ' ' GLU . 5.7 ttmt -67.44 -56.65 8.74 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.385 0.612 . . . . 0.0 111.606 -179.145 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.457 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 48.1 t -38.64 -61.51 0.7 Allowed 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.241 -0.89 . . . . 0.0 111.4 -178.786 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.625 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 0.0 OUTLIER -63.42 -49.09 75.13 Favored 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.435 -179.874 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.625 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 51.3 mttm -47.46 -37.73 12.26 Favored 'General case' 0 CA--C 1.515 -0.399 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.218 -179.721 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 98.4 m -63.8 -41.74 97.84 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.342 0.591 . . . . 0.0 109.775 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.452 ' SG ' ' C ' ' A' ' 33' ' ' GLY . 40.2 t -72.13 -34.71 68.76 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.585 0.707 . . . . 0.0 109.999 179.311 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.5 mm -65.33 -48.08 84.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.144 -179.282 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.507 ' C ' ' H ' ' A' ' 30' ' ' ASN . 3.0 pp20? -70.31 -29.01 65.63 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.554 -179.656 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.452 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 24.4 m -65.2 0.89 1.17 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.198 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.507 ' H ' ' C ' ' A' ' 28' ' ' GLU . 7.4 t-20 81.05 14.53 0.64 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.435 179.804 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.569 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 5.2 m-85 -100.19 -167.72 1.49 Allowed 'General case' 0 C--N 1.339 0.144 0 CA-C-O 120.76 0.314 . . . . 0.0 110.204 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -76.18 -55.38 5.63 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.141 0.496 . . . . 0.0 111.859 -179.196 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.452 ' C ' ' SG ' ' A' ' 26' ' ' CYS . . . 168.56 173.29 36.27 Favored Glycine 0 CA--C 1.519 0.337 0 N-CA-C 110.318 -1.113 . . . . 0.0 110.318 -179.135 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -134.59 161.02 24.42 Favored Glycine 0 N--CA 1.46 0.237 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 -179.341 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 2.1 ptmm? -160.06 -174.77 4.72 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.966 0.412 . . . . 0.0 110.69 -178.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 30.7 m -104.67 120.09 40.52 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.831 179.361 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 2.6 m -137.79 166.29 24.65 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-O 121.113 0.482 . . . . 0.0 110.896 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.702 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 0.1 OUTLIER -108.85 157.29 18.74 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.403 179.291 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 83.9 mt -122.58 128.64 75.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.551 -179.358 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 52.85 -126.1 31.84 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.481 -1.048 . . . . 0.0 110.481 179.766 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -111.33 27.64 9.48 Favored 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 110.381 -0.229 . . . . 0.0 110.381 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' SER . . . . . 0.497 ' O ' ' N ' ' A' ' 44' ' ' ASP . 52.0 m -85.14 -11.26 55.53 Favored 'General case' 0 CA--C 1.52 -0.199 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.914 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 36.79 28.26 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.063 -179.687 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . 0.497 ' N ' ' O ' ' A' ' 42' ' ' SER . 45.1 t0 -99.78 124.47 45.09 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.278 -179.903 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -85.72 124.55 32.36 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 -179.65 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 32.6 m -129.9 153.76 39.35 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.444 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.145 -179.348 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.474 ' SG ' ' CD1' ' A' ' 11' ' ' ILE . 34.9 t -93.75 116.43 28.91 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.436 -179.77 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.9 p -131.64 154.39 40.32 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.325 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.499 -178.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' CYS . . . . . 0.572 ' SG ' ' N ' ' A' ' 50' ' ' PHE . 16.4 t -97.42 164.49 12.43 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 179.833 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.572 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 29.6 m-85 -130.7 121.79 19.29 Favored Pre-proline 0 N--CA 1.465 0.321 0 C-N-CA 120.931 -0.307 . . . . 0.0 111.247 -178.68 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo . . . . . 0 N--CA 1.491 1.343 0 C-N-CA 121.721 1.614 . . . . 0.0 112.058 179.274 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo . . . . . 0 N--CA 1.494 1.535 0 N-CA-C 111.21 -0.342 . . . . 0.0 111.21 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.402 ' CD2' ' C ' ' A' ' 9' ' ' LEU . 4.0 tt -132.38 119.23 20.41 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.265 -179.615 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.7 tt -93.5 127.33 39.1 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 178.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.494 ' CD1' ' SG ' ' A' ' 47' ' ' CYS . 3.1 pt -103.38 -46.14 10.32 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.412 -179.036 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -170.06 -138.01 2.4 Favored Glycine 0 CA--C 1.521 0.451 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.516 ' C ' ' H ' ' A' ' 15' ' ' ILE . 70.0 p -133.21 163.73 28.63 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.843 0.354 . . . . 0.0 110.902 -179.437 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -57.87 -4.79 0.34 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.97 179.674 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.516 ' H ' ' C ' ' A' ' 13' ' ' THR . 95.8 mt -73.24 -24.18 20.43 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 CA-C-O 121.01 0.433 . . . . 0.0 110.136 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -130.55 -32.06 1.75 Allowed 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.741 -179.614 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 53.7 m-85 -114.65 88.88 17.07 Favored Pre-proline 0 CA--C 1.54 0.568 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 179.36 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.455 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 43.4 Cg_endo -70.17 -178.04 2.31 Favored 'Trans proline' 0 N--CA 1.499 1.809 0 C-N-CA 122.91 2.406 . . . . 0.0 111.968 -179.509 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.455 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 7.1 m -45.93 -68.62 0.18 Allowed 'General case' 0 C--N 1.319 -0.757 0 C-N-CA 120.826 -0.35 . . . . 0.0 111.442 -179.275 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.571 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 0.0 OUTLIER -44.36 -68.14 0.22 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.46 -0.337 . . . . 0.0 111.718 -178.794 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 6.9 ttmt -54.66 -51.63 64.86 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.039 0.447 . . . . 0.0 111.562 -178.043 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.455 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 45.3 t -46.03 -64.97 0.62 Allowed 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.368 -179.3 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.71 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 0.8 OUTLIER -61.86 -45.16 94.99 Favored 'General case' 0 C--O 1.22 -0.464 0 C-N-CA 120.721 -0.392 . . . . 0.0 110.478 -179.814 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.71 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 86.9 mttt -51.06 -37.08 43.35 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.443 -0.503 . . . . 0.0 109.852 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 13.4 m -64.36 -41.61 96.64 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.354 0.597 . . . . 0.0 110.352 -179.831 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.488 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 37.8 t -72.73 -34.91 67.39 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.029 179.467 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.2 mm -66.14 -47.68 83.94 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.571 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.884 -179.227 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.498 ' C ' ' H ' ' A' ' 30' ' ' ASN . 3.0 pp20? -70.21 -28.35 65.21 Favored 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.285 -179.413 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.465 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 56.1 m -66.25 1.05 1.71 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.051 -179.863 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.498 ' H ' ' C ' ' A' ' 28' ' ' GLU . 8.7 t-20 82.51 11.04 0.61 Allowed 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.406 179.858 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.552 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 23.0 m-85 -99.47 -171.22 2.03 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-O 121.036 0.445 . . . . 0.0 111.188 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -71.33 -59.91 2.51 Favored 'General case' 0 CA--C 1.532 0.254 0 CA-C-N 115.756 -0.657 . . . . 0.0 111.857 -179.03 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.488 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 172.39 176.8 41.4 Favored Glycine 0 CA--C 1.52 0.377 0 N-CA-C 110.345 -1.102 . . . . 0.0 110.345 -179.104 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -137.0 166.66 24.86 Favored Glycine 0 N--CA 1.462 0.402 0 N-CA-C 111.233 -0.747 . . . . 0.0 111.233 -179.529 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 12.2 ptmt -159.4 178.45 9.92 Favored 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.771 -179.393 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 1.4 m -106.5 127.71 53.52 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.008 178.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 28.8 m -134.41 159.75 41.84 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.247 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.32 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.713 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 0.1 OUTLIER -104.84 154.67 19.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.265 179.89 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.495 ' O ' ' N ' ' A' ' 41' ' ' GLN . 31.2 mm -107.01 128.02 62.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.361 -179.347 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 41.78 -91.56 0.01 OUTLIER Glycine 0 CA--C 1.525 0.711 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.495 ' N ' ' O ' ' A' ' 39' ' ' ILE . 40.6 tt0 -143.22 22.69 1.87 Allowed 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 121.039 0.447 . . . . 0.0 110.252 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 58.4 m -78.57 -9.45 59.36 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.079 0.466 . . . . 0.0 110.265 179.559 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' LEU . . . . . 0.416 ' CD2' ' O ' ' A' ' 43' ' ' LEU . 0.9 OUTLIER 47.03 30.42 1.28 Allowed 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.28 -179.715 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 67.8 t0 -98.78 119.91 38.32 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.597 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 58.1 m-85 -84.44 117.5 23.68 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.026 0.441 . . . . 0.0 110.342 -179.33 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 32.6 m -113.38 136.18 50.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.5 -179.454 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' CD1' ' A' ' 11' ' ' ILE . 27.4 t -93.03 115.4 28.08 Favored 'General case' 0 CA--C 1.514 -0.434 0 N-CA-C 109.284 -0.635 . . . . 0.0 109.284 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.5 p -130.88 150.41 34.58 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.261 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.8 -178.774 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' CYS . . . . . 0.552 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 23.6 t -96.82 162.9 13.22 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.529 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 33.7 m-85 -120.91 136.82 25.85 Favored Pre-proline 0 N--CA 1.47 0.541 0 C-N-CA 120.906 -0.318 . . . . 0.0 110.99 -178.85 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo . . . . . 0 N--CA 1.492 1.396 0 C-N-CA 121.759 1.64 . . . . 0.0 112.753 179.519 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo . . . . . 0 N--CA 1.494 1.511 0 N-CA-C 111.586 -0.198 . . . . 0.0 111.586 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.3 tt -133.67 120.89 21.21 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 120.568 0.223 . . . . 0.0 110.439 -179.008 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.8 tt -87.68 134.56 33.63 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 178.535 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 13.2 pt -109.04 -35.0 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 120.934 0.397 . . . . 0.0 110.8 -178.702 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 175.69 -150.0 10.49 Favored Glycine 0 N--CA 1.451 -0.358 0 N-CA-C 110.794 -0.923 . . . . 0.0 110.794 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.47 ' C ' ' H ' ' A' ' 15' ' ' ILE . 42.0 p -98.8 160.66 14.12 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.83 0.347 . . . . 0.0 110.235 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 9.2 t -72.04 6.99 1.81 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.171 179.818 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.47 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.8 mt -91.42 -44.39 14.4 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.199 0 CA-C-N 116.053 -0.522 . . . . 0.0 109.949 179.785 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -87.46 -20.59 26.37 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.735 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 60.1 m-85 -120.69 99.08 47.66 Favored Pre-proline 0 CA--C 1.546 0.796 0 CA-C-N 116.732 -0.213 . . . . 0.0 110.595 179.515 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.409 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 36.4 Cg_endo -71.68 173.23 12.92 Favored 'Trans proline' 0 N--CA 1.493 1.495 0 C-N-CA 122.579 2.186 . . . . 0.0 111.288 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.48 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 10.0 m -47.67 -50.56 24.41 Favored 'General case' 0 C--N 1.319 -0.736 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.712 -179.242 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.539 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 0.5 OUTLIER -56.34 -68.33 0.22 Allowed 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 112.293 0.479 . . . . 0.0 112.293 -179.13 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 6.9 ttmt -57.95 -46.37 85.18 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 121.362 0.601 . . . . 0.0 111.551 -178.126 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.409 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 49.0 t -47.58 -65.03 0.63 Allowed 'General case' 0 C--N 1.308 -1.231 0 CA-C-N 115.311 -0.859 . . . . 0.0 111.465 -178.64 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.717 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 0.4 OUTLIER -65.39 -43.73 89.75 Favored 'General case' 0 C--O 1.222 -0.375 0 C-N-CA 120.4 -0.52 . . . . 0.0 110.893 -179.944 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.717 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 48.8 mttp -52.5 -39.68 61.54 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 120.19 -0.604 . . . . 0.0 109.909 179.826 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 91.6 m -62.62 -43.69 98.18 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.741 -179.438 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.521 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 16.6 t -66.14 -34.93 79.17 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.017 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.3 mm -66.17 -37.77 80.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.717 0 CA-C-N 114.937 -1.029 . . . . 0.0 110.113 179.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.448 ' C ' ' H ' ' A' ' 30' ' ' ASN . 34.3 mm-40 -64.09 -37.54 87.8 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.973 -1.012 . . . . 0.0 110.155 -179.369 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 35.9 m -69.46 0.59 4.98 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.834 179.638 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.448 ' H ' ' C ' ' A' ' 28' ' ' GLU . 18.2 t-20 76.7 21.15 1.28 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.508 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.532 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 3.8 m-85 -96.16 -166.93 1.5 Allowed 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 120.811 0.339 . . . . 0.0 110.493 -179.88 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.61 -51.42 16.89 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 116.076 -0.511 . . . . 0.0 112.113 -178.68 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.521 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 161.59 -179.87 36.71 Favored Glycine 0 CA--C 1.519 0.323 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 -179.036 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -132.49 157.42 22.53 Favored Glycine 0 CA--C 1.52 0.351 0 N-CA-C 111.417 -0.673 . . . . 0.0 111.417 -179.181 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 16.2 ptpt -154.27 168.78 25.44 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.41 -0.395 . . . . 0.0 110.506 -179.319 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 37.8 m -103.86 124.29 48.68 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.042 179.609 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 36.0 m -136.6 161.39 36.69 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-O 120.758 0.313 . . . . 0.0 110.9 -179.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.452 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 2.3 p80 -90.07 155.04 19.34 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.326 179.55 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 40.4 mm -110.66 121.6 63.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.816 -179.672 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 46.63 27.74 3.24 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 179.074 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 12.6 mm100 62.72 35.69 13.82 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.943 0.401 . . . . 0.0 110.242 -179.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' SER . . . . . 0.422 ' O ' ' CB ' ' A' ' 43' ' ' LEU . 63.6 m -83.39 -7.93 59.48 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.883 -179.901 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' LEU . . . . . 0.422 ' CB ' ' O ' ' A' ' 42' ' ' SER . 0.9 OUTLIER 73.82 27.33 1.7 Allowed 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.239 0.542 . . . . 0.0 109.782 -179.523 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 36.0 t0 -111.74 117.05 31.79 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 178.547 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -91.42 120.61 32.42 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.241 0.543 . . . . 0.0 109.915 -179.819 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 33.5 m -123.5 140.13 47.99 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.449 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.079 -179.573 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -94.47 121.35 35.93 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.19 -179.727 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.2 p -134.35 151.87 32.82 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.312 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.844 -178.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' CYS . . . . . 0.532 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 28.4 t -93.9 161.89 14.13 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 -179.421 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.445 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 51.3 m-85 -127.93 142.52 44.64 Favored Pre-proline 0 N--CA 1.47 0.538 0 C-N-CA 120.619 -0.432 . . . . 0.0 111.359 -178.356 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo . . . . . 0 N--CA 1.494 1.528 0 C-N-CA 122.016 1.811 . . . . 0.0 112.219 179.636 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo . . . . . 0 N--CA 1.496 1.63 0 N-CA-C 111.416 -0.263 . . . . 0.0 111.416 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.8 tt -120.33 118.21 29.79 Favored 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.713 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.435 ' CD1' ' C ' ' A' ' 10' ' ' LEU . 2.7 tm? -89.04 124.99 34.81 Favored 'General case' 0 CA--C 1.522 -0.132 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.547 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 14.9 pt -105.59 -35.58 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.159 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.811 -179.131 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 176.92 -135.46 2.83 Favored Glycine 0 CA--C 1.522 0.5 0 N-CA-C 111.146 -0.781 . . . . 0.0 111.146 -179.873 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.42 ' C ' ' H ' ' A' ' 15' ' ' ILE . 68.0 p -132.92 161.73 33.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.94 0.4 . . . . 0.0 110.512 -179.629 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -55.91 -9.35 0.57 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.764 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.42 ' H ' ' C ' ' A' ' 13' ' ' THR . 6.2 mm -71.94 -43.13 68.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 C-N-CA 120.5 -0.48 . . . . 0.0 110.59 -179.313 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -99.75 -23.51 14.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.106 -179.429 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -119.54 83.09 26.53 Favored Pre-proline 0 N--CA 1.463 0.189 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.033 179.583 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -53.29 165.89 1.3 Allowed 'Trans proline' 0 N--CA 1.491 1.367 0 C-N-CA 122.495 2.13 . . . . 0.0 110.582 178.553 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.448 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 36.0 p -45.61 -58.94 3.04 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-O 120.852 0.358 . . . . 0.0 111.701 -178.601 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.443 ' HG3' ' H ' ' A' ' 21' ' ' LYS . 6.6 pt-20 -46.01 -60.04 2.49 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.934 -179.385 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.443 ' H ' ' HG3' ' A' ' 20' ' ' GLU . 17.8 mtmt -63.73 -45.79 88.31 Favored 'General case' 0 CA--C 1.51 -0.583 0 CA-C-O 121.105 0.478 . . . . 0.0 111.299 -179.784 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 17.9 t -44.47 -62.61 1.12 Allowed 'General case' 0 C--N 1.31 -1.138 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.351 -178.396 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.693 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.8 p-10 -64.1 -50.48 68.12 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.866 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.693 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 41.2 mttm -48.99 -35.94 16.45 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -179.586 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' THR . . . . . 0.43 ' OG1' ' O ' ' A' ' 21' ' ' LYS . 19.4 m -63.52 -42.26 98.47 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.192 -179.898 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.491 ' SG ' ' C ' ' A' ' 33' ' ' GLY . 32.9 t -73.42 -36.9 66.03 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.537 0.684 . . . . 0.0 110.016 178.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.3 mm -64.65 -47.42 88.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.996 -178.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.478 ' C ' ' H ' ' A' ' 30' ' ' ASN . 2.9 pp20? -71.22 -23.26 61.98 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.756 -179.485 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 39.5 m -71.6 3.71 3.74 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.52 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.478 ' H ' ' C ' ' A' ' 28' ' ' GLU . 2.2 m120 77.59 22.26 0.92 Allowed 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.913 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.554 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 31.1 m-85 -111.25 -167.91 1.24 Allowed 'General case' 0 N--CA 1.455 -0.178 0 CA-C-O 120.82 0.343 . . . . 0.0 111.006 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -74.1 -58.36 3.35 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.94 -0.573 . . . . 0.0 112.239 -178.417 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.491 ' C ' ' SG ' ' A' ' 26' ' ' CYS . . . 172.8 170.63 36.74 Favored Glycine 0 CA--C 1.521 0.465 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -178.85 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.43 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -122.42 159.97 16.94 Favored Glycine 0 N--CA 1.463 0.458 0 N-CA-C 111.186 -0.765 . . . . 0.0 111.186 -178.812 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 16.2 ptpt -155.34 166.38 33.72 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.05 0.452 . . . . 0.0 110.695 -179.558 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.504 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 4.5 m -106.35 123.69 48.44 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.354 179.522 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 32.9 m -137.08 160.77 36.16 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.464 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.689 179.796 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.523 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 8.8 p80 -89.64 157.15 18.14 Favored 'General case' 0 CA--C 1.521 -0.153 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.295 179.488 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.419 ' O ' ' OG ' ' A' ' 42' ' ' SER . 5.7 mm -117.97 129.25 74.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.778 -179.467 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 46.01 22.18 0.79 Allowed Glycine 0 C--O 1.228 -0.233 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 179.328 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.4 ' N ' ' C ' ' A' ' 39' ' ' ILE . 39.6 tt0 69.78 36.75 1.99 Allowed 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.062 0.458 . . . . 0.0 110.175 -179.753 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' SER . . . . . 0.419 ' OG ' ' O ' ' A' ' 39' ' ' ILE . 5.1 m -86.45 1.46 51.32 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.155 179.79 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER 57.16 26.89 12.69 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.526 -179.379 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 55.0 t0 -106.39 119.13 38.45 Favored 'General case' 0 N--CA 1.466 0.361 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 178.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 -85.12 115.68 23.06 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 121.181 0.515 . . . . 0.0 110.325 -179.112 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 11.6 m -111.18 134.57 53.08 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.262 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.19 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 0.8 OUTLIER -94.38 112.8 24.59 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.172 -179.792 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 4.8 p -129.58 155.0 41.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.306 -179.289 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' CYS . . . . . 0.587 ' SG ' ' N ' ' A' ' 50' ' ' PHE . 19.5 t -96.56 166.48 11.66 Favored 'General case' 0 N--CA 1.465 0.312 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.587 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 29.1 m-85 -126.92 117.88 22.25 Favored Pre-proline 0 N--CA 1.469 0.483 0 C-N-CA 121.028 -0.269 . . . . 0.0 110.745 -178.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_exo . . . . . 0 N--CA 1.486 1.083 0 C-N-CA 121.491 1.46 . . . . 0.0 112.27 179.218 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 72.4 mmtt . . . . . 0 N--CA 1.488 1.439 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.441 ' OD1' ' N ' ' A' ' 2' ' ' ASP . 29.1 p-10 -91.59 10.59 27.37 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.623 -179.874 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 27.2 mm -74.55 121.4 25.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.289 -179.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 65.0 t0 -64.06 -45.98 86.39 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.214 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 42.34 80.64 0.04 OUTLIER Glycine 0 CA--C 1.52 0.371 0 N-CA-C 111.15 -0.78 . . . . 0.0 111.15 179.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 2.7 ppt_? -133.47 38.13 3.29 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 111.952 0.352 . . . . 0.0 111.952 -179.084 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.59 ' NZ ' ' CE1' ' A' ' 54' ' ' TYR . 12.2 ptmt -128.54 78.74 75.39 Favored Pre-proline 0 N--CA 1.472 0.648 0 CA-C-O 121.173 0.511 . . . . 0.0 111.326 179.876 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_exo -61.5 145.04 98.26 Favored 'Trans proline' 0 C--N 1.303 -1.829 0 C-N-CA 122.256 1.971 . . . . 0.0 111.406 179.273 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 2.9 tt -116.68 118.66 33.18 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-O 120.626 0.25 . . . . 0.0 110.493 -179.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.4 tt -90.08 131.18 36.09 Favored 'General case' 0 N--CA 1.464 0.275 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 178.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.482 ' CD1' ' SG ' ' A' ' 47' ' ' CYS . 1.9 pt -108.67 -45.17 6.85 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 120.964 0.412 . . . . 0.0 110.415 -178.669 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -163.68 -176.38 35.55 Favored Glycine 0 N--CA 1.45 -0.421 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.54 ' C ' ' H ' ' A' ' 15' ' ' ILE . 13.6 m -86.65 137.3 32.58 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 8.7 t -46.93 -12.29 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 120.832 -0.347 . . . . 0.0 110.794 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.54 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.6 mt -69.86 -44.3 78.95 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.287 0 CA-C-O 121.364 0.602 . . . . 0.0 110.487 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -88.09 -29.69 20.44 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-N 115.223 -0.899 . . . . 0.0 110.514 -179.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 53.0 m-85 -124.85 84.05 58.84 Favored Pre-proline 0 N--CA 1.465 0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.815 179.564 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -53.08 -177.0 0.03 OUTLIER 'Trans proline' 0 N--CA 1.498 1.743 0 C-N-CA 122.959 2.44 . . . . 0.0 111.609 179.26 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.454 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 97.8 m -58.22 -49.71 76.12 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 112.547 0.573 . . . . 0.0 112.547 -178.275 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.534 ' CG ' ' H ' ' A' ' 21' ' ' LYS . 9.0 pt-20 -56.14 -58.18 9.04 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 111.767 0.284 . . . . 0.0 111.767 -178.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.534 ' H ' ' CG ' ' A' ' 20' ' ' GLU . 15.4 mtmt -64.11 -44.72 91.39 Favored 'General case' 0 CA--C 1.51 -0.569 0 CA-C-O 121.221 0.534 . . . . 0.0 111.522 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 28.9 t -44.7 -57.67 3.54 Favored 'General case' 0 C--N 1.312 -1.058 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.757 -177.778 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.693 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.7 p-10 -64.22 -50.73 66.89 Favored 'General case' 0 C--O 1.218 -0.587 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.375 -179.559 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.693 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 70.7 mttt -50.18 -42.12 50.66 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 -179.656 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 15.5 m -64.51 -39.16 93.26 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.645 0.736 . . . . 0.0 109.607 179.115 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.438 ' O ' ' OG ' ' A' ' 29' ' ' SER . 73.0 m -68.76 -31.51 70.6 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.149 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.404 HG12 ' O ' ' A' ' 23' ' ' ASN . 3.0 mm -64.39 -47.03 91.25 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.506 0 CA-C-O 121.087 0.47 . . . . 0.0 110.914 -179.512 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -70.14 -22.25 63.01 Favored 'General case' 0 N--CA 1.447 -0.622 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.872 -179.246 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.438 ' OG ' ' O ' ' A' ' 26' ' ' CYS . 59.8 p -74.81 -2.07 25.0 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 179.55 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 77.66 27.92 0.58 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.168 -0.923 . . . . 0.0 110.725 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.582 ' C ' ' H ' ' A' ' 33' ' ' GLY . 5.5 m-85 -110.96 162.32 14.95 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.74 -179.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.65 32.85 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.664 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.582 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 81.43 -173.96 54.24 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 -179.743 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -153.65 177.25 31.28 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 -179.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 17.0 ptpt -154.06 177.65 10.84 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.942 0.401 . . . . 0.0 110.784 -179.352 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 67.3 m -104.69 117.76 34.9 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.011 179.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 27.1 m -136.31 159.5 38.37 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-O 120.902 0.382 . . . . 0.0 110.865 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.685 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 0.1 OUTLIER -91.07 157.76 17.05 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.47 179.626 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 39.2 mm -105.85 126.92 61.23 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.18 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.451 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 41.02 -98.47 0.01 OUTLIER Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 179.651 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 40.3 tt0 -135.83 21.49 3.3 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 120.986 0.422 . . . . 0.0 109.957 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 58.1 m -79.65 -8.71 59.38 Favored 'General case' 0 CA--C 1.515 -0.397 0 CA-C-O 121.127 0.489 . . . . 0.0 110.418 179.564 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . 0.405 ' CD2' ' O ' ' A' ' 43' ' ' LEU . 0.9 OUTLIER 47.12 29.62 1.17 Allowed 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.246 -179.651 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -102.79 119.54 39.02 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 178.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -81.13 132.77 35.38 Favored 'General case' 0 CA--C 1.517 -0.326 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 -179.349 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 35.2 m -134.96 152.39 32.71 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.404 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.547 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.482 ' SG ' ' CD1' ' A' ' 11' ' ' ILE . 41.0 t -94.34 113.76 25.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.626 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.1 p -126.05 137.9 56.28 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.19 0 CA-C-O 121.001 0.429 . . . . 0.0 110.604 -179.388 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 8.3 m -97.44 165.05 12.19 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.784 -179.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 42.5 m-85 -117.39 145.79 36.92 Favored Pre-proline 0 N--CA 1.47 0.537 0 CA-C-N 116.742 -0.208 . . . . 0.0 111.256 -179.11 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -63.75 149.46 90.75 Favored 'Trans proline' 0 N--CA 1.496 1.658 0 C-N-CA 122.57 2.18 . . . . 0.0 112.077 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 13.5 tppt? -143.52 -43.6 0.28 Allowed 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.284 179.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -110.01 21.63 16.59 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.752 -179.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . 0.59 ' CE1' ' NZ ' ' A' ' 7' ' ' LYS . 62.1 t80 -82.48 98.21 8.8 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.784 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 49.7 mt . . . . . 0 C--O 1.22 -0.459 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.193 -179.73 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . 0.581 ' C ' ' H ' ' A' ' 3' ' ' ILE . 68.7 mttm . . . . . 0 N--CA 1.489 1.5 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -55.92 -2.73 0.06 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.456 179.764 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.581 ' H ' ' C ' ' A' ' 1' ' ' LYS . 4.0 mm -63.63 129.33 27.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 120.991 0.424 . . . . 0.0 109.9 -179.67 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 41.4 t0 -66.78 -27.8 67.87 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.436 179.73 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.13 70.21 1.85 Allowed Glycine 0 C--N 1.332 0.329 0 N-CA-C 111.066 -0.814 . . . . 0.0 111.066 -179.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 3.1 ppt_? -130.85 30.65 4.59 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.58 0.229 . . . . 0.0 110.457 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -126.68 150.03 69.96 Favored Pre-proline 0 N--CA 1.464 0.248 0 CA-C-N 116.662 -0.245 . . . . 0.0 110.866 -179.643 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -57.3 140.67 93.65 Favored 'Trans proline' 0 N--CA 1.491 1.354 0 C-N-CA 121.824 1.683 . . . . 0.0 111.691 179.849 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.6 tt -121.53 119.68 32.67 Favored 'General case' 0 N--CA 1.474 0.748 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.562 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.8 tt -92.29 125.54 36.99 Favored 'General case' 0 N--CA 1.464 0.269 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 178.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.512 ' CD1' ' SG ' ' A' ' 47' ' ' CYS . 2.6 pt -102.54 -48.3 10.86 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.667 -179.056 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.417 ' H ' HG13 ' A' ' 11' ' ' ILE . . . -167.72 -138.29 2.42 Favored Glycine 0 N--CA 1.45 -0.398 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.525 ' C ' ' H ' ' A' ' 15' ' ' ILE . 43.1 p -132.62 159.01 40.79 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.085 0.469 . . . . 0.0 110.847 -179.697 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -56.12 -5.56 0.19 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.051 179.786 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.525 ' H ' ' C ' ' A' ' 13' ' ' THR . 84.6 mt -75.94 -26.5 17.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.883 0.373 . . . . 0.0 110.723 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -124.47 -27.69 3.71 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.063 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -122.62 80.57 47.75 Favored Pre-proline 0 C--O 1.233 0.187 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.335 179.206 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_exo -53.0 179.33 0.04 OUTLIER 'Trans proline' 0 N--CA 1.495 1.563 0 C-N-CA 122.787 2.325 . . . . 0.0 111.141 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.467 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 30.5 p -53.74 -61.28 2.4 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 121.074 0.464 . . . . 0.0 111.995 -179.802 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.457 ' HG3' ' H ' ' A' ' 21' ' ' LYS . 5.4 pt-20 -43.8 -59.41 2.25 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.387 -178.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.457 ' H ' ' HG3' ' A' ' 20' ' ' GLU . 19.8 mtmt -64.43 -46.15 84.42 Favored 'General case' 0 CA--C 1.509 -0.608 0 CA-C-O 121.201 0.524 . . . . 0.0 111.269 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 41.2 t -45.07 -60.56 2.03 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-N 115.549 -0.75 . . . . 0.0 111.124 -178.475 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.693 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 2.1 p-10 -65.63 -54.86 21.8 Favored 'General case' 0 C--O 1.22 -0.466 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.517 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.693 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 80.3 mttt -44.91 -44.5 9.75 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 120.691 -0.403 . . . . 0.0 110.575 -179.602 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 17.5 m -63.64 -39.9 95.52 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.164 0.506 . . . . 0.0 110.02 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 51.4 m -66.46 -31.4 72.12 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.573 -0.74 . . . . 0.0 111.042 -179.882 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.4 mm -63.94 -41.33 92.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-O 121.323 0.582 . . . . 0.0 110.141 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.457 ' C ' ' H ' ' A' ' 30' ' ' ASN . 52.9 mm-40 -67.06 -37.7 84.49 Favored 'General case' 0 N--CA 1.445 -0.725 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.527 -178.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 33.7 m -69.07 5.8 1.1 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.029 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.457 ' H ' ' C ' ' A' ' 28' ' ' GLU . 48.4 t30 71.47 50.89 0.26 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.067 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.609 ' C ' ' H ' ' A' ' 33' ' ' GLY . 57.0 m-85 -133.81 162.78 31.08 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.733 179.887 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.434 ' N ' ' O ' ' A' ' 50' ' ' PHE . . . -69.17 23.06 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.053 -0.522 . . . . 0.0 110.719 -179.81 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.609 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 89.78 -175.8 42.22 Favored Glycine 0 CA--C 1.52 0.374 0 N-CA-C 110.533 -1.027 . . . . 0.0 110.533 -179.893 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -147.83 174.01 27.7 Favored Glycine 0 CA--C 1.522 0.482 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 -179.379 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 13.2 ptmt -155.44 178.57 10.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.885 0.374 . . . . 0.0 110.578 -179.377 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 1.8 m -105.17 128.07 53.21 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.144 179.227 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 19.3 m -134.47 158.62 41.93 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.047 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.625 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 0.9 OUTLIER -101.36 156.41 17.47 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.023 179.943 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 35.9 mm -112.67 127.27 70.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.98 -179.755 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.495 ' O ' ' NE2' ' A' ' 41' ' ' GLN . . . 40.11 -97.82 0.01 OUTLIER Glycine 0 CA--C 1.527 0.795 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.495 ' NE2' ' O ' ' A' ' 40' ' ' GLY . 99.2 mm-40 -137.45 28.38 2.75 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.838 0.351 . . . . 0.0 110.477 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' SER . . . . . 0.543 ' O ' ' N ' ' A' ' 44' ' ' ASP . 73.5 m -87.29 4.73 41.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.917 179.883 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . 0.42 ' CD2' ' C ' ' A' ' 42' ' ' SER . 1.2 pt? 34.65 27.99 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.27 0 O-C-N 123.788 0.68 . . . . 0.0 111.496 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . 0.543 ' N ' ' O ' ' A' ' 42' ' ' SER . 43.4 t0 -99.98 121.1 40.84 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.572 -179.466 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -87.65 117.75 26.68 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.087 0.47 . . . . 0.0 109.963 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 30.6 m -111.86 136.05 49.24 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.255 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.116 -179.623 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.512 ' SG ' ' CD1' ' A' ' 11' ' ' ILE . 14.0 t -93.39 115.84 28.39 Favored 'General case' 0 CA--C 1.518 -0.286 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.628 -179.575 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.8 p -131.89 152.03 36.19 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.507 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.762 -179.036 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 6.4 m -97.47 172.51 7.7 Favored 'General case' 0 CA--C 1.515 -0.376 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.636 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.434 ' O ' ' N ' ' A' ' 32' ' ' ALA . 56.4 m-85 -138.23 142.57 35.8 Favored Pre-proline 0 C--N 1.331 -0.225 0 C-N-CA 120.882 -0.327 . . . . 0.0 111.359 -179.487 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -67.94 161.49 43.89 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 122.408 2.072 . . . . 0.0 112.297 178.516 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 30.6 mmtp -57.56 -83.51 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.702 -179.794 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 13.6 p90 -130.59 38.18 3.75 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.631 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 59.2 t80 -79.6 97.3 6.44 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.946 0.403 . . . . 0.0 110.217 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 32.6 pt . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.961 -1.019 . . . . 0.0 110.493 -179.875 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 31.5 mtmm . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 43.6 t0 -69.0 -7.03 31.59 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.597 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 45.0 mm -70.22 134.33 30.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 121.148 0.499 . . . . 0.0 110.921 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . 0.477 ' OD1' ' N ' ' A' ' 4' ' ' ASP . 16.8 p-10 -63.72 -39.98 95.63 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.608 -0.723 . . . . 0.0 110.675 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 59.13 65.96 3.11 Favored Glycine 0 CA--C 1.516 0.125 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 179.414 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -130.22 22.53 5.23 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 110.525 -0.176 . . . . 0.0 110.525 -179.621 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 9.2 pttp -132.57 149.14 72.22 Favored Pre-proline 0 CA--C 1.533 0.322 0 C-N-CA 121.051 -0.259 . . . . 0.0 111.146 179.652 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_exo -48.4 135.87 25.92 Favored 'Trans proline' 0 N--CA 1.494 1.51 0 C-N-CA 121.991 1.794 . . . . 0.0 111.876 178.697 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -125.7 128.97 48.61 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-O 121.154 0.502 . . . . 0.0 110.708 179.895 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.1 tt -90.97 136.63 32.94 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.396 178.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -105.88 -47.47 8.93 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.262 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.125 -179.667 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -172.63 -124.74 0.79 Allowed Glycine 0 CA--C 1.519 0.307 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.564 ' C ' ' H ' ' A' ' 15' ' ' ILE . 66.3 p -127.81 150.36 49.86 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.912 0.387 . . . . 0.0 110.264 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 7.4 t -63.63 4.66 0.24 Allowed 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.353 179.714 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.564 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.2 mt -88.48 -40.75 13.69 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.181 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -99.6 -11.9 20.56 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.752 179.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -124.99 81.06 63.12 Favored Pre-proline 0 N--CA 1.464 0.275 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.028 179.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -53.44 168.03 0.75 Allowed 'Trans proline' 0 N--CA 1.5 1.9 0 C-N-CA 123.146 2.564 . . . . 0.0 111.507 178.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.447 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 39.9 p -45.71 -60.01 2.45 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 112.003 0.371 . . . . 0.0 112.003 -178.837 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.457 ' HG3' ' H ' ' A' ' 21' ' ' LYS . 6.6 pt-20 -46.37 -61.16 1.92 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.05 -179.27 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.457 ' H ' ' HG3' ' A' ' 20' ' ' GLU . 20.0 mtmt -63.11 -45.77 90.49 Favored 'General case' 0 CA--C 1.508 -0.644 0 CA-C-O 121.292 0.568 . . . . 0.0 111.629 -179.595 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 22.2 t -43.62 -59.35 2.22 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.024 -178.427 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.722 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 2.2 p-10 -67.3 -57.86 5.87 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.578 179.635 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.722 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 72.0 mttt -43.37 -43.62 5.2 Favored 'General case' 0 C--O 1.222 -0.358 0 CA-C-O 120.852 0.358 . . . . 0.0 110.51 -178.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 19.6 m -64.09 -40.61 96.61 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.177 0.513 . . . . 0.0 110.178 179.66 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.421 ' N ' ' O ' ' A' ' 23' ' ' ASN . 25.5 m -66.71 -30.73 71.04 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.795 -179.895 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.8 mm -64.87 -41.28 91.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-O 121.292 0.568 . . . . 0.0 110.009 -179.705 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.462 ' C ' ' H ' ' A' ' 30' ' ' ASN . 31.2 mm-40 -65.84 -38.07 87.89 Favored 'General case' 0 N--CA 1.447 -0.612 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.379 -178.705 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 26.8 m -69.49 5.15 1.46 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.639 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.462 ' H ' ' C ' ' A' ' 28' ' ' GLU . 44.6 t30 70.86 54.85 0.25 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.006 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.593 ' C ' ' H ' ' A' ' 33' ' ' GLY . 60.4 m-85 -137.76 161.98 35.13 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.592 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.47 28.28 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.981 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.593 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 85.07 -175.26 49.98 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 110.7 -0.96 . . . . 0.0 110.7 -179.784 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -148.63 174.0 28.42 Favored Glycine 0 CA--C 1.522 0.483 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 -179.403 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 4.7 ptmm? -155.86 -178.12 7.07 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.592 0.234 . . . . 0.0 110.384 -179.247 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 31.1 m -104.45 129.69 52.42 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.414 179.228 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 28.5 m -137.78 161.85 32.63 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.261 179.696 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 3.5 p80 -109.06 157.62 18.53 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.217 -0.447 . . . . 0.0 109.998 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 83.6 mt -122.21 125.98 73.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.339 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 42.03 -128.51 4.37 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.891 -0.883 . . . . 0.0 110.891 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 29.0 pt20 -106.82 31.7 5.1 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 120.694 0.283 . . . . 0.0 110.413 179.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 20.1 m -84.39 -9.77 58.13 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 120.983 0.42 . . . . 0.0 110.598 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 40.02 29.41 0.05 Allowed 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.635 -0.712 . . . . 0.0 110.872 -179.144 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -107.55 126.45 52.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.222 179.691 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -90.65 124.55 35.16 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.638 -0.505 . . . . 0.0 109.638 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 30.5 m -120.47 138.07 52.19 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 CA-C-N 116.068 -0.514 . . . . 0.0 109.997 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -94.31 119.22 32.75 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.1 p -134.18 153.18 35.4 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.448 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.588 -179.069 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 5.9 m -97.28 172.23 7.92 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.898 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 56.4 m-85 -132.6 148.07 68.11 Favored Pre-proline 0 CA--C 1.531 0.214 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.939 -179.163 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -68.0 161.0 46.09 Favored 'Trans proline' 0 N--CA 1.494 1.52 0 C-N-CA 122.74 2.293 . . . . 0.0 112.308 179.356 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -65.54 -81.5 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.761 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.419 ' O ' ' CD2' ' A' ' 53' ' ' TYR . 33.3 p90 -128.95 32.53 4.74 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.827 -179.742 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 46.0 t80 -73.86 125.5 28.31 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.784 0.326 . . . . 0.0 110.216 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 9.0 pt . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 118.087 -0.959 . . . . 0.0 110.391 -179.837 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 45.7 mmtt . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -99.43 4.61 46.25 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.196 179.602 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 12.9 tt -52.04 140.96 6.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.492 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -63.16 -38.93 93.13 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.109 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -91.05 88.49 1.41 Allowed Glycine 0 C--O 1.228 -0.238 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 3.8 ppt_? -133.49 41.11 3.1 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 120.743 0.306 . . . . 0.0 110.65 -179.55 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 10.3 tptm -130.41 78.93 73.41 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 120.843 0.354 . . . . 0.0 111.258 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 21.3 Cg_exo -65.46 155.92 66.24 Favored 'Trans proline' 0 C--N 1.307 -1.637 0 C-N-CA 122.856 2.37 . . . . 0.0 111.363 178.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.412 ' C ' ' CD2' ' A' ' 9' ' ' LEU . 3.8 tt -126.43 116.65 21.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.598 179.858 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.2 tt -91.71 129.11 37.73 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 179.009 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.472 ' CD1' ' SG ' ' A' ' 47' ' ' CYS . 1.4 pt -105.61 -50.07 8.65 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-O 120.837 0.351 . . . . 0.0 110.921 -178.496 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -160.43 -164.61 15.75 Favored Glycine 0 N--CA 1.451 -0.308 0 N-CA-C 110.694 -0.963 . . . . 0.0 110.694 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.485 ' C ' ' H ' ' A' ' 15' ' ' ILE . 6.5 m -89.33 158.29 17.86 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.843 0.354 . . . . 0.0 110.423 -179.385 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 9.5 t -69.35 6.6 0.98 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.207 179.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.485 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.5 mt -91.44 -45.62 14.52 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.148 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -90.92 -11.37 39.33 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.925 179.649 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 54.1 m-85 -142.78 82.02 12.7 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.684 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.42 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 15.9 Cg_exo -65.95 -172.72 0.28 Allowed 'Trans proline' 0 N--CA 1.493 1.479 0 C-N-CA 122.904 2.403 . . . . 0.0 111.83 179.279 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.512 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 26.2 p -48.07 -56.68 7.19 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 120.826 -0.35 . . . . 0.0 111.698 -179.054 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.602 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 0.0 OUTLIER -47.91 -72.2 0.06 Allowed 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.121 0.486 . . . . 0.0 111.736 -178.719 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 52.0 mtmt -60.49 -42.94 97.36 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.683 -178.273 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.42 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 44.7 t -44.94 -59.77 2.4 Favored 'General case' 0 C--N 1.313 -1.013 0 C-N-CA 120.215 -0.594 . . . . 0.0 111.089 -178.547 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.746 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.5 p-10 -64.58 -55.64 19.09 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.546 -179.468 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.746 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 69.1 mttt -47.14 -42.79 20.07 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 120.788 -0.365 . . . . 0.0 110.584 -178.742 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 11.4 m -65.8 -37.75 87.13 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.242 179.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 37.9 m -67.64 -33.63 75.34 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.877 -0.602 . . . . 0.0 110.287 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.6 mm -61.5 -46.35 96.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.564 -179.536 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -66.34 -31.07 71.64 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.494 -179.035 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 27.1 m -72.87 1.5 8.57 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.405 -179.12 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.3 m-80 74.51 52.98 0.09 Allowed 'General case' 0 C--N 1.329 -0.312 0 O-C-N 123.559 0.537 . . . . 0.0 111.032 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.59 ' C ' ' H ' ' A' ' 33' ' ' GLY . 68.6 m-85 -138.61 162.02 35.66 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.688 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.79 30.24 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.57 179.626 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.59 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 83.6 -176.87 52.53 Favored Glycine 0 CA--C 1.521 0.442 0 N-CA-C 110.568 -1.013 . . . . 0.0 110.568 -179.653 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -147.3 178.04 25.18 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 -179.595 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 14.7 ptmt -156.87 -176.79 6.17 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 110.237 -0.283 . . . . 0.0 110.237 -179.625 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 66.7 m -108.44 122.2 46.53 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.519 179.573 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 2.8 m -137.89 163.46 29.98 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.837 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.404 ' CD2' ' H ' ' A' ' 38' ' ' HIS . 2.4 p80 -92.97 157.61 16.24 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.341 179.714 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.437 ' O ' ' N ' ' A' ' 41' ' ' GLN . 34.1 mm -110.18 123.44 66.08 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 CA-C-O 121.086 0.47 . . . . 0.0 110.679 -179.741 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 43.99 20.74 0.17 Allowed Glycine 0 C--O 1.227 -0.307 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.575 179.629 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.437 ' N ' ' O ' ' A' ' 39' ' ' ILE . 37.3 tt0 72.61 36.18 1.01 Allowed 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.846 0.355 . . . . 0.0 110.721 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' SER . . . . . 0.422 ' N ' ' O ' ' A' ' 39' ' ' ILE . 41.0 m -85.61 -2.66 58.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.206 0.527 . . . . 0.0 110.885 -179.785 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 69.96 26.4 4.66 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.672 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 35.2 t70 -111.78 117.36 32.62 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 178.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -89.36 129.33 35.9 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 27.2 m -133.38 154.6 39.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.387 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.472 ' SG ' ' CD1' ' A' ' 11' ' ' ILE . 37.9 t -95.26 118.42 31.99 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 115.877 -0.601 . . . . 0.0 109.971 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.0 p -130.21 144.14 38.88 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 CA-C-O 120.87 0.366 . . . . 0.0 110.361 -179.466 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 4.9 m -97.93 167.52 10.86 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.889 -179.739 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 46.4 m-85 -122.18 143.05 38.14 Favored Pre-proline 0 CA--C 1.532 0.275 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.668 -179.428 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -66.11 144.33 75.08 Favored 'Trans proline' 0 N--CA 1.495 1.609 0 C-N-CA 122.544 2.163 . . . . 0.0 111.735 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 46.4 mtmt -93.44 -70.02 0.72 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.166 179.212 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 63.2 m-85 -130.66 34.24 4.15 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.459 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 54.3 t80 -62.23 132.06 51.46 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.49 -0.323 . . . . 0.0 110.426 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.3 pt . . . . . 0 C--O 1.219 -0.511 0 CA-C-O 117.859 -1.067 . . . . 0.0 110.44 -179.916 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . 0.44 ' C ' ' H ' ' A' ' 3' ' ' ILE . 70.5 mmtt . . . . . 0 N--CA 1.493 1.704 0 N-CA-C 108.642 -0.874 . . . . 0.0 108.642 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.544 ' C ' ' H ' ' A' ' 4' ' ' ASP . 58.6 t0 -64.05 -6.2 5.97 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 108.903 -0.776 . . . . 0.0 108.903 179.492 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.44 ' H ' ' C ' ' A' ' 1' ' ' LYS . 2.0 pp -59.11 -0.87 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-N 115.194 -0.912 . . . . 0.0 110.794 179.684 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . 0.544 ' H ' ' C ' ' A' ' 2' ' ' ASP . 41.2 t0 -54.5 -39.2 67.33 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.345 -179.408 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 73.73 85.31 0.26 Allowed Glycine 0 N--CA 1.449 -0.451 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 4.9 ppt_? -129.42 40.32 3.62 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 112.08 0.4 . . . . 0.0 112.08 -178.419 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 43.3 tttp -132.83 73.12 76.38 Favored Pre-proline 0 CA--C 1.532 0.261 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.752 179.01 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_exo -69.43 153.46 70.41 Favored 'Trans proline' 0 C--N 1.304 -1.8 0 C-N-CA 122.821 2.347 . . . . 0.0 110.84 178.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.5 tt -129.77 116.89 19.4 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 179.607 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.4 tt -89.27 124.81 34.75 Favored 'General case' 0 N--CA 1.465 0.321 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.519 ' CD1' ' SG ' ' A' ' 47' ' ' CYS . 3.2 pt -102.59 -46.97 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.842 -179.009 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -164.49 -138.45 2.41 Favored Glycine 0 CA--C 1.519 0.306 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.446 ' C ' ' H ' ' A' ' 15' ' ' ILE . 65.5 p -136.22 159.5 41.56 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.149 -0.526 . . . . 0.0 110.249 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -53.38 -12.27 0.41 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.05 179.54 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.446 ' H ' ' C ' ' A' ' 13' ' ' THR . 78.0 mt -71.78 -43.75 69.25 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.396 0 CA-C-O 121.353 0.597 . . . . 0.0 110.425 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 3.0 pt-20 -100.91 -34.3 9.85 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.094 -179.297 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 9.3 m-85 -116.93 85.0 16.85 Favored Pre-proline 0 N--CA 1.468 0.473 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.572 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -49.64 -178.63 0.01 OUTLIER 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 122.462 2.108 . . . . 0.0 111.508 -179.565 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.436 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 96.9 m -59.14 -51.41 70.12 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.629 -0.428 . . . . 0.0 111.443 -178.818 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.477 ' CG ' ' N ' ' A' ' 21' ' ' LYS . 11.1 pt-20 -60.62 -50.17 74.61 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 112.052 0.389 . . . . 0.0 112.052 -179.706 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.477 ' N ' ' CG ' ' A' ' 20' ' ' GLU . 2.5 ttpp -64.8 -45.9 84.32 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.232 0.539 . . . . 0.0 110.225 -178.327 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 43.3 t -45.7 -61.47 1.7 Allowed 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.25 -0.886 . . . . 0.0 111.433 -179.57 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.685 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.7 p-10 -64.65 -49.31 71.51 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.697 -179.42 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.685 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 82.3 mttt -48.11 -42.56 29.41 Favored 'General case' 0 C--O 1.218 -0.555 0 C-N-CA 120.544 -0.462 . . . . 0.0 109.852 -179.926 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 20.1 m -61.86 -42.4 99.0 Favored 'General case' 0 C--N 1.311 -1.073 0 C-N-CA 120.016 -0.674 . . . . 0.0 110.748 -179.586 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.495 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 10.2 t -65.51 -34.19 77.68 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.743 0.783 . . . . 0.0 109.229 179.363 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.6 mm -65.99 -41.29 89.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 115.008 -0.996 . . . . 0.0 110.289 -179.768 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.437 ' C ' ' H ' ' A' ' 30' ' ' ASN . 54.4 mm-40 -64.23 -34.38 77.97 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.502 -179.555 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.448 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 36.1 m -67.87 -0.15 3.98 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.994 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.448 ' CB ' ' O ' ' A' ' 29' ' ' SER . 4.3 t-20 80.9 14.81 0.66 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.483 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.556 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 4.0 m-85 -94.89 -168.3 1.79 Allowed 'General case' 0 CA--C 1.533 0.298 0 CA-C-O 120.781 0.324 . . . . 0.0 110.261 -179.671 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -76.59 -51.26 11.96 Favored 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 -178.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.495 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 163.3 -179.24 38.56 Favored Glycine 0 CA--C 1.519 0.318 0 N-CA-C 109.734 -1.347 . . . . 0.0 109.734 -178.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -142.96 170.35 25.31 Favored Glycine 0 N--CA 1.462 0.405 0 N-CA-C 111.36 -0.696 . . . . 0.0 111.36 -179.115 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 23.3 pttt -156.9 178.43 10.37 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.071 0.462 . . . . 0.0 110.891 -179.663 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 3.2 m -104.56 128.4 52.53 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.053 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 35.1 m -136.23 163.38 34.15 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.573 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 2.8 p80 -108.75 156.61 19.41 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.129 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 95.9 mt -122.82 130.07 74.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.606 -179.391 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 48.02 -107.99 0.31 Allowed Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -136.38 32.29 2.83 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 120.596 0.236 . . . . 0.0 110.48 -179.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 8.7 m -82.64 -12.03 57.95 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 121.134 0.492 . . . . 0.0 110.282 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 49.56 29.17 2.84 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.224 179.657 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -105.62 132.71 51.42 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.344 179.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -93.5 117.53 30.2 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-O 120.965 0.412 . . . . 0.0 109.95 179.823 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 16.3 m -111.0 137.16 44.65 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.41 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.007 -179.6 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.519 ' SG ' ' CD1' ' A' ' 11' ' ' ILE . 16.1 t -93.05 118.79 31.59 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.734 -179.837 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.9 p -128.05 150.91 34.22 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.093 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.84 -179.319 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' CYS . . . . . 0.556 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 28.9 t -96.88 165.4 12.12 Favored 'General case' 0 N--CA 1.467 0.419 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.508 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 25.3 m-85 -127.95 124.17 23.07 Favored Pre-proline 0 CA--C 1.544 0.731 0 C-N-CA 121.114 -0.234 . . . . 0.0 111.236 -178.444 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_exo -51.29 137.6 46.71 Favored 'Trans proline' 0 N--CA 1.499 1.818 0 C-N-CA 121.999 1.8 . . . . 0.0 113.018 179.092 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 64.2 tttp -112.34 -48.9 2.99 Favored 'General case' 0 CA--C 1.529 0.15 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.298 178.747 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.536 ' O ' ' CD2' ' A' ' 53' ' ' TYR . 24.4 p90 -129.89 40.33 3.58 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.778 -179.483 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 90.3 t80 -83.45 96.86 8.7 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.944 0.402 . . . . 0.0 110.003 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 18.2 mm . . . . . 0 C--O 1.22 -0.463 0 CA-C-O 118.053 -0.975 . . . . 0.0 110.505 -179.348 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 68.4 mttm . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.428 ' OD1' ' N ' ' A' ' 2' ' ' ASP . 34.4 p-10 -87.79 3.94 46.3 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.509 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 35.1 mm -74.07 129.84 36.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.517 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 59.8 t0 -61.68 -42.29 98.73 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.169 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 44.17 75.85 0.14 Allowed Glycine 0 C--N 1.331 0.277 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.706 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.0 31.47 4.68 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.748 0.309 . . . . 0.0 111.02 -179.312 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -121.69 150.07 54.47 Favored Pre-proline 0 N--CA 1.469 0.488 0 CA-C-N 116.438 -0.347 . . . . 0.0 110.746 -179.493 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -61.64 154.82 57.42 Favored 'Trans proline' 0 N--CA 1.497 1.693 0 C-N-CA 122.408 2.072 . . . . 0.0 111.984 179.065 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.8 tt -131.63 120.91 23.48 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.42 -179.272 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 4.4 tt -89.94 128.43 36.23 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 178.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 6.4 pt -101.72 -43.03 9.71 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-O 120.786 0.327 . . . . 0.0 110.865 -178.536 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -173.54 -143.29 4.22 Favored Glycine 0 N--CA 1.451 -0.307 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.744 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.421 ' C ' ' H ' ' A' ' 15' ' ' ILE . 7.7 p -99.46 163.66 12.42 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.824 0.345 . . . . 0.0 110.275 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 43.4 t -74.1 7.55 2.64 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.331 179.6 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.421 ' H ' ' C ' ' A' ' 13' ' ' THR . 97.1 mt -93.15 -43.68 13.63 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.12 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.523 -179.814 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -88.37 -11.71 45.43 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.652 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 53.6 m-85 -122.84 81.22 49.58 Favored Pre-proline 0 N--CA 1.463 0.214 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.853 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_exo -48.88 165.99 0.17 Allowed 'Trans proline' 0 N--CA 1.495 1.599 0 C-N-CA 122.714 2.276 . . . . 0.0 111.33 179.065 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.424 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 17.0 m -48.39 -52.58 21.22 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.85 -0.34 . . . . 0.0 111.627 -178.036 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.541 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 1.3 pm0 -61.92 -55.44 29.58 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.551 -0.295 . . . . 0.0 111.651 -179.722 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.417 ' O ' ' OG1' ' A' ' 25' ' ' THR . 0.5 OUTLIER -57.57 -45.82 84.71 Favored 'General case' 0 CA--C 1.518 -0.255 0 CA-C-O 121.302 0.572 . . . . 0.0 110.94 -178.208 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 12.7 t -48.02 -65.12 0.62 Allowed 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.402 -178.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.667 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.6 p-10 -63.71 -48.37 77.37 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.755 -179.597 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.667 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 89.5 mttt -47.27 -42.02 19.88 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 120.543 -0.463 . . . . 0.0 110.05 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' THR . . . . . 0.417 ' OG1' ' O ' ' A' ' 21' ' ' LYS . 18.6 m -61.57 -43.68 98.41 Favored 'General case' 0 C--N 1.314 -0.978 0 C-N-CA 120.456 -0.498 . . . . 0.0 110.909 -179.453 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.503 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 10.7 t -66.2 -32.51 73.99 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.525 0.679 . . . . 0.0 109.745 179.562 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.6 mm -66.54 -39.34 83.68 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.442 -179.623 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.462 ' C ' ' H ' ' A' ' 30' ' ' ASN . 54.9 mm-40 -64.34 -35.72 81.8 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.299 -179.356 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.401 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 58.6 m -67.86 1.65 2.47 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.268 179.797 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.462 ' H ' ' C ' ' A' ' 28' ' ' GLU . 43.8 t30 77.78 18.25 1.27 Allowed 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.705 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.553 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 4.1 m-85 -96.34 -167.83 1.64 Allowed 'General case' 0 CA--C 1.532 0.288 0 CA-C-O 120.945 0.402 . . . . 0.0 110.406 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -75.71 -51.51 12.55 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 115.893 -0.594 . . . . 0.0 112.076 -179.079 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.503 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 162.56 -178.06 38.46 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 -179.025 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -142.95 169.02 25.82 Favored Glycine 0 N--CA 1.462 0.375 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.136 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 11.4 ptmt -158.48 -176.25 5.78 Favored 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 120.681 -0.408 . . . . 0.0 110.716 -179.3 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 66.2 m -103.73 119.86 39.76 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.932 179.509 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 18.9 m -133.32 163.93 36.41 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.204 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.6 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 0.3 OUTLIER -132.83 157.67 44.44 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 121.02 0.438 . . . . 0.0 110.394 179.879 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.528 ' O ' ' N ' ' A' ' 41' ' ' GLN . 20.2 mm -99.38 135.84 32.99 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.569 179.673 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -61.84 65.1 0.02 OUTLIER Glycine 0 N--CA 1.461 0.346 0 N-CA-C 111.543 -0.623 . . . . 0.0 111.543 -179.418 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.528 ' N ' ' O ' ' A' ' 39' ' ' ILE . 59.7 tp60 -174.63 -57.49 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.884 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 73.4 m -90.88 -13.84 32.88 Favored 'General case' 0 CA--C 1.505 -0.755 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.588 179.719 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . 0.535 ' N ' ' CD1' ' A' ' 43' ' ' LEU . 8.3 mp 46.88 28.28 0.82 Allowed 'General case' 0 N--CA 1.436 -1.171 0 C-N-CA 119.697 -0.801 . . . . 0.0 111.378 178.934 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 54.4 t0 -96.36 136.63 36.59 Favored 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.571 ' CE1' ' CD2' ' A' ' 38' ' ' HIS . 64.6 m-85 -86.35 124.75 33.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.998 0.428 . . . . 0.0 110.0 -179.596 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 27.8 m -126.13 150.59 31.76 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.377 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.111 -179.713 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -98.55 125.96 43.96 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.582 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.1 p -136.77 155.0 32.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.188 -179.339 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' CYS . . . . . 0.553 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 17.7 t -97.07 164.65 12.42 Favored 'General case' 0 C--O 1.233 0.215 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.538 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 30.7 m-85 -133.98 126.59 18.78 Favored Pre-proline 0 C--N 1.33 -0.24 0 C-N-CA 121.031 -0.268 . . . . 0.0 110.856 -178.363 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.28 158.09 58.89 Favored 'Trans proline' 0 N--CA 1.491 1.339 0 C-N-CA 121.712 1.608 . . . . 0.0 112.218 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 22.6 mmtp -63.8 -8.84 11.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.779 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 87.7 m-85 -109.33 39.6 2.03 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.397 -179.698 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 82.9 t80 -111.59 121.69 45.82 Favored 'General case' 0 C--O 1.231 0.101 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 86.5 mt . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.244 -179.927 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 53.3 mtpt . . . . . 0 N--CA 1.492 1.651 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.643 ' C ' ' H ' ' A' ' 4' ' ' ASP . 17.0 p-10 -75.23 -58.08 3.5 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.16 -0.473 . . . . 0.0 109.763 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.459 ' H ' ' CG ' ' A' ' 2' ' ' ASP . 0.3 OUTLIER 62.25 -25.99 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.522 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.446 178.554 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . 0.643 ' H ' ' C ' ' A' ' 2' ' ' ASP . 37.4 t0 -58.83 -27.63 65.29 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.18 0.514 . . . . 0.0 110.056 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 93.67 74.14 1.24 Allowed Glycine 0 C--N 1.33 0.239 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.531 ' O ' ' NE ' ' A' ' 6' ' ' ARG . 0.0 OUTLIER -132.16 42.22 3.15 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 112.376 0.51 . . . . 0.0 112.376 -177.985 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.547 ' N ' ' CD ' ' A' ' 8' ' ' PRO . 27.8 tptt -125.64 43.99 1.05 Allowed Pre-proline 0 C--N 1.323 -0.567 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.208 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.547 ' CD ' ' N ' ' A' ' 7' ' ' LYS . 61.1 Cg_endo -69.38 154.35 69.35 Favored 'Trans proline' 0 N--CA 1.498 1.78 0 C-N-CA 122.71 2.273 . . . . 0.0 111.929 179.409 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.5 tt -129.65 120.61 25.5 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.126 -178.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.2 tt -92.49 125.66 37.23 Favored 'General case' 0 N--CA 1.468 0.438 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 178.494 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.527 ' CD1' ' SG ' ' A' ' 47' ' ' CYS . 2.9 pt -103.56 -47.45 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-O 120.752 0.31 . . . . 0.0 111.0 -179.188 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -165.14 -135.73 1.88 Allowed Glycine 0 CA--C 1.519 0.311 0 C-N-CA 120.705 -0.76 . . . . 0.0 111.307 -179.649 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.417 ' C ' ' H ' ' A' ' 15' ' ' ILE . 71.3 p -136.89 159.6 41.38 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 114.99 -0.605 . . . . 0.0 110.163 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -56.72 -11.07 1.2 Allowed 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.026 179.636 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.417 ' H ' ' C ' ' A' ' 13' ' ' THR . 97.3 mt -69.41 -43.24 81.05 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.329 0 CA-C-O 121.454 0.645 . . . . 0.0 109.782 179.71 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -104.34 -31.11 9.7 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 114.9 -1.045 . . . . 0.0 111.648 -178.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.427 ' O ' ' O ' ' A' ' 18' ' ' PRO . 12.0 m-85 -119.06 82.99 22.75 Favored Pre-proline 0 N--CA 1.471 0.612 0 N-CA-C 110.103 -0.332 . . . . 0.0 110.103 179.473 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.427 ' O ' ' O ' ' A' ' 17' ' ' PHE . 77.5 Cg_exo -47.61 179.87 0.01 OUTLIER 'Trans proline' 0 N--CA 1.495 1.57 0 C-N-CA 122.645 2.23 . . . . 0.0 111.701 -179.79 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.449 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 99.0 m -59.0 -50.71 73.06 Favored 'General case' 0 C--N 1.326 -0.428 0 C-N-CA 120.89 -0.324 . . . . 0.0 111.845 -178.513 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.546 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 1.1 pm0 -60.03 -52.59 64.73 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.161 -179.688 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.13 -47.29 85.24 Favored 'General case' 0 CA--C 1.519 -0.235 0 CA-C-O 121.297 0.57 . . . . 0.0 110.691 -179.212 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 38.5 t -45.12 -60.38 2.13 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 115.312 -0.858 . . . . 0.0 111.259 -178.792 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.666 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.9 p-10 -64.71 -51.69 61.07 Favored 'General case' 0 C--O 1.221 -0.411 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.734 -179.593 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.666 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 81.2 mttt -47.97 -42.86 28.77 Favored 'General case' 0 C--N 1.323 -0.554 0 C-N-CA 120.405 -0.518 . . . . 0.0 110.584 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 55.5 m -66.35 -33.3 75.41 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.163 0.506 . . . . 0.0 110.085 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 56.9 m -72.0 -34.04 68.56 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.876 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.3 mm -62.07 -48.51 88.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.727 -179.251 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.495 ' C ' ' H ' ' A' ' 30' ' ' ASN . 6.0 pt-20 -70.47 -30.81 67.71 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.799 -179.303 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 39.5 m -68.96 7.15 0.74 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.706 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.495 ' H ' ' C ' ' A' ' 28' ' ' GLU . 49.8 t30 72.73 47.86 0.22 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.366 179.487 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.577 ' C ' ' H ' ' A' ' 33' ' ' GLY . 73.9 m-85 -137.23 160.8 37.97 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.759 179.424 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.32 23.3 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.168 -179.66 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.577 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 91.92 -179.88 41.4 Favored Glycine 0 CA--C 1.519 0.338 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 -179.683 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -148.92 174.45 28.54 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 8.8 pttm -154.12 -179.08 7.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.035 0.445 . . . . 0.0 110.788 -179.781 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 3.9 m -105.03 124.46 49.56 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 115.718 -0.673 . . . . 0.0 110.308 179.658 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 35.7 m -136.67 165.91 27.38 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.75 -179.679 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 3.3 p80 -106.92 155.85 19.34 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-O 121.025 0.44 . . . . 0.0 110.66 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 96.0 mt -128.96 126.49 64.74 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.217 -179.481 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 61.46 22.48 61.41 Favored Glycine 0 CA--C 1.52 0.387 0 N-CA-C 111.555 -0.618 . . . . 0.0 111.555 178.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 26.7 mt-30 57.3 37.37 28.11 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.026 0.441 . . . . 0.0 110.03 -179.466 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 20.7 m -81.49 -11.09 59.33 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.181 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . 0.41 ' CD2' ' O ' ' A' ' 43' ' ' LEU . 0.9 OUTLIER 70.69 28.63 3.43 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.493 0.663 . . . . 0.0 109.659 -179.783 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -110.97 121.34 45.1 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.665 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 64.5 m-85 -90.63 117.1 29.03 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-O 121.163 0.506 . . . . 0.0 110.007 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.5 m -110.97 137.65 42.55 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.33 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.715 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.527 ' SG ' ' CD1' ' A' ' 11' ' ' ILE . 13.5 t -93.02 113.95 26.36 Favored 'General case' 0 CA--C 1.512 -0.481 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 -179.862 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 8.8 p -130.39 147.78 33.16 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.308 0 CA-C-O 121.143 0.497 . . . . 0.0 111.62 -178.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 4.8 m -97.43 170.82 8.79 Favored 'General case' 0 CA--C 1.518 -0.257 0 CA-C-N 115.258 -0.883 . . . . 0.0 109.793 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -130.15 143.29 48.57 Favored Pre-proline 0 CA--C 1.542 0.644 0 CA-C-N 116.512 -0.313 . . . . 0.0 111.266 -178.804 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.546 ' HG3' ' H ' ' A' ' 7' ' ' LYS . 40.8 Cg_exo -47.52 137.05 20.26 Favored 'Trans proline' 0 N--CA 1.498 1.736 0 C-N-CA 122.37 2.047 . . . . 0.0 112.011 177.676 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 41.6 mmtt -41.55 -86.0 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 114.97 -1.014 . . . . 0.0 112.695 -178.525 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 6.6 m-85 -116.05 17.41 15.85 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-O 121.208 0.528 . . . . 0.0 110.004 -178.688 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 2.4 m-85 -93.49 101.69 13.89 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.413 -0.812 . . . . 0.0 109.298 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 32.4 pt . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.455 -179.444 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 41.3 pttt . . . . . 0 N--CA 1.492 1.628 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 47.5 t0 58.68 36.68 25.09 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 -179.102 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 1.5 pp -122.92 163.18 22.01 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.225 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.816 -179.303 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 64.5 t0 -60.1 -45.66 92.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.25 -179.434 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 78.87 74.59 1.05 Allowed Glycine 0 C--O 1.228 -0.228 0 N-CA-C 110.772 -0.931 . . . . 0.0 110.772 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.539 ' NH2' ' O ' ' A' ' 53' ' ' TYR . 21.0 mmt180 -131.63 40.8 3.36 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 120.759 0.314 . . . . 0.0 110.817 -179.618 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 17.3 pttt -130.66 101.87 16.86 Favored Pre-proline 0 N--CA 1.466 0.334 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -179.438 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -50.79 142.94 31.19 Favored 'Trans proline' 0 N--CA 1.495 1.571 0 C-N-CA 121.588 1.526 . . . . 0.0 111.187 178.016 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -111.32 126.69 55.18 Favored 'General case' 0 N--CA 1.468 0.472 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.685 -179.006 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -92.05 128.5 37.91 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 178.336 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -108.06 -40.09 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -178.63 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -177.94 -140.59 3.84 Favored Glycine 0 CA--C 1.52 0.404 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 179.698 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.526 ' C ' ' H ' ' A' ' 15' ' ' ILE . 80.6 p -135.63 161.08 36.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.017 0.437 . . . . 0.0 111.045 -179.534 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -58.17 -2.96 0.21 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.26 179.54 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.526 ' H ' ' C ' ' A' ' 13' ' ' THR . 23.8 mm -73.45 -22.65 19.18 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 CA-C-O 121.092 0.473 . . . . 0.0 109.948 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . 0.477 ' OE1' ' CZ ' ' A' ' 17' ' ' PHE . 9.5 pt-20 -134.51 -30.76 1.11 Allowed 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.154 -179.515 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.477 ' CZ ' ' OE1' ' A' ' 16' ' ' GLU . 9.9 m-85 -114.88 93.4 34.01 Favored Pre-proline 0 N--CA 1.468 0.426 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.537 -179.619 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.45 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 56.5 Cg_endo -79.25 -179.08 5.1 Favored 'Trans proline' 0 N--CA 1.489 1.235 0 C-N-CA 122.489 2.126 . . . . 0.0 111.23 -179.543 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.411 ' OG1' ' OE2' ' A' ' 20' ' ' GLU . 23.4 p -45.4 -48.68 13.52 Favored 'General case' 0 C--N 1.32 -0.687 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.116 -178.74 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.443 ' CD ' ' N ' ' A' ' 20' ' ' GLU . 0.3 OUTLIER -52.55 -70.72 0.08 Allowed 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.614 -179.316 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 16.2 ttmt -64.59 -47.36 78.95 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-O 121.443 0.64 . . . . 0.0 111.304 -178.008 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.45 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 51.8 t -41.78 -59.8 1.56 Allowed 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.205 -0.907 . . . . 0.0 111.039 -178.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.688 ' ND2' ' H ' ' A' ' 24' ' ' LYS . 0.0 OUTLIER -66.89 -55.13 16.01 Favored 'General case' 0 C--O 1.218 -0.577 0 C-N-CA 120.205 -0.598 . . . . 0.0 110.421 -179.634 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.688 ' H ' ' ND2' ' A' ' 23' ' ' ASN . 71.7 mttt -44.53 -42.6 7.34 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.871 0.367 . . . . 0.0 110.71 -179.231 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' THR . . . . . 0.454 ' O ' ' OE2' ' A' ' 28' ' ' GLU . 8.8 m -65.12 -37.14 86.49 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.416 0.627 . . . . 0.0 109.558 179.408 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.463 ' N ' ' O ' ' A' ' 23' ' ' ASN . 67.9 m -72.08 -35.27 69.19 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.162 179.728 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.9 mm -62.67 -48.34 88.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.386 -179.192 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.454 ' OE2' ' O ' ' A' ' 25' ' ' THR . 2.6 pp20? -70.57 -31.09 67.97 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.601 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.434 ' N ' ' CD ' ' A' ' 28' ' ' GLU . 68.6 m -67.57 2.36 1.86 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.934 -179.688 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.44 ' H ' ' C ' ' A' ' 28' ' ' GLU . 41.6 t30 75.14 43.32 0.21 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.983 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.582 ' C ' ' H ' ' A' ' 33' ' ' GLY . 63.0 m-85 -131.92 160.99 34.13 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.459 179.463 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.48 31.19 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.96 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.582 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 84.11 -176.96 51.92 Favored Glycine 0 CA--C 1.52 0.4 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -150.58 172.13 30.35 Favored Glycine 0 CA--C 1.52 0.36 0 N-CA-C 110.715 -0.954 . . . . 0.0 110.715 -179.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 25.2 pttt -155.25 -179.02 7.68 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 120.935 0.398 . . . . 0.0 110.563 -179.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 3.3 m -103.94 127.08 51.48 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 115.866 -0.607 . . . . 0.0 110.172 179.384 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 34.5 m -136.77 159.81 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.419 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.492 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 2.9 p80 -104.6 156.94 17.53 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-O 121.072 0.463 . . . . 0.0 110.086 179.753 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.478 ' O ' ' N ' ' A' ' 41' ' ' GLN . 34.4 mm -109.21 125.13 66.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.243 -179.765 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 42.5 -92.42 0.01 OUTLIER Glycine 0 CA--C 1.526 0.75 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.484 ' N ' ' CD ' ' A' ' 41' ' ' GLN . 2.0 pm0 -143.9 30.44 1.31 Allowed 'General case' 0 N--CA 1.463 0.197 0 CA-C-O 120.702 0.287 . . . . 0.0 110.531 -179.64 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 66.3 m -84.43 -5.4 59.28 Favored 'General case' 0 CA--C 1.52 -0.188 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.689 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 45.14 28.37 0.4 Allowed 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.677 179.813 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -103.04 119.8 39.51 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.396 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 70.8 m-85 -87.75 117.8 26.83 Favored 'General case' 0 C--N 1.332 -0.191 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.725 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 33.4 m -112.82 137.09 47.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.331 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 25.2 t -92.25 108.2 19.77 Favored 'General case' 0 CA--C 1.513 -0.445 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 179.838 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.2 p -124.36 150.23 28.96 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.229 0 CA-C-O 120.941 0.4 . . . . 0.0 110.634 -178.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 10.6 m -97.26 163.13 13.03 Favored 'General case' 0 CA--C 1.515 -0.386 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 -179.696 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 -119.33 143.29 34.05 Favored Pre-proline 0 CA--C 1.531 0.249 0 C-N-CA 121.141 -0.224 . . . . 0.0 111.227 -178.879 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.445 ' C ' ' H ' ' A' ' 53' ' ' TYR . 39.4 Cg_endo -64.28 149.62 89.86 Favored 'Trans proline' 0 N--CA 1.494 1.522 0 C-N-CA 122.221 1.947 . . . . 0.0 111.989 178.81 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 68.1 mmtt -64.3 -2.69 2.31 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.534 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.539 ' O ' ' NH2' ' A' ' 6' ' ' ARG . 52.0 m-85 -109.02 18.4 20.68 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.463 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 86.7 t80 -83.4 123.08 29.32 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.089 179.681 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 8.0 pt . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.118 -0.944 . . . . 0.0 110.194 -179.759 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 35.7 tttp . . . . . 0 N--CA 1.49 1.557 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.425 ' OD1' ' N ' ' A' ' 2' ' ' ASP . 34.4 p-10 -74.0 -2.53 24.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.401 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 31.4 mm -88.41 125.63 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 CA-C-O 121.286 0.565 . . . . 0.0 110.762 179.61 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -65.13 -35.43 81.09 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.908 179.424 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -81.91 95.13 1.71 Allowed Glycine 0 CA--C 1.518 0.267 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -179.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 1.3 ppt_? -132.55 40.82 3.25 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.729 0.3 . . . . 0.0 111.048 -179.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 3.1 ptmm? -120.5 83.34 34.06 Favored Pre-proline 0 N--CA 1.464 0.226 0 CA-C-O 121.034 0.445 . . . . 0.0 110.955 -179.701 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -59.7 147.29 92.67 Favored 'Trans proline' 0 C--N 1.306 -1.678 0 C-N-CA 122.162 1.908 . . . . 0.0 110.993 179.641 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.419 ' C ' ' CD2' ' A' ' 9' ' ' LEU . 3.5 tt -117.0 114.79 24.29 Favored 'General case' 0 CA--C 1.511 -0.523 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 -179.777 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.427 ' CD1' ' C ' ' A' ' 10' ' ' LEU . 3.0 tm? -93.27 124.5 37.29 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.37 -0.532 . . . . 0.0 109.881 179.266 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.5 ' CD1' ' SG ' ' A' ' 47' ' ' CYS . 5.7 pt -103.37 -41.91 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-O 121.052 0.453 . . . . 0.0 110.588 -179.342 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -174.8 -139.5 3.03 Favored Glycine 0 CA--C 1.521 0.418 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.471 ' C ' ' H ' ' A' ' 15' ' ' ILE . 72.7 p -134.06 165.99 23.78 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.914 0.388 . . . . 0.0 110.924 -179.524 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -58.6 -5.6 0.58 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.206 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.471 ' H ' ' C ' ' A' ' 13' ' ' THR . 24.0 mm -74.5 -24.48 18.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.538 -179.292 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -128.33 -29.92 2.43 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.84 -179.592 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -117.34 91.96 38.84 Favored Pre-proline 0 CA--C 1.536 0.411 0 CA-C-N 116.486 -0.324 . . . . 0.0 110.474 179.759 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.463 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 52.9 Cg_endo -71.56 -177.33 2.4 Favored 'Trans proline' 0 N--CA 1.498 1.736 0 C-N-CA 123.12 2.547 . . . . 0.0 111.853 -179.25 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.473 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 31.0 m -46.73 -70.61 0.09 Allowed 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 120.568 -0.453 . . . . 0.0 111.358 -179.275 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.575 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 1.3 pm0 -41.39 -70.13 0.11 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.395 -178.865 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 5.3 ttmt -54.44 -53.88 48.23 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.021 0.439 . . . . 0.0 111.499 -177.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.463 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 43.0 t -41.41 -59.44 1.57 Allowed 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.071 -178.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.745 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 0.9 OUTLIER -65.82 -52.1 53.41 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.848 179.611 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.745 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 69.7 mttt -48.42 -42.61 32.65 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 120.839 0.352 . . . . 0.0 110.674 -178.539 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 20.0 m -63.93 -41.08 97.73 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-O 121.331 0.586 . . . . 0.0 109.995 179.789 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 57.5 m -65.23 -31.06 72.03 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.574 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 mm -65.37 -38.83 83.48 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.427 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 30.2 mm-40 -65.74 -33.06 75.0 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.551 -0.749 . . . . 0.0 110.626 -178.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 46.2 m -73.27 -2.66 22.8 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.307 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 1.9 m120 77.84 34.5 0.32 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.958 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.603 ' C ' ' H ' ' A' ' 33' ' ' GLY . 8.2 m-85 -110.34 164.7 12.42 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.049 179.892 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.19 21.29 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.57 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.603 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 90.32 -178.7 43.25 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.371 -1.091 . . . . 0.0 110.371 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -147.01 170.33 27.93 Favored Glycine 0 CA--C 1.52 0.406 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 -179.344 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 10.7 ptmt -156.36 -177.0 6.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.619 0.247 . . . . 0.0 110.601 -179.576 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 1.7 m -104.02 125.76 50.62 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.131 179.489 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 34.0 m -133.92 162.57 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.297 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 3.1 p80 -109.12 157.42 18.76 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.867 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 92.1 mt -123.27 131.59 72.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.716 -179.485 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 49.55 -103.98 0.09 OUTLIER Glycine 0 CA--C 1.519 0.307 0 N-CA-C 110.812 -0.915 . . . . 0.0 110.812 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 41.2 tp60 -141.44 30.98 1.71 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.876 0.37 . . . . 0.0 110.396 -179.757 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 58.2 m -85.93 -5.7 59.19 Favored 'General case' 0 CA--C 1.518 -0.252 0 CA-C-O 120.967 0.413 . . . . 0.0 110.91 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . 0.403 ' CD2' ' O ' ' A' ' 43' ' ' LEU . 0.9 OUTLIER 44.42 29.95 0.43 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.398 -179.499 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -99.8 124.88 45.53 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.073 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -89.7 118.01 28.99 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 109.692 -0.485 . . . . 0.0 109.692 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 29.8 m -112.84 136.21 49.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.102 -179.52 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' CD1' ' A' ' 11' ' ' ILE . 22.1 t -92.94 105.98 18.01 Favored 'General case' 0 CA--C 1.513 -0.464 0 N-CA-C 109.373 -0.602 . . . . 0.0 109.373 179.901 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 4.7 p -125.54 154.97 34.6 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.375 0 CA-C-O 120.94 0.4 . . . . 0.0 110.573 -178.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 8.1 m -99.31 173.36 6.81 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.168 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 64.3 m-85 -133.6 117.95 14.44 Favored Pre-proline 0 CA--C 1.536 0.43 0 CA-C-N 116.269 -0.423 . . . . 0.0 109.999 179.224 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -49.54 127.73 19.07 Favored 'Trans proline' 0 N--CA 1.499 1.826 0 C-N-CA 122.186 1.924 . . . . 0.0 112.328 179.666 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 56.6 tttp -96.33 -60.03 1.71 Allowed 'General case' 0 N--CA 1.451 -0.424 0 CA-C-N 116.249 -0.432 . . . . 0.0 109.877 179.081 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.472 ' O ' ' CD2' ' A' ' 53' ' ' TYR . 32.7 p90 -133.26 31.22 3.82 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.667 -179.794 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 85.0 t80 -60.04 95.45 0.03 OUTLIER 'General case' 0 N--CA 1.449 -0.516 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.184 -179.032 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 117.913 -1.041 . . . . 0.0 109.886 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . 0.605 ' NZ ' HD21 ' A' ' 30' ' ' ASN . 60.9 pttt . . . . . 0 N--CA 1.491 1.621 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 32.1 m-20 -65.49 -8.79 21.11 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.4 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 15.4 pt -58.23 170.18 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.467 179.409 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 64.4 t0 -61.91 -41.84 98.38 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.892 -179.486 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 66.82 62.99 4.11 Favored Glycine 0 N--CA 1.461 0.307 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.63 30.34 4.68 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.718 0.294 . . . . 0.0 111.028 -179.433 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.477 ' CB ' ' NZ ' ' A' ' 7' ' ' LYS . 0.1 OUTLIER -131.35 147.48 66.32 Favored Pre-proline 0 N--CA 1.47 0.574 0 CA-C-N 116.555 -0.293 . . . . 0.0 111.086 -179.568 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -74.02 158.96 45.34 Favored 'Trans proline' 0 N--CA 1.502 1.986 0 C-N-CA 122.908 2.405 . . . . 0.0 112.303 179.474 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.6 tt -128.42 120.79 27.59 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.755 -179.215 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.6 tt -89.05 133.9 34.19 Favored 'General case' 0 N--CA 1.468 0.46 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 178.128 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 12.8 pt -109.04 -37.02 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-O 120.869 0.366 . . . . 0.0 111.068 -178.775 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 175.32 -153.72 16.09 Favored Glycine 0 N--CA 1.452 -0.255 0 N-CA-C 110.913 -0.875 . . . . 0.0 110.913 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.409 ' HG1' ' HB ' ' A' ' 15' ' ' ILE . 6.7 p -90.03 164.85 14.35 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 179.764 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 10.4 t -76.07 7.35 4.19 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.214 179.601 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.409 ' HB ' ' HG1' ' A' ' 13' ' ' THR . 96.5 mt -91.46 -42.32 13.65 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.221 0 CA-C-O 121.149 0.499 . . . . 0.0 109.808 179.727 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -87.91 -12.63 44.15 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.361 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -124.81 81.2 61.81 Favored Pre-proline 0 N--CA 1.463 0.217 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.954 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -48.64 163.23 0.29 Allowed 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.05 1.833 . . . . 0.0 110.719 178.731 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.406 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 25.5 p -46.5 -53.24 11.63 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.919 0.39 . . . . 0.0 111.721 -177.837 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.573 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 0.0 OUTLIER -59.72 -55.4 34.78 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.573 -179.429 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -58.96 -44.79 91.53 Favored 'General case' 0 CA--C 1.516 -0.336 0 CA-C-O 121.332 0.587 . . . . 0.0 110.388 -178.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 14.7 t -48.28 -65.46 0.56 Allowed 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 115.265 -0.88 . . . . 0.0 111.427 -178.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.659 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.6 p-10 -64.97 -46.97 79.26 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.011 -179.438 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.659 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 92.9 mttt -50.59 -37.55 40.53 Favored 'General case' 0 CA--C 1.5 -0.952 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.23 179.592 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 86.8 m -63.93 -42.79 97.26 Favored 'General case' 0 C--N 1.319 -0.751 0 O-C-N 124.012 0.82 . . . . 0.0 110.468 -179.342 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.497 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 33.8 t -72.58 -33.4 66.74 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.106 179.68 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.2 mm -66.08 -46.7 87.19 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.616 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.112 -179.192 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.546 ' C ' ' H ' ' A' ' 30' ' ' ASN . 19.0 pt-20 -69.64 -30.46 68.17 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 115.349 -0.841 . . . . 0.0 110.151 -179.698 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.416 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 68.3 m -65.49 1.78 1.09 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.75 179.845 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.605 HD21 ' NZ ' ' A' ' 1' ' ' LYS . 16.9 t-20 79.82 12.56 1.1 Allowed 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.966 179.546 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.562 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 4.5 m-85 -98.07 -167.81 1.57 Allowed 'General case' 0 CA--C 1.533 0.322 0 CA-C-O 120.706 0.289 . . . . 0.0 110.27 -179.842 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -75.79 -53.97 7.65 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.582 0.586 . . . . 0.0 112.582 -178.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.497 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 166.5 178.9 39.45 Favored Glycine 0 CA--C 1.519 0.321 0 N-CA-C 110.068 -1.213 . . . . 0.0 110.068 -178.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -137.26 160.98 25.19 Favored Glycine 0 C--N 1.331 0.299 0 N-CA-C 111.579 -0.609 . . . . 0.0 111.579 -179.383 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 14.2 ptpt -153.45 170.23 21.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.29 -0.455 . . . . 0.0 110.779 -178.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 56.5 m -104.86 117.7 34.7 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.891 179.493 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 4.8 m -139.65 -178.5 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-O 120.873 0.368 . . . . 0.0 111.129 -179.427 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.619 ' ND1' ' N ' ' A' ' 44' ' ' ASP . 95.3 m-70 -114.0 147.98 37.72 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.802 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 95.6 mt -124.06 127.8 73.7 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.849 -179.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 68.74 21.78 75.09 Favored Glycine 0 CA--C 1.52 0.35 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 179.374 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 57.79 30.8 19.55 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.196 0.522 . . . . 0.0 109.794 -179.215 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 50.6 m -72.22 -10.92 60.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.443 -0.798 . . . . 0.0 110.511 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . 0.445 ' C ' ' ND1' ' A' ' 38' ' ' HIS . 0.9 OUTLIER 63.14 29.33 16.14 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.649 -179.636 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . 0.619 ' N ' ' ND1' ' A' ' 38' ' ' HIS . 67.2 t0 -111.05 138.69 47.16 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.714 179.499 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.489 ' N ' ' OD1' ' A' ' 44' ' ' ASP . 50.2 m-85 -92.95 117.38 29.98 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.645 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 25.9 m -124.29 136.81 59.29 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.328 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.052 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -94.46 122.59 37.19 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.352 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.0 p -135.52 152.52 31.71 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.318 0 C-N-CA 120.655 -0.418 . . . . 0.0 111.319 -179.393 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' CYS . . . . . 0.562 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 23.9 t -96.01 164.18 12.81 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.078 -179.937 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.494 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 37.7 m-85 -130.75 136.55 29.11 Favored Pre-proline 0 N--CA 1.476 0.849 0 C-N-CA 120.788 -0.365 . . . . 0.0 111.352 -178.427 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -70.41 156.35 61.85 Favored 'Trans proline' 0 N--CA 1.491 1.355 0 C-N-CA 121.865 1.71 . . . . 0.0 112.207 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 29.5 mmtp -67.04 -19.92 65.76 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.879 -0.6 . . . . 0.0 109.925 179.379 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 73.2 m-85 -109.53 40.0 1.97 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.493 -179.525 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 90.3 t80 -73.24 126.79 30.9 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.193 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 5.2 pt . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.066 -0.969 . . . . 0.0 110.222 -179.889 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 98.6 mttt . . . . . 0 N--CA 1.489 1.495 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 45.8 t0 -67.42 -9.76 44.81 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.663 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 5.9 mm -81.16 130.29 36.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.476 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 66.6 t0 -62.12 -42.1 98.9 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.502 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 42.4 87.57 0.01 OUTLIER Glycine 0 N--CA 1.46 0.258 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.33 25.63 5.15 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.67 -0.265 . . . . 0.0 110.699 -179.339 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.1 153.25 76.65 Favored Pre-proline 0 CA--C 1.54 0.591 0 CA-C-N 116.689 -0.232 . . . . 0.0 111.534 -179.276 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -57.71 145.34 90.32 Favored 'Trans proline' 0 N--CA 1.501 1.934 0 C-N-CA 121.879 1.719 . . . . 0.0 111.797 178.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.5 tt -128.33 119.5 25.2 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.6 tt -88.65 126.58 35.36 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 108.839 -0.801 . . . . 0.0 108.839 179.199 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.505 ' CD1' ' SG ' ' A' ' 47' ' ' CYS . 2.2 pt -105.36 -48.12 9.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-O 120.983 0.421 . . . . 0.0 110.852 -178.549 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -159.87 -144.22 3.9 Favored Glycine 0 CA--C 1.52 0.369 0 N-CA-C 110.771 -0.931 . . . . 0.0 110.771 -179.802 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.5 ' C ' ' H ' ' A' ' 15' ' ' ILE . 55.2 p -138.89 161.22 37.83 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.994 0.426 . . . . 0.0 110.809 -179.826 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -59.81 -1.28 0.26 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.221 179.652 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.5 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.2 mt -77.9 -23.65 13.98 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.406 0 CA-C-O 121.164 0.506 . . . . 0.0 109.806 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 2.7 pt-20 -134.24 -34.17 0.98 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.589 -0.732 . . . . 0.0 111.197 -179.381 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.478 ' CE1' ' NZ ' ' A' ' 21' ' ' LYS . 6.4 m-85 -106.82 88.85 3.84 Favored Pre-proline 0 CA--C 1.538 0.5 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.416 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 19.0 Cg_endo -63.43 -173.6 0.18 Allowed 'Trans proline' 0 N--CA 1.499 1.799 0 C-N-CA 121.832 1.688 . . . . 0.0 112.461 -178.789 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 70.5 m -58.11 -49.81 75.66 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.021 -179.227 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.484 ' CG ' ' H ' ' A' ' 21' ' ' LYS . 8.9 pt-20 -59.06 -56.66 19.42 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.806 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.484 ' H ' ' CG ' ' A' ' 20' ' ' GLU . 0.6 OUTLIER -64.51 -47.22 79.68 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-O 121.235 0.541 . . . . 0.0 111.087 -177.989 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.416 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 32.4 t -45.4 -63.18 1.0 Allowed 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.375 -0.83 . . . . 0.0 111.682 -179.149 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.625 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 0.0 OUTLIER -63.45 -49.6 73.03 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.008 -179.276 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.625 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 47.5 mttp -45.1 -42.37 8.72 Favored 'General case' 0 C--O 1.218 -0.563 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.087 -179.7 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 17.8 m -62.34 -43.49 98.7 Favored 'General case' 0 C--N 1.311 -1.094 0 C-N-CA 119.98 -0.688 . . . . 0.0 110.366 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.492 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 11.4 t -66.99 -32.65 74.03 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 121.574 0.702 . . . . 0.0 109.788 179.615 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.5 mm -65.9 -41.76 90.63 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.213 -179.445 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.484 ' C ' ' H ' ' A' ' 30' ' ' ASN . 25.6 mm-40 -65.43 -34.87 79.31 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.146 -0.933 . . . . 0.0 110.371 -179.477 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.412 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 27.3 m -66.76 2.38 1.41 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.189 -179.742 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.484 ' H ' ' C ' ' A' ' 28' ' ' GLU . 17.5 t-20 78.24 15.28 1.38 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.59 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.553 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 4.1 m-85 -95.79 -168.62 1.8 Allowed 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 120.898 0.38 . . . . 0.0 110.343 -179.764 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -76.05 -50.13 15.62 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.987 -178.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.492 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 160.39 -176.17 37.08 Favored Glycine 0 C--O 1.226 -0.402 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 -179.148 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -146.02 168.14 27.66 Favored Glycine 0 CA--C 1.519 0.331 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 -179.41 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 14.6 ptpt -155.76 178.65 10.02 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.003 0.43 . . . . 0.0 110.81 -179.126 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 4.6 m -103.59 123.52 47.11 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.077 179.506 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 27.6 m -136.4 161.16 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.45 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.54 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 2.1 p80 -109.34 157.09 19.22 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.074 179.818 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.457 ' O ' ' N ' ' A' ' 41' ' ' GLN . 34.5 mm -107.83 125.74 64.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.174 -179.655 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 41.72 -94.4 0.01 OUTLIER Glycine 0 CA--C 1.527 0.782 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 179.694 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.457 ' N ' ' O ' ' A' ' 39' ' ' ILE . 16.6 mp0 -139.67 35.63 2.01 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.796 0.332 . . . . 0.0 110.348 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' SER . . . . . 0.529 ' O ' ' N ' ' A' ' 44' ' ' ASP . 63.7 m -87.02 2.22 50.29 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.951 -179.875 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . 0.409 ' CD2' ' C ' ' A' ' 42' ' ' SER . 1.3 pt? 34.64 28.06 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 O-C-N 123.756 0.66 . . . . 0.0 111.618 -179.583 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 42' ' ' SER . 52.5 t0 -107.78 120.42 42.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.478 -179.843 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 -88.79 117.66 27.93 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 32.5 m -115.12 142.85 26.43 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.269 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.177 -179.431 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.505 ' SG ' ' CD1' ' A' ' 11' ' ' ILE . 17.0 t -94.03 119.15 32.51 Favored 'General case' 0 CA--C 1.515 -0.396 0 CA-C-N 115.894 -0.594 . . . . 0.0 109.462 179.749 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.4 p -126.39 152.46 33.94 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.204 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.398 -179.512 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' CYS . . . . . 0.553 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 33.0 t -96.41 163.31 13.11 Favored 'General case' 0 N--CA 1.466 0.341 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 -179.771 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.484 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 19.0 m-85 -129.86 125.47 22.15 Favored Pre-proline 0 N--CA 1.469 0.497 0 C-N-CA 121.147 -0.221 . . . . 0.0 110.73 -178.738 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_endo -74.3 159.81 43.1 Favored 'Trans proline' 0 N--CA 1.488 1.168 0 C-N-CA 121.812 1.674 . . . . 0.0 112.188 179.789 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -62.85 -28.04 69.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.693 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 98.9 m-85 -107.33 41.02 1.56 Allowed 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.71 -179.326 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 41.2 p90 -65.3 134.01 52.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.263 179.762 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 3.1 pt . . . . . 0 C--O 1.22 -0.498 0 CA-C-O 117.982 -1.008 . . . . 0.0 110.071 -179.844 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 64.0 mttp . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 44.8 t0 57.54 35.53 25.89 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.537 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 5.8 mm -98.77 127.87 50.91 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-O 120.955 0.407 . . . . 0.0 110.19 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -62.54 -39.32 93.22 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.773 -179.811 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 52.73 89.04 0.01 OUTLIER Glycine 0 C--O 1.23 -0.14 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -128.54 23.61 5.86 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.581 -0.31 . . . . 0.0 110.617 -179.789 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.604 ' H ' ' CD ' ' A' ' 7' ' ' LYS . 0.0 OUTLIER -109.11 144.97 30.79 Favored Pre-proline 0 N--CA 1.471 0.619 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.825 -179.936 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.435 ' CB ' ' O ' ' A' ' 49' ' ' CYS . 74.2 Cg_endo -71.58 161.67 44.62 Favored 'Trans proline' 0 N--CA 1.493 1.494 0 C-N-CA 122.215 1.943 . . . . 0.0 111.909 179.217 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.4 tt -135.55 119.68 17.66 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-O 120.764 0.316 . . . . 0.0 110.725 -179.312 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.3 tt -88.97 133.43 34.32 Favored 'General case' 0 N--CA 1.464 0.255 0 N-CA-C 109.584 -0.525 . . . . 0.0 109.584 178.238 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.477 ' CD1' ' SG ' ' A' ' 47' ' ' CYS . 2.3 pt -109.62 -46.17 6.68 Favored 'Isoleucine or valine' 0 C--O 1.231 0.11 0 CA-C-O 120.835 0.35 . . . . 0.0 110.232 -178.716 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 179.46 -159.74 24.59 Favored Glycine 0 N--CA 1.452 -0.26 0 N-CA-C 111.276 -0.73 . . . . 0.0 111.276 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 68.7 p -100.99 164.09 11.98 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.193 -0.503 . . . . 0.0 110.245 179.755 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -59.12 -11.46 3.73 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.455 179.448 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 97.0 mt -70.35 -43.73 78.08 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 CA-C-O 121.159 0.505 . . . . 0.0 110.296 -179.693 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -98.05 -31.2 12.26 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.954 -179.402 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.433 ' O ' ' O ' ' A' ' 18' ' ' PRO . 13.9 m-85 -121.11 80.47 35.33 Favored Pre-proline 0 N--CA 1.469 0.52 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 178.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.433 ' O ' ' O ' ' A' ' 17' ' ' PHE . 75.3 Cg_exo -47.05 -178.9 0.0 OUTLIER 'Trans proline' 0 N--CA 1.495 1.583 0 C-N-CA 122.794 2.329 . . . . 0.0 111.747 -179.667 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 37.4 p -58.77 -54.71 44.04 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.418 0.628 . . . . 0.0 111.536 -179.278 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.404 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 8.9 pt-20 -55.74 -52.24 64.62 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.01 -0.996 . . . . 0.0 111.216 -179.685 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -63.64 -47.36 81.67 Favored 'General case' 0 CA--C 1.519 -0.215 0 CA-C-O 121.312 0.577 . . . . 0.0 110.534 -179.623 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 36.8 t -45.44 -63.18 1.01 Allowed 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 115.12 -0.945 . . . . 0.0 111.229 -179.233 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.609 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 0.0 OUTLIER -64.36 -47.9 77.58 Favored 'General case' 0 C--O 1.221 -0.424 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.867 -178.953 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.609 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 83.4 mttt -48.73 -39.51 25.1 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.22 -179.675 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' THR . . . . . 0.434 ' O ' ' OG ' ' A' ' 29' ' ' SER . 16.7 m -64.9 -40.66 95.44 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.207 0.527 . . . . 0.0 110.112 -179.714 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.508 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 41.2 t -72.58 -36.3 68.13 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.409 0.623 . . . . 0.0 110.492 179.54 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.2 mm -64.62 -47.61 88.23 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.928 -179.097 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.446 ' C ' ' H ' ' A' ' 30' ' ' ASN . 2.9 pp20? -70.95 -27.52 63.8 Favored 'General case' 0 N--CA 1.446 -0.645 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.638 -179.504 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.477 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 72.8 m -67.17 0.66 2.55 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.611 -179.639 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.477 ' CB ' ' O ' ' A' ' 29' ' ' SER . 14.6 t-20 85.59 3.42 0.59 Allowed 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.534 179.781 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.578 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 47.5 m-85 -91.47 -167.79 1.88 Allowed 'General case' 0 N--CA 1.456 -0.169 0 CA-C-O 120.871 0.367 . . . . 0.0 110.525 179.608 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -78.34 -59.12 2.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.35 0.595 . . . . 0.0 111.756 -178.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.508 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 175.18 177.64 44.42 Favored Glycine 0 N--CA 1.449 -0.47 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -178.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -135.27 157.84 23.33 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -179.538 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 17.6 ptpt -149.62 166.96 27.71 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.915 0.388 . . . . 0.0 110.814 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 1.8 m -103.78 122.91 46.08 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.037 179.577 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 33.4 m -136.98 169.57 19.58 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.601 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.514 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 1.8 m-70 -97.45 154.04 17.74 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.116 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.464 ' O ' ' N ' ' A' ' 41' ' ' GLN . 42.2 mm -115.03 128.69 72.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 42.32 -94.41 0.01 OUTLIER Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.933 -0.867 . . . . 0.0 110.933 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.464 ' N ' ' O ' ' A' ' 39' ' ' ILE . 88.4 mt-30 -140.72 27.5 2.03 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.654 0.264 . . . . 0.0 110.672 -179.768 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 58.8 m -80.2 -9.99 59.74 Favored 'General case' 0 CA--C 1.518 -0.254 0 CA-C-O 121.012 0.434 . . . . 0.0 110.665 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . 0.403 ' O ' ' CD2' ' A' ' 43' ' ' LEU . 0.9 OUTLIER 41.92 30.85 0.19 Allowed 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.38 -179.355 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' A' ' 45' ' ' PHE . 66.2 t0 -110.24 141.17 43.57 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.139 179.877 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.521 ' N ' ' OD1' ' A' ' 44' ' ' ASP . 56.8 m-85 -88.59 116.43 26.82 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.045 0.45 . . . . 0.0 110.312 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 19.8 m -114.62 133.53 60.45 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.307 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.28 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.477 ' SG ' ' CD1' ' A' ' 11' ' ' ILE . 27.9 t -93.58 114.67 27.07 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.317 179.859 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.8 p -125.03 139.83 49.93 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.229 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.029 -178.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' CYS . . . . . 0.578 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 39.2 t -97.27 157.33 16.01 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 115.517 -0.765 . . . . 0.0 109.716 -179.687 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.431 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 0.2 OUTLIER -149.93 151.62 32.65 Favored Pre-proline 0 N--CA 1.473 0.688 0 C-N-CA 120.593 -0.443 . . . . 0.0 110.933 179.775 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_endo -70.95 165.33 32.66 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 C-N-CA 122.686 2.257 . . . . 0.0 111.956 178.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -71.79 -20.89 61.79 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.591 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -109.17 40.14 1.9 Allowed 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.676 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 89.8 t80 -75.48 100.29 4.47 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.025 179.802 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 26.5 pt . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.402 -179.742 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 45.6 mmtt . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -99.22 7.22 45.92 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.388 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.5 tt -58.52 141.36 15.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.511 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . 0.419 ' OD1' ' N ' ' A' ' 5' ' ' GLY . 1.3 p30 -63.29 -39.07 93.55 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 120.888 -0.325 . . . . 0.0 110.533 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.419 ' N ' ' OD1' ' A' ' 4' ' ' ASP . . . 79.97 -94.89 1.48 Allowed Glycine 0 C--N 1.329 0.189 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 179.748 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -126.61 37.89 4.22 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 110.172 -0.307 . . . . 0.0 110.172 -179.58 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 2.8 tppp? -120.17 126.54 26.78 Favored Pre-proline 0 CA--C 1.534 0.351 0 C-N-CA 121.083 -0.247 . . . . 0.0 111.394 -179.463 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -74.5 171.77 17.47 Favored 'Trans proline' 0 N--CA 1.489 1.246 0 C-N-CA 122.055 1.837 . . . . 0.0 111.647 179.142 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.0 tt -133.74 119.75 19.69 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 120.78 0.324 . . . . 0.0 110.524 -179.751 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.8 tt -91.03 130.75 36.91 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.978 0.418 . . . . 0.0 109.947 178.326 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.514 ' CD1' ' SG ' ' A' ' 47' ' ' CYS . 5.8 pt -106.37 -44.59 7.75 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.632 -179.624 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -176.12 -133.74 1.83 Allowed Glycine 0 CA--C 1.519 0.305 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 -179.593 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.463 ' C ' ' H ' ' A' ' 15' ' ' ILE . 80.7 p -131.56 166.19 21.94 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.925 0.393 . . . . 0.0 111.034 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -61.66 -3.85 1.22 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.974 179.5 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.463 ' H ' ' C ' ' A' ' 13' ' ' THR . 34.2 mm -70.85 -42.73 77.36 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 CA-C-O 121.224 0.535 . . . . 0.0 109.92 -179.562 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -108.24 -23.07 12.09 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.628 -0.715 . . . . 0.0 111.072 -179.568 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 44.7 m-85 -124.67 79.17 63.15 Favored Pre-proline 0 C--O 1.223 -0.292 0 CA-C-N 116.577 -0.283 . . . . 0.0 110.553 179.687 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 71.4 Cg_exo -49.05 -179.01 0.01 OUTLIER 'Trans proline' 0 N--CA 1.501 1.93 0 C-N-CA 123.137 2.558 . . . . 0.0 111.733 179.457 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.454 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 96.2 m -58.22 -50.38 73.75 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 112.321 0.489 . . . . 0.0 112.321 -178.795 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.524 ' CG ' ' H ' ' A' ' 21' ' ' LYS . 6.6 pt-20 -56.57 -57.21 13.34 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.771 0.32 . . . . 0.0 111.257 -179.137 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.524 ' H ' ' CG ' ' A' ' 20' ' ' GLU . 18.7 mtmt -62.91 -44.99 94.58 Favored 'General case' 0 CA--C 1.509 -0.604 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.377 -179.718 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.409 ' O ' ' SG ' ' A' ' 26' ' ' CYS . 53.2 t -47.64 -46.43 28.81 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-O 121.233 0.54 . . . . 0.0 111.235 -178.292 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.734 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.6 p-10 -78.92 -53.11 7.39 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 120.483 -0.487 . . . . 0.0 110.39 179.305 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.734 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 29.7 mttp -50.71 -45.04 58.28 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.646 -0.422 . . . . 0.0 110.734 -178.004 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' THR . . . . . 0.403 HG21 ' O ' ' A' ' 22' ' ' CYS . 11.6 t -64.81 -37.86 89.04 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 121.391 0.615 . . . . 0.0 109.845 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.409 ' SG ' ' O ' ' A' ' 22' ' ' CYS . 54.8 m -63.61 -33.75 76.3 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.32 179.299 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.418 HG12 ' O ' ' A' ' 23' ' ' ASN . 3.3 mm -63.26 -36.86 77.75 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.054 179.728 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 29.0 mt-10 -66.1 -34.6 78.42 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.809 -178.639 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.411 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 7.1 m -72.59 -2.37 19.66 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.446 -179.173 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.411 ' CB ' ' O ' ' A' ' 29' ' ' SER . 4.5 m-80 78.31 33.68 0.3 Allowed 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.732 -179.88 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.608 ' C ' ' H ' ' A' ' 33' ' ' GLY . 8.0 m-85 -109.35 162.34 14.42 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.114 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.63 26.75 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.745 179.619 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.608 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 87.0 -174.92 46.23 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 110.739 -0.944 . . . . 0.0 110.739 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -151.67 172.04 31.12 Favored Glycine 0 CA--C 1.52 0.348 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 -179.313 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 20.0 pttt -156.27 -179.28 8.01 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.037 0.446 . . . . 0.0 110.63 -179.535 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 4.0 m -107.76 125.71 51.73 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.12 179.158 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 20.2 m -141.13 174.19 7.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.325 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.64 ' NE2' ' CE1' ' A' ' 45' ' ' PHE . 38.2 m80 -105.67 152.42 23.16 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.477 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 96.7 mt -129.8 125.58 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.477 179.497 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 66.46 21.66 70.74 Favored Glycine 0 CA--C 1.52 0.39 0 N-CA-C 111.339 -0.705 . . . . 0.0 111.339 179.126 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 58.24 38.08 26.14 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.933 0.396 . . . . 0.0 110.586 -179.818 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 44.1 m -82.26 -11.23 58.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.015 -179.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . 0.409 ' CD2' ' O ' ' A' ' 43' ' ' LEU . 0.8 OUTLIER 68.24 27.99 6.52 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.258 -179.607 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -111.7 135.49 52.23 Favored 'General case' 0 N--CA 1.463 0.188 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 179.262 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.64 ' CE1' ' NE2' ' A' ' 38' ' ' HIS . 52.6 m-85 -91.71 116.15 28.64 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 13.2 m -112.9 133.7 57.88 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.272 0 CA-C-N 115.964 -0.562 . . . . 0.0 109.807 -179.824 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.514 ' SG ' ' CD1' ' A' ' 11' ' ' ILE . 34.6 t -92.48 115.35 28.02 Favored 'General case' 0 CA--C 1.511 -0.536 0 CA-C-N 116.167 -0.47 . . . . 0.0 109.842 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.2 p -134.36 148.58 29.75 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.412 0 CA-C-O 121.118 0.485 . . . . 0.0 110.861 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 6.6 m -97.59 161.66 13.66 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.505 179.729 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 53.0 m-85 -116.84 147.96 41.09 Favored Pre-proline 0 N--CA 1.464 0.259 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.028 -179.326 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -65.92 154.42 74.04 Favored 'Trans proline' 0 N--CA 1.492 1.42 0 C-N-CA 122.405 2.07 . . . . 0.0 111.895 179.298 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 56.8 mtpt -63.76 -21.51 66.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.046 0.451 . . . . 0.0 110.302 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -108.95 40.58 1.78 Allowed 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.56 -179.763 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 46.3 p90 -65.3 134.93 54.67 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.195 179.777 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.2 pt . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 118.06 -0.971 . . . . 0.0 109.983 -179.883 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 72.3 mmtt . . . . . 0 N--CA 1.492 1.663 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.432 ' OD1' ' O ' ' A' ' 2' ' ' ASP . 47.9 t0 58.33 37.19 25.94 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.258 -179.552 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 1.3 pp -123.53 163.37 22.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.006 -179.198 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . 0.474 ' OD1' ' N ' ' A' ' 5' ' ' GLY . 42.0 p-10 -74.93 -34.72 62.15 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.537 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.474 ' N ' ' OD1' ' A' ' 4' ' ' ASP . . . -77.91 71.75 2.35 Favored Glycine 0 CA--C 1.52 0.369 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 -179.609 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.21 31.04 4.15 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.879 0.371 . . . . 0.0 110.181 -178.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.506 ' CB ' ' NZ ' ' A' ' 7' ' ' LYS . 0.0 OUTLIER -105.12 147.15 34.03 Favored Pre-proline 0 CA--C 1.533 0.31 0 C-N-CA 120.597 -0.441 . . . . 0.0 110.645 179.577 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -68.35 166.48 25.28 Favored 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 122.865 2.377 . . . . 0.0 111.947 179.403 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.41 ' C ' ' CD2' ' A' ' 9' ' ' LEU . 3.9 tt -136.67 117.31 13.91 Favored 'General case' 0 CA--C 1.52 -0.196 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.543 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.8 tt -92.8 131.95 37.4 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 179.21 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 10.2 pt -104.18 -36.9 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.281 -179.285 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -177.31 -127.62 1.07 Allowed Glycine 0 CA--C 1.517 0.163 0 N-CA-C 110.674 -0.971 . . . . 0.0 110.674 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.528 ' C ' ' H ' ' A' ' 15' ' ' ILE . 71.5 p -127.77 154.42 45.4 Favored 'General case' 0 CA--C 1.52 -0.189 0 CA-C-O 120.861 0.363 . . . . 0.0 110.479 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 6.6 t -66.3 6.67 0.39 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.521 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.528 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.7 mt -86.58 -40.97 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.138 0 CA-C-O 120.86 0.362 . . . . 0.0 110.143 -179.858 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -102.41 -5.48 24.07 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.978 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 51.2 m-85 -123.5 79.87 54.38 Favored Pre-proline 0 N--CA 1.465 0.293 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.847 179.57 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -47.77 168.01 0.09 OUTLIER 'Trans proline' 0 N--CA 1.495 1.572 0 C-N-CA 122.963 2.442 . . . . 0.0 111.866 179.164 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.436 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 10.0 m -49.78 -52.85 28.93 Favored 'General case' 0 C--N 1.326 -0.425 0 C-N-CA 120.642 -0.423 . . . . 0.0 111.62 -178.806 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.566 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 1.3 pm0 -61.91 -56.96 13.85 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.081 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -56.6 -45.13 81.6 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 121.046 0.451 . . . . 0.0 110.69 -178.201 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 12.4 t -47.75 -65.46 0.56 Allowed 'General case' 0 C--N 1.314 -0.978 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.011 -178.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.656 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 2.4 p-10 -62.51 -54.43 40.09 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.339 -179.756 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.656 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 43.8 mtpt -44.53 -43.91 8.31 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 120.546 -0.462 . . . . 0.0 110.853 -179.698 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 99.3 m -64.13 -39.62 94.42 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-O 121.495 0.664 . . . . 0.0 109.875 -179.651 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 58.5 m -67.42 -32.59 73.58 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.698 -179.681 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.3 mm -63.14 -43.63 98.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.518 -179.396 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -65.31 -35.63 81.59 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.42 -178.888 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.445 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 84.0 p -67.12 -3.41 7.43 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.459 -179.325 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.445 ' CB ' ' O ' ' A' ' 29' ' ' SER . 3.2 t-20 80.52 37.14 0.1 Allowed 'General case' 0 N--CA 1.466 0.358 0 O-C-N 123.478 0.486 . . . . 0.0 110.783 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.609 ' C ' ' H ' ' A' ' 33' ' ' GLY . 13.9 m-85 -119.54 160.7 21.91 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 120.993 0.425 . . . . 0.0 110.084 -179.843 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.428 ' N ' ' O ' ' A' ' 50' ' ' PHE . . . -68.96 27.99 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.584 -179.86 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.609 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 87.06 -172.92 44.24 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 179.829 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -154.04 174.48 32.52 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.731 -0.947 . . . . 0.0 110.731 -179.437 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 11.6 ptmt -155.89 -178.7 7.49 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.806 0.336 . . . . 0.0 110.507 -179.459 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 69.0 m -105.28 127.72 53.09 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.23 179.359 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 32.5 m -135.59 161.34 39.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.101 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 3.3 p80 -108.9 157.23 18.82 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.295 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.414 ' O ' ' N ' ' A' ' 41' ' ' GLN . 32.8 mm -104.59 122.42 57.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.328 -179.748 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 40.56 -96.47 0.01 OUTLIER Glycine 0 CA--C 1.524 0.634 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.414 ' N ' ' O ' ' A' ' 39' ' ' ILE . 97.5 mt-30 -139.65 30.47 2.1 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 120.675 0.274 . . . . 0.0 110.525 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 16.8 m -80.78 -6.22 58.21 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.138 0.494 . . . . 0.0 110.738 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 50.07 28.57 3.05 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.549 -179.702 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 38.7 t0 -109.43 120.79 43.59 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.112 179.594 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 70.6 m-85 -88.74 129.03 35.63 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-O 120.962 0.41 . . . . 0.0 109.919 -179.771 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 33.1 m -124.06 142.31 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.42 -179.359 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -95.25 119.84 34.45 Favored 'General case' 0 CA--C 1.518 -0.27 0 N-CA-C 109.211 -0.662 . . . . 0.0 109.211 -179.803 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.1 p -134.38 149.46 29.98 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.358 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.715 -179.195 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 14.1 m -98.69 177.97 5.14 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.79 179.741 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.428 ' O ' ' N ' ' A' ' 32' ' ' ALA . 45.7 m-85 -137.28 121.12 11.95 Favored Pre-proline 0 CA--C 1.537 0.461 0 C-N-CA 120.82 -0.352 . . . . 0.0 111.035 179.828 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -66.7 146.86 80.27 Favored 'Trans proline' 0 N--CA 1.495 1.61 0 C-N-CA 122.626 2.217 . . . . 0.0 111.916 -179.744 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -119.28 -58.05 1.95 Allowed 'General case' 0 N--CA 1.465 0.294 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 179.708 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 7.4 p90 -131.81 19.22 4.63 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.589 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 25.8 t80 -64.51 141.26 58.84 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 110.086 -0.339 . . . . 0.0 110.086 -178.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.7 mt . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 118.039 -0.981 . . . . 0.0 110.41 -179.695 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 53.9 mtmt . . . . . 0 N--CA 1.489 1.504 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 56.88 35.01 25.73 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.847 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 5.2 mm -111.91 130.62 65.21 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 CA-C-O 121.202 0.525 . . . . 0.0 110.488 179.801 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -63.92 -36.81 85.16 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.36 -0.836 . . . . 0.0 110.22 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 69.17 60.23 5.32 Favored Glycine 0 C--N 1.331 0.254 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.48 29.05 5.83 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.66 0.267 . . . . 0.0 110.534 -179.637 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 23.5 pttt -131.45 146.02 60.12 Favored Pre-proline 0 N--CA 1.462 0.152 0 C-N-CA 120.989 -0.284 . . . . 0.0 111.184 -179.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -65.69 149.28 87.27 Favored 'Trans proline' 0 N--CA 1.491 1.325 0 C-N-CA 122.42 2.08 . . . . 0.0 111.642 179.512 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.472 ' CD1' ' O ' ' A' ' 10' ' ' LEU . 0.4 OUTLIER -125.05 122.78 38.23 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-O 121.258 0.551 . . . . 0.0 110.798 179.781 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.472 ' O ' ' CD1' ' A' ' 9' ' ' LEU . 5.9 tt -86.01 147.7 26.09 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.45 178.371 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -126.74 -58.96 1.58 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.569 -178.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -160.2 -140.1 2.82 Favored Glycine 0 CA--C 1.519 0.294 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.35 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.471 ' C ' ' H ' ' A' ' 15' ' ' ILE . 43.5 p -131.5 160.12 36.15 Favored 'General case' 0 CA--C 1.518 -0.261 0 CA-C-O 121.006 0.431 . . . . 0.0 110.857 -179.79 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -52.63 -11.2 0.19 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.066 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.471 ' H ' ' C ' ' A' ' 13' ' ' THR . 39.0 mm -72.3 -43.12 65.45 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 CA-C-O 121.158 0.504 . . . . 0.0 110.288 -179.398 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 1.9 pt-20 -102.27 -31.36 10.58 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.39 -0.823 . . . . 0.0 110.945 -179.531 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 15.6 m-85 -120.94 82.78 36.44 Favored Pre-proline 0 N--CA 1.466 0.339 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.128 179.73 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo -48.46 -179.14 0.01 OUTLIER 'Trans proline' 0 N--CA 1.493 1.487 0 C-N-CA 122.807 2.338 . . . . 0.0 111.965 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.431 ' OG1' ' OE2' ' A' ' 20' ' ' GLU . 28.6 p -57.27 -52.31 65.84 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 120.942 0.401 . . . . 0.0 111.557 -179.336 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.572 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 0.2 OUTLIER -58.94 -57.84 11.3 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.474 -179.88 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -59.14 -43.94 92.05 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.736 -178.505 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.1 t -48.11 -60.97 2.22 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.881 -179.271 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.73 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.3 p-10 -62.59 -51.56 66.85 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.453 -179.631 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.73 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 31.7 mttp -47.36 -41.21 19.18 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.873 0.368 . . . . 0.0 110.168 -179.403 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 20.1 m -62.11 -43.9 97.81 Favored 'General case' 0 C--N 1.314 -0.939 0 C-N-CA 120.294 -0.563 . . . . 0.0 110.104 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 5.1 t -65.23 -32.68 74.48 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 179.645 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.5 mm -68.27 -31.71 52.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.538 -179.468 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.429 ' C ' ' H ' ' A' ' 30' ' ' ASN . 30.7 mm-40 -67.92 -34.99 77.68 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.762 -179.504 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.417 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 31.2 m -70.73 1.25 5.6 Favored 'General case' 0 CA--C 1.514 -0.408 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.944 -179.647 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.429 ' H ' ' C ' ' A' ' 28' ' ' GLU . 4.1 m-20 78.19 25.95 0.59 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.618 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.554 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 5.4 m-85 -103.29 -168.68 1.54 Allowed 'General case' 0 N--CA 1.452 -0.326 0 CA-C-O 120.952 0.406 . . . . 0.0 110.226 -179.744 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -76.2 -49.3 17.54 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.586 -179.596 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.496 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 160.54 -175.25 37.29 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 -179.478 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -148.03 170.4 28.67 Favored Glycine 0 C--O 1.226 -0.374 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -179.05 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 11.2 ptmt -158.68 -179.97 8.56 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.775 0.321 . . . . 0.0 110.525 -179.575 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 23.3 m -105.31 127.65 53.06 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.502 179.139 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 17.7 m -137.58 164.55 28.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.499 179.672 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.592 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 2.4 p80 -103.64 155.84 18.25 Favored 'General case' 0 N--CA 1.462 0.153 0 CA-C-O 121.002 0.429 . . . . 0.0 110.223 179.775 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.408 HD13 HG21 ' A' ' 39' ' ' ILE . 97.0 mt -131.37 128.59 61.51 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.627 -179.809 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 60.4 23.36 60.15 Favored Glycine 0 CA--C 1.52 0.35 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 179.343 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 87.5 mt-30 56.43 30.9 17.82 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 120.881 0.372 . . . . 0.0 110.573 -179.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 4.0 m -78.64 -7.2 57.41 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.767 -179.701 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 68.92 27.84 5.43 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.559 -179.641 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 40.3 t0 -107.44 118.49 36.86 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.091 179.65 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 3.3 m-30 -91.07 115.89 28.37 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-O 121.225 0.536 . . . . 0.0 109.705 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 28.3 m -113.95 142.34 26.89 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.301 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.097 -179.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 24.2 t -94.33 119.0 32.45 Favored 'General case' 0 CA--C 1.516 -0.333 0 CA-C-N 116.024 -0.535 . . . . 0.0 109.771 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 10.7 p -128.81 151.33 35.44 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.409 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.392 -179.423 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' CYS . . . . . 0.557 ' SG ' ' N ' ' A' ' 50' ' ' PHE . 33.0 t -96.52 164.83 12.45 Favored 'General case' 0 CA--C 1.514 -0.435 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 -179.634 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.557 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 37.2 m-85 -132.25 131.93 22.67 Favored Pre-proline 0 N--CA 1.465 0.284 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.136 -179.068 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.78 155.82 57.81 Favored 'Trans proline' 0 N--CA 1.489 1.237 0 C-N-CA 122.068 1.845 . . . . 0.0 112.122 179.541 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -63.9 -27.92 69.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.631 179.543 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 99.7 m-85 -107.38 41.88 1.42 Allowed 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.751 -179.331 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 92.0 t80 -68.34 131.4 45.26 Favored 'General case' 0 N--CA 1.455 -0.209 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.286 179.694 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.9 pt . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 118.101 -0.952 . . . . 0.0 110.28 -179.93 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 52.6 mtmt . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 54.6 t0 -69.54 -7.43 38.34 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.464 179.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 22.5 mm -79.27 96.63 2.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.221 -179.766 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 67.8 t0 -63.09 -43.08 99.51 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.503 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 52.94 71.29 0.71 Allowed Glycine 0 C--O 1.229 -0.18 0 N-CA-C 110.847 -0.901 . . . . 0.0 110.847 179.647 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.06 22.82 4.89 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.814 -0.193 . . . . 0.0 110.737 -179.839 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.35 153.92 53.8 Favored Pre-proline 0 N--CA 1.47 0.571 0 C-N-CA 121.116 -0.233 . . . . 0.0 111.378 -179.29 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_exo -57.81 144.46 93.54 Favored 'Trans proline' 0 N--CA 1.496 1.655 0 C-N-CA 121.527 1.484 . . . . 0.0 111.783 178.683 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.7 tt -122.87 117.17 24.99 Favored 'General case' 0 N--CA 1.476 0.874 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.294 179.41 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.6 tt -95.11 127.48 41.19 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 179.187 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.443 HG13 ' H ' ' A' ' 12' ' ' GLY . 1.3 pt -103.51 -51.42 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-O 120.779 0.323 . . . . 0.0 110.831 -179.014 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.443 ' H ' HG13 ' A' ' 11' ' ' ILE . . . -160.27 -136.45 2.02 Favored Glycine 0 N--CA 1.451 -0.316 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -179.879 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.5 p -132.1 170.96 14.24 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.1 0.476 . . . . 0.0 110.415 -179.416 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -67.9 -1.86 6.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.332 -179.326 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 2.4 pp -78.2 -20.99 13.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.236 -179.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -131.91 -28.94 1.72 Allowed 'General case' 0 C--O 1.233 0.214 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.621 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 42.3 m-85 -116.3 81.77 11.06 Favored Pre-proline 0 CA--C 1.534 0.331 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.367 179.239 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.436 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 16.8 Cg_endo -59.35 -176.41 0.11 Allowed 'Trans proline' 0 N--CA 1.5 1.861 0 C-N-CA 122.449 2.099 . . . . 0.0 112.17 -179.644 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.444 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 83.3 m -58.89 -49.55 77.36 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.678 -0.409 . . . . 0.0 111.299 -179.347 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.533 ' CG ' ' H ' ' A' ' 21' ' ' LYS . 8.0 pt-20 -55.57 -59.59 4.62 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.616 -179.516 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.533 ' H ' ' CG ' ' A' ' 20' ' ' GLU . 17.3 mtpp -64.68 -48.39 74.92 Favored 'General case' 0 CA--C 1.512 -0.501 0 CA-C-O 121.084 0.468 . . . . 0.0 111.818 -179.43 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.436 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 34.8 t -43.02 -52.51 5.24 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.106 -177.641 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.721 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 0.8 OUTLIER -65.05 -44.51 88.78 Favored 'General case' 0 C--O 1.22 -0.474 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.783 -179.955 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.721 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 89.1 mttt -50.72 -40.79 55.15 Favored 'General case' 0 CA--C 1.509 -0.609 0 C-N-CA 120.294 -0.562 . . . . 0.0 110.321 -179.575 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' THR . . . . . 0.604 ' HG1' ' N ' ' A' ' 26' ' ' CYS . 70.0 p -63.2 -41.53 99.18 Favored 'General case' 0 C--N 1.313 -1.0 0 C-N-CA 119.179 -1.008 . . . . 0.0 110.376 -179.079 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.604 ' N ' ' HG1' ' A' ' 25' ' ' THR . 19.5 t -68.09 -34.1 75.76 Favored 'General case' 0 C--N 1.322 -0.587 0 C-N-CA 120.176 -0.61 . . . . 0.0 109.896 179.733 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.3 mm -66.3 -41.55 89.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.72 -179.258 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.46 ' C ' ' H ' ' A' ' 30' ' ' ASN . 40.2 mm-40 -64.13 -34.97 79.27 Favored 'General case' 0 N--CA 1.444 -0.746 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.654 -179.409 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.414 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 78.1 p -68.44 1.92 2.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.221 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.46 ' H ' ' C ' ' A' ' 28' ' ' GLU . 16.4 t-20 78.05 19.67 1.04 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.623 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.552 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 4.5 m-85 -98.32 -168.23 1.62 Allowed 'General case' 0 CA--C 1.53 0.191 0 CA-C-O 120.938 0.399 . . . . 0.0 110.351 -179.833 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -74.93 -53.26 9.32 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.791 -179.01 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.524 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 165.42 -178.51 40.3 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.151 -1.179 . . . . 0.0 110.151 -179.251 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.405 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -141.07 167.85 25.54 Favored Glycine 0 CA--C 1.519 0.293 0 N-CA-C 111.274 -0.73 . . . . 0.0 111.274 -179.219 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 15.0 ptpt -158.09 178.06 10.62 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.095 0.474 . . . . 0.0 110.401 -179.311 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 3.2 m -105.39 120.3 41.24 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.866 179.159 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 33.0 m -132.17 161.22 41.75 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.102 -179.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.496 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 3.2 p80 -107.07 157.14 18.06 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.184 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.512 ' O ' ' N ' ' A' ' 41' ' ' GLN . 33.2 mm -106.46 124.79 62.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.049 -179.549 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 43.34 -91.12 0.01 OUTLIER Glycine 0 C--N 1.33 0.205 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.512 ' N ' ' O ' ' A' ' 39' ' ' ILE . 42.0 tp60 -148.46 37.66 0.84 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.812 0.339 . . . . 0.0 110.436 -179.577 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 71.0 m -87.98 -2.39 58.58 Favored 'General case' 0 CA--C 1.519 -0.235 0 CA-C-O 121.042 0.449 . . . . 0.0 110.613 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 45.81 28.99 0.64 Allowed 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.551 179.522 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 68.3 t0 -108.88 119.32 39.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.919 179.455 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 81.3 m-85 -88.56 118.45 28.22 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.721 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 31.1 m -114.88 143.05 25.46 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.35 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.259 -179.406 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.414 ' SG ' ' CD1' ' A' ' 11' ' ' ILE . 18.4 t -94.07 117.88 30.73 Favored 'General case' 0 CA--C 1.513 -0.455 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.459 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.7 p -129.07 152.96 37.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-O 120.708 0.29 . . . . 0.0 110.306 -179.689 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' CYS . . . . . 0.552 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 17.2 t -96.83 164.94 12.34 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.547 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 38.1 m-85 -132.34 136.31 27.82 Favored Pre-proline 0 N--CA 1.468 0.474 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.842 -179.319 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -67.13 158.1 58.55 Favored 'Trans proline' 0 N--CA 1.495 1.571 0 C-N-CA 121.945 1.763 . . . . 0.0 112.391 179.903 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -51.65 -79.25 0.02 OUTLIER 'General case' 0 C--N 1.333 -0.141 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.655 -179.124 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 58.9 m-85 -130.55 39.2 3.65 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.764 -179.815 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -108.98 127.66 54.26 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 120.922 0.391 . . . . 0.0 110.132 -179.682 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.5 mp . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.268 -179.836 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 18.2 pttp . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 51.3 t0 -63.79 -32.74 74.35 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.903 -0.589 . . . . 0.0 109.955 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.403 HG21 HD13 ' A' ' 3' ' ' ILE . 23.4 mm -53.49 100.16 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.59 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 66.8 t0 -63.75 -39.71 94.94 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.397 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 55.05 69.52 1.24 Allowed Glycine 0 C--N 1.329 0.161 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 179.819 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.08 18.67 5.49 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.488 0.185 . . . . 0.0 110.629 -179.42 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 2.6 pttm -132.46 147.08 64.22 Favored Pre-proline 0 N--CA 1.465 0.317 0 CA-C-N 116.62 -0.264 . . . . 0.0 110.99 -179.476 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -67.8 164.08 32.87 Favored 'Trans proline' 0 N--CA 1.494 1.539 0 C-N-CA 122.488 2.125 . . . . 0.0 111.885 179.264 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.404 ' CD2' ' C ' ' A' ' 9' ' ' LEU . 3.8 tt -138.3 118.02 13.14 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.273 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.8 tt -92.68 130.87 38.18 Favored 'General case' 0 N--CA 1.465 0.305 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 178.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.474 ' CD1' ' SG ' ' A' ' 47' ' ' CYS . 1.5 pt -107.09 -50.18 7.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-O 120.917 0.389 . . . . 0.0 110.294 -178.78 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.402 ' H ' HG13 ' A' ' 11' ' ' ILE . . . -163.35 -162.99 15.04 Favored Glycine 0 N--CA 1.449 -0.491 0 N-CA-C 110.754 -0.938 . . . . 0.0 110.754 179.689 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.403 ' C ' ' H ' ' A' ' 15' ' ' ILE . 7.5 p -83.93 163.07 20.24 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.829 0.347 . . . . 0.0 110.12 -179.792 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 48.3 t -71.2 2.79 4.18 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.331 179.703 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.403 ' H ' ' C ' ' A' ' 13' ' ' THR . 86.8 mt -91.08 -52.48 10.26 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.217 0 CA-C-N 116.234 -0.439 . . . . 0.0 109.826 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . 0.464 ' OE1' ' CE2' ' A' ' 17' ' ' PHE . 7.5 pt-20 -70.82 -35.45 72.5 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.16 179.113 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.464 ' CE2' ' OE1' ' A' ' 16' ' ' GLU . 59.9 m-85 -114.96 104.61 53.94 Favored Pre-proline 0 CA--C 1.544 0.738 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.44 179.92 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.457 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 56.9 Cg_endo -74.23 -179.8 5.08 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 C-N-CA 123.043 2.495 . . . . 0.0 111.752 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 70.8 m -57.38 -49.12 77.18 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.576 -179.613 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.49 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 6.7 pt-20 -54.63 -58.24 8.27 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.574 -0.285 . . . . 0.0 111.592 -179.477 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.414 ' H ' ' CG ' ' A' ' 20' ' ' GLU . 5.7 ttmt -67.44 -56.65 8.74 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.385 0.612 . . . . 0.0 111.606 -179.145 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.457 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 48.1 t -38.64 -61.51 0.7 Allowed 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.241 -0.89 . . . . 0.0 111.4 -178.786 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.625 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 0.0 OUTLIER -63.42 -49.09 75.13 Favored 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.435 -179.874 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.625 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 51.3 mttm -47.46 -37.73 12.26 Favored 'General case' 0 CA--C 1.515 -0.399 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.218 -179.721 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 98.4 m -63.8 -41.74 97.84 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.342 0.591 . . . . 0.0 109.775 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.452 ' SG ' ' C ' ' A' ' 33' ' ' GLY . 40.2 t -72.13 -34.71 68.76 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.585 0.707 . . . . 0.0 109.999 179.311 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.5 mm -65.33 -48.08 84.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.144 -179.282 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.507 ' C ' ' H ' ' A' ' 30' ' ' ASN . 3.0 pp20? -70.31 -29.01 65.63 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.554 -179.656 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.452 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 24.4 m -65.2 0.89 1.17 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.198 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.537 ' O ' ' NZ ' ' A' ' 52' ' ' LYS . 7.4 t-20 81.05 14.53 0.64 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.435 179.804 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.569 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 5.2 m-85 -100.19 -167.72 1.49 Allowed 'General case' 0 C--N 1.339 0.144 0 CA-C-O 120.76 0.314 . . . . 0.0 110.204 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -76.18 -55.38 5.63 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.141 0.496 . . . . 0.0 111.859 -179.196 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.452 ' C ' ' SG ' ' A' ' 26' ' ' CYS . . . 168.56 173.29 36.27 Favored Glycine 0 CA--C 1.519 0.337 0 N-CA-C 110.318 -1.113 . . . . 0.0 110.318 -179.135 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -134.59 161.02 24.42 Favored Glycine 0 N--CA 1.46 0.237 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 -179.341 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 2.1 ptmm? -160.06 -174.77 4.72 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.966 0.412 . . . . 0.0 110.69 -178.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 30.7 m -104.67 120.09 40.52 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.831 179.361 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 2.6 m -137.79 166.29 24.65 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-O 121.113 0.482 . . . . 0.0 110.896 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.702 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 0.1 OUTLIER -108.85 157.29 18.74 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.403 179.291 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 83.9 mt -122.58 128.64 75.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.551 -179.358 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 52.85 -126.1 31.84 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.481 -1.048 . . . . 0.0 110.481 179.766 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -111.33 27.64 9.48 Favored 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 110.381 -0.229 . . . . 0.0 110.381 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' SER . . . . . 0.497 ' O ' ' N ' ' A' ' 44' ' ' ASP . 52.0 m -85.14 -11.26 55.53 Favored 'General case' 0 CA--C 1.52 -0.199 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.914 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 36.79 28.26 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.063 -179.687 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . 0.497 ' N ' ' O ' ' A' ' 42' ' ' SER . 45.1 t0 -99.78 124.47 45.09 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.278 -179.903 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -85.72 124.55 32.36 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 -179.65 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 32.6 m -129.9 153.76 39.35 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.444 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.145 -179.348 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.474 ' SG ' ' CD1' ' A' ' 11' ' ' ILE . 34.9 t -93.75 116.43 28.91 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.436 -179.77 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.9 p -131.64 154.39 40.32 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.325 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.499 -178.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' CYS . . . . . 0.572 ' SG ' ' N ' ' A' ' 50' ' ' PHE . 16.4 t -97.42 164.49 12.43 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 179.833 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.572 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 29.6 m-85 -130.7 121.79 19.29 Favored Pre-proline 0 N--CA 1.465 0.321 0 C-N-CA 120.931 -0.307 . . . . 0.0 111.247 -178.68 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -72.62 160.2 47.04 Favored 'Trans proline' 0 N--CA 1.491 1.343 0 C-N-CA 121.721 1.614 . . . . 0.0 112.058 179.274 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.537 ' NZ ' ' O ' ' A' ' 30' ' ' ASN . 64.2 mttp -67.93 -16.57 64.12 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.478 179.803 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -109.08 41.45 1.62 Allowed 'General case' 0 N--CA 1.468 0.436 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.777 -179.801 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 88.1 t80 -86.07 96.33 9.83 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.778 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 16.1 mm . . . . . 0 C--O 1.22 -0.465 0 CA-C-O 118.022 -0.99 . . . . 0.0 110.43 -179.597 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 53.1 mtmt . . . . . 0 N--CA 1.491 1.608 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -86.53 9.81 17.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.633 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 29.5 mm -80.44 118.5 28.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.208 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 54.8 t0 -66.03 -41.15 91.28 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.639 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 49.89 69.26 1.1 Allowed Glycine 0 CA--C 1.518 0.235 0 N-CA-C 111.021 -0.832 . . . . 0.0 111.021 179.775 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.491 ' NE ' ' OH ' ' A' ' 54' ' ' TYR . 0.0 OUTLIER -132.46 37.96 3.48 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.758 0.313 . . . . 0.0 110.987 -179.865 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.506 ' N ' ' CD ' ' A' ' 8' ' ' PRO . 2.5 tppp? -125.43 50.41 4.34 Favored Pre-proline 0 N--CA 1.465 0.294 0 CA-C-O 120.855 0.36 . . . . 0.0 110.708 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.506 ' CD ' ' N ' ' A' ' 7' ' ' LYS . 33.9 Cg_endo -64.93 159.0 48.35 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.824 2.349 . . . . 0.0 111.21 178.987 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.402 ' CD2' ' C ' ' A' ' 9' ' ' LEU . 4.0 tt -132.38 119.23 20.41 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.265 -179.615 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.7 tt -93.5 127.33 39.1 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 178.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.494 ' CD1' ' SG ' ' A' ' 47' ' ' CYS . 3.1 pt -103.38 -46.14 10.32 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.412 -179.036 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -170.06 -138.01 2.4 Favored Glycine 0 CA--C 1.521 0.451 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.516 ' C ' ' H ' ' A' ' 15' ' ' ILE . 70.0 p -133.21 163.73 28.63 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.843 0.354 . . . . 0.0 110.902 -179.437 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -57.87 -4.79 0.34 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.97 179.674 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.516 ' H ' ' C ' ' A' ' 13' ' ' THR . 95.8 mt -73.24 -24.18 20.43 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 CA-C-O 121.01 0.433 . . . . 0.0 110.136 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -130.55 -32.06 1.75 Allowed 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.741 -179.614 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 53.7 m-85 -114.65 88.88 17.07 Favored Pre-proline 0 CA--C 1.54 0.568 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 179.36 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.455 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 43.4 Cg_endo -70.17 -178.04 2.31 Favored 'Trans proline' 0 N--CA 1.499 1.809 0 C-N-CA 122.91 2.406 . . . . 0.0 111.968 -179.509 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.455 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 7.1 m -45.93 -68.62 0.18 Allowed 'General case' 0 C--N 1.319 -0.757 0 C-N-CA 120.826 -0.35 . . . . 0.0 111.442 -179.275 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.571 ' CD ' ' H ' ' A' ' 20' ' ' GLU . 0.0 OUTLIER -44.36 -68.14 0.22 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.46 -0.337 . . . . 0.0 111.718 -178.794 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 6.9 ttmt -54.66 -51.63 64.86 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.039 0.447 . . . . 0.0 111.562 -178.043 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.455 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 45.3 t -46.03 -64.97 0.62 Allowed 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.368 -179.3 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.71 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 0.8 OUTLIER -61.86 -45.16 94.99 Favored 'General case' 0 C--O 1.22 -0.464 0 C-N-CA 120.721 -0.392 . . . . 0.0 110.478 -179.814 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.71 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 86.9 mttt -51.06 -37.08 43.35 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.443 -0.503 . . . . 0.0 109.852 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 13.4 m -64.36 -41.61 96.64 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.354 0.597 . . . . 0.0 110.352 -179.831 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.488 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 37.8 t -72.73 -34.91 67.39 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.029 179.467 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.2 mm -66.14 -47.68 83.94 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.571 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.884 -179.227 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.498 ' C ' ' H ' ' A' ' 30' ' ' ASN . 3.0 pp20? -70.21 -28.35 65.21 Favored 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.285 -179.413 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.465 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 56.1 m -66.25 1.05 1.71 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.051 -179.863 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.498 ' H ' ' C ' ' A' ' 28' ' ' GLU . 8.7 t-20 82.51 11.04 0.61 Allowed 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.406 179.858 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.552 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 23.0 m-85 -99.47 -171.22 2.03 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-O 121.036 0.445 . . . . 0.0 111.188 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -71.33 -59.91 2.51 Favored 'General case' 0 CA--C 1.532 0.254 0 CA-C-N 115.756 -0.657 . . . . 0.0 111.857 -179.03 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.488 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 172.39 176.8 41.4 Favored Glycine 0 CA--C 1.52 0.377 0 N-CA-C 110.345 -1.102 . . . . 0.0 110.345 -179.104 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -137.0 166.66 24.86 Favored Glycine 0 N--CA 1.462 0.402 0 N-CA-C 111.233 -0.747 . . . . 0.0 111.233 -179.529 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 12.2 ptmt -159.4 178.45 9.92 Favored 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.771 -179.393 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 1.4 m -106.5 127.71 53.52 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.008 178.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 28.8 m -134.41 159.75 41.84 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.247 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.32 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.713 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 0.1 OUTLIER -104.84 154.67 19.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.265 179.89 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.495 ' O ' ' N ' ' A' ' 41' ' ' GLN . 31.2 mm -107.01 128.02 62.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.361 -179.347 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 41.78 -91.56 0.01 OUTLIER Glycine 0 CA--C 1.525 0.711 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.495 ' N ' ' O ' ' A' ' 39' ' ' ILE . 40.6 tt0 -143.22 22.69 1.87 Allowed 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 121.039 0.447 . . . . 0.0 110.252 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 58.4 m -78.57 -9.45 59.36 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.079 0.466 . . . . 0.0 110.265 179.559 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . 0.416 ' O ' ' CD2' ' A' ' 43' ' ' LEU . 0.9 OUTLIER 47.03 30.42 1.28 Allowed 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.28 -179.715 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 67.8 t0 -98.78 119.91 38.32 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.597 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 58.1 m-85 -84.44 117.5 23.68 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.026 0.441 . . . . 0.0 110.342 -179.33 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 32.6 m -113.38 136.18 50.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.5 -179.454 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' CD1' ' A' ' 11' ' ' ILE . 27.4 t -93.03 115.4 28.08 Favored 'General case' 0 CA--C 1.514 -0.434 0 N-CA-C 109.284 -0.635 . . . . 0.0 109.284 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.5 p -130.88 150.41 34.58 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.261 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.8 -178.774 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' CYS . . . . . 0.552 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 23.6 t -96.82 162.9 13.22 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.529 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 33.7 m-85 -120.91 136.82 25.85 Favored Pre-proline 0 N--CA 1.47 0.541 0 C-N-CA 120.906 -0.318 . . . . 0.0 110.99 -178.85 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -62.33 150.03 88.61 Favored 'Trans proline' 0 N--CA 1.492 1.396 0 C-N-CA 121.759 1.64 . . . . 0.0 112.753 179.519 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 8.1 tptp -136.8 -41.14 0.6 Allowed 'General case' 0 CA--C 1.528 0.106 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.002 179.476 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -112.64 18.91 17.95 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-O 120.634 0.254 . . . . 0.0 111.136 -179.49 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . 0.491 ' OH ' ' NE ' ' A' ' 6' ' ' ARG . 74.6 t80 -74.78 131.01 40.47 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-O 120.866 0.365 . . . . 0.0 110.377 179.498 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.2 pt . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 117.895 -1.05 . . . . 0.0 109.975 179.977 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 71.0 mmtt . . . . . 0 N--CA 1.492 1.674 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 34.6 p-10 -73.41 0.84 11.08 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 179.338 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -93.46 143.78 10.82 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.176 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.916 -179.912 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -62.38 -40.89 97.92 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.291 179.567 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -80.78 104.25 2.29 Favored Glycine 0 C--N 1.329 0.156 0 N-CA-C 110.665 -0.974 . . . . 0.0 110.665 -179.821 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.85 38.13 3.4 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.695 -0.252 . . . . 0.0 111.302 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.426 ' H ' ' HG3' ' A' ' 51' ' ' PRO . 14.5 ttmt -125.4 69.69 61.9 Favored Pre-proline 0 N--CA 1.47 0.567 0 CA-C-O 120.455 0.169 . . . . 0.0 111.165 -179.66 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -77.25 161.68 31.89 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 122.68 2.253 . . . . 0.0 111.586 179.007 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.3 tt -133.67 120.89 21.21 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 120.568 0.223 . . . . 0.0 110.439 -179.008 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.8 tt -87.68 134.56 33.63 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 178.535 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 13.2 pt -109.04 -35.0 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 120.934 0.397 . . . . 0.0 110.8 -178.702 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 175.69 -150.0 10.49 Favored Glycine 0 N--CA 1.451 -0.358 0 N-CA-C 110.794 -0.923 . . . . 0.0 110.794 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.47 ' C ' ' H ' ' A' ' 15' ' ' ILE . 42.0 p -98.8 160.66 14.12 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.83 0.347 . . . . 0.0 110.235 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 9.2 t -72.04 6.99 1.81 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.171 179.818 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.47 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.8 mt -91.42 -44.39 14.4 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.199 0 CA-C-N 116.053 -0.522 . . . . 0.0 109.949 179.785 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -87.46 -20.59 26.37 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.735 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 60.1 m-85 -120.69 99.08 47.66 Favored Pre-proline 0 CA--C 1.546 0.796 0 CA-C-N 116.732 -0.213 . . . . 0.0 110.595 179.515 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.409 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 36.4 Cg_endo -71.68 173.23 12.92 Favored 'Trans proline' 0 N--CA 1.493 1.495 0 C-N-CA 122.579 2.186 . . . . 0.0 111.288 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.48 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 10.0 m -47.67 -50.56 24.41 Favored 'General case' 0 C--N 1.319 -0.736 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.712 -179.242 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.539 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 0.5 OUTLIER -56.34 -68.33 0.22 Allowed 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 112.293 0.479 . . . . 0.0 112.293 -179.13 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 6.9 ttmt -57.95 -46.37 85.18 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 121.362 0.601 . . . . 0.0 111.551 -178.126 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.409 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 49.0 t -47.58 -65.03 0.63 Allowed 'General case' 0 C--N 1.308 -1.231 0 CA-C-N 115.311 -0.859 . . . . 0.0 111.465 -178.64 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.717 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 0.4 OUTLIER -65.39 -43.73 89.75 Favored 'General case' 0 C--O 1.222 -0.375 0 C-N-CA 120.4 -0.52 . . . . 0.0 110.893 -179.944 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.717 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 48.8 mttp -52.5 -39.68 61.54 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 120.19 -0.604 . . . . 0.0 109.909 179.826 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 91.6 m -62.62 -43.69 98.18 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.741 -179.438 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.521 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 16.6 t -66.14 -34.93 79.17 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.017 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.3 mm -66.17 -37.77 80.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.717 0 CA-C-N 114.937 -1.029 . . . . 0.0 110.113 179.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.448 ' C ' ' H ' ' A' ' 30' ' ' ASN . 34.3 mm-40 -64.09 -37.54 87.8 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.973 -1.012 . . . . 0.0 110.155 -179.369 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 35.9 m -69.46 0.59 4.98 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.834 179.638 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.448 ' H ' ' C ' ' A' ' 28' ' ' GLU . 18.2 t-20 76.7 21.15 1.28 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.508 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.532 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 3.8 m-85 -96.16 -166.93 1.5 Allowed 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 120.811 0.339 . . . . 0.0 110.493 -179.88 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.61 -51.42 16.89 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 116.076 -0.511 . . . . 0.0 112.113 -178.68 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.521 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 161.59 -179.87 36.71 Favored Glycine 0 CA--C 1.519 0.323 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 -179.036 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -132.49 157.42 22.53 Favored Glycine 0 CA--C 1.52 0.351 0 N-CA-C 111.417 -0.673 . . . . 0.0 111.417 -179.181 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 16.2 ptpt -154.27 168.78 25.44 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.41 -0.395 . . . . 0.0 110.506 -179.319 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 37.8 m -103.86 124.29 48.68 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.042 179.609 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 36.0 m -136.6 161.39 36.69 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-O 120.758 0.313 . . . . 0.0 110.9 -179.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.452 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 2.3 p80 -90.07 155.04 19.34 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.326 179.55 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 40.4 mm -110.66 121.6 63.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.816 -179.672 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 46.63 27.74 3.24 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 179.074 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 12.6 mm100 62.72 35.69 13.82 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.943 0.401 . . . . 0.0 110.242 -179.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' SER . . . . . 0.422 ' O ' ' CB ' ' A' ' 43' ' ' LEU . 63.6 m -83.39 -7.93 59.48 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.883 -179.901 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . 0.422 ' CB ' ' O ' ' A' ' 42' ' ' SER . 0.9 OUTLIER 73.82 27.33 1.7 Allowed 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.239 0.542 . . . . 0.0 109.782 -179.523 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 36.0 t0 -111.74 117.05 31.79 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 178.547 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -91.42 120.61 32.42 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.241 0.543 . . . . 0.0 109.915 -179.819 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 33.5 m -123.5 140.13 47.99 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.449 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.079 -179.573 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -94.47 121.35 35.93 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.19 -179.727 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.2 p -134.35 151.87 32.82 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.312 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.844 -178.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' CYS . . . . . 0.532 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 28.4 t -93.9 161.89 14.13 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 -179.421 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.445 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 51.3 m-85 -127.93 142.52 44.64 Favored Pre-proline 0 N--CA 1.47 0.538 0 C-N-CA 120.619 -0.432 . . . . 0.0 111.359 -178.356 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.426 ' HG3' ' H ' ' A' ' 7' ' ' LYS . 29.6 Cg_endo -62.73 148.36 93.5 Favored 'Trans proline' 0 N--CA 1.494 1.528 0 C-N-CA 122.016 1.811 . . . . 0.0 112.219 179.636 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 38.8 ttpt -121.75 -53.34 1.98 Allowed 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.654 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 45.5 p90 -117.25 20.94 13.45 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.876 -179.538 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . 0.405 ' HH ' ' NZ ' ' A' ' 7' ' ' LYS . 51.4 t80 -81.36 129.28 34.56 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 179.908 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 10.7 mt . . . . . 0 C--O 1.219 -0.544 0 CA-C-O 117.934 -1.031 . . . . 0.0 110.391 -179.756 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 25.3 mtpp . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -84.36 3.01 37.82 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.421 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 37.8 mm -68.94 130.87 34.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 121.051 0.453 . . . . 0.0 110.745 179.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . 0.489 ' OD1' ' N ' ' A' ' 4' ' ' ASP . 18.2 p-10 -65.14 -36.35 83.99 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.55 179.669 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.435 ' C ' ' O ' ' A' ' 4' ' ' ASP . . . -29.86 96.12 0.01 OUTLIER Glycine 0 N--CA 1.465 0.58 0 O-C-N 123.704 0.628 . . . . 0.0 111.685 -179.725 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.99 40.12 3.82 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.334 -0.433 . . . . 0.0 110.878 -178.679 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.96 155.14 64.38 Favored Pre-proline 0 N--CA 1.467 0.402 0 C-N-CA 121.192 -0.203 . . . . 0.0 110.581 -179.241 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -57.92 149.05 72.65 Favored 'Trans proline' 0 N--CA 1.496 1.63 0 C-N-CA 121.725 1.617 . . . . 0.0 111.416 178.291 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.8 tt -120.33 118.21 29.79 Favored 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.713 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.435 ' CD1' ' C ' ' A' ' 10' ' ' LEU . 2.7 tm? -89.04 124.99 34.81 Favored 'General case' 0 CA--C 1.522 -0.132 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.547 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 14.9 pt -105.59 -35.58 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.159 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.811 -179.131 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 176.92 -135.46 2.83 Favored Glycine 0 CA--C 1.522 0.5 0 N-CA-C 111.146 -0.781 . . . . 0.0 111.146 -179.873 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.42 ' C ' ' H ' ' A' ' 15' ' ' ILE . 68.0 p -132.92 161.73 33.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.94 0.4 . . . . 0.0 110.512 -179.629 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -55.91 -9.35 0.57 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.764 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.42 ' H ' ' C ' ' A' ' 13' ' ' THR . 6.2 mm -71.94 -43.13 68.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 C-N-CA 120.5 -0.48 . . . . 0.0 110.59 -179.313 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -99.75 -23.51 14.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.106 -179.429 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -119.54 83.09 26.53 Favored Pre-proline 0 N--CA 1.463 0.189 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.033 179.583 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -53.29 165.89 1.3 Allowed 'Trans proline' 0 N--CA 1.491 1.367 0 C-N-CA 122.495 2.13 . . . . 0.0 110.582 178.553 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.448 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 36.0 p -45.61 -58.94 3.04 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-O 120.852 0.358 . . . . 0.0 111.701 -178.601 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.443 ' HG3' ' H ' ' A' ' 21' ' ' LYS . 6.6 pt-20 -46.01 -60.04 2.49 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.934 -179.385 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.443 ' H ' ' HG3' ' A' ' 20' ' ' GLU . 17.8 mtmt -63.73 -45.79 88.31 Favored 'General case' 0 CA--C 1.51 -0.583 0 CA-C-O 121.105 0.478 . . . . 0.0 111.299 -179.784 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 17.9 t -44.47 -62.61 1.12 Allowed 'General case' 0 C--N 1.31 -1.138 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.351 -178.396 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.693 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.8 p-10 -64.1 -50.48 68.12 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.866 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.693 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 41.2 mttm -48.99 -35.94 16.45 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -179.586 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' THR . . . . . 0.43 ' OG1' ' O ' ' A' ' 21' ' ' LYS . 19.4 m -63.52 -42.26 98.47 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.192 -179.898 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.491 ' SG ' ' C ' ' A' ' 33' ' ' GLY . 32.9 t -73.42 -36.9 66.03 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.537 0.684 . . . . 0.0 110.016 178.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.3 mm -64.65 -47.42 88.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.996 -178.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.478 ' C ' ' H ' ' A' ' 30' ' ' ASN . 2.9 pp20? -71.22 -23.26 61.98 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.756 -179.485 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 39.5 m -71.6 3.71 3.74 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.52 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.478 ' H ' ' C ' ' A' ' 28' ' ' GLU . 2.2 m120 77.59 22.26 0.92 Allowed 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.913 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.554 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 31.1 m-85 -111.25 -167.91 1.24 Allowed 'General case' 0 N--CA 1.455 -0.178 0 CA-C-O 120.82 0.343 . . . . 0.0 111.006 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -74.1 -58.36 3.35 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.94 -0.573 . . . . 0.0 112.239 -178.417 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.491 ' C ' ' SG ' ' A' ' 26' ' ' CYS . . . 172.8 170.63 36.74 Favored Glycine 0 CA--C 1.521 0.465 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -178.85 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.43 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -122.42 159.97 16.94 Favored Glycine 0 N--CA 1.463 0.458 0 N-CA-C 111.186 -0.765 . . . . 0.0 111.186 -178.812 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 16.2 ptpt -155.34 166.38 33.72 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.05 0.452 . . . . 0.0 110.695 -179.558 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.504 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 4.5 m -106.35 123.69 48.44 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.354 179.522 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 32.9 m -137.08 160.77 36.16 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.464 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.689 179.796 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.523 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 8.8 p80 -89.64 157.15 18.14 Favored 'General case' 0 CA--C 1.521 -0.153 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.295 179.488 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.419 ' O ' ' OG ' ' A' ' 42' ' ' SER . 5.7 mm -117.97 129.25 74.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.778 -179.467 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 46.01 22.18 0.79 Allowed Glycine 0 C--O 1.228 -0.233 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 179.328 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.4 ' N ' ' C ' ' A' ' 39' ' ' ILE . 39.6 tt0 69.78 36.75 1.99 Allowed 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.062 0.458 . . . . 0.0 110.175 -179.753 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' SER . . . . . 0.419 ' OG ' ' O ' ' A' ' 39' ' ' ILE . 5.1 m -86.45 1.46 51.32 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.155 179.79 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER 57.16 26.89 12.69 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.526 -179.379 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 55.0 t0 -106.39 119.13 38.45 Favored 'General case' 0 N--CA 1.466 0.361 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 178.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 -85.12 115.68 23.06 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 121.181 0.515 . . . . 0.0 110.325 -179.112 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 11.6 m -111.18 134.57 53.08 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.262 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.19 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 0.8 OUTLIER -94.38 112.8 24.59 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.172 -179.792 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 4.8 p -129.58 155.0 41.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.306 -179.289 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' CYS . . . . . 0.587 ' SG ' ' N ' ' A' ' 50' ' ' PHE . 19.5 t -96.56 166.48 11.66 Favored 'General case' 0 N--CA 1.465 0.312 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.587 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 29.1 m-85 -126.92 117.88 22.25 Favored Pre-proline 0 N--CA 1.469 0.483 0 C-N-CA 121.028 -0.269 . . . . 0.0 110.745 -178.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_exo -51.8 137.28 51.48 Favored 'Trans proline' 0 N--CA 1.486 1.083 0 C-N-CA 121.491 1.46 . . . . 0.0 112.27 179.218 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 26.4 tptp -65.8 -18.08 65.08 Favored 'General case' 0 N--CA 1.453 -0.316 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.651 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -106.93 40.9 1.56 Allowed 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.558 -179.471 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 75.4 t80 -113.75 126.22 54.98 Favored 'General case' 0 C--O 1.231 0.115 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.833 179.416 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 83.5 mt . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.277 179.841 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_exo . . . . . 0 N--CA 1.495 1.61 0 N-CA-C 111.406 -0.267 . . . . 0.0 111.406 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.623 HD23 ' N ' ' A' ' 10' ' ' LEU . 2.9 tt -116.68 118.66 33.18 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-O 120.626 0.25 . . . . 0.0 110.493 -179.393 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.623 ' N ' HD23 ' A' ' 9' ' ' LEU . 8.4 tt -90.08 131.18 36.09 Favored 'General case' 0 N--CA 1.464 0.275 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 178.769 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.904 HD11 ' SG ' ' A' ' 47' ' ' CYS . 1.9 pt -108.67 -45.17 6.85 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 120.964 0.412 . . . . 0.0 110.415 -178.669 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -163.68 -176.38 35.55 Favored Glycine 0 N--CA 1.45 -0.421 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.515 ' O ' ' N ' ' A' ' 15' ' ' ILE . 13.6 m -86.65 137.3 32.58 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 8.7 t -46.93 -12.29 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 120.832 -0.347 . . . . 0.0 110.794 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.515 ' N ' ' O ' ' A' ' 13' ' ' THR . 96.6 mt -69.86 -44.3 78.95 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.287 0 CA-C-O 121.364 0.602 . . . . 0.0 110.487 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -88.09 -29.69 20.44 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-N 115.223 -0.899 . . . . 0.0 110.514 -179.599 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 53.0 m-85 -124.85 84.05 58.84 Favored Pre-proline 0 N--CA 1.465 0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.815 179.564 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -53.08 -177.0 0.03 OUTLIER 'Trans proline' 0 N--CA 1.498 1.743 0 C-N-CA 122.959 2.44 . . . . 0.0 111.609 179.26 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.604 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 97.8 m -58.22 -49.71 76.12 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 112.547 0.573 . . . . 0.0 112.547 -178.275 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.499 ' CG ' ' H ' ' A' ' 21' ' ' LYS . 9.0 pt-20 -56.14 -58.18 9.04 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 111.767 0.284 . . . . 0.0 111.767 -178.924 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.499 ' H ' ' CG ' ' A' ' 20' ' ' GLU . 15.4 mtmt -64.11 -44.72 91.39 Favored 'General case' 0 CA--C 1.51 -0.569 0 CA-C-O 121.221 0.534 . . . . 0.0 111.522 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 28.9 t -44.7 -57.67 3.54 Favored 'General case' 0 C--N 1.312 -1.058 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.757 -177.778 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.604 ' ND2' ' O ' ' A' ' 19' ' ' THR . 12.5 p30 -64.22 -50.73 66.89 Favored 'General case' 0 C--O 1.218 -0.587 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.375 -179.559 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.543 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 70.7 mttt -50.18 -42.12 50.66 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 -179.656 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 15.5 m -64.51 -39.16 93.26 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.645 0.736 . . . . 0.0 109.607 179.115 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 73.0 m -68.76 -31.51 70.6 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.149 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.438 HG12 ' O ' ' A' ' 23' ' ' ASN . 3.0 mm -64.39 -47.03 91.25 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.506 0 CA-C-O 121.087 0.47 . . . . 0.0 110.914 -179.512 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.405 ' HG2' ' H ' ' A' ' 28' ' ' GLU . 9.1 pt-20 -70.14 -22.25 63.01 Favored 'General case' 0 N--CA 1.447 -0.622 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.872 -179.246 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 59.8 p -74.81 -2.07 25.0 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 179.55 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 77.66 27.92 0.58 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.168 -0.923 . . . . 0.0 110.725 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.552 ' C ' ' H ' ' A' ' 33' ' ' GLY . 5.5 m-85 -110.96 162.32 14.95 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.74 -179.79 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.65 32.85 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.664 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.552 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 81.43 -173.96 54.24 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 -179.743 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -153.65 177.25 31.28 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 -179.653 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 17.0 ptpt -154.06 177.65 10.84 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.942 0.401 . . . . 0.0 110.784 -179.352 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 67.3 m -104.69 117.76 34.9 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.011 179.123 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 27.1 m -136.31 159.5 38.37 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-O 120.902 0.382 . . . . 0.0 110.865 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -91.07 157.76 17.05 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.47 179.626 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 39.2 mm -105.85 126.92 61.23 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.18 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.451 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 41.02 -98.47 0.01 OUTLIER Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 179.651 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 40.3 tt0 -135.83 21.49 3.3 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 120.986 0.422 . . . . 0.0 109.957 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 58.1 m -79.65 -8.71 59.38 Favored 'General case' 0 CA--C 1.515 -0.397 0 CA-C-O 121.127 0.489 . . . . 0.0 110.418 179.564 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' LEU . . . . . 0.405 ' CD2' ' O ' ' A' ' 43' ' ' LEU . 0.9 OUTLIER 47.12 29.62 1.17 Allowed 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.246 -179.651 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -102.79 119.54 39.02 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 178.893 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -81.13 132.77 35.38 Favored 'General case' 0 CA--C 1.517 -0.326 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 -179.349 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 35.2 m -134.96 152.39 32.71 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.404 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.547 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.904 ' SG ' HD11 ' A' ' 11' ' ' ILE . 41.0 t -94.34 113.76 25.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.626 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.1 p -126.05 137.9 56.28 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.19 0 CA-C-O 121.001 0.429 . . . . 0.0 110.604 -179.388 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 8.3 m -97.44 165.05 12.19 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.784 -179.579 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 42.5 m-85 -117.39 145.79 36.92 Favored Pre-proline 0 N--CA 1.47 0.537 0 CA-C-N 116.742 -0.208 . . . . 0.0 111.256 -179.11 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo . . . . . 0 N--CA 1.496 1.658 0 C-N-CA 122.57 2.18 . . . . 0.0 112.077 179.553 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo . . . . . 0 N--CA 1.491 1.354 0 CA-C-O 120.964 0.318 . . . . 0.0 111.691 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.668 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.6 tt -121.53 119.68 32.67 Favored 'General case' 0 N--CA 1.474 0.748 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.562 -179.676 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.668 ' N ' HD23 ' A' ' 9' ' ' LEU . 6.8 tt -92.29 125.54 36.99 Favored 'General case' 0 N--CA 1.464 0.269 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 178.879 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.904 HD11 ' SG ' ' A' ' 47' ' ' CYS . 2.6 pt -102.54 -48.3 10.86 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.667 -179.056 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.411 ' H ' HG13 ' A' ' 11' ' ' ILE . . . -167.72 -138.29 2.42 Favored Glycine 0 N--CA 1.45 -0.398 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.487 ' C ' ' H ' ' A' ' 15' ' ' ILE . 43.1 p -132.62 159.01 40.79 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.085 0.469 . . . . 0.0 110.847 -179.697 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -56.12 -5.56 0.19 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.051 179.786 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.487 ' H ' ' C ' ' A' ' 13' ' ' THR . 84.6 mt -75.94 -26.5 17.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.883 0.373 . . . . 0.0 110.723 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -124.47 -27.69 3.71 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.063 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -122.62 80.57 47.75 Favored Pre-proline 0 C--O 1.233 0.187 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.335 179.206 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_exo -53.0 179.33 0.04 OUTLIER 'Trans proline' 0 N--CA 1.495 1.563 0 C-N-CA 122.787 2.325 . . . . 0.0 111.141 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.617 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 30.5 p -53.74 -61.28 2.4 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 121.074 0.464 . . . . 0.0 111.995 -179.802 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.553 ' HA ' HD22 ' A' ' 23' ' ' ASN . 5.4 pt-20 -43.8 -59.41 2.25 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.387 -178.907 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.479 ' H ' ' HG3' ' A' ' 20' ' ' GLU . 19.8 mtmt -64.43 -46.15 84.42 Favored 'General case' 0 CA--C 1.509 -0.608 0 CA-C-O 121.201 0.524 . . . . 0.0 111.269 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 41.2 t -45.07 -60.56 2.03 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-N 115.549 -0.75 . . . . 0.0 111.124 -178.475 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.617 ' ND2' ' O ' ' A' ' 19' ' ' THR . 11.0 p30 -65.63 -54.86 21.8 Favored 'General case' 0 C--O 1.22 -0.466 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.517 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.543 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 80.3 mttt -44.91 -44.5 9.75 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 120.691 -0.403 . . . . 0.0 110.575 -179.602 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 17.5 m -63.64 -39.9 95.52 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.164 0.506 . . . . 0.0 110.02 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 51.4 m -66.46 -31.4 72.12 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.573 -0.74 . . . . 0.0 111.042 -179.882 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.4 mm -63.94 -41.33 92.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-O 121.323 0.582 . . . . 0.0 110.141 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.415 ' C ' ' H ' ' A' ' 30' ' ' ASN . 52.9 mm-40 -67.06 -37.7 84.49 Favored 'General case' 0 N--CA 1.445 -0.725 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.527 -178.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 33.7 m -69.07 5.8 1.1 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.029 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.415 ' H ' ' C ' ' A' ' 28' ' ' GLU . 48.4 t30 71.47 50.89 0.26 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.067 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.581 ' C ' ' H ' ' A' ' 33' ' ' GLY . 57.0 m-85 -133.81 162.78 31.08 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.733 179.887 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.17 23.06 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.053 -0.522 . . . . 0.0 110.719 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.581 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 89.78 -175.8 42.22 Favored Glycine 0 CA--C 1.52 0.374 0 N-CA-C 110.533 -1.027 . . . . 0.0 110.533 -179.893 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -147.83 174.01 27.7 Favored Glycine 0 CA--C 1.522 0.482 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 -179.379 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 13.2 ptmt -155.44 178.57 10.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.885 0.374 . . . . 0.0 110.578 -179.377 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 1.8 m -105.17 128.07 53.21 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.144 179.227 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 19.3 m -134.47 158.62 41.93 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.047 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -101.36 156.41 17.47 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.023 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 35.9 mm -112.67 127.27 70.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.98 -179.755 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 40.11 -97.82 0.01 OUTLIER Glycine 0 CA--C 1.527 0.795 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 30.4 mm100 -137.45 28.38 2.75 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.838 0.351 . . . . 0.0 110.477 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' SER . . . . . 0.774 ' C ' HD23 ' A' ' 43' ' ' LEU . 73.5 m -87.29 4.73 41.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.917 179.883 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' LEU . . . . . 0.774 HD23 ' C ' ' A' ' 42' ' ' SER . 1.2 pt? 34.65 27.99 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.27 0 O-C-N 123.788 0.68 . . . . 0.0 111.496 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' ASP . . . . . 0.543 ' N ' ' O ' ' A' ' 42' ' ' SER . 43.4 t0 -99.98 121.1 40.84 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.572 -179.466 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -87.65 117.75 26.68 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.087 0.47 . . . . 0.0 109.963 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 30.6 m -111.86 136.05 49.24 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.255 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.116 -179.623 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.904 ' SG ' HD11 ' A' ' 11' ' ' ILE . 14.0 t -93.39 115.84 28.39 Favored 'General case' 0 CA--C 1.518 -0.286 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.628 -179.575 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.8 p -131.89 152.03 36.19 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.507 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.762 -179.036 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 6.4 m -97.47 172.51 7.7 Favored 'General case' 0 CA--C 1.515 -0.376 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.636 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 56.4 m-85 -138.23 142.57 35.8 Favored Pre-proline 0 C--N 1.331 -0.225 0 C-N-CA 120.882 -0.327 . . . . 0.0 111.359 -179.487 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo . . . . . 0 N--CA 1.494 1.547 0 C-N-CA 122.408 2.072 . . . . 0.0 112.297 178.516 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_exo . . . . . 0 N--CA 1.494 1.51 0 CA-C-O 120.647 0.186 . . . . 0.0 111.876 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.695 HD13 ' N ' ' A' ' 10' ' ' LEU . 0.2 OUTLIER -125.7 128.97 48.61 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-O 121.154 0.502 . . . . 0.0 110.708 179.895 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.695 ' N ' HD13 ' A' ' 9' ' ' LEU . 6.1 tt -90.97 136.63 32.94 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.396 178.867 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.467 HD13 ' N ' ' A' ' 11' ' ' ILE . 0.0 OUTLIER -105.88 -47.47 8.93 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.262 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.125 -179.667 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -172.63 -124.74 0.79 Allowed Glycine 0 CA--C 1.519 0.307 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.53 ' C ' ' H ' ' A' ' 15' ' ' ILE . 66.3 p -127.81 150.36 49.86 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.912 0.387 . . . . 0.0 110.264 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 7.4 t -63.63 4.66 0.24 Allowed 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.353 179.714 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.53 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.2 mt -88.48 -40.75 13.69 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.181 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -99.6 -11.9 20.56 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.752 179.796 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -124.99 81.06 63.12 Favored Pre-proline 0 N--CA 1.464 0.275 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.028 179.602 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -53.44 168.03 0.75 Allowed 'Trans proline' 0 N--CA 1.5 1.9 0 C-N-CA 123.146 2.564 . . . . 0.0 111.507 178.573 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.598 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 39.9 p -45.71 -60.01 2.45 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 112.003 0.371 . . . . 0.0 112.003 -178.837 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.51 ' HA ' HD22 ' A' ' 23' ' ' ASN . 6.6 pt-20 -46.37 -61.16 1.92 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.05 -179.27 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.492 ' H ' ' HG3' ' A' ' 20' ' ' GLU . 20.0 mtmt -63.11 -45.77 90.49 Favored 'General case' 0 CA--C 1.508 -0.644 0 CA-C-O 121.292 0.568 . . . . 0.0 111.629 -179.595 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 22.2 t -43.62 -59.35 2.22 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.024 -178.427 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.598 ' ND2' ' O ' ' A' ' 19' ' ' THR . 11.1 p30 -67.3 -57.86 5.87 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.578 179.635 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.576 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 72.0 mttt -43.37 -43.62 5.2 Favored 'General case' 0 C--O 1.222 -0.358 0 CA-C-O 120.852 0.358 . . . . 0.0 110.51 -178.978 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 19.6 m -64.09 -40.61 96.61 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.177 0.513 . . . . 0.0 110.178 179.66 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.421 ' N ' ' O ' ' A' ' 23' ' ' ASN . 25.5 m -66.71 -30.73 71.04 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.795 -179.895 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.8 mm -64.87 -41.28 91.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-O 121.292 0.568 . . . . 0.0 110.009 -179.705 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.418 ' C ' ' H ' ' A' ' 30' ' ' ASN . 31.2 mm-40 -65.84 -38.07 87.89 Favored 'General case' 0 N--CA 1.447 -0.612 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.379 -178.705 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 26.8 m -69.49 5.15 1.46 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.639 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.418 ' H ' ' C ' ' A' ' 28' ' ' GLU . 44.6 t30 70.86 54.85 0.25 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.006 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.563 ' C ' ' H ' ' A' ' 33' ' ' GLY . 60.4 m-85 -137.76 161.98 35.13 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.592 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.47 28.28 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.981 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.563 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 85.07 -175.26 49.98 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 110.7 -0.96 . . . . 0.0 110.7 -179.784 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.418 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -148.63 174.0 28.42 Favored Glycine 0 CA--C 1.522 0.483 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 -179.403 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 4.7 ptmm? -155.86 -178.12 7.07 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.592 0.234 . . . . 0.0 110.384 -179.247 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 31.1 m -104.45 129.69 52.42 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.414 179.228 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 28.5 m -137.78 161.85 32.63 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.261 179.696 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 3.5 p80 -109.06 157.62 18.53 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.217 -0.447 . . . . 0.0 109.998 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 83.6 mt -122.21 125.98 73.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.339 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 42.03 -128.51 4.37 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.891 -0.883 . . . . 0.0 110.891 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 29.0 pt20 -106.82 31.7 5.1 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 120.694 0.283 . . . . 0.0 110.413 179.693 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 20.1 m -84.39 -9.77 58.13 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 120.983 0.42 . . . . 0.0 110.598 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' LEU . . . . . 0.444 HD22 ' HA ' ' A' ' 43' ' ' LEU . 0.2 OUTLIER 40.02 29.41 0.05 Allowed 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.635 -0.712 . . . . 0.0 110.872 -179.144 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -107.55 126.45 52.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.222 179.691 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -90.65 124.55 35.16 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.638 -0.505 . . . . 0.0 109.638 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 30.5 m -120.47 138.07 52.19 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 CA-C-N 116.068 -0.514 . . . . 0.0 109.997 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -94.31 119.22 32.75 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.1 p -134.18 153.18 35.4 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.448 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.588 -179.069 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 5.9 m -97.28 172.23 7.92 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.898 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 56.4 m-85 -132.6 148.07 68.11 Favored Pre-proline 0 CA--C 1.531 0.214 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.939 -179.163 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo . . . . . 0 N--CA 1.494 1.52 0 C-N-CA 122.74 2.293 . . . . 0.0 112.308 179.356 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 21.3 Cg_exo . . . . . 0 N--CA 1.487 1.129 0 N-CA-C 111.363 -0.284 . . . . 0.0 111.363 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.64 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.8 tt -126.43 116.65 21.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.598 179.858 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.67 HD23 ' N ' ' A' ' 11' ' ' ILE . 7.2 tt -91.71 129.11 37.73 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 179.009 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.907 HD11 ' SG ' ' A' ' 47' ' ' CYS . 1.4 pt -105.61 -50.07 8.65 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-O 120.837 0.351 . . . . 0.0 110.921 -178.496 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -160.43 -164.61 15.75 Favored Glycine 0 N--CA 1.451 -0.308 0 N-CA-C 110.694 -0.963 . . . . 0.0 110.694 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.457 ' C ' ' H ' ' A' ' 15' ' ' ILE . 6.5 m -89.33 158.29 17.86 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.843 0.354 . . . . 0.0 110.423 -179.385 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 9.5 t -69.35 6.6 0.98 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.207 179.586 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.457 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.5 mt -91.44 -45.62 14.52 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.148 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -90.92 -11.37 39.33 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.925 179.649 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 54.1 m-85 -142.78 82.02 12.7 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.684 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.42 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 15.9 Cg_exo -65.95 -172.72 0.28 Allowed 'Trans proline' 0 N--CA 1.493 1.479 0 C-N-CA 122.904 2.403 . . . . 0.0 111.83 179.279 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.662 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 26.2 p -48.07 -56.68 7.19 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 120.826 -0.35 . . . . 0.0 111.698 -179.054 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.649 ' CD ' ' H ' ' A' ' 20' ' ' GLU . 0.0 OUTLIER -47.91 -72.2 0.06 Allowed 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.121 0.486 . . . . 0.0 111.736 -178.719 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 52.0 mtmt -60.49 -42.94 97.36 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.683 -178.273 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.42 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 44.7 t -44.94 -59.77 2.4 Favored 'General case' 0 C--N 1.313 -1.013 0 C-N-CA 120.215 -0.594 . . . . 0.0 111.089 -178.547 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.662 ' ND2' ' O ' ' A' ' 19' ' ' THR . 13.3 p30 -64.58 -55.64 19.09 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.546 -179.468 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.598 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 69.1 mttt -47.14 -42.79 20.07 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 120.788 -0.365 . . . . 0.0 110.584 -178.742 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 11.4 m -65.8 -37.75 87.13 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.242 179.71 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 37.9 m -67.64 -33.63 75.34 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.877 -0.602 . . . . 0.0 110.287 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.6 mm -61.5 -46.35 96.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.564 -179.536 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -66.34 -31.07 71.64 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.494 -179.035 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 27.1 m -72.87 1.5 8.57 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.405 -179.12 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 2.0 m120 74.51 52.98 0.09 Allowed 'General case' 0 C--N 1.329 -0.312 0 O-C-N 123.559 0.537 . . . . 0.0 111.032 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.565 ' C ' ' H ' ' A' ' 33' ' ' GLY . 68.6 m-85 -138.61 162.02 35.66 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.688 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.79 30.24 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.57 179.626 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.565 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 83.6 -176.87 52.53 Favored Glycine 0 CA--C 1.521 0.442 0 N-CA-C 110.568 -1.013 . . . . 0.0 110.568 -179.653 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.428 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -147.3 178.04 25.18 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 -179.595 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 14.7 ptmt -156.87 -176.79 6.17 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 110.237 -0.283 . . . . 0.0 110.237 -179.625 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 66.7 m -108.44 122.2 46.53 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.519 179.573 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 2.8 m -137.89 163.46 29.98 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.837 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 3.3 p-80 -92.97 157.61 16.24 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.341 179.714 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.437 ' O ' ' N ' ' A' ' 41' ' ' GLN . 34.1 mm -110.18 123.44 66.08 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 CA-C-O 121.086 0.47 . . . . 0.0 110.679 -179.741 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 43.99 20.74 0.17 Allowed Glycine 0 C--O 1.227 -0.307 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.575 179.629 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.437 ' N ' ' O ' ' A' ' 39' ' ' ILE . 37.3 tt0 72.61 36.18 1.01 Allowed 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.846 0.355 . . . . 0.0 110.721 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' SER . . . . . 0.422 ' N ' ' O ' ' A' ' 39' ' ' ILE . 41.0 m -85.61 -2.66 58.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.206 0.527 . . . . 0.0 110.885 -179.785 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' LEU . . . . . 0.447 HD22 ' HA ' ' A' ' 43' ' ' LEU . 0.2 OUTLIER 69.96 26.4 4.66 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.672 179.86 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 35.2 t70 -111.78 117.36 32.62 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 178.823 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -89.36 129.33 35.9 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 27.2 m -133.38 154.6 39.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.387 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.907 ' SG ' HD11 ' A' ' 11' ' ' ILE . 37.9 t -95.26 118.42 31.99 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 115.877 -0.601 . . . . 0.0 109.971 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.0 p -130.21 144.14 38.88 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 CA-C-O 120.87 0.366 . . . . 0.0 110.361 -179.466 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 4.9 m -97.93 167.52 10.86 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.889 -179.739 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 46.4 m-85 -122.18 143.05 38.14 Favored Pre-proline 0 CA--C 1.532 0.275 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.668 -179.428 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo . . . . . 0 N--CA 1.495 1.609 0 C-N-CA 122.544 2.163 . . . . 0.0 111.735 179.579 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_exo . . . . . 0 N--CA 1.494 1.554 0 N-CA-C 110.84 -0.485 . . . . 0.0 110.84 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.602 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.5 tt -129.77 116.89 19.4 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 179.607 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.602 ' N ' HD23 ' A' ' 9' ' ' LEU . 6.4 tt -89.27 124.81 34.75 Favored 'General case' 0 N--CA 1.465 0.321 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 179.711 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.909 HD11 ' SG ' ' A' ' 47' ' ' CYS . 3.2 pt -102.59 -46.97 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.842 -179.009 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -164.49 -138.45 2.41 Favored Glycine 0 CA--C 1.519 0.306 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.42 ' C ' ' N ' ' A' ' 15' ' ' ILE . 65.5 p -136.22 159.5 41.56 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.149 -0.526 . . . . 0.0 110.249 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -53.38 -12.27 0.41 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.05 179.54 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.42 ' N ' ' C ' ' A' ' 13' ' ' THR . 78.0 mt -71.78 -43.75 69.25 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.396 0 CA-C-O 121.353 0.597 . . . . 0.0 110.425 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 3.0 pt-20 -100.91 -34.3 9.85 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.094 -179.297 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.475 ' CD2' HD12 ' A' ' 11' ' ' ILE . 9.3 m-85 -116.93 85.0 16.85 Favored Pre-proline 0 N--CA 1.468 0.473 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.572 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -49.64 -178.63 0.01 OUTLIER 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 122.462 2.108 . . . . 0.0 111.508 -179.565 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.585 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 96.9 m -59.14 -51.41 70.12 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.629 -0.428 . . . . 0.0 111.443 -178.818 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.729 ' HA ' HD22 ' A' ' 23' ' ' ASN . 11.1 pt-20 -60.62 -50.17 74.61 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 112.052 0.389 . . . . 0.0 112.052 -179.706 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.477 ' N ' ' CG ' ' A' ' 20' ' ' GLU . 2.5 ttpp -64.8 -45.9 84.32 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.232 0.539 . . . . 0.0 110.225 -178.327 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 43.3 t -45.7 -61.47 1.7 Allowed 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.25 -0.886 . . . . 0.0 111.433 -179.57 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.729 HD22 ' HA ' ' A' ' 20' ' ' GLU . 13.4 p30 -64.65 -49.31 71.51 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.697 -179.42 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.535 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 82.3 mttt -48.11 -42.56 29.41 Favored 'General case' 0 C--O 1.218 -0.555 0 C-N-CA 120.544 -0.462 . . . . 0.0 109.852 -179.926 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 20.1 m -61.86 -42.4 99.0 Favored 'General case' 0 C--N 1.311 -1.073 0 C-N-CA 120.016 -0.674 . . . . 0.0 110.748 -179.586 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.495 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 10.2 t -65.51 -34.19 77.68 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.743 0.783 . . . . 0.0 109.229 179.363 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.6 mm -65.99 -41.29 89.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 115.008 -0.996 . . . . 0.0 110.289 -179.768 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.41 ' HG2' ' O ' ' A' ' 24' ' ' LYS . 54.4 mm-40 -64.23 -34.38 77.97 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.502 -179.555 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.448 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 36.1 m -67.87 -0.15 3.98 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.994 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.448 ' CB ' ' O ' ' A' ' 29' ' ' SER . 0.5 OUTLIER 80.9 14.81 0.66 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.483 -179.943 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.556 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 4.0 m-85 -94.89 -168.3 1.79 Allowed 'General case' 0 CA--C 1.533 0.298 0 CA-C-O 120.781 0.324 . . . . 0.0 110.261 -179.671 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -76.59 -51.26 11.96 Favored 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 -178.748 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.495 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 163.3 -179.24 38.56 Favored Glycine 0 CA--C 1.519 0.318 0 N-CA-C 109.734 -1.347 . . . . 0.0 109.734 -178.917 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.405 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -142.96 170.35 25.31 Favored Glycine 0 N--CA 1.462 0.405 0 N-CA-C 111.36 -0.696 . . . . 0.0 111.36 -179.115 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 23.3 pttt -156.9 178.43 10.37 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.071 0.462 . . . . 0.0 110.891 -179.663 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 3.2 m -104.56 128.4 52.53 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.053 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 35.1 m -136.23 163.38 34.15 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.573 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 2.8 p80 -108.75 156.61 19.41 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.129 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 95.9 mt -122.82 130.07 74.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.606 -179.391 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 48.02 -107.99 0.31 Allowed Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 29.8 mm100 -136.38 32.29 2.83 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 120.596 0.236 . . . . 0.0 110.48 -179.769 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 8.7 m -82.64 -12.03 57.95 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 121.134 0.492 . . . . 0.0 110.282 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' LEU . . . . . 0.419 HD22 ' HA ' ' A' ' 43' ' ' LEU . 0.2 OUTLIER 49.56 29.17 2.84 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.224 179.657 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -105.62 132.71 51.42 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.344 179.778 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -93.5 117.53 30.2 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-O 120.965 0.412 . . . . 0.0 109.95 179.823 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 16.3 m -111.0 137.16 44.65 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.41 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.007 -179.6 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.909 ' SG ' HD11 ' A' ' 11' ' ' ILE . 16.1 t -93.05 118.79 31.59 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.734 -179.837 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.9 p -128.05 150.91 34.22 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.093 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.84 -179.319 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' CYS . . . . . 0.556 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 28.9 t -96.88 165.4 12.12 Favored 'General case' 0 N--CA 1.467 0.419 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.508 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 25.3 m-85 -127.95 124.17 23.07 Favored Pre-proline 0 CA--C 1.544 0.731 0 C-N-CA 121.114 -0.234 . . . . 0.0 111.236 -178.444 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_exo . . . . . 0 N--CA 1.499 1.818 0 C-N-CA 121.999 1.8 . . . . 0.0 113.018 179.092 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo . . . . . 0 N--CA 1.497 1.693 0 CA-C-O 120.745 0.227 . . . . 0.0 111.984 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.659 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.8 tt -131.63 120.91 23.48 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.42 -179.272 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.729 HD23 ' N ' ' A' ' 11' ' ' ILE . 4.4 tt -89.94 128.43 36.23 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 178.883 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.729 ' N ' HD23 ' A' ' 10' ' ' LEU . 6.4 pt -101.72 -43.03 9.71 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-O 120.786 0.327 . . . . 0.0 110.865 -178.536 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.46 ' O ' HD21 ' A' ' 10' ' ' LEU . . . -173.54 -143.29 4.22 Favored Glycine 0 N--CA 1.451 -0.307 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.744 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.7 p -99.46 163.66 12.42 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.824 0.345 . . . . 0.0 110.275 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 43.4 t -74.1 7.55 2.64 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.331 179.6 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 97.1 mt -93.15 -43.68 13.63 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.12 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.523 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -88.37 -11.71 45.43 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.652 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 53.6 m-85 -122.84 81.22 49.58 Favored Pre-proline 0 N--CA 1.463 0.214 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.853 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_exo -48.88 165.99 0.17 Allowed 'Trans proline' 0 N--CA 1.495 1.599 0 C-N-CA 122.714 2.276 . . . . 0.0 111.33 179.065 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.582 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 17.0 m -48.39 -52.58 21.22 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.85 -0.34 . . . . 0.0 111.627 -178.036 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.703 ' HA ' HD22 ' A' ' 23' ' ' ASN . 1.3 pm0 -61.92 -55.44 29.58 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.551 -0.295 . . . . 0.0 111.651 -179.722 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -57.57 -45.82 84.71 Favored 'General case' 0 CA--C 1.518 -0.255 0 CA-C-O 121.302 0.572 . . . . 0.0 110.94 -178.208 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 12.7 t -48.02 -65.12 0.62 Allowed 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.402 -178.893 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.703 HD22 ' HA ' ' A' ' 20' ' ' GLU . 13.2 p30 -63.71 -48.37 77.37 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.755 -179.597 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.527 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 89.5 mttt -47.27 -42.02 19.88 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 120.543 -0.463 . . . . 0.0 110.05 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 18.6 m -61.57 -43.68 98.41 Favored 'General case' 0 C--N 1.314 -0.978 0 C-N-CA 120.456 -0.498 . . . . 0.0 110.909 -179.453 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.503 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 10.7 t -66.2 -32.51 73.99 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.525 0.679 . . . . 0.0 109.745 179.562 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.6 mm -66.54 -39.34 83.68 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.442 -179.623 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.422 ' C ' ' H ' ' A' ' 30' ' ' ASN . 54.9 mm-40 -64.34 -35.72 81.8 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.299 -179.356 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.401 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 58.6 m -67.86 1.65 2.47 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.268 179.797 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.422 ' H ' ' C ' ' A' ' 28' ' ' GLU . 43.8 t30 77.78 18.25 1.27 Allowed 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.705 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.553 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 4.1 m-85 -96.34 -167.83 1.64 Allowed 'General case' 0 CA--C 1.532 0.288 0 CA-C-O 120.945 0.402 . . . . 0.0 110.406 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -75.71 -51.51 12.55 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 115.893 -0.594 . . . . 0.0 112.076 -179.079 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.503 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 162.56 -178.06 38.46 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 -179.025 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.435 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -142.95 169.02 25.82 Favored Glycine 0 N--CA 1.462 0.375 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.136 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 11.4 ptmt -158.48 -176.25 5.78 Favored 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 120.681 -0.408 . . . . 0.0 110.716 -179.3 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 66.2 m -103.73 119.86 39.76 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.932 179.509 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 18.9 m -133.32 163.93 36.41 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.204 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -132.83 157.67 44.44 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 121.02 0.438 . . . . 0.0 110.394 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.556 ' O ' ' N ' ' A' ' 41' ' ' GLN . 20.2 mm -99.38 135.84 32.99 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.569 179.673 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -61.84 65.1 0.02 OUTLIER Glycine 0 N--CA 1.461 0.346 0 N-CA-C 111.543 -0.623 . . . . 0.0 111.543 -179.418 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.556 ' N ' ' O ' ' A' ' 39' ' ' ILE . 59.7 tp60 -174.63 -57.49 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.884 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 73.4 m -90.88 -13.84 32.88 Favored 'General case' 0 CA--C 1.505 -0.755 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.588 179.719 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' LEU . . . . . 0.54 ' N ' HD12 ' A' ' 43' ' ' LEU . 8.3 mp 46.88 28.28 0.82 Allowed 'General case' 0 N--CA 1.436 -1.171 0 C-N-CA 119.697 -0.801 . . . . 0.0 111.378 178.934 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 54.4 t0 -96.36 136.63 36.59 Favored 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.612 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -86.35 124.75 33.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.998 0.428 . . . . 0.0 110.0 -179.596 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 27.8 m -126.13 150.59 31.76 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.377 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.111 -179.713 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -98.55 125.96 43.96 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.582 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.1 p -136.77 155.0 32.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.188 -179.339 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' CYS . . . . . 0.553 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 17.7 t -97.07 164.65 12.42 Favored 'General case' 0 C--O 1.233 0.215 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.538 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 30.7 m-85 -133.98 126.59 18.78 Favored Pre-proline 0 C--N 1.33 -0.24 0 C-N-CA 121.031 -0.268 . . . . 0.0 110.856 -178.363 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 N--CA 1.491 1.339 0 C-N-CA 121.712 1.608 . . . . 0.0 112.218 179.97 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo . . . . . 0 N--CA 1.498 1.78 0 CA-C-O 120.641 0.184 . . . . 0.0 111.929 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.661 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.5 tt -129.65 120.61 25.5 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.126 -178.974 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.661 ' N ' HD23 ' A' ' 9' ' ' LEU . 7.2 tt -92.49 125.66 37.23 Favored 'General case' 0 N--CA 1.468 0.438 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 178.494 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.906 HD11 ' SG ' ' A' ' 47' ' ' CYS . 2.9 pt -103.56 -47.45 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-O 120.752 0.31 . . . . 0.0 111.0 -179.188 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -165.14 -135.73 1.88 Allowed Glycine 0 CA--C 1.519 0.311 0 C-N-CA 120.705 -0.76 . . . . 0.0 111.307 -179.649 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 71.3 p -136.89 159.6 41.38 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 114.99 -0.605 . . . . 0.0 110.163 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -56.72 -11.07 1.2 Allowed 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.026 179.636 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 97.3 mt -69.41 -43.24 81.05 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.329 0 CA-C-O 121.454 0.645 . . . . 0.0 109.782 179.71 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -104.34 -31.11 9.7 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 114.9 -1.045 . . . . 0.0 111.648 -178.797 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.427 ' O ' ' O ' ' A' ' 18' ' ' PRO . 12.0 m-85 -119.06 82.99 22.75 Favored Pre-proline 0 N--CA 1.471 0.612 0 N-CA-C 110.103 -0.332 . . . . 0.0 110.103 179.473 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.427 ' O ' ' O ' ' A' ' 17' ' ' PHE . 77.5 Cg_exo -47.61 179.87 0.01 OUTLIER 'Trans proline' 0 N--CA 1.495 1.57 0 C-N-CA 122.645 2.23 . . . . 0.0 111.701 -179.79 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.449 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 99.0 m -59.0 -50.71 73.06 Favored 'General case' 0 C--N 1.326 -0.428 0 C-N-CA 120.89 -0.324 . . . . 0.0 111.845 -178.513 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.628 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 1.1 pm0 -60.03 -52.59 64.73 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.161 -179.688 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.13 -47.29 85.24 Favored 'General case' 0 CA--C 1.519 -0.235 0 CA-C-O 121.297 0.57 . . . . 0.0 110.691 -179.212 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 38.5 t -45.12 -60.38 2.13 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 115.312 -0.858 . . . . 0.0 111.259 -178.792 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.666 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.9 p-10 -64.71 -51.69 61.07 Favored 'General case' 0 C--O 1.221 -0.411 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.734 -179.593 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.666 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 81.2 mttt -47.97 -42.86 28.77 Favored 'General case' 0 C--N 1.323 -0.554 0 C-N-CA 120.405 -0.518 . . . . 0.0 110.584 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 55.5 m -66.35 -33.3 75.41 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.163 0.506 . . . . 0.0 110.085 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 56.9 m -72.0 -34.04 68.56 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.876 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.3 mm -62.07 -48.51 88.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.727 -179.251 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.459 ' C ' ' H ' ' A' ' 30' ' ' ASN . 6.0 pt-20 -70.47 -30.81 67.71 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.799 -179.303 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 39.5 m -68.96 7.15 0.74 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.706 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.459 ' H ' ' C ' ' A' ' 28' ' ' GLU . 49.8 t30 72.73 47.86 0.22 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.366 179.487 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.55 ' C ' ' H ' ' A' ' 33' ' ' GLY . 73.9 m-85 -137.23 160.8 37.97 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.759 179.424 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.32 23.3 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.168 -179.66 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.55 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 91.92 -179.88 41.4 Favored Glycine 0 CA--C 1.519 0.338 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 -179.683 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -148.92 174.45 28.54 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.433 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 8.8 pttm -154.12 -179.08 7.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.035 0.445 . . . . 0.0 110.788 -179.781 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 3.9 m -105.03 124.46 49.56 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 115.718 -0.673 . . . . 0.0 110.308 179.658 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 35.7 m -136.67 165.91 27.38 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.75 -179.679 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 3.3 p80 -106.92 155.85 19.34 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-O 121.025 0.44 . . . . 0.0 110.66 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 96.0 mt -128.96 126.49 64.74 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.217 -179.481 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 61.46 22.48 61.41 Favored Glycine 0 CA--C 1.52 0.387 0 N-CA-C 111.555 -0.618 . . . . 0.0 111.555 178.797 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 57.3 37.37 28.11 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.026 0.441 . . . . 0.0 110.03 -179.466 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 20.7 m -81.49 -11.09 59.33 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.181 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' LEU . . . . . 0.41 ' CD2' ' O ' ' A' ' 43' ' ' LEU . 0.9 OUTLIER 70.69 28.63 3.43 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.493 0.663 . . . . 0.0 109.659 -179.783 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -110.97 121.34 45.1 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.665 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 64.5 m-85 -90.63 117.1 29.03 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-O 121.163 0.506 . . . . 0.0 110.007 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.5 m -110.97 137.65 42.55 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.33 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.715 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.906 ' SG ' HD11 ' A' ' 11' ' ' ILE . 13.5 t -93.02 113.95 26.36 Favored 'General case' 0 CA--C 1.512 -0.481 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 -179.862 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 8.8 p -130.39 147.78 33.16 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.308 0 CA-C-O 121.143 0.497 . . . . 0.0 111.62 -178.748 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 4.8 m -97.43 170.82 8.79 Favored 'General case' 0 CA--C 1.518 -0.257 0 CA-C-N 115.258 -0.883 . . . . 0.0 109.793 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -130.15 143.29 48.57 Favored Pre-proline 0 CA--C 1.542 0.644 0 CA-C-N 116.512 -0.313 . . . . 0.0 111.266 -178.804 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_exo . . . . . 0 N--CA 1.498 1.736 0 C-N-CA 122.37 2.047 . . . . 0.0 112.011 177.676 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo . . . . . 0 N--CA 1.495 1.571 0 N-CA-C 111.187 -0.351 . . . . 0.0 111.187 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.69 HD13 ' N ' ' A' ' 10' ' ' LEU . 0.2 OUTLIER -111.32 126.69 55.18 Favored 'General case' 0 N--CA 1.468 0.472 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.685 -179.006 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.69 ' N ' HD13 ' A' ' 9' ' ' LEU . 2.6 tm? -92.05 128.5 37.91 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 178.336 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.47 HD11 ' SG ' ' A' ' 26' ' ' CYS . 0.0 OUTLIER -108.06 -40.09 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -178.63 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -177.94 -140.59 3.84 Favored Glycine 0 CA--C 1.52 0.404 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 179.698 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.496 ' C ' ' H ' ' A' ' 15' ' ' ILE . 80.6 p -135.63 161.08 36.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.017 0.437 . . . . 0.0 111.045 -179.534 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -58.17 -2.96 0.21 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.26 179.54 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.496 ' H ' ' C ' ' A' ' 13' ' ' THR . 23.8 mm -73.45 -22.65 19.18 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 CA-C-O 121.092 0.473 . . . . 0.0 109.948 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLU . . . . . 0.477 ' OE1' ' CZ ' ' A' ' 17' ' ' PHE . 9.5 pt-20 -134.51 -30.76 1.11 Allowed 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.154 -179.515 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.477 ' CZ ' ' OE1' ' A' ' 16' ' ' GLU . 9.9 m-85 -114.88 93.4 34.01 Favored Pre-proline 0 N--CA 1.468 0.426 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.537 -179.619 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.45 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 56.5 Cg_endo -79.25 -179.08 5.1 Favored 'Trans proline' 0 N--CA 1.489 1.235 0 C-N-CA 122.489 2.126 . . . . 0.0 111.23 -179.543 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.411 ' OG1' ' OE2' ' A' ' 20' ' ' GLU . 23.4 p -45.4 -48.68 13.52 Favored 'General case' 0 C--N 1.32 -0.687 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.116 -178.74 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.469 ' CD ' ' H ' ' A' ' 20' ' ' GLU . 0.3 OUTLIER -52.55 -70.72 0.08 Allowed 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.614 -179.316 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 16.2 ttmt -64.59 -47.36 78.95 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-O 121.443 0.64 . . . . 0.0 111.304 -178.008 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.45 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 51.8 t -41.78 -59.8 1.56 Allowed 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.205 -0.907 . . . . 0.0 111.039 -178.954 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.483 ' OD1' ' N ' ' A' ' 24' ' ' LYS . 0.2 OUTLIER -66.89 -55.13 16.01 Favored 'General case' 0 C--O 1.218 -0.577 0 C-N-CA 120.205 -0.598 . . . . 0.0 110.421 -179.634 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.483 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 71.7 mttt -44.53 -42.6 7.34 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.871 0.367 . . . . 0.0 110.71 -179.231 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' THR . . . . . 0.454 ' O ' ' OE2' ' A' ' 28' ' ' GLU . 8.8 m -65.12 -37.14 86.49 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.416 0.627 . . . . 0.0 109.558 179.408 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.47 ' SG ' HD11 ' A' ' 11' ' ' ILE . 67.9 m -72.08 -35.27 69.19 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.162 179.728 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.9 mm -62.67 -48.34 88.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.386 -179.192 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.454 ' OE2' ' O ' ' A' ' 25' ' ' THR . 2.6 pp20? -70.57 -31.09 67.97 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.601 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.434 ' N ' ' CD ' ' A' ' 28' ' ' GLU . 68.6 m -67.57 2.36 1.86 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.934 -179.688 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.411 ' H ' ' C ' ' A' ' 28' ' ' GLU . 41.6 t30 75.14 43.32 0.21 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.983 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.553 ' C ' ' H ' ' A' ' 33' ' ' GLY . 63.0 m-85 -131.92 160.99 34.13 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.459 179.463 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.48 31.19 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.96 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.553 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 84.11 -176.96 51.92 Favored Glycine 0 CA--C 1.52 0.4 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -150.58 172.13 30.35 Favored Glycine 0 CA--C 1.52 0.36 0 N-CA-C 110.715 -0.954 . . . . 0.0 110.715 -179.73 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 25.2 pttt -155.25 -179.02 7.68 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 120.935 0.398 . . . . 0.0 110.563 -179.558 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 3.3 m -103.94 127.08 51.48 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 115.866 -0.607 . . . . 0.0 110.172 179.384 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 34.5 m -136.77 159.81 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.419 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 4.5 p-80 -104.6 156.94 17.53 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-O 121.072 0.463 . . . . 0.0 110.086 179.753 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.478 ' O ' ' N ' ' A' ' 41' ' ' GLN . 34.4 mm -109.21 125.13 66.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.243 -179.765 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 42.5 -92.42 0.01 OUTLIER Glycine 0 CA--C 1.526 0.75 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.484 ' N ' ' CD ' ' A' ' 41' ' ' GLN . 2.0 pm0 -143.9 30.44 1.31 Allowed 'General case' 0 N--CA 1.463 0.197 0 CA-C-O 120.702 0.287 . . . . 0.0 110.531 -179.64 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 66.3 m -84.43 -5.4 59.28 Favored 'General case' 0 CA--C 1.52 -0.188 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.689 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 45.14 28.37 0.4 Allowed 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.677 179.813 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -103.04 119.8 39.51 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.396 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 70.8 m-85 -87.75 117.8 26.83 Favored 'General case' 0 C--N 1.332 -0.191 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.725 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 33.4 m -112.82 137.09 47.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.331 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.432 ' O ' HD22 ' A' ' 10' ' ' LEU . 25.2 t -92.25 108.2 19.77 Favored 'General case' 0 CA--C 1.513 -0.445 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 179.838 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.2 p -124.36 150.23 28.96 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.229 0 CA-C-O 120.941 0.4 . . . . 0.0 110.634 -178.809 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 10.6 m -97.26 163.13 13.03 Favored 'General case' 0 CA--C 1.515 -0.386 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 -179.696 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 -119.33 143.29 34.05 Favored Pre-proline 0 CA--C 1.531 0.249 0 C-N-CA 121.141 -0.224 . . . . 0.0 111.227 -178.879 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo . . . . . 0 N--CA 1.494 1.522 0 C-N-CA 122.221 1.947 . . . . 0.0 111.989 178.81 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo . . . . . 0 N--CA 1.486 1.051 0 N-CA-C 110.993 -0.426 . . . . 0.0 110.993 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.611 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.5 tt -117.0 114.79 24.29 Favored 'General case' 0 CA--C 1.511 -0.523 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 -179.777 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.669 HD13 ' C ' ' A' ' 10' ' ' LEU . 3.0 tm? -93.27 124.5 37.29 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.37 -0.532 . . . . 0.0 109.881 179.266 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.962 HD11 ' SG ' ' A' ' 47' ' ' CYS . 5.7 pt -103.37 -41.91 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-O 121.052 0.453 . . . . 0.0 110.588 -179.342 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.453 ' O ' HD21 ' A' ' 10' ' ' LEU . . . -174.8 -139.5 3.03 Favored Glycine 0 CA--C 1.521 0.418 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.444 ' C ' ' H ' ' A' ' 15' ' ' ILE . 72.7 p -134.06 165.99 23.78 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.914 0.388 . . . . 0.0 110.924 -179.524 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -58.6 -5.6 0.58 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.206 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.444 ' H ' ' C ' ' A' ' 13' ' ' THR . 24.0 mm -74.5 -24.48 18.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.538 -179.292 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -128.33 -29.92 2.43 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.84 -179.592 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -117.34 91.96 38.84 Favored Pre-proline 0 CA--C 1.536 0.411 0 CA-C-N 116.486 -0.324 . . . . 0.0 110.474 179.759 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.463 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 52.9 Cg_endo -71.56 -177.33 2.4 Favored 'Trans proline' 0 N--CA 1.498 1.736 0 C-N-CA 123.12 2.547 . . . . 0.0 111.853 -179.25 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.473 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 31.0 m -46.73 -70.61 0.09 Allowed 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 120.568 -0.453 . . . . 0.0 111.358 -179.275 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.648 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 1.3 pm0 -41.39 -70.13 0.11 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.395 -178.865 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 5.3 ttmt -54.44 -53.88 48.23 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.021 0.439 . . . . 0.0 111.499 -177.867 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.463 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 43.0 t -41.41 -59.44 1.57 Allowed 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.071 -178.937 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.745 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 0.9 OUTLIER -65.82 -52.1 53.41 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.848 179.611 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.745 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 69.7 mttt -48.42 -42.61 32.65 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 120.839 0.352 . . . . 0.0 110.674 -178.539 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 20.0 m -63.93 -41.08 97.73 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-O 121.331 0.586 . . . . 0.0 109.995 179.789 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 57.5 m -65.23 -31.06 72.03 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.574 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.41 HG12 ' O ' ' A' ' 23' ' ' ASN . 3.1 mm -65.37 -38.83 83.48 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.427 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 30.2 mm-40 -65.74 -33.06 75.0 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.551 -0.749 . . . . 0.0 110.626 -178.739 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 46.2 m -73.27 -2.66 22.8 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.307 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 1.9 m120 77.84 34.5 0.32 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.958 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.573 ' C ' ' H ' ' A' ' 33' ' ' GLY . 8.2 m-85 -110.34 164.7 12.42 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.049 179.892 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.19 21.29 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.57 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.573 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 90.32 -178.7 43.25 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.371 -1.091 . . . . 0.0 110.371 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.421 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -147.01 170.33 27.93 Favored Glycine 0 CA--C 1.52 0.406 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 -179.344 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 10.7 ptmt -156.36 -177.0 6.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.619 0.247 . . . . 0.0 110.601 -179.576 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 1.7 m -104.02 125.76 50.62 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.131 179.489 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 34.0 m -133.92 162.57 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.297 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 5.1 p-80 -109.12 157.42 18.76 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.867 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 92.1 mt -123.27 131.59 72.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.716 -179.485 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 49.55 -103.98 0.09 OUTLIER Glycine 0 CA--C 1.519 0.307 0 N-CA-C 110.812 -0.915 . . . . 0.0 110.812 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 41.2 tp60 -141.44 30.98 1.71 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.876 0.37 . . . . 0.0 110.396 -179.757 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 58.2 m -85.93 -5.7 59.19 Favored 'General case' 0 CA--C 1.518 -0.252 0 CA-C-O 120.967 0.413 . . . . 0.0 110.91 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' LEU . . . . . 0.403 ' CD2' ' O ' ' A' ' 43' ' ' LEU . 0.9 OUTLIER 44.42 29.95 0.43 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.398 -179.499 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -99.8 124.88 45.53 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.073 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -89.7 118.01 28.99 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 109.692 -0.485 . . . . 0.0 109.692 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 29.8 m -112.84 136.21 49.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.102 -179.52 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.962 ' SG ' HD11 ' A' ' 11' ' ' ILE . 22.1 t -92.94 105.98 18.01 Favored 'General case' 0 CA--C 1.513 -0.464 0 N-CA-C 109.373 -0.602 . . . . 0.0 109.373 179.901 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 4.7 p -125.54 154.97 34.6 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.375 0 CA-C-O 120.94 0.4 . . . . 0.0 110.573 -178.826 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 8.1 m -99.31 173.36 6.81 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.168 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 64.3 m-85 -133.6 117.95 14.44 Favored Pre-proline 0 CA--C 1.536 0.43 0 CA-C-N 116.269 -0.423 . . . . 0.0 109.999 179.224 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo . . . . . 0 N--CA 1.499 1.826 0 C-N-CA 122.186 1.924 . . . . 0.0 112.328 179.666 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo . . . . . 0 N--CA 1.502 1.986 0 CA-C-O 120.8 0.25 . . . . 0.0 112.303 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.657 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.6 tt -128.42 120.79 27.59 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.755 -179.215 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.657 ' N ' HD23 ' A' ' 9' ' ' LEU . 6.6 tt -89.05 133.9 34.19 Favored 'General case' 0 N--CA 1.468 0.46 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 178.128 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 12.8 pt -109.04 -37.02 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-O 120.869 0.366 . . . . 0.0 111.068 -178.775 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 175.32 -153.72 16.09 Favored Glycine 0 N--CA 1.452 -0.255 0 N-CA-C 110.913 -0.875 . . . . 0.0 110.913 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 6.7 p -90.03 164.85 14.35 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 10.4 t -76.07 7.35 4.19 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.214 179.601 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.5 mt -91.46 -42.32 13.65 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.221 0 CA-C-O 121.149 0.499 . . . . 0.0 109.808 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -87.91 -12.63 44.15 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.361 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -124.81 81.2 61.81 Favored Pre-proline 0 N--CA 1.463 0.217 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.954 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -48.64 163.23 0.29 Allowed 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.05 1.833 . . . . 0.0 110.719 178.731 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.564 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 25.5 p -46.5 -53.24 11.63 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.919 0.39 . . . . 0.0 111.721 -177.837 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.656 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 0.0 OUTLIER -59.72 -55.4 34.78 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.573 -179.429 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -58.96 -44.79 91.53 Favored 'General case' 0 CA--C 1.516 -0.336 0 CA-C-O 121.332 0.587 . . . . 0.0 110.388 -178.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 14.7 t -48.28 -65.46 0.56 Allowed 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 115.265 -0.88 . . . . 0.0 111.427 -178.964 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.654 HD22 ' HA ' ' A' ' 20' ' ' GLU . 13.8 p30 -64.97 -46.97 79.26 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.011 -179.438 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.516 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 92.9 mttt -50.59 -37.55 40.53 Favored 'General case' 0 CA--C 1.5 -0.952 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.23 179.592 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 86.8 m -63.93 -42.79 97.26 Favored 'General case' 0 C--N 1.319 -0.751 0 O-C-N 124.012 0.82 . . . . 0.0 110.468 -179.342 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.497 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 33.8 t -72.58 -33.4 66.74 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.106 179.68 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.2 mm -66.08 -46.7 87.19 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.616 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.112 -179.192 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.505 ' C ' ' H ' ' A' ' 30' ' ' ASN . 19.0 pt-20 -69.64 -30.46 68.17 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 115.349 -0.841 . . . . 0.0 110.151 -179.698 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.416 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 68.3 m -65.49 1.78 1.09 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.75 179.845 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.505 ' H ' ' C ' ' A' ' 28' ' ' GLU . 16.9 t-20 79.82 12.56 1.1 Allowed 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.966 179.546 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.562 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 4.5 m-85 -98.07 -167.81 1.57 Allowed 'General case' 0 CA--C 1.533 0.322 0 CA-C-O 120.706 0.289 . . . . 0.0 110.27 -179.842 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -75.79 -53.97 7.65 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.582 0.586 . . . . 0.0 112.582 -178.543 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.497 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 166.5 178.9 39.45 Favored Glycine 0 CA--C 1.519 0.321 0 N-CA-C 110.068 -1.213 . . . . 0.0 110.068 -178.921 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -137.26 160.98 25.19 Favored Glycine 0 C--N 1.331 0.299 0 N-CA-C 111.579 -0.609 . . . . 0.0 111.579 -179.383 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 14.2 ptpt -153.45 170.23 21.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.29 -0.455 . . . . 0.0 110.779 -178.98 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 56.5 m -104.86 117.7 34.7 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.891 179.493 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 4.8 m -139.65 -178.5 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-O 120.873 0.368 . . . . 0.0 111.129 -179.427 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.619 ' ND1' ' N ' ' A' ' 44' ' ' ASP . 95.3 m-70 -114.0 147.98 37.72 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.802 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 95.6 mt -124.06 127.8 73.7 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.849 -179.847 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 68.74 21.78 75.09 Favored Glycine 0 CA--C 1.52 0.35 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 179.374 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 57.79 30.8 19.55 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.196 0.522 . . . . 0.0 109.794 -179.215 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 50.6 m -72.22 -10.92 60.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.443 -0.798 . . . . 0.0 110.511 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' LEU . . . . . 0.445 ' C ' ' ND1' ' A' ' 38' ' ' HIS . 0.9 OUTLIER 63.14 29.33 16.14 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.649 -179.636 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 44' ' ' ASP . . . . . 0.619 ' N ' ' ND1' ' A' ' 38' ' ' HIS . 67.2 t0 -111.05 138.69 47.16 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.714 179.499 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.489 ' N ' ' OD1' ' A' ' 44' ' ' ASP . 50.2 m-85 -92.95 117.38 29.98 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.645 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 25.9 m -124.29 136.81 59.29 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.328 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.052 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -94.46 122.59 37.19 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.352 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.0 p -135.52 152.52 31.71 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.318 0 C-N-CA 120.655 -0.418 . . . . 0.0 111.319 -179.393 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' CYS . . . . . 0.562 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 23.9 t -96.01 164.18 12.81 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.078 -179.937 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.494 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 37.7 m-85 -130.75 136.55 29.11 Favored Pre-proline 0 N--CA 1.476 0.849 0 C-N-CA 120.788 -0.365 . . . . 0.0 111.352 -178.427 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo . . . . . 0 N--CA 1.491 1.355 0 C-N-CA 121.865 1.71 . . . . 0.0 112.207 179.888 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo . . . . . 0 N--CA 1.501 1.934 0 CA-C-O 120.561 0.15 . . . . 0.0 111.797 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.634 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.5 tt -128.33 119.5 25.2 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.637 HD23 ' N ' ' A' ' 11' ' ' ILE . 6.6 tt -88.65 126.58 35.36 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 108.839 -0.801 . . . . 0.0 108.839 179.199 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.896 HD11 ' SG ' ' A' ' 47' ' ' CYS . 2.2 pt -105.36 -48.12 9.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-O 120.983 0.421 . . . . 0.0 110.852 -178.549 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -159.87 -144.22 3.9 Favored Glycine 0 CA--C 1.52 0.369 0 N-CA-C 110.771 -0.931 . . . . 0.0 110.771 -179.802 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.478 ' C ' ' H ' ' A' ' 15' ' ' ILE . 55.2 p -138.89 161.22 37.83 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.994 0.426 . . . . 0.0 110.809 -179.826 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -59.81 -1.28 0.26 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.221 179.652 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.478 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.2 mt -77.9 -23.65 13.98 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.406 0 CA-C-O 121.164 0.506 . . . . 0.0 109.806 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 2.7 pt-20 -134.24 -34.17 0.98 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.589 -0.732 . . . . 0.0 111.197 -179.381 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.431 ' CZ ' ' NZ ' ' A' ' 21' ' ' LYS . 6.4 m-85 -106.82 88.85 3.84 Favored Pre-proline 0 CA--C 1.538 0.5 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.416 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 19.0 Cg_endo -63.43 -173.6 0.18 Allowed 'Trans proline' 0 N--CA 1.499 1.799 0 C-N-CA 121.832 1.688 . . . . 0.0 112.461 -178.789 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 70.5 m -58.11 -49.81 75.66 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.021 -179.227 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.43 ' CG ' ' N ' ' A' ' 21' ' ' LYS . 8.9 pt-20 -59.06 -56.66 19.42 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.806 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.431 ' NZ ' ' CZ ' ' A' ' 17' ' ' PHE . 0.6 OUTLIER -64.51 -47.22 79.68 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-O 121.235 0.541 . . . . 0.0 111.087 -177.989 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.416 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 32.4 t -45.4 -63.18 1.0 Allowed 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.375 -0.83 . . . . 0.0 111.682 -179.149 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.475 ' OD1' ' N ' ' A' ' 24' ' ' LYS . 0.2 OUTLIER -63.45 -49.6 73.03 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.008 -179.276 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.475 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 47.5 mttp -45.1 -42.37 8.72 Favored 'General case' 0 C--O 1.218 -0.563 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.087 -179.7 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 17.8 m -62.34 -43.49 98.7 Favored 'General case' 0 C--N 1.311 -1.094 0 C-N-CA 119.98 -0.688 . . . . 0.0 110.366 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.492 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 11.4 t -66.99 -32.65 74.03 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 121.574 0.702 . . . . 0.0 109.788 179.615 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.5 mm -65.9 -41.76 90.63 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.213 -179.445 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.447 ' C ' ' H ' ' A' ' 30' ' ' ASN . 25.6 mm-40 -65.43 -34.87 79.31 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.146 -0.933 . . . . 0.0 110.371 -179.477 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.412 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 27.3 m -66.76 2.38 1.41 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.189 -179.742 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.447 ' H ' ' C ' ' A' ' 28' ' ' GLU . 17.5 t-20 78.24 15.28 1.38 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.59 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.553 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 4.1 m-85 -95.79 -168.62 1.8 Allowed 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 120.898 0.38 . . . . 0.0 110.343 -179.764 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -76.05 -50.13 15.62 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.987 -178.906 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.492 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 160.39 -176.17 37.08 Favored Glycine 0 C--O 1.226 -0.402 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 -179.148 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.449 ' H ' ' HB2' ' A' ' 23' ' ' ASN . . . -146.02 168.14 27.66 Favored Glycine 0 CA--C 1.519 0.331 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 -179.41 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 14.6 ptpt -155.76 178.65 10.02 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.003 0.43 . . . . 0.0 110.81 -179.126 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 4.6 m -103.59 123.52 47.11 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.077 179.506 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 27.6 m -136.4 161.16 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.45 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 2.5 p-80 -109.34 157.09 19.22 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.074 179.818 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.457 ' O ' ' N ' ' A' ' 41' ' ' GLN . 34.5 mm -107.83 125.74 64.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.174 -179.655 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 41.72 -94.4 0.01 OUTLIER Glycine 0 CA--C 1.527 0.782 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 179.694 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.457 ' N ' ' O ' ' A' ' 39' ' ' ILE . 16.6 mp0 -139.67 35.63 2.01 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.796 0.332 . . . . 0.0 110.348 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' SER . . . . . 0.759 ' C ' HD23 ' A' ' 43' ' ' LEU . 63.7 m -87.02 2.22 50.29 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.951 -179.875 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' LEU . . . . . 0.759 HD23 ' C ' ' A' ' 42' ' ' SER . 1.3 pt? 34.64 28.06 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 O-C-N 123.756 0.66 . . . . 0.0 111.618 -179.583 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 42' ' ' SER . 52.5 t0 -107.78 120.42 42.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.478 -179.843 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 -88.79 117.66 27.93 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 32.5 m -115.12 142.85 26.43 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.269 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.177 -179.431 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.896 ' SG ' HD11 ' A' ' 11' ' ' ILE . 17.0 t -94.03 119.15 32.51 Favored 'General case' 0 CA--C 1.515 -0.396 0 CA-C-N 115.894 -0.594 . . . . 0.0 109.462 179.749 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.4 p -126.39 152.46 33.94 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.204 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.398 -179.512 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' CYS . . . . . 0.553 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 33.0 t -96.41 163.31 13.11 Favored 'General case' 0 N--CA 1.466 0.341 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 -179.771 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.484 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 19.0 m-85 -129.86 125.47 22.15 Favored Pre-proline 0 N--CA 1.469 0.497 0 C-N-CA 121.147 -0.221 . . . . 0.0 110.73 -178.738 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_endo . . . . . 0 N--CA 1.488 1.168 0 C-N-CA 121.812 1.674 . . . . 0.0 112.188 179.789 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.435 ' CB ' ' O ' ' A' ' 49' ' ' CYS . 74.2 Cg_endo . . . . . 0 N--CA 1.493 1.494 0 CA-C-O 120.548 0.145 . . . . 0.0 111.909 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.651 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.4 tt -135.55 119.68 17.66 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-O 120.764 0.316 . . . . 0.0 110.725 -179.312 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.651 ' N ' HD23 ' A' ' 9' ' ' LEU . 6.3 tt -88.97 133.43 34.32 Favored 'General case' 0 N--CA 1.464 0.255 0 N-CA-C 109.584 -0.525 . . . . 0.0 109.584 178.238 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.892 HD11 ' SG ' ' A' ' 47' ' ' CYS . 2.3 pt -109.62 -46.17 6.68 Favored 'Isoleucine or valine' 0 C--O 1.231 0.11 0 CA-C-O 120.835 0.35 . . . . 0.0 110.232 -178.716 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 179.46 -159.74 24.59 Favored Glycine 0 N--CA 1.452 -0.26 0 N-CA-C 111.276 -0.73 . . . . 0.0 111.276 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 68.7 p -100.99 164.09 11.98 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.193 -0.503 . . . . 0.0 110.245 179.755 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -59.12 -11.46 3.73 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.455 179.448 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 97.0 mt -70.35 -43.73 78.08 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 CA-C-O 121.159 0.505 . . . . 0.0 110.296 -179.693 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -98.05 -31.2 12.26 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.954 -179.402 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.779 ' CD2' HD12 ' A' ' 11' ' ' ILE . 13.9 m-85 -121.11 80.47 35.33 Favored Pre-proline 0 N--CA 1.469 0.52 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 178.945 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.433 ' O ' ' O ' ' A' ' 17' ' ' PHE . 75.3 Cg_exo -47.05 -178.9 0.0 OUTLIER 'Trans proline' 0 N--CA 1.495 1.583 0 C-N-CA 122.794 2.329 . . . . 0.0 111.747 -179.667 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 37.4 p -58.77 -54.71 44.04 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.418 0.628 . . . . 0.0 111.536 -179.278 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -55.74 -52.24 64.62 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.01 -0.996 . . . . 0.0 111.216 -179.685 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -63.64 -47.36 81.67 Favored 'General case' 0 CA--C 1.519 -0.215 0 CA-C-O 121.312 0.577 . . . . 0.0 110.534 -179.623 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 36.8 t -45.44 -63.18 1.01 Allowed 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 115.12 -0.945 . . . . 0.0 111.229 -179.233 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.458 ' OD1' ' N ' ' A' ' 24' ' ' LYS . 0.2 OUTLIER -64.36 -47.9 77.58 Favored 'General case' 0 C--O 1.221 -0.424 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.867 -178.953 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.458 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 83.4 mttt -48.73 -39.51 25.1 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.22 -179.675 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' THR . . . . . 0.434 ' O ' ' OG ' ' A' ' 29' ' ' SER . 16.7 m -64.9 -40.66 95.44 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.207 0.527 . . . . 0.0 110.112 -179.714 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.508 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 41.2 t -72.58 -36.3 68.13 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.409 0.623 . . . . 0.0 110.492 179.54 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.2 mm -64.62 -47.61 88.23 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.928 -179.097 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.411 ' C ' ' H ' ' A' ' 30' ' ' ASN . 2.9 pp20? -70.95 -27.52 63.8 Favored 'General case' 0 N--CA 1.446 -0.645 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.638 -179.504 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.477 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 72.8 m -67.17 0.66 2.55 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.611 -179.639 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.477 ' CB ' ' O ' ' A' ' 29' ' ' SER . 14.6 t-20 85.59 3.42 0.59 Allowed 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.534 179.781 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.578 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 47.5 m-85 -91.47 -167.79 1.88 Allowed 'General case' 0 N--CA 1.456 -0.169 0 CA-C-O 120.871 0.367 . . . . 0.0 110.525 179.608 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -78.34 -59.12 2.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.35 0.595 . . . . 0.0 111.756 -178.95 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.508 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 175.18 177.64 44.42 Favored Glycine 0 N--CA 1.449 -0.47 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -178.928 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.44 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -135.27 157.84 23.33 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -179.538 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 17.6 ptpt -149.62 166.96 27.71 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.915 0.388 . . . . 0.0 110.814 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 1.8 m -103.78 122.91 46.08 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.037 179.577 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 33.4 m -136.98 169.57 19.58 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.601 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 1.1 m80 -97.45 154.04 17.74 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.116 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.464 ' O ' ' N ' ' A' ' 41' ' ' GLN . 42.2 mm -115.03 128.69 72.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 42.32 -94.41 0.01 OUTLIER Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.933 -0.867 . . . . 0.0 110.933 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.464 ' N ' ' O ' ' A' ' 39' ' ' ILE . 88.4 mt-30 -140.72 27.5 2.03 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.654 0.264 . . . . 0.0 110.672 -179.768 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 58.8 m -80.2 -9.99 59.74 Favored 'General case' 0 CA--C 1.518 -0.254 0 CA-C-O 121.012 0.434 . . . . 0.0 110.665 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' LEU . . . . . 0.403 ' O ' ' CD2' ' A' ' 43' ' ' LEU . 0.9 OUTLIER 41.92 30.85 0.19 Allowed 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.38 -179.355 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 44' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' A' ' 45' ' ' PHE . 66.2 t0 -110.24 141.17 43.57 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.139 179.877 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.521 ' N ' ' OD1' ' A' ' 44' ' ' ASP . 56.8 m-85 -88.59 116.43 26.82 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.045 0.45 . . . . 0.0 110.312 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 19.8 m -114.62 133.53 60.45 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.307 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.28 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.892 ' SG ' HD11 ' A' ' 11' ' ' ILE . 27.9 t -93.58 114.67 27.07 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.317 179.859 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.8 p -125.03 139.83 49.93 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.229 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.029 -178.92 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' CYS . . . . . 0.578 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 39.2 t -97.27 157.33 16.01 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 115.517 -0.765 . . . . 0.0 109.716 -179.687 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.431 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 0.2 OUTLIER -149.93 151.62 32.65 Favored Pre-proline 0 N--CA 1.473 0.688 0 C-N-CA 120.593 -0.443 . . . . 0.0 110.933 179.775 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_endo . . . . . 0 C--N 1.309 -1.514 0 C-N-CA 122.686 2.257 . . . . 0.0 111.956 178.851 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo . . . . . 0 N--CA 1.489 1.246 0 CA-C-O 120.757 0.232 . . . . 0.0 111.647 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.662 HD23 ' N ' ' A' ' 10' ' ' LEU . 4.0 tt -133.74 119.75 19.69 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 120.78 0.324 . . . . 0.0 110.524 -179.751 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.662 ' N ' HD23 ' A' ' 9' ' ' LEU . 5.8 tt -91.03 130.75 36.91 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.978 0.418 . . . . 0.0 109.947 178.326 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.961 HD11 ' SG ' ' A' ' 47' ' ' CYS . 5.8 pt -106.37 -44.59 7.75 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.632 -179.624 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -176.12 -133.74 1.83 Allowed Glycine 0 CA--C 1.519 0.305 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 -179.593 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.436 ' C ' ' H ' ' A' ' 15' ' ' ILE . 80.7 p -131.56 166.19 21.94 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.925 0.393 . . . . 0.0 111.034 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -61.66 -3.85 1.22 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.974 179.5 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.436 ' H ' ' C ' ' A' ' 13' ' ' THR . 34.2 mm -70.85 -42.73 77.36 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 CA-C-O 121.224 0.535 . . . . 0.0 109.92 -179.562 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -108.24 -23.07 12.09 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.628 -0.715 . . . . 0.0 111.072 -179.568 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 44.7 m-85 -124.67 79.17 63.15 Favored Pre-proline 0 C--O 1.223 -0.292 0 CA-C-N 116.577 -0.283 . . . . 0.0 110.553 179.687 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 71.4 Cg_exo -49.05 -179.01 0.01 OUTLIER 'Trans proline' 0 N--CA 1.501 1.93 0 C-N-CA 123.137 2.558 . . . . 0.0 111.733 179.457 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.604 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 96.2 m -58.22 -50.38 73.75 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 112.321 0.489 . . . . 0.0 112.321 -178.795 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.68 ' HA ' HD22 ' A' ' 23' ' ' ASN . 6.6 pt-20 -56.57 -57.21 13.34 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.771 0.32 . . . . 0.0 111.257 -179.137 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.578 ' O ' HG22 ' A' ' 25' ' ' THR . 18.7 mtmt -62.91 -44.99 94.58 Favored 'General case' 0 CA--C 1.509 -0.604 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.377 -179.718 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.409 ' O ' ' SG ' ' A' ' 26' ' ' CYS . 53.2 t -47.64 -46.43 28.81 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-O 121.233 0.54 . . . . 0.0 111.235 -178.292 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.68 HD22 ' HA ' ' A' ' 20' ' ' GLU . 13.6 p30 -78.92 -53.11 7.39 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 120.483 -0.487 . . . . 0.0 110.39 179.305 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.584 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 29.7 mttp -50.71 -45.04 58.28 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.646 -0.422 . . . . 0.0 110.734 -178.004 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' THR . . . . . 0.578 HG22 ' O ' ' A' ' 21' ' ' LYS . 11.6 t -64.81 -37.86 89.04 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 121.391 0.615 . . . . 0.0 109.845 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.409 ' SG ' ' O ' ' A' ' 22' ' ' CYS . 54.8 m -63.61 -33.75 76.3 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.32 179.299 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.454 HG12 ' O ' ' A' ' 23' ' ' ASN . 3.3 mm -63.26 -36.86 77.75 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.054 179.728 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 29.0 mt-10 -66.1 -34.6 78.42 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.809 -178.639 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.411 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 7.1 m -72.59 -2.37 19.66 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.446 -179.173 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.411 ' CB ' ' O ' ' A' ' 29' ' ' SER . 2.9 m120 78.31 33.68 0.3 Allowed 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.732 -179.88 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.581 ' C ' ' H ' ' A' ' 33' ' ' GLY . 8.0 m-85 -109.35 162.34 14.42 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.114 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.63 26.75 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.745 179.619 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.581 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 87.0 -174.92 46.23 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 110.739 -0.944 . . . . 0.0 110.739 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.425 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -151.67 172.04 31.12 Favored Glycine 0 CA--C 1.52 0.348 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 -179.313 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 20.0 pttt -156.27 -179.28 8.01 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.037 0.446 . . . . 0.0 110.63 -179.535 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 4.0 m -107.76 125.71 51.73 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.12 179.158 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 20.2 m -141.13 174.19 7.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.325 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.64 ' NE2' ' CE1' ' A' ' 45' ' ' PHE . 38.2 m80 -105.67 152.42 23.16 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.477 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 96.7 mt -129.8 125.58 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.477 179.497 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 66.46 21.66 70.74 Favored Glycine 0 CA--C 1.52 0.39 0 N-CA-C 111.339 -0.705 . . . . 0.0 111.339 179.126 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 58.24 38.08 26.14 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.933 0.396 . . . . 0.0 110.586 -179.818 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 44.1 m -82.26 -11.23 58.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.015 -179.847 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' LEU . . . . . 0.409 ' O ' ' CD2' ' A' ' 43' ' ' LEU . 0.8 OUTLIER 68.24 27.99 6.52 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.258 -179.607 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -111.7 135.49 52.23 Favored 'General case' 0 N--CA 1.463 0.188 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 179.262 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.64 ' CE1' ' NE2' ' A' ' 38' ' ' HIS . 52.6 m-85 -91.71 116.15 28.64 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.419 ' O ' HG23 ' A' ' 46' ' ' VAL . 13.2 m -112.9 133.7 57.88 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.272 0 CA-C-N 115.964 -0.562 . . . . 0.0 109.807 -179.824 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.961 ' SG ' HD11 ' A' ' 11' ' ' ILE . 34.6 t -92.48 115.35 28.02 Favored 'General case' 0 CA--C 1.511 -0.536 0 CA-C-N 116.167 -0.47 . . . . 0.0 109.842 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.2 p -134.36 148.58 29.75 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.412 0 CA-C-O 121.118 0.485 . . . . 0.0 110.861 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 6.6 m -97.59 161.66 13.66 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.505 179.729 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 53.0 m-85 -116.84 147.96 41.09 Favored Pre-proline 0 N--CA 1.464 0.259 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.028 -179.326 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo . . . . . 0 N--CA 1.492 1.42 0 C-N-CA 122.405 2.07 . . . . 0.0 111.895 179.298 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo . . . . . 0 N--CA 1.493 1.492 0 CA-C-O 121.023 0.343 . . . . 0.0 111.947 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.65 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.9 tt -136.67 117.31 13.91 Favored 'General case' 0 CA--C 1.52 -0.196 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.543 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.65 ' N ' HD23 ' A' ' 9' ' ' LEU . 8.8 tt -92.8 131.95 37.4 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 179.21 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 10.2 pt -104.18 -36.9 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.281 -179.285 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -177.31 -127.62 1.07 Allowed Glycine 0 CA--C 1.517 0.163 0 N-CA-C 110.674 -0.971 . . . . 0.0 110.674 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.496 ' C ' ' H ' ' A' ' 15' ' ' ILE . 71.5 p -127.77 154.42 45.4 Favored 'General case' 0 CA--C 1.52 -0.189 0 CA-C-O 120.861 0.363 . . . . 0.0 110.479 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 6.6 t -66.3 6.67 0.39 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.521 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.496 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.7 mt -86.58 -40.97 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.138 0 CA-C-O 120.86 0.362 . . . . 0.0 110.143 -179.858 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -102.41 -5.48 24.07 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.978 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 51.2 m-85 -123.5 79.87 54.38 Favored Pre-proline 0 N--CA 1.465 0.293 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.847 179.57 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -47.77 168.01 0.09 OUTLIER 'Trans proline' 0 N--CA 1.495 1.572 0 C-N-CA 122.963 2.442 . . . . 0.0 111.866 179.164 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.436 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 10.0 m -49.78 -52.85 28.93 Favored 'General case' 0 C--N 1.326 -0.425 0 C-N-CA 120.642 -0.423 . . . . 0.0 111.62 -178.806 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.648 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 1.3 pm0 -61.91 -56.96 13.85 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.081 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -56.6 -45.13 81.6 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 121.046 0.451 . . . . 0.0 110.69 -178.201 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 12.4 t -47.75 -65.46 0.56 Allowed 'General case' 0 C--N 1.314 -0.978 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.011 -178.923 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.656 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 2.4 p-10 -62.51 -54.43 40.09 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.339 -179.756 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.656 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 43.8 mtpt -44.53 -43.91 8.31 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 120.546 -0.462 . . . . 0.0 110.853 -179.698 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 99.3 m -64.13 -39.62 94.42 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-O 121.495 0.664 . . . . 0.0 109.875 -179.651 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 58.5 m -67.42 -32.59 73.58 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.698 -179.681 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.3 mm -63.14 -43.63 98.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.518 -179.396 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -65.31 -35.63 81.59 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.42 -178.888 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.445 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 84.0 p -67.12 -3.41 7.43 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.459 -179.325 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.445 ' CB ' ' O ' ' A' ' 29' ' ' SER . 3.2 t-20 80.52 37.14 0.1 Allowed 'General case' 0 N--CA 1.466 0.358 0 O-C-N 123.478 0.486 . . . . 0.0 110.783 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.585 ' C ' ' H ' ' A' ' 33' ' ' GLY . 13.9 m-85 -119.54 160.7 21.91 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 120.993 0.425 . . . . 0.0 110.084 -179.843 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -68.96 27.99 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.584 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.585 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 87.06 -172.92 44.24 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 179.829 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -154.04 174.48 32.52 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.731 -0.947 . . . . 0.0 110.731 -179.437 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 11.6 ptmt -155.89 -178.7 7.49 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.806 0.336 . . . . 0.0 110.507 -179.459 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 69.0 m -105.28 127.72 53.09 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.23 179.359 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 32.5 m -135.59 161.34 39.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.101 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 3.3 p80 -108.9 157.23 18.82 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.295 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.414 ' O ' ' N ' ' A' ' 41' ' ' GLN . 32.8 mm -104.59 122.42 57.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.328 -179.748 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 40.56 -96.47 0.01 OUTLIER Glycine 0 CA--C 1.524 0.634 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.85 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.414 ' N ' ' O ' ' A' ' 39' ' ' ILE . 97.5 mt-30 -139.65 30.47 2.1 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 120.675 0.274 . . . . 0.0 110.525 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 16.8 m -80.78 -6.22 58.21 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.138 0.494 . . . . 0.0 110.738 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' LEU . . . . . 0.443 HD22 ' HA ' ' A' ' 43' ' ' LEU . 0.2 OUTLIER 50.07 28.57 3.05 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.549 -179.702 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 38.7 t0 -109.43 120.79 43.59 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.112 179.594 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 70.6 m-85 -88.74 129.03 35.63 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-O 120.962 0.41 . . . . 0.0 109.919 -179.771 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 33.1 m -124.06 142.31 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.42 -179.359 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -95.25 119.84 34.45 Favored 'General case' 0 CA--C 1.518 -0.27 0 N-CA-C 109.211 -0.662 . . . . 0.0 109.211 -179.803 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.1 p -134.38 149.46 29.98 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.358 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.715 -179.195 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 14.1 m -98.69 177.97 5.14 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.79 179.741 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -137.28 121.12 11.95 Favored Pre-proline 0 CA--C 1.537 0.461 0 C-N-CA 120.82 -0.352 . . . . 0.0 111.035 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo . . . . . 0 N--CA 1.495 1.61 0 C-N-CA 122.626 2.217 . . . . 0.0 111.916 -179.744 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo . . . . . 0 N--CA 1.491 1.325 0 N-CA-C 111.642 -0.176 . . . . 0.0 111.642 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.733 HD13 ' N ' ' A' ' 10' ' ' LEU . 0.4 OUTLIER -125.05 122.78 38.23 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-O 121.258 0.551 . . . . 0.0 110.798 179.781 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.733 ' N ' HD13 ' A' ' 9' ' ' LEU . 5.9 tt -86.01 147.7 26.09 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.45 178.371 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -126.74 -58.96 1.58 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.569 -178.956 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -160.2 -140.1 2.82 Favored Glycine 0 CA--C 1.519 0.294 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.35 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.443 ' C ' ' H ' ' A' ' 15' ' ' ILE . 43.5 p -131.5 160.12 36.15 Favored 'General case' 0 CA--C 1.518 -0.261 0 CA-C-O 121.006 0.431 . . . . 0.0 110.857 -179.79 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -52.63 -11.2 0.19 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.066 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.443 ' H ' ' C ' ' A' ' 13' ' ' THR . 39.0 mm -72.3 -43.12 65.45 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 CA-C-O 121.158 0.504 . . . . 0.0 110.288 -179.398 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 1.9 pt-20 -102.27 -31.36 10.58 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.39 -0.823 . . . . 0.0 110.945 -179.531 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 15.6 m-85 -120.94 82.78 36.44 Favored Pre-proline 0 N--CA 1.466 0.339 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.128 179.73 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo -48.46 -179.14 0.01 OUTLIER 'Trans proline' 0 N--CA 1.493 1.487 0 C-N-CA 122.807 2.338 . . . . 0.0 111.965 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.431 ' OG1' ' OE2' ' A' ' 20' ' ' GLU . 28.6 p -57.27 -52.31 65.84 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 120.942 0.401 . . . . 0.0 111.557 -179.336 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.631 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 0.2 OUTLIER -58.94 -57.84 11.3 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.474 -179.88 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -59.14 -43.94 92.05 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.736 -178.505 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.1 t -48.11 -60.97 2.22 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.881 -179.271 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.73 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.3 p-10 -62.59 -51.56 66.85 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.453 -179.631 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.73 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 31.7 mttp -47.36 -41.21 19.18 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.873 0.368 . . . . 0.0 110.168 -179.403 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 20.1 m -62.11 -43.9 97.81 Favored 'General case' 0 C--N 1.314 -0.939 0 C-N-CA 120.294 -0.563 . . . . 0.0 110.104 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 5.1 t -65.23 -32.68 74.48 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 179.645 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.5 mm -68.27 -31.71 52.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.538 -179.468 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 30.7 mm-40 -67.92 -34.99 77.68 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.762 -179.504 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.417 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 31.2 m -70.73 1.25 5.6 Favored 'General case' 0 CA--C 1.514 -0.408 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.944 -179.647 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.417 ' CB ' ' O ' ' A' ' 29' ' ' SER . 4.1 m-20 78.19 25.95 0.59 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.618 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.554 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 5.4 m-85 -103.29 -168.68 1.54 Allowed 'General case' 0 N--CA 1.452 -0.326 0 CA-C-O 120.952 0.406 . . . . 0.0 110.226 -179.744 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -76.2 -49.3 17.54 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.586 -179.596 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.496 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 160.54 -175.25 37.29 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 -179.478 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.427 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -148.03 170.4 28.67 Favored Glycine 0 C--O 1.226 -0.374 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -179.05 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 11.2 ptmt -158.68 -179.97 8.56 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.775 0.321 . . . . 0.0 110.525 -179.575 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 23.3 m -105.31 127.65 53.06 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.502 179.139 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 17.7 m -137.58 164.55 28.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.499 179.672 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 3.3 p-80 -103.64 155.84 18.25 Favored 'General case' 0 N--CA 1.462 0.153 0 CA-C-O 121.002 0.429 . . . . 0.0 110.223 179.775 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 97.0 mt -131.37 128.59 61.51 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.627 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 60.4 23.36 60.15 Favored Glycine 0 CA--C 1.52 0.35 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 179.343 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 87.5 mt-30 56.43 30.9 17.82 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 120.881 0.372 . . . . 0.0 110.573 -179.874 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 4.0 m -78.64 -7.2 57.41 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.767 -179.701 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' LEU . . . . . 0.422 HD22 ' HA ' ' A' ' 43' ' ' LEU . 0.2 OUTLIER 68.92 27.84 5.43 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.559 -179.641 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 40.3 t0 -107.44 118.49 36.86 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.091 179.65 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 3.3 m-30 -91.07 115.89 28.37 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-O 121.225 0.536 . . . . 0.0 109.705 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 28.3 m -113.95 142.34 26.89 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.301 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.097 -179.471 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 24.2 t -94.33 119.0 32.45 Favored 'General case' 0 CA--C 1.516 -0.333 0 CA-C-N 116.024 -0.535 . . . . 0.0 109.771 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 10.7 p -128.81 151.33 35.44 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.409 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.392 -179.423 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' CYS . . . . . 0.557 ' SG ' ' N ' ' A' ' 50' ' ' PHE . 33.0 t -96.52 164.83 12.45 Favored 'General case' 0 CA--C 1.514 -0.435 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 -179.634 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.557 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 37.2 m-85 -132.25 131.93 22.67 Favored Pre-proline 0 N--CA 1.465 0.284 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.136 -179.068 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo . . . . . 0 N--CA 1.489 1.237 0 C-N-CA 122.068 1.845 . . . . 0.0 112.122 179.541 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_exo . . . . . 0 N--CA 1.496 1.655 0 N-CA-C 111.783 -0.122 . . . . 0.0 111.783 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.634 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.7 tt -122.87 117.17 24.99 Favored 'General case' 0 N--CA 1.476 0.874 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.294 179.41 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.656 HD23 ' N ' ' A' ' 11' ' ' ILE . 6.6 tt -95.11 127.48 41.19 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 179.187 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.812 HD11 ' SG ' ' A' ' 47' ' ' CYS . 1.3 pt -103.51 -51.42 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-O 120.779 0.323 . . . . 0.0 110.831 -179.014 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.431 ' H ' HG13 ' A' ' 11' ' ' ILE . . . -160.27 -136.45 2.02 Favored Glycine 0 N--CA 1.451 -0.316 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -179.879 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.5 p -132.1 170.96 14.24 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.1 0.476 . . . . 0.0 110.415 -179.416 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -67.9 -1.86 6.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.332 -179.326 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 2.4 pp -78.2 -20.99 13.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.236 -179.731 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -131.91 -28.94 1.72 Allowed 'General case' 0 C--O 1.233 0.214 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.621 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 42.3 m-85 -116.3 81.77 11.06 Favored Pre-proline 0 CA--C 1.534 0.331 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.367 179.239 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.436 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 16.8 Cg_endo -59.35 -176.41 0.11 Allowed 'Trans proline' 0 N--CA 1.5 1.861 0 C-N-CA 122.449 2.099 . . . . 0.0 112.17 -179.644 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.597 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 83.3 m -58.89 -49.55 77.36 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.678 -0.409 . . . . 0.0 111.299 -179.347 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.55 ' HA ' HD22 ' A' ' 23' ' ' ASN . 8.0 pt-20 -55.57 -59.59 4.62 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.616 -179.516 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.493 ' H ' ' CG ' ' A' ' 20' ' ' GLU . 17.3 mtpp -64.68 -48.39 74.92 Favored 'General case' 0 CA--C 1.512 -0.501 0 CA-C-O 121.084 0.468 . . . . 0.0 111.818 -179.43 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.436 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 34.8 t -43.02 -52.51 5.24 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.106 -177.641 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.597 ' ND2' ' O ' ' A' ' 19' ' ' THR . 18.2 p30 -65.05 -44.51 88.78 Favored 'General case' 0 C--O 1.22 -0.474 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.783 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.576 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 89.1 mttt -50.72 -40.79 55.15 Favored 'General case' 0 CA--C 1.509 -0.609 0 C-N-CA 120.294 -0.562 . . . . 0.0 110.321 -179.575 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 70.0 p -63.2 -41.53 99.18 Favored 'General case' 0 C--N 1.313 -1.0 0 C-N-CA 119.179 -1.008 . . . . 0.0 110.376 -179.079 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.524 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 19.5 t -68.09 -34.1 75.76 Favored 'General case' 0 C--N 1.322 -0.587 0 C-N-CA 120.176 -0.61 . . . . 0.0 109.896 179.733 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.3 mm -66.3 -41.55 89.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.72 -179.258 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.418 ' C ' ' H ' ' A' ' 30' ' ' ASN . 40.2 mm-40 -64.13 -34.97 79.27 Favored 'General case' 0 N--CA 1.444 -0.746 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.654 -179.409 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.414 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 78.1 p -68.44 1.92 2.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.221 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.418 ' H ' ' C ' ' A' ' 28' ' ' GLU . 16.4 t-20 78.05 19.67 1.04 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.623 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.552 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 4.5 m-85 -98.32 -168.23 1.62 Allowed 'General case' 0 CA--C 1.53 0.191 0 CA-C-O 120.938 0.399 . . . . 0.0 110.351 -179.833 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -74.93 -53.26 9.32 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.791 -179.01 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.524 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 165.42 -178.51 40.3 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.151 -1.179 . . . . 0.0 110.151 -179.251 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.457 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -141.07 167.85 25.54 Favored Glycine 0 CA--C 1.519 0.293 0 N-CA-C 111.274 -0.73 . . . . 0.0 111.274 -179.219 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 15.0 ptpt -158.09 178.06 10.62 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.095 0.474 . . . . 0.0 110.401 -179.311 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 3.2 m -105.39 120.3 41.24 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.866 179.159 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 33.0 m -132.17 161.22 41.75 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.102 -179.888 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 5.5 p-80 -107.07 157.14 18.06 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.184 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.512 ' O ' ' N ' ' A' ' 41' ' ' GLN . 33.2 mm -106.46 124.79 62.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.049 -179.549 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 43.34 -91.12 0.01 OUTLIER Glycine 0 C--N 1.33 0.205 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.512 ' N ' ' O ' ' A' ' 39' ' ' ILE . 42.0 tp60 -148.46 37.66 0.84 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.812 0.339 . . . . 0.0 110.436 -179.577 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 71.0 m -87.98 -2.39 58.58 Favored 'General case' 0 CA--C 1.519 -0.235 0 CA-C-O 121.042 0.449 . . . . 0.0 110.613 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 45.81 28.99 0.64 Allowed 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.551 179.522 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 68.3 t0 -108.88 119.32 39.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.919 179.455 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 81.3 m-85 -88.56 118.45 28.22 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.721 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 31.1 m -114.88 143.05 25.46 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.35 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.259 -179.406 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.812 ' SG ' HD11 ' A' ' 11' ' ' ILE . 18.4 t -94.07 117.88 30.73 Favored 'General case' 0 CA--C 1.513 -0.455 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.459 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.7 p -129.07 152.96 37.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-O 120.708 0.29 . . . . 0.0 110.306 -179.689 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' CYS . . . . . 0.552 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 17.2 t -96.83 164.94 12.34 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.547 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 38.1 m-85 -132.34 136.31 27.82 Favored Pre-proline 0 N--CA 1.468 0.474 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.842 -179.319 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo . . . . . 0 N--CA 1.495 1.571 0 C-N-CA 121.945 1.763 . . . . 0.0 112.391 179.903 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo . . . . . 0 N--CA 1.494 1.539 0 CA-C-O 120.699 0.208 . . . . 0.0 111.885 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.635 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.8 tt -138.3 118.02 13.14 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.273 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.663 HD23 ' N ' ' A' ' 11' ' ' ILE . 6.8 tt -92.68 130.87 38.18 Favored 'General case' 0 N--CA 1.465 0.305 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 178.893 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.899 HD11 ' SG ' ' A' ' 47' ' ' CYS . 1.5 pt -107.09 -50.18 7.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-O 120.917 0.389 . . . . 0.0 110.294 -178.78 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -163.35 -162.99 15.04 Favored Glycine 0 N--CA 1.449 -0.491 0 N-CA-C 110.754 -0.938 . . . . 0.0 110.754 179.689 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.5 p -83.93 163.07 20.24 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.829 0.347 . . . . 0.0 110.12 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 48.3 t -71.2 2.79 4.18 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.331 179.703 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 86.8 mt -91.08 -52.48 10.26 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.217 0 CA-C-N 116.234 -0.439 . . . . 0.0 109.826 179.717 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLU . . . . . 0.464 ' OE1' ' CE2' ' A' ' 17' ' ' PHE . 7.5 pt-20 -70.82 -35.45 72.5 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.16 179.113 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.464 ' CE2' ' OE1' ' A' ' 16' ' ' GLU . 59.9 m-85 -114.96 104.61 53.94 Favored Pre-proline 0 CA--C 1.544 0.738 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.44 179.92 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.457 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 56.9 Cg_endo -74.23 -179.8 5.08 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 C-N-CA 123.043 2.495 . . . . 0.0 111.752 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 70.8 m -57.38 -49.12 77.18 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.576 -179.613 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -54.63 -58.24 8.27 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.574 -0.285 . . . . 0.0 111.592 -179.477 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 5.7 ttmt -67.44 -56.65 8.74 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.385 0.612 . . . . 0.0 111.606 -179.145 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.457 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 48.1 t -38.64 -61.51 0.7 Allowed 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.241 -0.89 . . . . 0.0 111.4 -178.786 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.474 ' OD1' ' N ' ' A' ' 24' ' ' LYS . 0.3 OUTLIER -63.42 -49.09 75.13 Favored 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.435 -179.874 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.474 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 51.3 mttm -47.46 -37.73 12.26 Favored 'General case' 0 CA--C 1.515 -0.399 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.218 -179.721 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 98.4 m -63.8 -41.74 97.84 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.342 0.591 . . . . 0.0 109.775 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.452 ' SG ' ' C ' ' A' ' 33' ' ' GLY . 40.2 t -72.13 -34.71 68.76 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.585 0.707 . . . . 0.0 109.999 179.311 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.5 mm -65.33 -48.08 84.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.144 -179.282 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.463 ' C ' ' H ' ' A' ' 30' ' ' ASN . 3.0 pp20? -70.31 -29.01 65.63 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.554 -179.656 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.452 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 24.4 m -65.2 0.89 1.17 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.198 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.463 ' H ' ' C ' ' A' ' 28' ' ' GLU . 0.2 OUTLIER 81.05 14.53 0.64 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.435 179.804 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.569 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 5.2 m-85 -100.19 -167.72 1.49 Allowed 'General case' 0 C--N 1.339 0.144 0 CA-C-O 120.76 0.314 . . . . 0.0 110.204 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -76.18 -55.38 5.63 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.141 0.496 . . . . 0.0 111.859 -179.196 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.452 ' C ' ' SG ' ' A' ' 26' ' ' CYS . . . 168.56 173.29 36.27 Favored Glycine 0 CA--C 1.519 0.337 0 N-CA-C 110.318 -1.113 . . . . 0.0 110.318 -179.135 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.448 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -134.59 161.02 24.42 Favored Glycine 0 N--CA 1.46 0.237 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 -179.341 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 2.1 ptmm? -160.06 -174.77 4.72 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.966 0.412 . . . . 0.0 110.69 -178.89 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 30.7 m -104.67 120.09 40.52 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.831 179.361 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 2.6 m -137.79 166.29 24.65 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-O 121.113 0.482 . . . . 0.0 110.896 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -108.85 157.29 18.74 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.403 179.291 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 83.9 mt -122.58 128.64 75.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.551 -179.358 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 52.85 -126.1 31.84 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.481 -1.048 . . . . 0.0 110.481 179.766 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -111.33 27.64 9.48 Favored 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 110.381 -0.229 . . . . 0.0 110.381 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' SER . . . . . 0.497 ' O ' ' N ' ' A' ' 44' ' ' ASP . 52.0 m -85.14 -11.26 55.53 Favored 'General case' 0 CA--C 1.52 -0.199 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.914 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' LEU . . . . . 0.433 HD22 ' HA ' ' A' ' 43' ' ' LEU . 0.2 OUTLIER 36.79 28.26 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.063 -179.687 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 44' ' ' ASP . . . . . 0.497 ' N ' ' O ' ' A' ' 42' ' ' SER . 45.1 t0 -99.78 124.47 45.09 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.278 -179.903 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -85.72 124.55 32.36 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 -179.65 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 32.6 m -129.9 153.76 39.35 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.444 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.145 -179.348 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.899 ' SG ' HD11 ' A' ' 11' ' ' ILE . 34.9 t -93.75 116.43 28.91 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.436 -179.77 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.9 p -131.64 154.39 40.32 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.325 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.499 -178.986 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' CYS . . . . . 0.572 ' SG ' ' N ' ' A' ' 50' ' ' PHE . 16.4 t -97.42 164.49 12.43 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 179.833 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.572 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 29.6 m-85 -130.7 121.79 19.29 Favored Pre-proline 0 N--CA 1.465 0.321 0 C-N-CA 120.931 -0.307 . . . . 0.0 111.247 -178.68 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo . . . . . 0 N--CA 1.491 1.343 0 C-N-CA 121.721 1.614 . . . . 0.0 112.058 179.274 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo . . . . . 0 N--CA 1.494 1.535 0 N-CA-C 111.21 -0.342 . . . . 0.0 111.21 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.65 HD23 ' N ' ' A' ' 10' ' ' LEU . 4.0 tt -132.38 119.23 20.41 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.265 -179.615 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.65 ' N ' HD23 ' A' ' 9' ' ' LEU . 7.7 tt -93.5 127.33 39.1 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 178.959 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.92 HD11 ' SG ' ' A' ' 47' ' ' CYS . 3.1 pt -103.38 -46.14 10.32 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.412 -179.036 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -170.06 -138.01 2.4 Favored Glycine 0 CA--C 1.521 0.451 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.485 ' C ' ' H ' ' A' ' 15' ' ' ILE . 70.0 p -133.21 163.73 28.63 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.843 0.354 . . . . 0.0 110.902 -179.437 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -57.87 -4.79 0.34 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.97 179.674 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.485 ' H ' ' C ' ' A' ' 13' ' ' THR . 95.8 mt -73.24 -24.18 20.43 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 CA-C-O 121.01 0.433 . . . . 0.0 110.136 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -130.55 -32.06 1.75 Allowed 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.741 -179.614 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 53.7 m-85 -114.65 88.88 17.07 Favored Pre-proline 0 CA--C 1.54 0.568 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 179.36 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.455 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 43.4 Cg_endo -70.17 -178.04 2.31 Favored 'Trans proline' 0 N--CA 1.499 1.809 0 C-N-CA 122.91 2.406 . . . . 0.0 111.968 -179.509 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.605 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 7.1 m -45.93 -68.62 0.18 Allowed 'General case' 0 C--N 1.319 -0.757 0 C-N-CA 120.826 -0.35 . . . . 0.0 111.442 -179.275 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.645 ' CD ' ' H ' ' A' ' 20' ' ' GLU . 0.0 OUTLIER -44.36 -68.14 0.22 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.46 -0.337 . . . . 0.0 111.718 -178.794 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 6.9 ttmt -54.66 -51.63 64.86 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.039 0.447 . . . . 0.0 111.562 -178.043 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.455 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 45.3 t -46.03 -64.97 0.62 Allowed 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.368 -179.3 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.605 ' ND2' ' O ' ' A' ' 19' ' ' THR . 16.8 p30 -61.86 -45.16 94.99 Favored 'General case' 0 C--O 1.22 -0.464 0 C-N-CA 120.721 -0.392 . . . . 0.0 110.478 -179.814 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.57 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 86.9 mttt -51.06 -37.08 43.35 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.443 -0.503 . . . . 0.0 109.852 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 13.4 m -64.36 -41.61 96.64 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.354 0.597 . . . . 0.0 110.352 -179.831 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.488 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 37.8 t -72.73 -34.91 67.39 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.029 179.467 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.2 mm -66.14 -47.68 83.94 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.571 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.884 -179.227 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.458 ' C ' ' H ' ' A' ' 30' ' ' ASN . 3.0 pp20? -70.21 -28.35 65.21 Favored 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.285 -179.413 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.465 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 56.1 m -66.25 1.05 1.71 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.051 -179.863 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.465 ' CB ' ' O ' ' A' ' 29' ' ' SER . 0.2 OUTLIER 82.51 11.04 0.61 Allowed 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.406 179.858 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.552 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 23.0 m-85 -99.47 -171.22 2.03 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-O 121.036 0.445 . . . . 0.0 111.188 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -71.33 -59.91 2.51 Favored 'General case' 0 CA--C 1.532 0.254 0 CA-C-N 115.756 -0.657 . . . . 0.0 111.857 -179.03 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.488 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 172.39 176.8 41.4 Favored Glycine 0 CA--C 1.52 0.377 0 N-CA-C 110.345 -1.102 . . . . 0.0 110.345 -179.104 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.423 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -137.0 166.66 24.86 Favored Glycine 0 N--CA 1.462 0.402 0 N-CA-C 111.233 -0.747 . . . . 0.0 111.233 -179.529 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 12.2 ptmt -159.4 178.45 9.92 Favored 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.771 -179.393 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 1.4 m -106.5 127.71 53.52 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.008 178.984 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 28.8 m -134.41 159.75 41.84 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.247 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.32 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -104.84 154.67 19.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.265 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.495 ' O ' ' N ' ' A' ' 41' ' ' GLN . 31.2 mm -107.01 128.02 62.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.361 -179.347 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 41.78 -91.56 0.01 OUTLIER Glycine 0 CA--C 1.525 0.711 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.495 ' N ' ' O ' ' A' ' 39' ' ' ILE . 40.6 tt0 -143.22 22.69 1.87 Allowed 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 121.039 0.447 . . . . 0.0 110.252 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 58.4 m -78.57 -9.45 59.36 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.079 0.466 . . . . 0.0 110.265 179.559 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' LEU . . . . . 0.416 ' O ' ' CD2' ' A' ' 43' ' ' LEU . 0.9 OUTLIER 47.03 30.42 1.28 Allowed 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.28 -179.715 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 67.8 t0 -98.78 119.91 38.32 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.597 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 58.1 m-85 -84.44 117.5 23.68 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.026 0.441 . . . . 0.0 110.342 -179.33 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 32.6 m -113.38 136.18 50.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.5 -179.454 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.92 ' SG ' HD11 ' A' ' 11' ' ' ILE . 27.4 t -93.03 115.4 28.08 Favored 'General case' 0 CA--C 1.514 -0.434 0 N-CA-C 109.284 -0.635 . . . . 0.0 109.284 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.5 p -130.88 150.41 34.58 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.261 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.8 -178.774 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' CYS . . . . . 0.552 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 23.6 t -96.82 162.9 13.22 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.529 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 33.7 m-85 -120.91 136.82 25.85 Favored Pre-proline 0 N--CA 1.47 0.541 0 C-N-CA 120.906 -0.318 . . . . 0.0 110.99 -178.85 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.4 ' HA ' ' CD1' ' A' ' 31' ' ' PHE . 23.1 Cg_endo . . . . . 0 N--CA 1.492 1.396 0 C-N-CA 121.759 1.64 . . . . 0.0 112.753 179.519 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo . . . . . 0 N--CA 1.494 1.511 0 N-CA-C 111.586 -0.198 . . . . 0.0 111.586 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.66 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.3 tt -133.67 120.89 21.21 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 120.568 0.223 . . . . 0.0 110.439 -179.008 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.66 ' N ' HD23 ' A' ' 9' ' ' LEU . 5.8 tt -87.68 134.56 33.63 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 178.535 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 13.2 pt -109.04 -35.0 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 120.934 0.397 . . . . 0.0 110.8 -178.702 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 175.69 -150.0 10.49 Favored Glycine 0 N--CA 1.451 -0.358 0 N-CA-C 110.794 -0.923 . . . . 0.0 110.794 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.416 ' C ' ' H ' ' A' ' 15' ' ' ILE . 42.0 p -98.8 160.66 14.12 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.83 0.347 . . . . 0.0 110.235 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 9.2 t -72.04 6.99 1.81 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.171 179.818 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.416 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.8 mt -91.42 -44.39 14.4 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.199 0 CA-C-N 116.053 -0.522 . . . . 0.0 109.949 179.785 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -87.46 -20.59 26.37 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.735 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 60.1 m-85 -120.69 99.08 47.66 Favored Pre-proline 0 CA--C 1.546 0.796 0 CA-C-N 116.732 -0.213 . . . . 0.0 110.595 179.515 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.409 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 36.4 Cg_endo -71.68 173.23 12.92 Favored 'Trans proline' 0 N--CA 1.493 1.495 0 C-N-CA 122.579 2.186 . . . . 0.0 111.288 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.631 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 10.0 m -47.67 -50.56 24.41 Favored 'General case' 0 C--N 1.319 -0.736 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.712 -179.242 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.603 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 0.5 OUTLIER -56.34 -68.33 0.22 Allowed 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 112.293 0.479 . . . . 0.0 112.293 -179.13 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 6.9 ttmt -57.95 -46.37 85.18 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 121.362 0.601 . . . . 0.0 111.551 -178.126 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.409 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 49.0 t -47.58 -65.03 0.63 Allowed 'General case' 0 C--N 1.308 -1.231 0 CA-C-N 115.311 -0.859 . . . . 0.0 111.465 -178.64 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.631 ' ND2' ' O ' ' A' ' 19' ' ' THR . 15.3 p30 -65.39 -43.73 89.75 Favored 'General case' 0 C--O 1.222 -0.375 0 C-N-CA 120.4 -0.52 . . . . 0.0 110.893 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.577 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 48.8 mttp -52.5 -39.68 61.54 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 120.19 -0.604 . . . . 0.0 109.909 179.826 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 91.6 m -62.62 -43.69 98.18 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.741 -179.438 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.521 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 16.6 t -66.14 -34.93 79.17 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.017 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.3 mm -66.17 -37.77 80.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.717 0 CA-C-N 114.937 -1.029 . . . . 0.0 110.113 179.674 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.41 ' C ' ' H ' ' A' ' 30' ' ' ASN . 34.3 mm-40 -64.09 -37.54 87.8 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.973 -1.012 . . . . 0.0 110.155 -179.369 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 35.9 m -69.46 0.59 4.98 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.834 179.638 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.41 ' H ' ' C ' ' A' ' 28' ' ' GLU . 18.2 t-20 76.7 21.15 1.28 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.508 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.532 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 3.8 m-85 -96.16 -166.93 1.5 Allowed 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 120.811 0.339 . . . . 0.0 110.493 -179.88 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.61 -51.42 16.89 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 116.076 -0.511 . . . . 0.0 112.113 -178.68 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.521 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 161.59 -179.87 36.71 Favored Glycine 0 CA--C 1.519 0.323 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 -179.036 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.424 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -132.49 157.42 22.53 Favored Glycine 0 CA--C 1.52 0.351 0 N-CA-C 111.417 -0.673 . . . . 0.0 111.417 -179.181 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 16.2 ptpt -154.27 168.78 25.44 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.41 -0.395 . . . . 0.0 110.506 -179.319 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 37.8 m -103.86 124.29 48.68 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.042 179.609 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 36.0 m -136.6 161.39 36.69 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-O 120.758 0.313 . . . . 0.0 110.9 -179.904 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.511 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 2.3 p80 -90.07 155.04 19.34 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.326 179.55 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 40.4 mm -110.66 121.6 63.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.816 -179.672 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 46.63 27.74 3.24 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 179.074 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 12.6 mm100 62.72 35.69 13.82 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.943 0.401 . . . . 0.0 110.242 -179.546 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' SER . . . . . 0.422 ' O ' ' CB ' ' A' ' 43' ' ' LEU . 63.6 m -83.39 -7.93 59.48 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.883 -179.901 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' LEU . . . . . 0.422 ' CB ' ' O ' ' A' ' 42' ' ' SER . 0.9 OUTLIER 73.82 27.33 1.7 Allowed 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.239 0.542 . . . . 0.0 109.782 -179.523 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 36.0 t0 -111.74 117.05 31.79 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 178.547 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -91.42 120.61 32.42 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.241 0.543 . . . . 0.0 109.915 -179.819 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 33.5 m -123.5 140.13 47.99 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.449 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.079 -179.573 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -94.47 121.35 35.93 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.19 -179.727 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.2 p -134.35 151.87 32.82 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.312 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.844 -178.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' CYS . . . . . 0.532 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 28.4 t -93.9 161.89 14.13 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 -179.421 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.445 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 51.3 m-85 -127.93 142.52 44.64 Favored Pre-proline 0 N--CA 1.47 0.538 0 C-N-CA 120.619 -0.432 . . . . 0.0 111.359 -178.356 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo . . . . . 0 N--CA 1.494 1.528 0 C-N-CA 122.016 1.811 . . . . 0.0 112.219 179.636 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo . . . . . 0 N--CA 1.496 1.63 0 N-CA-C 111.416 -0.263 . . . . 0.0 111.416 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.619 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.8 tt -120.33 118.21 29.79 Favored 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.713 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.682 HD13 ' C ' ' A' ' 10' ' ' LEU . 2.7 tm? -89.04 124.99 34.81 Favored 'General case' 0 CA--C 1.522 -0.132 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.547 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.41 ' N ' HD13 ' A' ' 10' ' ' LEU . 14.9 pt -105.59 -35.58 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.159 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.811 -179.131 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.405 ' O ' HD21 ' A' ' 10' ' ' LEU . . . 176.92 -135.46 2.83 Favored Glycine 0 CA--C 1.522 0.5 0 N-CA-C 111.146 -0.781 . . . . 0.0 111.146 -179.873 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 68.0 p -132.92 161.73 33.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.94 0.4 . . . . 0.0 110.512 -179.629 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -55.91 -9.35 0.57 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.764 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 6.2 mm -71.94 -43.13 68.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 C-N-CA 120.5 -0.48 . . . . 0.0 110.59 -179.313 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -99.75 -23.51 14.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.106 -179.429 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -119.54 83.09 26.53 Favored Pre-proline 0 N--CA 1.463 0.189 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.033 179.583 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -53.29 165.89 1.3 Allowed 'Trans proline' 0 N--CA 1.491 1.367 0 C-N-CA 122.495 2.13 . . . . 0.0 110.582 178.553 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.598 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 36.0 p -45.61 -58.94 3.04 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-O 120.852 0.358 . . . . 0.0 111.701 -178.601 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.497 ' HA ' HD22 ' A' ' 23' ' ' ASN . 6.6 pt-20 -46.01 -60.04 2.49 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.934 -179.385 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.47 ' H ' ' HG3' ' A' ' 20' ' ' GLU . 17.8 mtmt -63.73 -45.79 88.31 Favored 'General case' 0 CA--C 1.51 -0.583 0 CA-C-O 121.105 0.478 . . . . 0.0 111.299 -179.784 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 17.9 t -44.47 -62.61 1.12 Allowed 'General case' 0 C--N 1.31 -1.138 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.351 -178.396 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.598 ' ND2' ' O ' ' A' ' 19' ' ' THR . 12.6 p30 -64.1 -50.48 68.12 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.866 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.543 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 41.2 mttm -48.99 -35.94 16.45 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -179.586 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 19.4 m -63.52 -42.26 98.47 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.192 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.491 ' SG ' ' C ' ' A' ' 33' ' ' GLY . 32.9 t -73.42 -36.9 66.03 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.537 0.684 . . . . 0.0 110.016 178.975 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.3 mm -64.65 -47.42 88.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.996 -178.92 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.433 ' C ' ' H ' ' A' ' 30' ' ' ASN . 2.9 pp20? -71.22 -23.26 61.98 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.756 -179.485 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 39.5 m -71.6 3.71 3.74 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.52 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.433 ' H ' ' C ' ' A' ' 28' ' ' GLU . 2.2 m120 77.59 22.26 0.92 Allowed 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.913 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.554 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 31.1 m-85 -111.25 -167.91 1.24 Allowed 'General case' 0 N--CA 1.455 -0.178 0 CA-C-O 120.82 0.343 . . . . 0.0 111.006 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -74.1 -58.36 3.35 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.94 -0.573 . . . . 0.0 112.239 -178.417 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.491 ' C ' ' SG ' ' A' ' 26' ' ' CYS . . . 172.8 170.63 36.74 Favored Glycine 0 CA--C 1.521 0.465 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -178.85 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.496 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -122.42 159.97 16.94 Favored Glycine 0 N--CA 1.463 0.458 0 N-CA-C 111.186 -0.765 . . . . 0.0 111.186 -178.812 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 16.2 ptpt -155.34 166.38 33.72 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.05 0.452 . . . . 0.0 110.695 -179.558 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.504 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 4.5 m -106.35 123.69 48.44 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.354 179.522 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 32.9 m -137.08 160.77 36.16 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.464 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.689 179.796 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 34.6 p-80 -89.64 157.15 18.14 Favored 'General case' 0 CA--C 1.521 -0.153 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.295 179.488 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.4 ' C ' ' N ' ' A' ' 41' ' ' GLN . 5.7 mm -117.97 129.25 74.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.778 -179.467 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 46.01 22.18 0.79 Allowed Glycine 0 C--O 1.228 -0.233 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 179.328 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.4 ' N ' ' C ' ' A' ' 39' ' ' ILE . 39.6 tt0 69.78 36.75 1.99 Allowed 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.062 0.458 . . . . 0.0 110.175 -179.753 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 5.1 m -86.45 1.46 51.32 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.155 179.79 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER 57.16 26.89 12.69 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.526 -179.379 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 55.0 t0 -106.39 119.13 38.45 Favored 'General case' 0 N--CA 1.466 0.361 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 178.916 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 -85.12 115.68 23.06 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 121.181 0.515 . . . . 0.0 110.325 -179.112 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 11.6 m -111.18 134.57 53.08 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.262 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.19 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 0.8 OUTLIER -94.38 112.8 24.59 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.172 -179.792 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 4.8 p -129.58 155.0 41.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.306 -179.289 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' CYS . . . . . 0.587 ' SG ' ' N ' ' A' ' 50' ' ' PHE . 19.5 t -96.56 166.48 11.66 Favored 'General case' 0 N--CA 1.465 0.312 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.587 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 29.1 m-85 -126.92 117.88 22.25 Favored Pre-proline 0 N--CA 1.469 0.483 0 C-N-CA 121.028 -0.269 . . . . 0.0 110.745 -178.903 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_exo . . . . . 0 N--CA 1.486 1.083 0 C-N-CA 121.491 1.46 . . . . 0.0 112.27 179.218 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 72.4 mmtt . . . . . 0 N--CA 1.488 1.439 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 29.1 p-10 -91.59 10.59 27.37 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.623 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 27.2 mm -74.55 121.4 25.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.289 -179.67 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 65.0 t0 -64.06 -45.98 86.39 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.214 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 42.34 80.64 0.04 OUTLIER Glycine 0 CA--C 1.52 0.371 0 N-CA-C 111.15 -0.78 . . . . 0.0 111.15 179.676 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 2.7 ppt_? -133.47 38.13 3.29 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 111.952 0.352 . . . . 0.0 111.952 -179.084 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.497 ' NZ ' ' CE1' ' A' ' 54' ' ' TYR . 12.2 ptmt -128.54 78.74 75.39 Favored Pre-proline 0 N--CA 1.472 0.648 0 CA-C-O 121.173 0.511 . . . . 0.0 111.326 179.876 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_exo -61.5 145.04 98.26 Favored 'Trans proline' 0 C--N 1.303 -1.829 0 C-N-CA 122.256 1.971 . . . . 0.0 111.406 179.273 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.623 HD23 ' N ' ' A' ' 10' ' ' LEU . 2.9 tt -116.68 118.66 33.18 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-O 120.626 0.25 . . . . 0.0 110.493 -179.393 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.623 ' N ' HD23 ' A' ' 9' ' ' LEU . 8.4 tt -90.08 131.18 36.09 Favored 'General case' 0 N--CA 1.464 0.275 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 178.769 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.904 HD11 ' SG ' ' A' ' 47' ' ' CYS . 1.9 pt -108.67 -45.17 6.85 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 120.964 0.412 . . . . 0.0 110.415 -178.669 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -163.68 -176.38 35.55 Favored Glycine 0 N--CA 1.45 -0.421 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.515 ' O ' ' N ' ' A' ' 15' ' ' ILE . 13.6 m -86.65 137.3 32.58 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 8.7 t -46.93 -12.29 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 120.832 -0.347 . . . . 0.0 110.794 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.515 ' N ' ' O ' ' A' ' 13' ' ' THR . 96.6 mt -69.86 -44.3 78.95 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.287 0 CA-C-O 121.364 0.602 . . . . 0.0 110.487 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -88.09 -29.69 20.44 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-N 115.223 -0.899 . . . . 0.0 110.514 -179.599 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 53.0 m-85 -124.85 84.05 58.84 Favored Pre-proline 0 N--CA 1.465 0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.815 179.564 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -53.08 -177.0 0.03 OUTLIER 'Trans proline' 0 N--CA 1.498 1.743 0 C-N-CA 122.959 2.44 . . . . 0.0 111.609 179.26 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.604 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 97.8 m -58.22 -49.71 76.12 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 112.547 0.573 . . . . 0.0 112.547 -178.275 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.499 ' CG ' ' H ' ' A' ' 21' ' ' LYS . 9.0 pt-20 -56.14 -58.18 9.04 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 111.767 0.284 . . . . 0.0 111.767 -178.924 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.499 ' H ' ' CG ' ' A' ' 20' ' ' GLU . 15.4 mtmt -64.11 -44.72 91.39 Favored 'General case' 0 CA--C 1.51 -0.569 0 CA-C-O 121.221 0.534 . . . . 0.0 111.522 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 28.9 t -44.7 -57.67 3.54 Favored 'General case' 0 C--N 1.312 -1.058 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.757 -177.778 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.604 ' ND2' ' O ' ' A' ' 19' ' ' THR . 12.5 p30 -64.22 -50.73 66.89 Favored 'General case' 0 C--O 1.218 -0.587 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.375 -179.559 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.543 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 70.7 mttt -50.18 -42.12 50.66 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 -179.656 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 15.5 m -64.51 -39.16 93.26 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.645 0.736 . . . . 0.0 109.607 179.115 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 73.0 m -68.76 -31.51 70.6 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.149 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.438 HG12 ' O ' ' A' ' 23' ' ' ASN . 3.0 mm -64.39 -47.03 91.25 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.506 0 CA-C-O 121.087 0.47 . . . . 0.0 110.914 -179.512 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.405 ' HG2' ' H ' ' A' ' 28' ' ' GLU . 9.1 pt-20 -70.14 -22.25 63.01 Favored 'General case' 0 N--CA 1.447 -0.622 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.872 -179.246 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 59.8 p -74.81 -2.07 25.0 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 179.55 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 77.66 27.92 0.58 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.168 -0.923 . . . . 0.0 110.725 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.552 ' C ' ' H ' ' A' ' 33' ' ' GLY . 5.5 m-85 -110.96 162.32 14.95 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.74 -179.79 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.65 32.85 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.664 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.552 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 81.43 -173.96 54.24 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 -179.743 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -153.65 177.25 31.28 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 -179.653 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 17.0 ptpt -154.06 177.65 10.84 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.942 0.401 . . . . 0.0 110.784 -179.352 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 67.3 m -104.69 117.76 34.9 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.011 179.123 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 27.1 m -136.31 159.5 38.37 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-O 120.902 0.382 . . . . 0.0 110.865 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -91.07 157.76 17.05 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.47 179.626 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 39.2 mm -105.85 126.92 61.23 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.18 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.451 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 41.02 -98.47 0.01 OUTLIER Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 179.651 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 40.3 tt0 -135.83 21.49 3.3 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 120.986 0.422 . . . . 0.0 109.957 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 58.1 m -79.65 -8.71 59.38 Favored 'General case' 0 CA--C 1.515 -0.397 0 CA-C-O 121.127 0.489 . . . . 0.0 110.418 179.564 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' LEU . . . . . 0.405 ' O ' ' CD2' ' A' ' 43' ' ' LEU . 0.9 OUTLIER 47.12 29.62 1.17 Allowed 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.246 -179.651 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -102.79 119.54 39.02 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 178.893 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -81.13 132.77 35.38 Favored 'General case' 0 CA--C 1.517 -0.326 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 -179.349 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 35.2 m -134.96 152.39 32.71 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.404 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.547 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.904 ' SG ' HD11 ' A' ' 11' ' ' ILE . 41.0 t -94.34 113.76 25.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.626 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.1 p -126.05 137.9 56.28 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.19 0 CA-C-O 121.001 0.429 . . . . 0.0 110.604 -179.388 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 8.3 m -97.44 165.05 12.19 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.784 -179.579 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 42.5 m-85 -117.39 145.79 36.92 Favored Pre-proline 0 N--CA 1.47 0.537 0 CA-C-N 116.742 -0.208 . . . . 0.0 111.256 -179.11 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.404 ' HG3' ' H ' ' A' ' 7' ' ' LYS . 27.5 Cg_endo -63.75 149.46 90.75 Favored 'Trans proline' 0 N--CA 1.496 1.658 0 C-N-CA 122.57 2.18 . . . . 0.0 112.077 179.553 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 13.5 tppt? -143.52 -43.6 0.28 Allowed 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.284 179.77 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -110.01 21.63 16.59 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.752 -179.302 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' TYR . . . . . 0.497 ' CE1' ' NZ ' ' A' ' 7' ' ' LYS . 62.1 t80 -82.48 98.21 8.8 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.784 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 49.7 mt . . . . . 0 C--O 1.22 -0.459 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.193 -179.73 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' LYS . . . . . 0.543 ' C ' ' H ' ' A' ' 3' ' ' ILE . 68.7 mttm . . . . . 0 N--CA 1.489 1.5 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -55.92 -2.73 0.06 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.456 179.764 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.543 ' H ' ' C ' ' A' ' 1' ' ' LYS . 4.0 mm -63.63 129.33 27.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 120.991 0.424 . . . . 0.0 109.9 -179.67 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 41.4 t0 -66.78 -27.8 67.87 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.436 179.73 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.464 ' N ' HG22 ' A' ' 3' ' ' ILE . . . -75.13 70.21 1.85 Allowed Glycine 0 C--N 1.332 0.329 0 N-CA-C 111.066 -0.814 . . . . 0.0 111.066 -179.71 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.435 ' H ' ' HD3' ' A' ' 7' ' ' LYS . 3.1 ppt_? -130.85 30.65 4.59 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.58 0.229 . . . . 0.0 110.457 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.435 ' HD3' ' H ' ' A' ' 6' ' ' ARG . 0.2 OUTLIER -126.68 150.03 69.96 Favored Pre-proline 0 N--CA 1.464 0.248 0 CA-C-N 116.662 -0.245 . . . . 0.0 110.866 -179.643 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -57.3 140.67 93.65 Favored 'Trans proline' 0 N--CA 1.491 1.354 0 C-N-CA 121.824 1.683 . . . . 0.0 111.691 179.849 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.668 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.6 tt -121.53 119.68 32.67 Favored 'General case' 0 N--CA 1.474 0.748 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.562 -179.676 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.668 ' N ' HD23 ' A' ' 9' ' ' LEU . 6.8 tt -92.29 125.54 36.99 Favored 'General case' 0 N--CA 1.464 0.269 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 178.879 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.904 HD11 ' SG ' ' A' ' 47' ' ' CYS . 2.6 pt -102.54 -48.3 10.86 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.667 -179.056 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.411 ' H ' HG13 ' A' ' 11' ' ' ILE . . . -167.72 -138.29 2.42 Favored Glycine 0 N--CA 1.45 -0.398 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.487 ' C ' ' H ' ' A' ' 15' ' ' ILE . 43.1 p -132.62 159.01 40.79 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.085 0.469 . . . . 0.0 110.847 -179.697 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -56.12 -5.56 0.19 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.051 179.786 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.487 ' H ' ' C ' ' A' ' 13' ' ' THR . 84.6 mt -75.94 -26.5 17.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.883 0.373 . . . . 0.0 110.723 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -124.47 -27.69 3.71 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.063 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -122.62 80.57 47.75 Favored Pre-proline 0 C--O 1.233 0.187 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.335 179.206 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_exo -53.0 179.33 0.04 OUTLIER 'Trans proline' 0 N--CA 1.495 1.563 0 C-N-CA 122.787 2.325 . . . . 0.0 111.141 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.617 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 30.5 p -53.74 -61.28 2.4 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 121.074 0.464 . . . . 0.0 111.995 -179.802 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.553 ' HA ' HD22 ' A' ' 23' ' ' ASN . 5.4 pt-20 -43.8 -59.41 2.25 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.387 -178.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.479 ' H ' ' HG3' ' A' ' 20' ' ' GLU . 19.8 mtmt -64.43 -46.15 84.42 Favored 'General case' 0 CA--C 1.509 -0.608 0 CA-C-O 121.201 0.524 . . . . 0.0 111.269 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 41.2 t -45.07 -60.56 2.03 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-N 115.549 -0.75 . . . . 0.0 111.124 -178.475 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.617 ' ND2' ' O ' ' A' ' 19' ' ' THR . 11.0 p30 -65.63 -54.86 21.8 Favored 'General case' 0 C--O 1.22 -0.466 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.517 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.543 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 80.3 mttt -44.91 -44.5 9.75 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 120.691 -0.403 . . . . 0.0 110.575 -179.602 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 17.5 m -63.64 -39.9 95.52 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.164 0.506 . . . . 0.0 110.02 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 51.4 m -66.46 -31.4 72.12 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.573 -0.74 . . . . 0.0 111.042 -179.882 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.4 mm -63.94 -41.33 92.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-O 121.323 0.582 . . . . 0.0 110.141 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.415 ' C ' ' H ' ' A' ' 30' ' ' ASN . 52.9 mm-40 -67.06 -37.7 84.49 Favored 'General case' 0 N--CA 1.445 -0.725 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.527 -178.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 33.7 m -69.07 5.8 1.1 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.029 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.415 ' H ' ' C ' ' A' ' 28' ' ' GLU . 48.4 t30 71.47 50.89 0.26 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.067 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.581 ' C ' ' H ' ' A' ' 33' ' ' GLY . 57.0 m-85 -133.81 162.78 31.08 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.733 179.887 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.17 23.06 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.053 -0.522 . . . . 0.0 110.719 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.581 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 89.78 -175.8 42.22 Favored Glycine 0 CA--C 1.52 0.374 0 N-CA-C 110.533 -1.027 . . . . 0.0 110.533 -179.893 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -147.83 174.01 27.7 Favored Glycine 0 CA--C 1.522 0.482 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 -179.379 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 13.2 ptmt -155.44 178.57 10.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.885 0.374 . . . . 0.0 110.578 -179.377 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 1.8 m -105.17 128.07 53.21 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.144 179.227 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 19.3 m -134.47 158.62 41.93 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.047 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -101.36 156.41 17.47 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.023 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 35.9 mm -112.67 127.27 70.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.98 -179.755 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 40.11 -97.82 0.01 OUTLIER Glycine 0 CA--C 1.527 0.795 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 30.4 mm100 -137.45 28.38 2.75 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.838 0.351 . . . . 0.0 110.477 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' SER . . . . . 0.774 ' C ' HD23 ' A' ' 43' ' ' LEU . 73.5 m -87.29 4.73 41.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.917 179.883 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' LEU . . . . . 0.774 HD23 ' C ' ' A' ' 42' ' ' SER . 1.2 pt? 34.65 27.99 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.27 0 O-C-N 123.788 0.68 . . . . 0.0 111.496 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ASP . . . . . 0.543 ' N ' ' O ' ' A' ' 42' ' ' SER . 43.4 t0 -99.98 121.1 40.84 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.572 -179.466 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -87.65 117.75 26.68 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.087 0.47 . . . . 0.0 109.963 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 30.6 m -111.86 136.05 49.24 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.255 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.116 -179.623 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.904 ' SG ' HD11 ' A' ' 11' ' ' ILE . 14.0 t -93.39 115.84 28.39 Favored 'General case' 0 CA--C 1.518 -0.286 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.628 -179.575 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.8 p -131.89 152.03 36.19 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.507 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.762 -179.036 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 6.4 m -97.47 172.51 7.7 Favored 'General case' 0 CA--C 1.515 -0.376 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.636 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 56.4 m-85 -138.23 142.57 35.8 Favored Pre-proline 0 C--N 1.331 -0.225 0 C-N-CA 120.882 -0.327 . . . . 0.0 111.359 -179.487 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -67.94 161.49 43.89 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 122.408 2.072 . . . . 0.0 112.297 178.516 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 30.6 mmtp -57.56 -83.51 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.702 -179.794 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 13.6 p90 -130.59 38.18 3.75 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.631 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 59.2 t80 -79.6 97.3 6.44 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.946 0.403 . . . . 0.0 110.217 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 32.6 pt . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.961 -1.019 . . . . 0.0 110.493 -179.875 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 31.5 mtmm . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 43.6 t0 -69.0 -7.03 31.59 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.597 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.412 HG22 ' H ' ' A' ' 5' ' ' GLY . 45.0 mm -70.22 134.33 30.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 121.148 0.499 . . . . 0.0 110.921 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ASP . . . . . 0.477 ' OD1' ' N ' ' A' ' 4' ' ' ASP . 16.8 p-10 -63.72 -39.98 95.63 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.608 -0.723 . . . . 0.0 110.675 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.412 ' H ' HG22 ' A' ' 3' ' ' ILE . . . 59.13 65.96 3.11 Favored Glycine 0 CA--C 1.516 0.125 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 179.414 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -130.22 22.53 5.23 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 110.525 -0.176 . . . . 0.0 110.525 -179.621 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 9.2 pttp -132.57 149.14 72.22 Favored Pre-proline 0 CA--C 1.533 0.322 0 C-N-CA 121.051 -0.259 . . . . 0.0 111.146 179.652 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_exo -48.4 135.87 25.92 Favored 'Trans proline' 0 N--CA 1.494 1.51 0 C-N-CA 121.991 1.794 . . . . 0.0 111.876 178.697 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.695 HD13 ' N ' ' A' ' 10' ' ' LEU . 0.2 OUTLIER -125.7 128.97 48.61 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-O 121.154 0.502 . . . . 0.0 110.708 179.895 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.695 ' N ' HD13 ' A' ' 9' ' ' LEU . 6.1 tt -90.97 136.63 32.94 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.396 178.867 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.467 HD13 ' N ' ' A' ' 11' ' ' ILE . 0.0 OUTLIER -105.88 -47.47 8.93 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.262 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.125 -179.667 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -172.63 -124.74 0.79 Allowed Glycine 0 CA--C 1.519 0.307 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.53 ' C ' ' H ' ' A' ' 15' ' ' ILE . 66.3 p -127.81 150.36 49.86 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.912 0.387 . . . . 0.0 110.264 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 7.4 t -63.63 4.66 0.24 Allowed 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.353 179.714 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.53 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.2 mt -88.48 -40.75 13.69 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.181 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -99.6 -11.9 20.56 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.752 179.796 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -124.99 81.06 63.12 Favored Pre-proline 0 N--CA 1.464 0.275 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.028 179.602 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -53.44 168.03 0.75 Allowed 'Trans proline' 0 N--CA 1.5 1.9 0 C-N-CA 123.146 2.564 . . . . 0.0 111.507 178.573 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.598 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 39.9 p -45.71 -60.01 2.45 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 112.003 0.371 . . . . 0.0 112.003 -178.837 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.51 ' HA ' HD22 ' A' ' 23' ' ' ASN . 6.6 pt-20 -46.37 -61.16 1.92 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.05 -179.27 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.492 ' H ' ' HG3' ' A' ' 20' ' ' GLU . 20.0 mtmt -63.11 -45.77 90.49 Favored 'General case' 0 CA--C 1.508 -0.644 0 CA-C-O 121.292 0.568 . . . . 0.0 111.629 -179.595 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 22.2 t -43.62 -59.35 2.22 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.024 -178.427 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.598 ' ND2' ' O ' ' A' ' 19' ' ' THR . 11.1 p30 -67.3 -57.86 5.87 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.578 179.635 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.576 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 72.0 mttt -43.37 -43.62 5.2 Favored 'General case' 0 C--O 1.222 -0.358 0 CA-C-O 120.852 0.358 . . . . 0.0 110.51 -178.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 19.6 m -64.09 -40.61 96.61 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.177 0.513 . . . . 0.0 110.178 179.66 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.421 ' N ' ' O ' ' A' ' 23' ' ' ASN . 25.5 m -66.71 -30.73 71.04 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.795 -179.895 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.8 mm -64.87 -41.28 91.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-O 121.292 0.568 . . . . 0.0 110.009 -179.705 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.418 ' C ' ' H ' ' A' ' 30' ' ' ASN . 31.2 mm-40 -65.84 -38.07 87.89 Favored 'General case' 0 N--CA 1.447 -0.612 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.379 -178.705 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 26.8 m -69.49 5.15 1.46 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.639 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.418 ' H ' ' C ' ' A' ' 28' ' ' GLU . 44.6 t30 70.86 54.85 0.25 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.006 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.563 ' C ' ' H ' ' A' ' 33' ' ' GLY . 60.4 m-85 -137.76 161.98 35.13 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.592 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.47 28.28 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.981 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.563 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 85.07 -175.26 49.98 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 110.7 -0.96 . . . . 0.0 110.7 -179.784 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.418 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -148.63 174.0 28.42 Favored Glycine 0 CA--C 1.522 0.483 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 -179.403 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 4.7 ptmm? -155.86 -178.12 7.07 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.592 0.234 . . . . 0.0 110.384 -179.247 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 31.1 m -104.45 129.69 52.42 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.414 179.228 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 28.5 m -137.78 161.85 32.63 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.261 179.696 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 3.5 p80 -109.06 157.62 18.53 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.217 -0.447 . . . . 0.0 109.998 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 83.6 mt -122.21 125.98 73.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.339 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 42.03 -128.51 4.37 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.891 -0.883 . . . . 0.0 110.891 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 29.0 pt20 -106.82 31.7 5.1 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 120.694 0.283 . . . . 0.0 110.413 179.693 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 20.1 m -84.39 -9.77 58.13 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 120.983 0.42 . . . . 0.0 110.598 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' LEU . . . . . 0.444 HD22 ' HA ' ' A' ' 43' ' ' LEU . 0.2 OUTLIER 40.02 29.41 0.05 Allowed 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.635 -0.712 . . . . 0.0 110.872 -179.144 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -107.55 126.45 52.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.222 179.691 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -90.65 124.55 35.16 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.638 -0.505 . . . . 0.0 109.638 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 30.5 m -120.47 138.07 52.19 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 CA-C-N 116.068 -0.514 . . . . 0.0 109.997 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -94.31 119.22 32.75 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.1 p -134.18 153.18 35.4 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.448 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.588 -179.069 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 5.9 m -97.28 172.23 7.92 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.898 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 56.4 m-85 -132.6 148.07 68.11 Favored Pre-proline 0 CA--C 1.531 0.214 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.939 -179.163 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -68.0 161.0 46.09 Favored 'Trans proline' 0 N--CA 1.494 1.52 0 C-N-CA 122.74 2.293 . . . . 0.0 112.308 179.356 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -65.54 -81.5 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.761 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.419 ' O ' ' CD2' ' A' ' 53' ' ' TYR . 33.3 p90 -128.95 32.53 4.74 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.827 -179.742 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' TYR . . . . . 0.47 ' O ' HG23 ' A' ' 55' ' ' ILE . 46.0 t80 -73.86 125.5 28.31 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.784 0.326 . . . . 0.0 110.216 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.47 HG23 ' O ' ' A' ' 54' ' ' TYR . 9.0 pt . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 118.087 -0.959 . . . . 0.0 110.391 -179.837 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 45.7 mmtt . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -99.43 4.61 46.25 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.196 179.602 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 12.9 tt -52.04 140.96 6.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.492 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -63.16 -38.93 93.13 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.109 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -91.05 88.49 1.41 Allowed Glycine 0 C--O 1.228 -0.238 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 3.8 ppt_? -133.49 41.11 3.1 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 120.743 0.306 . . . . 0.0 110.65 -179.55 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.401 ' H ' ' HG3' ' A' ' 51' ' ' PRO . 10.3 tptm -130.41 78.93 73.41 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 120.843 0.354 . . . . 0.0 111.258 -179.79 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 21.3 Cg_exo -65.46 155.92 66.24 Favored 'Trans proline' 0 C--N 1.307 -1.637 0 C-N-CA 122.856 2.37 . . . . 0.0 111.363 178.859 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.64 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.8 tt -126.43 116.65 21.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.598 179.858 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.67 HD23 ' N ' ' A' ' 11' ' ' ILE . 7.2 tt -91.71 129.11 37.73 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 179.009 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.907 HD11 ' SG ' ' A' ' 47' ' ' CYS . 1.4 pt -105.61 -50.07 8.65 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-O 120.837 0.351 . . . . 0.0 110.921 -178.496 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -160.43 -164.61 15.75 Favored Glycine 0 N--CA 1.451 -0.308 0 N-CA-C 110.694 -0.963 . . . . 0.0 110.694 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.457 ' C ' ' H ' ' A' ' 15' ' ' ILE . 6.5 m -89.33 158.29 17.86 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.843 0.354 . . . . 0.0 110.423 -179.385 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 9.5 t -69.35 6.6 0.98 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.207 179.586 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.457 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.5 mt -91.44 -45.62 14.52 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.148 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -90.92 -11.37 39.33 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.925 179.649 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 54.1 m-85 -142.78 82.02 12.7 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.684 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.42 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 15.9 Cg_exo -65.95 -172.72 0.28 Allowed 'Trans proline' 0 N--CA 1.493 1.479 0 C-N-CA 122.904 2.403 . . . . 0.0 111.83 179.279 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.662 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 26.2 p -48.07 -56.68 7.19 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 120.826 -0.35 . . . . 0.0 111.698 -179.054 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.649 ' CD ' ' H ' ' A' ' 20' ' ' GLU . 0.0 OUTLIER -47.91 -72.2 0.06 Allowed 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.121 0.486 . . . . 0.0 111.736 -178.719 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 52.0 mtmt -60.49 -42.94 97.36 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.683 -178.273 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.42 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 44.7 t -44.94 -59.77 2.4 Favored 'General case' 0 C--N 1.313 -1.013 0 C-N-CA 120.215 -0.594 . . . . 0.0 111.089 -178.547 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.662 ' ND2' ' O ' ' A' ' 19' ' ' THR . 13.3 p30 -64.58 -55.64 19.09 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.546 -179.468 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.598 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 69.1 mttt -47.14 -42.79 20.07 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 120.788 -0.365 . . . . 0.0 110.584 -178.742 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 11.4 m -65.8 -37.75 87.13 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.242 179.71 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 37.9 m -67.64 -33.63 75.34 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.877 -0.602 . . . . 0.0 110.287 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.6 mm -61.5 -46.35 96.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.564 -179.536 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -66.34 -31.07 71.64 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.494 -179.035 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 27.1 m -72.87 1.5 8.57 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.405 -179.12 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 2.0 m120 74.51 52.98 0.09 Allowed 'General case' 0 C--N 1.329 -0.312 0 O-C-N 123.559 0.537 . . . . 0.0 111.032 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.565 ' C ' ' H ' ' A' ' 33' ' ' GLY . 68.6 m-85 -138.61 162.02 35.66 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.688 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.79 30.24 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.57 179.626 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.565 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 83.6 -176.87 52.53 Favored Glycine 0 CA--C 1.521 0.442 0 N-CA-C 110.568 -1.013 . . . . 0.0 110.568 -179.653 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.428 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -147.3 178.04 25.18 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 -179.595 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 14.7 ptmt -156.87 -176.79 6.17 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 110.237 -0.283 . . . . 0.0 110.237 -179.625 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 66.7 m -108.44 122.2 46.53 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.519 179.573 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 2.8 m -137.89 163.46 29.98 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.837 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 3.3 p-80 -92.97 157.61 16.24 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.341 179.714 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.437 ' O ' ' N ' ' A' ' 41' ' ' GLN . 34.1 mm -110.18 123.44 66.08 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 CA-C-O 121.086 0.47 . . . . 0.0 110.679 -179.741 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 43.99 20.74 0.17 Allowed Glycine 0 C--O 1.227 -0.307 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.575 179.629 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.437 ' N ' ' O ' ' A' ' 39' ' ' ILE . 37.3 tt0 72.61 36.18 1.01 Allowed 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.846 0.355 . . . . 0.0 110.721 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' SER . . . . . 0.422 ' N ' ' O ' ' A' ' 39' ' ' ILE . 41.0 m -85.61 -2.66 58.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.206 0.527 . . . . 0.0 110.885 -179.785 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' LEU . . . . . 0.447 HD22 ' HA ' ' A' ' 43' ' ' LEU . 0.2 OUTLIER 69.96 26.4 4.66 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.672 179.86 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 35.2 t70 -111.78 117.36 32.62 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 178.823 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -89.36 129.33 35.9 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 27.2 m -133.38 154.6 39.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.387 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.907 ' SG ' HD11 ' A' ' 11' ' ' ILE . 37.9 t -95.26 118.42 31.99 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 115.877 -0.601 . . . . 0.0 109.971 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.0 p -130.21 144.14 38.88 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 CA-C-O 120.87 0.366 . . . . 0.0 110.361 -179.466 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 4.9 m -97.93 167.52 10.86 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.889 -179.739 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 46.4 m-85 -122.18 143.05 38.14 Favored Pre-proline 0 CA--C 1.532 0.275 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.668 -179.428 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.401 ' HG3' ' H ' ' A' ' 7' ' ' LYS . 35.4 Cg_endo -66.11 144.33 75.08 Favored 'Trans proline' 0 N--CA 1.495 1.609 0 C-N-CA 122.544 2.163 . . . . 0.0 111.735 179.579 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 46.4 mtmt -93.44 -70.02 0.72 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.166 179.212 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 63.2 m-85 -130.66 34.24 4.15 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.459 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 54.3 t80 -62.23 132.06 51.46 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.49 -0.323 . . . . 0.0 110.426 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.3 pt . . . . . 0 C--O 1.219 -0.511 0 CA-C-O 117.859 -1.067 . . . . 0.0 110.44 -179.916 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' LYS . . . . . 0.413 ' C ' ' H ' ' A' ' 3' ' ' ILE . 70.5 mmtt . . . . . 0 N--CA 1.493 1.704 0 N-CA-C 108.642 -0.874 . . . . 0.0 108.642 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ASP . . . . . 0.51 ' C ' ' H ' ' A' ' 4' ' ' ASP . 58.6 t0 -64.05 -6.2 5.97 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 108.903 -0.776 . . . . 0.0 108.903 179.492 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.413 ' H ' ' C ' ' A' ' 1' ' ' LYS . 2.0 pp -59.11 -0.87 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-N 115.194 -0.912 . . . . 0.0 110.794 179.684 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ASP . . . . . 0.51 ' H ' ' C ' ' A' ' 2' ' ' ASP . 41.2 t0 -54.5 -39.2 67.33 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.345 -179.408 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 73.73 85.31 0.26 Allowed Glycine 0 N--CA 1.449 -0.451 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 4.9 ppt_? -129.42 40.32 3.62 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 112.08 0.4 . . . . 0.0 112.08 -178.419 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.434 ' H ' ' HG2' ' A' ' 51' ' ' PRO . 43.3 tttp -132.83 73.12 76.38 Favored Pre-proline 0 CA--C 1.532 0.261 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.752 179.01 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_exo -69.43 153.46 70.41 Favored 'Trans proline' 0 C--N 1.304 -1.8 0 C-N-CA 122.821 2.347 . . . . 0.0 110.84 178.898 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.602 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.5 tt -129.77 116.89 19.4 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 179.607 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.602 ' N ' HD23 ' A' ' 9' ' ' LEU . 6.4 tt -89.27 124.81 34.75 Favored 'General case' 0 N--CA 1.465 0.321 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 179.711 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.909 HD11 ' SG ' ' A' ' 47' ' ' CYS . 3.2 pt -102.59 -46.97 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.842 -179.009 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -164.49 -138.45 2.41 Favored Glycine 0 CA--C 1.519 0.306 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.42 ' C ' ' N ' ' A' ' 15' ' ' ILE . 65.5 p -136.22 159.5 41.56 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.149 -0.526 . . . . 0.0 110.249 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -53.38 -12.27 0.41 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.05 179.54 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.42 ' N ' ' C ' ' A' ' 13' ' ' THR . 78.0 mt -71.78 -43.75 69.25 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.396 0 CA-C-O 121.353 0.597 . . . . 0.0 110.425 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 3.0 pt-20 -100.91 -34.3 9.85 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.094 -179.297 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.475 ' CD2' HD12 ' A' ' 11' ' ' ILE . 9.3 m-85 -116.93 85.0 16.85 Favored Pre-proline 0 N--CA 1.468 0.473 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.572 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -49.64 -178.63 0.01 OUTLIER 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 122.462 2.108 . . . . 0.0 111.508 -179.565 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.585 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 96.9 m -59.14 -51.41 70.12 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.629 -0.428 . . . . 0.0 111.443 -178.818 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.729 ' HA ' HD22 ' A' ' 23' ' ' ASN . 11.1 pt-20 -60.62 -50.17 74.61 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 112.052 0.389 . . . . 0.0 112.052 -179.706 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.477 ' N ' ' CG ' ' A' ' 20' ' ' GLU . 2.5 ttpp -64.8 -45.9 84.32 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.232 0.539 . . . . 0.0 110.225 -178.327 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 43.3 t -45.7 -61.47 1.7 Allowed 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.25 -0.886 . . . . 0.0 111.433 -179.57 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.729 HD22 ' HA ' ' A' ' 20' ' ' GLU . 13.4 p30 -64.65 -49.31 71.51 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.697 -179.42 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.535 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 82.3 mttt -48.11 -42.56 29.41 Favored 'General case' 0 C--O 1.218 -0.555 0 C-N-CA 120.544 -0.462 . . . . 0.0 109.852 -179.926 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 20.1 m -61.86 -42.4 99.0 Favored 'General case' 0 C--N 1.311 -1.073 0 C-N-CA 120.016 -0.674 . . . . 0.0 110.748 -179.586 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.495 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 10.2 t -65.51 -34.19 77.68 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.743 0.783 . . . . 0.0 109.229 179.363 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.6 mm -65.99 -41.29 89.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 115.008 -0.996 . . . . 0.0 110.289 -179.768 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.41 ' HG2' ' O ' ' A' ' 24' ' ' LYS . 54.4 mm-40 -64.23 -34.38 77.97 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.502 -179.555 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.448 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 36.1 m -67.87 -0.15 3.98 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.994 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.448 ' CB ' ' O ' ' A' ' 29' ' ' SER . 0.5 OUTLIER 80.9 14.81 0.66 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.483 -179.943 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.556 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 4.0 m-85 -94.89 -168.3 1.79 Allowed 'General case' 0 CA--C 1.533 0.298 0 CA-C-O 120.781 0.324 . . . . 0.0 110.261 -179.671 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -76.59 -51.26 11.96 Favored 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 -178.748 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.495 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 163.3 -179.24 38.56 Favored Glycine 0 CA--C 1.519 0.318 0 N-CA-C 109.734 -1.347 . . . . 0.0 109.734 -178.917 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.405 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -142.96 170.35 25.31 Favored Glycine 0 N--CA 1.462 0.405 0 N-CA-C 111.36 -0.696 . . . . 0.0 111.36 -179.115 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 23.3 pttt -156.9 178.43 10.37 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.071 0.462 . . . . 0.0 110.891 -179.663 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 3.2 m -104.56 128.4 52.53 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.053 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 35.1 m -136.23 163.38 34.15 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.573 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 2.8 p80 -108.75 156.61 19.41 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.129 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 95.9 mt -122.82 130.07 74.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.606 -179.391 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 48.02 -107.99 0.31 Allowed Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 29.8 mm100 -136.38 32.29 2.83 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 120.596 0.236 . . . . 0.0 110.48 -179.769 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 8.7 m -82.64 -12.03 57.95 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 121.134 0.492 . . . . 0.0 110.282 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' LEU . . . . . 0.419 HD22 ' HA ' ' A' ' 43' ' ' LEU . 0.2 OUTLIER 49.56 29.17 2.84 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.224 179.657 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -105.62 132.71 51.42 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.344 179.778 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -93.5 117.53 30.2 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-O 120.965 0.412 . . . . 0.0 109.95 179.823 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 16.3 m -111.0 137.16 44.65 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.41 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.007 -179.6 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.909 ' SG ' HD11 ' A' ' 11' ' ' ILE . 16.1 t -93.05 118.79 31.59 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.734 -179.837 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.9 p -128.05 150.91 34.22 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.093 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.84 -179.319 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' CYS . . . . . 0.556 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 28.9 t -96.88 165.4 12.12 Favored 'General case' 0 N--CA 1.467 0.419 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.508 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 25.3 m-85 -127.95 124.17 23.07 Favored Pre-proline 0 CA--C 1.544 0.731 0 C-N-CA 121.114 -0.234 . . . . 0.0 111.236 -178.444 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.434 ' HG2' ' H ' ' A' ' 7' ' ' LYS . 48.4 Cg_exo -51.29 137.6 46.71 Favored 'Trans proline' 0 N--CA 1.499 1.818 0 C-N-CA 121.999 1.8 . . . . 0.0 113.018 179.092 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 64.2 tttp -112.34 -48.9 2.99 Favored 'General case' 0 CA--C 1.529 0.15 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.298 178.747 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.536 ' CD2' ' O ' ' A' ' 53' ' ' TYR . 24.4 p90 -129.89 40.33 3.58 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.778 -179.483 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 90.3 t80 -83.45 96.86 8.7 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.944 0.402 . . . . 0.0 110.003 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 18.2 mm . . . . . 0 C--O 1.22 -0.463 0 CA-C-O 118.053 -0.975 . . . . 0.0 110.505 -179.348 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 68.4 mttm . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ASP . . . . . 0.428 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 34.4 p-10 -87.79 3.94 46.3 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.509 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 35.1 mm -74.07 129.84 36.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.517 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 59.8 t0 -61.68 -42.29 98.73 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.169 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 44.17 75.85 0.14 Allowed Glycine 0 C--N 1.331 0.277 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.706 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.0 31.47 4.68 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.748 0.309 . . . . 0.0 111.02 -179.312 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -121.69 150.07 54.47 Favored Pre-proline 0 N--CA 1.469 0.488 0 CA-C-N 116.438 -0.347 . . . . 0.0 110.746 -179.493 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -61.64 154.82 57.42 Favored 'Trans proline' 0 N--CA 1.497 1.693 0 C-N-CA 122.408 2.072 . . . . 0.0 111.984 179.065 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.659 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.8 tt -131.63 120.91 23.48 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.42 -179.272 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.729 HD23 ' N ' ' A' ' 11' ' ' ILE . 4.4 tt -89.94 128.43 36.23 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 178.883 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.729 ' N ' HD23 ' A' ' 10' ' ' LEU . 6.4 pt -101.72 -43.03 9.71 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-O 120.786 0.327 . . . . 0.0 110.865 -178.536 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.46 ' O ' HD21 ' A' ' 10' ' ' LEU . . . -173.54 -143.29 4.22 Favored Glycine 0 N--CA 1.451 -0.307 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.744 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.7 p -99.46 163.66 12.42 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.824 0.345 . . . . 0.0 110.275 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 43.4 t -74.1 7.55 2.64 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.331 179.6 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 97.1 mt -93.15 -43.68 13.63 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.12 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.523 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -88.37 -11.71 45.43 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.652 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 53.6 m-85 -122.84 81.22 49.58 Favored Pre-proline 0 N--CA 1.463 0.214 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.853 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_exo -48.88 165.99 0.17 Allowed 'Trans proline' 0 N--CA 1.495 1.599 0 C-N-CA 122.714 2.276 . . . . 0.0 111.33 179.065 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.582 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 17.0 m -48.39 -52.58 21.22 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.85 -0.34 . . . . 0.0 111.627 -178.036 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.703 ' HA ' HD22 ' A' ' 23' ' ' ASN . 1.3 pm0 -61.92 -55.44 29.58 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.551 -0.295 . . . . 0.0 111.651 -179.722 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -57.57 -45.82 84.71 Favored 'General case' 0 CA--C 1.518 -0.255 0 CA-C-O 121.302 0.572 . . . . 0.0 110.94 -178.208 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 12.7 t -48.02 -65.12 0.62 Allowed 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.402 -178.893 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.703 HD22 ' HA ' ' A' ' 20' ' ' GLU . 13.2 p30 -63.71 -48.37 77.37 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.755 -179.597 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.527 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 89.5 mttt -47.27 -42.02 19.88 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 120.543 -0.463 . . . . 0.0 110.05 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 18.6 m -61.57 -43.68 98.41 Favored 'General case' 0 C--N 1.314 -0.978 0 C-N-CA 120.456 -0.498 . . . . 0.0 110.909 -179.453 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.503 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 10.7 t -66.2 -32.51 73.99 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.525 0.679 . . . . 0.0 109.745 179.562 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.6 mm -66.54 -39.34 83.68 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.442 -179.623 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.422 ' C ' ' H ' ' A' ' 30' ' ' ASN . 54.9 mm-40 -64.34 -35.72 81.8 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.299 -179.356 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.401 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 58.6 m -67.86 1.65 2.47 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.268 179.797 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.422 ' H ' ' C ' ' A' ' 28' ' ' GLU . 43.8 t30 77.78 18.25 1.27 Allowed 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.705 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.553 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 4.1 m-85 -96.34 -167.83 1.64 Allowed 'General case' 0 CA--C 1.532 0.288 0 CA-C-O 120.945 0.402 . . . . 0.0 110.406 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -75.71 -51.51 12.55 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 115.893 -0.594 . . . . 0.0 112.076 -179.079 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.503 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 162.56 -178.06 38.46 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 -179.025 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.435 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -142.95 169.02 25.82 Favored Glycine 0 N--CA 1.462 0.375 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.136 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 11.4 ptmt -158.48 -176.25 5.78 Favored 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 120.681 -0.408 . . . . 0.0 110.716 -179.3 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 66.2 m -103.73 119.86 39.76 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.932 179.509 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 18.9 m -133.32 163.93 36.41 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.204 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -132.83 157.67 44.44 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 121.02 0.438 . . . . 0.0 110.394 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.556 ' O ' ' N ' ' A' ' 41' ' ' GLN . 20.2 mm -99.38 135.84 32.99 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.569 179.673 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -61.84 65.1 0.02 OUTLIER Glycine 0 N--CA 1.461 0.346 0 N-CA-C 111.543 -0.623 . . . . 0.0 111.543 -179.418 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.556 ' N ' ' O ' ' A' ' 39' ' ' ILE . 59.7 tp60 -174.63 -57.49 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.884 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 73.4 m -90.88 -13.84 32.88 Favored 'General case' 0 CA--C 1.505 -0.755 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.588 179.719 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' LEU . . . . . 0.54 ' N ' HD12 ' A' ' 43' ' ' LEU . 8.3 mp 46.88 28.28 0.82 Allowed 'General case' 0 N--CA 1.436 -1.171 0 C-N-CA 119.697 -0.801 . . . . 0.0 111.378 178.934 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 54.4 t0 -96.36 136.63 36.59 Favored 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.612 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -86.35 124.75 33.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.998 0.428 . . . . 0.0 110.0 -179.596 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 27.8 m -126.13 150.59 31.76 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.377 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.111 -179.713 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -98.55 125.96 43.96 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.582 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.1 p -136.77 155.0 32.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.188 -179.339 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' CYS . . . . . 0.553 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 17.7 t -97.07 164.65 12.42 Favored 'General case' 0 C--O 1.233 0.215 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.538 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 30.7 m-85 -133.98 126.59 18.78 Favored Pre-proline 0 C--N 1.33 -0.24 0 C-N-CA 121.031 -0.268 . . . . 0.0 110.856 -178.363 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.28 158.09 58.89 Favored 'Trans proline' 0 N--CA 1.491 1.339 0 C-N-CA 121.712 1.608 . . . . 0.0 112.218 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 22.6 mmtp -63.8 -8.84 11.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.779 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 87.7 m-85 -109.33 39.6 2.03 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.397 -179.698 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 82.9 t80 -111.59 121.69 45.82 Favored 'General case' 0 C--O 1.231 0.101 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.75 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 86.5 mt . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.244 -179.927 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 53.3 mtpt . . . . . 0 N--CA 1.492 1.651 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ASP . . . . . 0.613 ' C ' ' H ' ' A' ' 4' ' ' ASP . 17.0 p-10 -75.23 -58.08 3.5 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.16 -0.473 . . . . 0.0 109.763 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.437 ' H ' ' CG ' ' A' ' 2' ' ' ASP . 0.3 OUTLIER 62.25 -25.99 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.522 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.446 178.554 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ASP . . . . . 0.613 ' H ' ' C ' ' A' ' 2' ' ' ASP . 37.4 t0 -58.83 -27.63 65.29 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.18 0.514 . . . . 0.0 110.056 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 93.67 74.14 1.24 Allowed Glycine 0 C--N 1.33 0.239 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.531 ' NE ' ' O ' ' A' ' 6' ' ' ARG . 0.0 OUTLIER -132.16 42.22 3.15 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 112.376 0.51 . . . . 0.0 112.376 -177.985 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.684 ' H ' ' HG3' ' A' ' 51' ' ' PRO . 27.8 tptt -125.64 43.99 1.05 Allowed Pre-proline 0 C--N 1.323 -0.567 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.208 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.547 ' CD ' ' N ' ' A' ' 7' ' ' LYS . 61.1 Cg_endo -69.38 154.35 69.35 Favored 'Trans proline' 0 N--CA 1.498 1.78 0 C-N-CA 122.71 2.273 . . . . 0.0 111.929 179.409 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.661 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.5 tt -129.65 120.61 25.5 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.126 -178.974 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.661 ' N ' HD23 ' A' ' 9' ' ' LEU . 7.2 tt -92.49 125.66 37.23 Favored 'General case' 0 N--CA 1.468 0.438 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 178.494 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.906 HD11 ' SG ' ' A' ' 47' ' ' CYS . 2.9 pt -103.56 -47.45 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-O 120.752 0.31 . . . . 0.0 111.0 -179.188 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -165.14 -135.73 1.88 Allowed Glycine 0 CA--C 1.519 0.311 0 C-N-CA 120.705 -0.76 . . . . 0.0 111.307 -179.649 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 71.3 p -136.89 159.6 41.38 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 114.99 -0.605 . . . . 0.0 110.163 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -56.72 -11.07 1.2 Allowed 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.026 179.636 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 97.3 mt -69.41 -43.24 81.05 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.329 0 CA-C-O 121.454 0.645 . . . . 0.0 109.782 179.71 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -104.34 -31.11 9.7 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 114.9 -1.045 . . . . 0.0 111.648 -178.797 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.427 ' O ' ' O ' ' A' ' 18' ' ' PRO . 12.0 m-85 -119.06 82.99 22.75 Favored Pre-proline 0 N--CA 1.471 0.612 0 N-CA-C 110.103 -0.332 . . . . 0.0 110.103 179.473 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.427 ' O ' ' O ' ' A' ' 17' ' ' PHE . 77.5 Cg_exo -47.61 179.87 0.01 OUTLIER 'Trans proline' 0 N--CA 1.495 1.57 0 C-N-CA 122.645 2.23 . . . . 0.0 111.701 -179.79 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.449 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 99.0 m -59.0 -50.71 73.06 Favored 'General case' 0 C--N 1.326 -0.428 0 C-N-CA 120.89 -0.324 . . . . 0.0 111.845 -178.513 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.628 ' CD ' ' H ' ' A' ' 20' ' ' GLU . 1.1 pm0 -60.03 -52.59 64.73 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.161 -179.688 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.13 -47.29 85.24 Favored 'General case' 0 CA--C 1.519 -0.235 0 CA-C-O 121.297 0.57 . . . . 0.0 110.691 -179.212 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 38.5 t -45.12 -60.38 2.13 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 115.312 -0.858 . . . . 0.0 111.259 -178.792 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.666 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.9 p-10 -64.71 -51.69 61.07 Favored 'General case' 0 C--O 1.221 -0.411 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.734 -179.593 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.666 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 81.2 mttt -47.97 -42.86 28.77 Favored 'General case' 0 C--N 1.323 -0.554 0 C-N-CA 120.405 -0.518 . . . . 0.0 110.584 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 55.5 m -66.35 -33.3 75.41 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.163 0.506 . . . . 0.0 110.085 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 56.9 m -72.0 -34.04 68.56 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.876 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.3 mm -62.07 -48.51 88.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.727 -179.251 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.459 ' C ' ' H ' ' A' ' 30' ' ' ASN . 6.0 pt-20 -70.47 -30.81 67.71 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.799 -179.303 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 39.5 m -68.96 7.15 0.74 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.706 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.459 ' H ' ' C ' ' A' ' 28' ' ' GLU . 49.8 t30 72.73 47.86 0.22 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.366 179.487 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.55 ' C ' ' H ' ' A' ' 33' ' ' GLY . 73.9 m-85 -137.23 160.8 37.97 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.759 179.424 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.32 23.3 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.168 -179.66 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.55 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 91.92 -179.88 41.4 Favored Glycine 0 CA--C 1.519 0.338 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 -179.683 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -148.92 174.45 28.54 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.433 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 8.8 pttm -154.12 -179.08 7.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.035 0.445 . . . . 0.0 110.788 -179.781 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 3.9 m -105.03 124.46 49.56 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 115.718 -0.673 . . . . 0.0 110.308 179.658 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 35.7 m -136.67 165.91 27.38 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.75 -179.679 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 3.3 p80 -106.92 155.85 19.34 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-O 121.025 0.44 . . . . 0.0 110.66 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 96.0 mt -128.96 126.49 64.74 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.217 -179.481 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 61.46 22.48 61.41 Favored Glycine 0 CA--C 1.52 0.387 0 N-CA-C 111.555 -0.618 . . . . 0.0 111.555 178.797 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 57.3 37.37 28.11 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.026 0.441 . . . . 0.0 110.03 -179.466 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 20.7 m -81.49 -11.09 59.33 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.181 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' LEU . . . . . 0.41 ' O ' ' CD2' ' A' ' 43' ' ' LEU . 0.9 OUTLIER 70.69 28.63 3.43 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.493 0.663 . . . . 0.0 109.659 -179.783 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -110.97 121.34 45.1 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.665 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 64.5 m-85 -90.63 117.1 29.03 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-O 121.163 0.506 . . . . 0.0 110.007 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.5 m -110.97 137.65 42.55 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.33 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.715 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.906 ' SG ' HD11 ' A' ' 11' ' ' ILE . 13.5 t -93.02 113.95 26.36 Favored 'General case' 0 CA--C 1.512 -0.481 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 -179.862 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 8.8 p -130.39 147.78 33.16 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.308 0 CA-C-O 121.143 0.497 . . . . 0.0 111.62 -178.748 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 4.8 m -97.43 170.82 8.79 Favored 'General case' 0 CA--C 1.518 -0.257 0 CA-C-N 115.258 -0.883 . . . . 0.0 109.793 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -130.15 143.29 48.57 Favored Pre-proline 0 CA--C 1.542 0.644 0 CA-C-N 116.512 -0.313 . . . . 0.0 111.266 -178.804 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.684 ' HG3' ' H ' ' A' ' 7' ' ' LYS . 40.8 Cg_exo -47.52 137.05 20.26 Favored 'Trans proline' 0 N--CA 1.498 1.736 0 C-N-CA 122.37 2.047 . . . . 0.0 112.011 177.676 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 41.6 mmtt -41.55 -86.0 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 114.97 -1.014 . . . . 0.0 112.695 -178.525 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 6.6 m-85 -116.05 17.41 15.85 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-O 121.208 0.528 . . . . 0.0 110.004 -178.688 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 2.4 m-85 -93.49 101.69 13.89 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.413 -0.812 . . . . 0.0 109.298 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 32.4 pt . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.455 -179.444 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 41.3 pttt . . . . . 0 N--CA 1.492 1.628 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 47.5 t0 58.68 36.68 25.09 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 -179.102 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.608 ' O ' HD12 ' A' ' 3' ' ' ILE . 1.5 pp -122.92 163.18 22.01 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.225 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.816 -179.303 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 64.5 t0 -60.1 -45.66 92.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.25 -179.434 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 78.87 74.59 1.05 Allowed Glycine 0 C--O 1.228 -0.228 0 N-CA-C 110.772 -0.931 . . . . 0.0 110.772 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.539 ' NH2' ' O ' ' A' ' 53' ' ' TYR . 21.0 mmt180 -131.63 40.8 3.36 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 120.759 0.314 . . . . 0.0 110.817 -179.618 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 17.3 pttt -130.66 101.87 16.86 Favored Pre-proline 0 N--CA 1.466 0.334 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -179.438 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -50.79 142.94 31.19 Favored 'Trans proline' 0 N--CA 1.495 1.571 0 C-N-CA 121.588 1.526 . . . . 0.0 111.187 178.016 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.69 HD13 ' N ' ' A' ' 10' ' ' LEU . 0.2 OUTLIER -111.32 126.69 55.18 Favored 'General case' 0 N--CA 1.468 0.472 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.685 -179.006 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.69 ' N ' HD13 ' A' ' 9' ' ' LEU . 2.6 tm? -92.05 128.5 37.91 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 178.336 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.47 HD11 ' SG ' ' A' ' 26' ' ' CYS . 0.0 OUTLIER -108.06 -40.09 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -178.63 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -177.94 -140.59 3.84 Favored Glycine 0 CA--C 1.52 0.404 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 179.698 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.496 ' C ' ' H ' ' A' ' 15' ' ' ILE . 80.6 p -135.63 161.08 36.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.017 0.437 . . . . 0.0 111.045 -179.534 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -58.17 -2.96 0.21 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.26 179.54 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.496 ' H ' ' C ' ' A' ' 13' ' ' THR . 23.8 mm -73.45 -22.65 19.18 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 CA-C-O 121.092 0.473 . . . . 0.0 109.948 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLU . . . . . 0.477 ' OE1' ' CZ ' ' A' ' 17' ' ' PHE . 9.5 pt-20 -134.51 -30.76 1.11 Allowed 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.154 -179.515 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.477 ' CZ ' ' OE1' ' A' ' 16' ' ' GLU . 9.9 m-85 -114.88 93.4 34.01 Favored Pre-proline 0 N--CA 1.468 0.426 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.537 -179.619 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.45 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 56.5 Cg_endo -79.25 -179.08 5.1 Favored 'Trans proline' 0 N--CA 1.489 1.235 0 C-N-CA 122.489 2.126 . . . . 0.0 111.23 -179.543 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.411 ' OG1' ' OE2' ' A' ' 20' ' ' GLU . 23.4 p -45.4 -48.68 13.52 Favored 'General case' 0 C--N 1.32 -0.687 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.116 -178.74 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.469 ' CD ' ' H ' ' A' ' 20' ' ' GLU . 0.3 OUTLIER -52.55 -70.72 0.08 Allowed 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.614 -179.316 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 16.2 ttmt -64.59 -47.36 78.95 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-O 121.443 0.64 . . . . 0.0 111.304 -178.008 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.45 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 51.8 t -41.78 -59.8 1.56 Allowed 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.205 -0.907 . . . . 0.0 111.039 -178.954 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.483 ' OD1' ' N ' ' A' ' 24' ' ' LYS . 0.2 OUTLIER -66.89 -55.13 16.01 Favored 'General case' 0 C--O 1.218 -0.577 0 C-N-CA 120.205 -0.598 . . . . 0.0 110.421 -179.634 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.483 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 71.7 mttt -44.53 -42.6 7.34 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.871 0.367 . . . . 0.0 110.71 -179.231 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' THR . . . . . 0.454 ' O ' ' OE2' ' A' ' 28' ' ' GLU . 8.8 m -65.12 -37.14 86.49 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.416 0.627 . . . . 0.0 109.558 179.408 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.47 ' SG ' HD11 ' A' ' 11' ' ' ILE . 67.9 m -72.08 -35.27 69.19 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.162 179.728 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.9 mm -62.67 -48.34 88.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.386 -179.192 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.454 ' OE2' ' O ' ' A' ' 25' ' ' THR . 2.6 pp20? -70.57 -31.09 67.97 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.601 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.434 ' N ' ' CD ' ' A' ' 28' ' ' GLU . 68.6 m -67.57 2.36 1.86 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.934 -179.688 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.411 ' H ' ' C ' ' A' ' 28' ' ' GLU . 41.6 t30 75.14 43.32 0.21 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.983 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.553 ' C ' ' H ' ' A' ' 33' ' ' GLY . 63.0 m-85 -131.92 160.99 34.13 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.459 179.463 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.48 31.19 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.96 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.553 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 84.11 -176.96 51.92 Favored Glycine 0 CA--C 1.52 0.4 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -150.58 172.13 30.35 Favored Glycine 0 CA--C 1.52 0.36 0 N-CA-C 110.715 -0.954 . . . . 0.0 110.715 -179.73 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 25.2 pttt -155.25 -179.02 7.68 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 120.935 0.398 . . . . 0.0 110.563 -179.558 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 3.3 m -103.94 127.08 51.48 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 115.866 -0.607 . . . . 0.0 110.172 179.384 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 34.5 m -136.77 159.81 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.419 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 4.5 p-80 -104.6 156.94 17.53 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-O 121.072 0.463 . . . . 0.0 110.086 179.753 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.478 ' O ' ' N ' ' A' ' 41' ' ' GLN . 34.4 mm -109.21 125.13 66.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.243 -179.765 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 42.5 -92.42 0.01 OUTLIER Glycine 0 CA--C 1.526 0.75 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.484 ' N ' ' CD ' ' A' ' 41' ' ' GLN . 2.0 pm0 -143.9 30.44 1.31 Allowed 'General case' 0 N--CA 1.463 0.197 0 CA-C-O 120.702 0.287 . . . . 0.0 110.531 -179.64 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 66.3 m -84.43 -5.4 59.28 Favored 'General case' 0 CA--C 1.52 -0.188 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.689 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 45.14 28.37 0.4 Allowed 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.677 179.813 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -103.04 119.8 39.51 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.396 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 70.8 m-85 -87.75 117.8 26.83 Favored 'General case' 0 C--N 1.332 -0.191 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.725 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 33.4 m -112.82 137.09 47.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.331 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.432 ' O ' HD22 ' A' ' 10' ' ' LEU . 25.2 t -92.25 108.2 19.77 Favored 'General case' 0 CA--C 1.513 -0.445 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 179.838 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.2 p -124.36 150.23 28.96 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.229 0 CA-C-O 120.941 0.4 . . . . 0.0 110.634 -178.809 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 10.6 m -97.26 163.13 13.03 Favored 'General case' 0 CA--C 1.515 -0.386 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 -179.696 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 -119.33 143.29 34.05 Favored Pre-proline 0 CA--C 1.531 0.249 0 C-N-CA 121.141 -0.224 . . . . 0.0 111.227 -178.879 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.404 ' C ' ' H ' ' A' ' 53' ' ' TYR . 39.4 Cg_endo -64.28 149.62 89.86 Favored 'Trans proline' 0 N--CA 1.494 1.522 0 C-N-CA 122.221 1.947 . . . . 0.0 111.989 178.81 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 68.1 mmtt -64.3 -2.69 2.31 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.534 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.539 ' O ' ' NH2' ' A' ' 6' ' ' ARG . 52.0 m-85 -109.02 18.4 20.68 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.463 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 86.7 t80 -83.4 123.08 29.32 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.089 179.681 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 8.0 pt . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.118 -0.944 . . . . 0.0 110.194 -179.759 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 35.7 tttp . . . . . 0 N--CA 1.49 1.557 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ASP . . . . . 0.425 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 34.4 p-10 -74.0 -2.53 24.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.401 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 31.4 mm -88.41 125.63 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 CA-C-O 121.286 0.565 . . . . 0.0 110.762 179.61 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -65.13 -35.43 81.09 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.908 179.424 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -81.91 95.13 1.71 Allowed Glycine 0 CA--C 1.518 0.267 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -179.888 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 1.3 ppt_? -132.55 40.82 3.25 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.729 0.3 . . . . 0.0 111.048 -179.705 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 3.1 ptmm? -120.5 83.34 34.06 Favored Pre-proline 0 N--CA 1.464 0.226 0 CA-C-O 121.034 0.445 . . . . 0.0 110.955 -179.701 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -59.7 147.29 92.67 Favored 'Trans proline' 0 C--N 1.306 -1.678 0 C-N-CA 122.162 1.908 . . . . 0.0 110.993 179.641 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.611 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.5 tt -117.0 114.79 24.29 Favored 'General case' 0 CA--C 1.511 -0.523 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 -179.777 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.669 HD13 ' C ' ' A' ' 10' ' ' LEU . 3.0 tm? -93.27 124.5 37.29 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.37 -0.532 . . . . 0.0 109.881 179.266 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.962 HD11 ' SG ' ' A' ' 47' ' ' CYS . 5.7 pt -103.37 -41.91 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-O 121.052 0.453 . . . . 0.0 110.588 -179.342 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.453 ' O ' HD21 ' A' ' 10' ' ' LEU . . . -174.8 -139.5 3.03 Favored Glycine 0 CA--C 1.521 0.418 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.444 ' C ' ' H ' ' A' ' 15' ' ' ILE . 72.7 p -134.06 165.99 23.78 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.914 0.388 . . . . 0.0 110.924 -179.524 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -58.6 -5.6 0.58 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.206 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.444 ' H ' ' C ' ' A' ' 13' ' ' THR . 24.0 mm -74.5 -24.48 18.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.538 -179.292 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -128.33 -29.92 2.43 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.84 -179.592 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -117.34 91.96 38.84 Favored Pre-proline 0 CA--C 1.536 0.411 0 CA-C-N 116.486 -0.324 . . . . 0.0 110.474 179.759 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.463 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 52.9 Cg_endo -71.56 -177.33 2.4 Favored 'Trans proline' 0 N--CA 1.498 1.736 0 C-N-CA 123.12 2.547 . . . . 0.0 111.853 -179.25 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.473 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 31.0 m -46.73 -70.61 0.09 Allowed 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 120.568 -0.453 . . . . 0.0 111.358 -179.275 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.648 ' CD ' ' H ' ' A' ' 20' ' ' GLU . 1.3 pm0 -41.39 -70.13 0.11 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.395 -178.865 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 5.3 ttmt -54.44 -53.88 48.23 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.021 0.439 . . . . 0.0 111.499 -177.867 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.463 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 43.0 t -41.41 -59.44 1.57 Allowed 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.071 -178.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.745 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 0.9 OUTLIER -65.82 -52.1 53.41 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.848 179.611 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.745 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 69.7 mttt -48.42 -42.61 32.65 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 120.839 0.352 . . . . 0.0 110.674 -178.539 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 20.0 m -63.93 -41.08 97.73 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-O 121.331 0.586 . . . . 0.0 109.995 179.789 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 57.5 m -65.23 -31.06 72.03 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.574 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.41 HG12 ' O ' ' A' ' 23' ' ' ASN . 3.1 mm -65.37 -38.83 83.48 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.427 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 30.2 mm-40 -65.74 -33.06 75.0 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.551 -0.749 . . . . 0.0 110.626 -178.739 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 46.2 m -73.27 -2.66 22.8 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.307 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 1.9 m120 77.84 34.5 0.32 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.958 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.573 ' C ' ' H ' ' A' ' 33' ' ' GLY . 8.2 m-85 -110.34 164.7 12.42 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.049 179.892 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.19 21.29 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.57 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.573 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 90.32 -178.7 43.25 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.371 -1.091 . . . . 0.0 110.371 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.421 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -147.01 170.33 27.93 Favored Glycine 0 CA--C 1.52 0.406 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 -179.344 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 10.7 ptmt -156.36 -177.0 6.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.619 0.247 . . . . 0.0 110.601 -179.576 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 1.7 m -104.02 125.76 50.62 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.131 179.489 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 34.0 m -133.92 162.57 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.297 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 5.1 p-80 -109.12 157.42 18.76 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.867 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 92.1 mt -123.27 131.59 72.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.716 -179.485 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 49.55 -103.98 0.09 OUTLIER Glycine 0 CA--C 1.519 0.307 0 N-CA-C 110.812 -0.915 . . . . 0.0 110.812 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 41.2 tp60 -141.44 30.98 1.71 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.876 0.37 . . . . 0.0 110.396 -179.757 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 58.2 m -85.93 -5.7 59.19 Favored 'General case' 0 CA--C 1.518 -0.252 0 CA-C-O 120.967 0.413 . . . . 0.0 110.91 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' LEU . . . . . 0.403 ' O ' ' CD2' ' A' ' 43' ' ' LEU . 0.9 OUTLIER 44.42 29.95 0.43 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.398 -179.499 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -99.8 124.88 45.53 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.073 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -89.7 118.01 28.99 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 109.692 -0.485 . . . . 0.0 109.692 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 29.8 m -112.84 136.21 49.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.102 -179.52 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.962 ' SG ' HD11 ' A' ' 11' ' ' ILE . 22.1 t -92.94 105.98 18.01 Favored 'General case' 0 CA--C 1.513 -0.464 0 N-CA-C 109.373 -0.602 . . . . 0.0 109.373 179.901 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 4.7 p -125.54 154.97 34.6 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.375 0 CA-C-O 120.94 0.4 . . . . 0.0 110.573 -178.826 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 8.1 m -99.31 173.36 6.81 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.168 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 64.3 m-85 -133.6 117.95 14.44 Favored Pre-proline 0 CA--C 1.536 0.43 0 CA-C-N 116.269 -0.423 . . . . 0.0 109.999 179.224 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -49.54 127.73 19.07 Favored 'Trans proline' 0 N--CA 1.499 1.826 0 C-N-CA 122.186 1.924 . . . . 0.0 112.328 179.666 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 56.6 tttp -96.33 -60.03 1.71 Allowed 'General case' 0 N--CA 1.451 -0.424 0 CA-C-N 116.249 -0.432 . . . . 0.0 109.877 179.081 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.472 ' CD2' ' O ' ' A' ' 53' ' ' TYR . 32.7 p90 -133.26 31.22 3.82 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.667 -179.794 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 85.0 t80 -60.04 95.45 0.03 OUTLIER 'General case' 0 N--CA 1.449 -0.516 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.184 -179.032 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 117.913 -1.041 . . . . 0.0 109.886 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 60.9 pttt . . . . . 0 N--CA 1.491 1.621 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 32.1 m-20 -65.49 -8.79 21.11 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.4 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 15.4 pt -58.23 170.18 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.467 179.409 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 64.4 t0 -61.91 -41.84 98.38 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.892 -179.486 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 66.82 62.99 4.11 Favored Glycine 0 N--CA 1.461 0.307 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.63 30.34 4.68 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.718 0.294 . . . . 0.0 111.028 -179.433 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.477 ' CB ' ' NZ ' ' A' ' 7' ' ' LYS . 0.1 OUTLIER -131.35 147.48 66.32 Favored Pre-proline 0 N--CA 1.47 0.574 0 CA-C-N 116.555 -0.293 . . . . 0.0 111.086 -179.568 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -74.02 158.96 45.34 Favored 'Trans proline' 0 N--CA 1.502 1.986 0 C-N-CA 122.908 2.405 . . . . 0.0 112.303 179.474 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.657 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.6 tt -128.42 120.79 27.59 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.755 -179.215 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.657 ' N ' HD23 ' A' ' 9' ' ' LEU . 6.6 tt -89.05 133.9 34.19 Favored 'General case' 0 N--CA 1.468 0.46 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 178.128 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 12.8 pt -109.04 -37.02 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-O 120.869 0.366 . . . . 0.0 111.068 -178.775 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 175.32 -153.72 16.09 Favored Glycine 0 N--CA 1.452 -0.255 0 N-CA-C 110.913 -0.875 . . . . 0.0 110.913 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 6.7 p -90.03 164.85 14.35 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 10.4 t -76.07 7.35 4.19 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.214 179.601 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.5 mt -91.46 -42.32 13.65 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.221 0 CA-C-O 121.149 0.499 . . . . 0.0 109.808 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -87.91 -12.63 44.15 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.361 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -124.81 81.2 61.81 Favored Pre-proline 0 N--CA 1.463 0.217 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.954 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -48.64 163.23 0.29 Allowed 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.05 1.833 . . . . 0.0 110.719 178.731 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.564 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 25.5 p -46.5 -53.24 11.63 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.919 0.39 . . . . 0.0 111.721 -177.837 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.656 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 0.0 OUTLIER -59.72 -55.4 34.78 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.573 -179.429 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -58.96 -44.79 91.53 Favored 'General case' 0 CA--C 1.516 -0.336 0 CA-C-O 121.332 0.587 . . . . 0.0 110.388 -178.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 14.7 t -48.28 -65.46 0.56 Allowed 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 115.265 -0.88 . . . . 0.0 111.427 -178.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.654 HD22 ' HA ' ' A' ' 20' ' ' GLU . 13.8 p30 -64.97 -46.97 79.26 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.011 -179.438 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.516 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 92.9 mttt -50.59 -37.55 40.53 Favored 'General case' 0 CA--C 1.5 -0.952 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.23 179.592 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 86.8 m -63.93 -42.79 97.26 Favored 'General case' 0 C--N 1.319 -0.751 0 O-C-N 124.012 0.82 . . . . 0.0 110.468 -179.342 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.497 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 33.8 t -72.58 -33.4 66.74 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.106 179.68 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.2 mm -66.08 -46.7 87.19 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.616 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.112 -179.192 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.505 ' C ' ' H ' ' A' ' 30' ' ' ASN . 19.0 pt-20 -69.64 -30.46 68.17 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 115.349 -0.841 . . . . 0.0 110.151 -179.698 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.416 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 68.3 m -65.49 1.78 1.09 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.75 179.845 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.505 ' H ' ' C ' ' A' ' 28' ' ' GLU . 0.3 OUTLIER 79.82 12.56 1.1 Allowed 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.966 179.546 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.562 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 4.5 m-85 -98.07 -167.81 1.57 Allowed 'General case' 0 CA--C 1.533 0.322 0 CA-C-O 120.706 0.289 . . . . 0.0 110.27 -179.842 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -75.79 -53.97 7.65 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.582 0.586 . . . . 0.0 112.582 -178.543 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.497 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 166.5 178.9 39.45 Favored Glycine 0 CA--C 1.519 0.321 0 N-CA-C 110.068 -1.213 . . . . 0.0 110.068 -178.921 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -137.26 160.98 25.19 Favored Glycine 0 C--N 1.331 0.299 0 N-CA-C 111.579 -0.609 . . . . 0.0 111.579 -179.383 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 14.2 ptpt -153.45 170.23 21.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.29 -0.455 . . . . 0.0 110.779 -178.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 56.5 m -104.86 117.7 34.7 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.891 179.493 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 4.8 m -139.65 -178.5 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-O 120.873 0.368 . . . . 0.0 111.129 -179.427 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.619 ' ND1' ' N ' ' A' ' 44' ' ' ASP . 95.3 m-70 -114.0 147.98 37.72 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.802 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 95.6 mt -124.06 127.8 73.7 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.849 -179.847 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 68.74 21.78 75.09 Favored Glycine 0 CA--C 1.52 0.35 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 179.374 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 57.79 30.8 19.55 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.196 0.522 . . . . 0.0 109.794 -179.215 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 50.6 m -72.22 -10.92 60.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.443 -0.798 . . . . 0.0 110.511 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' LEU . . . . . 0.445 ' C ' ' ND1' ' A' ' 38' ' ' HIS . 0.9 OUTLIER 63.14 29.33 16.14 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.649 -179.636 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ASP . . . . . 0.619 ' N ' ' ND1' ' A' ' 38' ' ' HIS . 67.2 t0 -111.05 138.69 47.16 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.714 179.499 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.489 ' N ' ' OD1' ' A' ' 44' ' ' ASP . 50.2 m-85 -92.95 117.38 29.98 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.645 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 25.9 m -124.29 136.81 59.29 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.328 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.052 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -94.46 122.59 37.19 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.352 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.0 p -135.52 152.52 31.71 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.318 0 C-N-CA 120.655 -0.418 . . . . 0.0 111.319 -179.393 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' CYS . . . . . 0.562 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 23.9 t -96.01 164.18 12.81 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.078 -179.937 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.494 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 37.7 m-85 -130.75 136.55 29.11 Favored Pre-proline 0 N--CA 1.476 0.849 0 C-N-CA 120.788 -0.365 . . . . 0.0 111.352 -178.427 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -70.41 156.35 61.85 Favored 'Trans proline' 0 N--CA 1.491 1.355 0 C-N-CA 121.865 1.71 . . . . 0.0 112.207 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 29.5 mmtp -67.04 -19.92 65.76 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.879 -0.6 . . . . 0.0 109.925 179.379 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 73.2 m-85 -109.53 40.0 1.97 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.493 -179.525 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 90.3 t80 -73.24 126.79 30.9 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.193 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 5.2 pt . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.066 -0.969 . . . . 0.0 110.222 -179.889 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 98.6 mttt . . . . . 0 N--CA 1.489 1.495 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 45.8 t0 -67.42 -9.76 44.81 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.663 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 5.9 mm -81.16 130.29 36.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.476 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 66.6 t0 -62.12 -42.1 98.9 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.502 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 42.4 87.57 0.01 OUTLIER Glycine 0 N--CA 1.46 0.258 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.43 ' HD3' ' H ' ' A' ' 6' ' ' ARG . 0.0 OUTLIER -130.33 25.63 5.15 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.67 -0.265 . . . . 0.0 110.699 -179.339 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.1 153.25 76.65 Favored Pre-proline 0 CA--C 1.54 0.591 0 CA-C-N 116.689 -0.232 . . . . 0.0 111.534 -179.276 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -57.71 145.34 90.32 Favored 'Trans proline' 0 N--CA 1.501 1.934 0 C-N-CA 121.879 1.719 . . . . 0.0 111.797 178.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.634 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.5 tt -128.33 119.5 25.2 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.637 HD23 ' N ' ' A' ' 11' ' ' ILE . 6.6 tt -88.65 126.58 35.36 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 108.839 -0.801 . . . . 0.0 108.839 179.199 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.896 HD11 ' SG ' ' A' ' 47' ' ' CYS . 2.2 pt -105.36 -48.12 9.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-O 120.983 0.421 . . . . 0.0 110.852 -178.549 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -159.87 -144.22 3.9 Favored Glycine 0 CA--C 1.52 0.369 0 N-CA-C 110.771 -0.931 . . . . 0.0 110.771 -179.802 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.478 ' C ' ' H ' ' A' ' 15' ' ' ILE . 55.2 p -138.89 161.22 37.83 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.994 0.426 . . . . 0.0 110.809 -179.826 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -59.81 -1.28 0.26 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.221 179.652 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.478 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.2 mt -77.9 -23.65 13.98 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.406 0 CA-C-O 121.164 0.506 . . . . 0.0 109.806 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 2.7 pt-20 -134.24 -34.17 0.98 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.589 -0.732 . . . . 0.0 111.197 -179.381 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.431 ' CZ ' ' NZ ' ' A' ' 21' ' ' LYS . 6.4 m-85 -106.82 88.85 3.84 Favored Pre-proline 0 CA--C 1.538 0.5 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.416 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 19.0 Cg_endo -63.43 -173.6 0.18 Allowed 'Trans proline' 0 N--CA 1.499 1.799 0 C-N-CA 121.832 1.688 . . . . 0.0 112.461 -178.789 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 70.5 m -58.11 -49.81 75.66 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.021 -179.227 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.43 ' CG ' ' N ' ' A' ' 21' ' ' LYS . 8.9 pt-20 -59.06 -56.66 19.42 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.806 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.431 ' NZ ' ' CZ ' ' A' ' 17' ' ' PHE . 0.6 OUTLIER -64.51 -47.22 79.68 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-O 121.235 0.541 . . . . 0.0 111.087 -177.989 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.416 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 32.4 t -45.4 -63.18 1.0 Allowed 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.375 -0.83 . . . . 0.0 111.682 -179.149 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.475 ' OD1' ' N ' ' A' ' 24' ' ' LYS . 0.2 OUTLIER -63.45 -49.6 73.03 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.008 -179.276 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.475 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 47.5 mttp -45.1 -42.37 8.72 Favored 'General case' 0 C--O 1.218 -0.563 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.087 -179.7 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 17.8 m -62.34 -43.49 98.7 Favored 'General case' 0 C--N 1.311 -1.094 0 C-N-CA 119.98 -0.688 . . . . 0.0 110.366 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.492 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 11.4 t -66.99 -32.65 74.03 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 121.574 0.702 . . . . 0.0 109.788 179.615 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.5 mm -65.9 -41.76 90.63 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.213 -179.445 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.447 ' C ' ' H ' ' A' ' 30' ' ' ASN . 25.6 mm-40 -65.43 -34.87 79.31 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.146 -0.933 . . . . 0.0 110.371 -179.477 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.412 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 27.3 m -66.76 2.38 1.41 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.189 -179.742 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.447 ' H ' ' C ' ' A' ' 28' ' ' GLU . 17.5 t-20 78.24 15.28 1.38 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.59 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.553 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 4.1 m-85 -95.79 -168.62 1.8 Allowed 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 120.898 0.38 . . . . 0.0 110.343 -179.764 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -76.05 -50.13 15.62 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.987 -178.906 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.492 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 160.39 -176.17 37.08 Favored Glycine 0 C--O 1.226 -0.402 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 -179.148 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.449 ' H ' ' HB2' ' A' ' 23' ' ' ASN . . . -146.02 168.14 27.66 Favored Glycine 0 CA--C 1.519 0.331 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 -179.41 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 14.6 ptpt -155.76 178.65 10.02 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.003 0.43 . . . . 0.0 110.81 -179.126 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 4.6 m -103.59 123.52 47.11 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.077 179.506 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 27.6 m -136.4 161.16 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.45 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 2.5 p-80 -109.34 157.09 19.22 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.074 179.818 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.457 ' O ' ' N ' ' A' ' 41' ' ' GLN . 34.5 mm -107.83 125.74 64.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.174 -179.655 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 41.72 -94.4 0.01 OUTLIER Glycine 0 CA--C 1.527 0.782 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 179.694 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.457 ' N ' ' O ' ' A' ' 39' ' ' ILE . 16.6 mp0 -139.67 35.63 2.01 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.796 0.332 . . . . 0.0 110.348 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' SER . . . . . 0.759 ' C ' HD23 ' A' ' 43' ' ' LEU . 63.7 m -87.02 2.22 50.29 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.951 -179.875 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' LEU . . . . . 0.759 HD23 ' C ' ' A' ' 42' ' ' SER . 1.3 pt? 34.64 28.06 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 O-C-N 123.756 0.66 . . . . 0.0 111.618 -179.583 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 42' ' ' SER . 52.5 t0 -107.78 120.42 42.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.478 -179.843 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 -88.79 117.66 27.93 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 32.5 m -115.12 142.85 26.43 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.269 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.177 -179.431 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.896 ' SG ' HD11 ' A' ' 11' ' ' ILE . 17.0 t -94.03 119.15 32.51 Favored 'General case' 0 CA--C 1.515 -0.396 0 CA-C-N 115.894 -0.594 . . . . 0.0 109.462 179.749 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.4 p -126.39 152.46 33.94 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.204 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.398 -179.512 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' CYS . . . . . 0.553 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 33.0 t -96.41 163.31 13.11 Favored 'General case' 0 N--CA 1.466 0.341 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 -179.771 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.484 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 19.0 m-85 -129.86 125.47 22.15 Favored Pre-proline 0 N--CA 1.469 0.497 0 C-N-CA 121.147 -0.221 . . . . 0.0 110.73 -178.738 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_endo -74.3 159.81 43.1 Favored 'Trans proline' 0 N--CA 1.488 1.168 0 C-N-CA 121.812 1.674 . . . . 0.0 112.188 179.789 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -62.85 -28.04 69.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.693 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 98.9 m-85 -107.33 41.02 1.56 Allowed 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.71 -179.326 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 41.2 p90 -65.3 134.01 52.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.263 179.762 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 3.1 pt . . . . . 0 C--O 1.22 -0.498 0 CA-C-O 117.982 -1.008 . . . . 0.0 110.071 -179.844 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 64.0 mttp . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 44.8 t0 57.54 35.53 25.89 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.537 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 5.8 mm -98.77 127.87 50.91 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-O 120.955 0.407 . . . . 0.0 110.19 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -62.54 -39.32 93.22 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.773 -179.811 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 52.73 89.04 0.01 OUTLIER Glycine 0 C--O 1.23 -0.14 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.415 ' H ' ' HD2' ' A' ' 6' ' ' ARG . 0.0 OUTLIER -128.54 23.61 5.86 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.581 -0.31 . . . . 0.0 110.617 -179.789 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.694 ' H ' ' CD ' ' A' ' 7' ' ' LYS . 0.0 OUTLIER -109.11 144.97 30.79 Favored Pre-proline 0 N--CA 1.471 0.619 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.825 -179.936 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.435 ' CB ' ' O ' ' A' ' 49' ' ' CYS . 74.2 Cg_endo -71.58 161.67 44.62 Favored 'Trans proline' 0 N--CA 1.493 1.494 0 C-N-CA 122.215 1.943 . . . . 0.0 111.909 179.217 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.651 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.4 tt -135.55 119.68 17.66 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-O 120.764 0.316 . . . . 0.0 110.725 -179.312 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.651 ' N ' HD23 ' A' ' 9' ' ' LEU . 6.3 tt -88.97 133.43 34.32 Favored 'General case' 0 N--CA 1.464 0.255 0 N-CA-C 109.584 -0.525 . . . . 0.0 109.584 178.238 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.892 HD11 ' SG ' ' A' ' 47' ' ' CYS . 2.3 pt -109.62 -46.17 6.68 Favored 'Isoleucine or valine' 0 C--O 1.231 0.11 0 CA-C-O 120.835 0.35 . . . . 0.0 110.232 -178.716 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 179.46 -159.74 24.59 Favored Glycine 0 N--CA 1.452 -0.26 0 N-CA-C 111.276 -0.73 . . . . 0.0 111.276 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 68.7 p -100.99 164.09 11.98 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.193 -0.503 . . . . 0.0 110.245 179.755 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -59.12 -11.46 3.73 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.455 179.448 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 97.0 mt -70.35 -43.73 78.08 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 CA-C-O 121.159 0.505 . . . . 0.0 110.296 -179.693 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -98.05 -31.2 12.26 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.954 -179.402 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.779 ' CD2' HD12 ' A' ' 11' ' ' ILE . 13.9 m-85 -121.11 80.47 35.33 Favored Pre-proline 0 N--CA 1.469 0.52 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 178.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.433 ' O ' ' O ' ' A' ' 17' ' ' PHE . 75.3 Cg_exo -47.05 -178.9 0.0 OUTLIER 'Trans proline' 0 N--CA 1.495 1.583 0 C-N-CA 122.794 2.329 . . . . 0.0 111.747 -179.667 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 37.4 p -58.77 -54.71 44.04 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.418 0.628 . . . . 0.0 111.536 -179.278 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -55.74 -52.24 64.62 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.01 -0.996 . . . . 0.0 111.216 -179.685 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -63.64 -47.36 81.67 Favored 'General case' 0 CA--C 1.519 -0.215 0 CA-C-O 121.312 0.577 . . . . 0.0 110.534 -179.623 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 36.8 t -45.44 -63.18 1.01 Allowed 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 115.12 -0.945 . . . . 0.0 111.229 -179.233 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.458 ' OD1' ' N ' ' A' ' 24' ' ' LYS . 0.2 OUTLIER -64.36 -47.9 77.58 Favored 'General case' 0 C--O 1.221 -0.424 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.867 -178.953 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.458 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 83.4 mttt -48.73 -39.51 25.1 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.22 -179.675 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' THR . . . . . 0.434 ' O ' ' OG ' ' A' ' 29' ' ' SER . 16.7 m -64.9 -40.66 95.44 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.207 0.527 . . . . 0.0 110.112 -179.714 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.508 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 41.2 t -72.58 -36.3 68.13 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.409 0.623 . . . . 0.0 110.492 179.54 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.2 mm -64.62 -47.61 88.23 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.928 -179.097 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.411 ' C ' ' H ' ' A' ' 30' ' ' ASN . 2.9 pp20? -70.95 -27.52 63.8 Favored 'General case' 0 N--CA 1.446 -0.645 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.638 -179.504 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.477 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 72.8 m -67.17 0.66 2.55 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.611 -179.639 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.477 ' CB ' ' O ' ' A' ' 29' ' ' SER . 14.6 t-20 85.59 3.42 0.59 Allowed 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.534 179.781 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.578 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 47.5 m-85 -91.47 -167.79 1.88 Allowed 'General case' 0 N--CA 1.456 -0.169 0 CA-C-O 120.871 0.367 . . . . 0.0 110.525 179.608 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -78.34 -59.12 2.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.35 0.595 . . . . 0.0 111.756 -178.95 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.508 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 175.18 177.64 44.42 Favored Glycine 0 N--CA 1.449 -0.47 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -178.928 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.44 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -135.27 157.84 23.33 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -179.538 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 17.6 ptpt -149.62 166.96 27.71 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.915 0.388 . . . . 0.0 110.814 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 1.8 m -103.78 122.91 46.08 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.037 179.577 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 33.4 m -136.98 169.57 19.58 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.601 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 1.1 m80 -97.45 154.04 17.74 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.116 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.464 ' O ' ' N ' ' A' ' 41' ' ' GLN . 42.2 mm -115.03 128.69 72.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 42.32 -94.41 0.01 OUTLIER Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.933 -0.867 . . . . 0.0 110.933 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.464 ' N ' ' O ' ' A' ' 39' ' ' ILE . 88.4 mt-30 -140.72 27.5 2.03 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.654 0.264 . . . . 0.0 110.672 -179.768 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 58.8 m -80.2 -9.99 59.74 Favored 'General case' 0 CA--C 1.518 -0.254 0 CA-C-O 121.012 0.434 . . . . 0.0 110.665 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' LEU . . . . . 0.403 ' O ' ' CD2' ' A' ' 43' ' ' LEU . 0.9 OUTLIER 41.92 30.85 0.19 Allowed 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.38 -179.355 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' A' ' 45' ' ' PHE . 66.2 t0 -110.24 141.17 43.57 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.139 179.877 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.521 ' N ' ' OD1' ' A' ' 44' ' ' ASP . 56.8 m-85 -88.59 116.43 26.82 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.045 0.45 . . . . 0.0 110.312 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 19.8 m -114.62 133.53 60.45 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.307 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.28 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.892 ' SG ' HD11 ' A' ' 11' ' ' ILE . 27.9 t -93.58 114.67 27.07 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.317 179.859 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.8 p -125.03 139.83 49.93 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.229 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.029 -178.92 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' CYS . . . . . 0.578 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 39.2 t -97.27 157.33 16.01 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 115.517 -0.765 . . . . 0.0 109.716 -179.687 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.431 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 0.2 OUTLIER -149.93 151.62 32.65 Favored Pre-proline 0 N--CA 1.473 0.688 0 C-N-CA 120.593 -0.443 . . . . 0.0 110.933 179.775 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_endo -70.95 165.33 32.66 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 C-N-CA 122.686 2.257 . . . . 0.0 111.956 178.851 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -71.79 -20.89 61.79 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.591 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -109.17 40.14 1.9 Allowed 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.676 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' TYR . . . . . 0.403 ' O ' HG23 ' A' ' 55' ' ' ILE . 89.8 t80 -75.48 100.29 4.47 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.025 179.802 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.403 HG23 ' O ' ' A' ' 54' ' ' TYR . 26.5 pt . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.402 -179.742 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 45.6 mmtt . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -99.22 7.22 45.92 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.388 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.5 tt -58.52 141.36 15.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.511 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ASP . . . . . 0.419 ' OD1' ' N ' ' A' ' 5' ' ' GLY . 1.3 p30 -63.29 -39.07 93.55 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 120.888 -0.325 . . . . 0.0 110.533 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.419 ' N ' ' OD1' ' A' ' 4' ' ' ASP . . . 79.97 -94.89 1.48 Allowed Glycine 0 C--N 1.329 0.189 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 179.748 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.425 ' H ' ' HD2' ' A' ' 6' ' ' ARG . 0.8 OUTLIER -126.61 37.89 4.22 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 110.172 -0.307 . . . . 0.0 110.172 -179.58 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 2.8 tppp? -120.17 126.54 26.78 Favored Pre-proline 0 CA--C 1.534 0.351 0 C-N-CA 121.083 -0.247 . . . . 0.0 111.394 -179.463 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -74.5 171.77 17.47 Favored 'Trans proline' 0 N--CA 1.489 1.246 0 C-N-CA 122.055 1.837 . . . . 0.0 111.647 179.142 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.662 HD23 ' N ' ' A' ' 10' ' ' LEU . 4.0 tt -133.74 119.75 19.69 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 120.78 0.324 . . . . 0.0 110.524 -179.751 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.662 ' N ' HD23 ' A' ' 9' ' ' LEU . 5.8 tt -91.03 130.75 36.91 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.978 0.418 . . . . 0.0 109.947 178.326 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.961 HD11 ' SG ' ' A' ' 47' ' ' CYS . 5.8 pt -106.37 -44.59 7.75 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.632 -179.624 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -176.12 -133.74 1.83 Allowed Glycine 0 CA--C 1.519 0.305 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 -179.593 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.436 ' C ' ' H ' ' A' ' 15' ' ' ILE . 80.7 p -131.56 166.19 21.94 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.925 0.393 . . . . 0.0 111.034 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -61.66 -3.85 1.22 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.974 179.5 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.436 ' H ' ' C ' ' A' ' 13' ' ' THR . 34.2 mm -70.85 -42.73 77.36 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 CA-C-O 121.224 0.535 . . . . 0.0 109.92 -179.562 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -108.24 -23.07 12.09 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.628 -0.715 . . . . 0.0 111.072 -179.568 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 44.7 m-85 -124.67 79.17 63.15 Favored Pre-proline 0 C--O 1.223 -0.292 0 CA-C-N 116.577 -0.283 . . . . 0.0 110.553 179.687 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 71.4 Cg_exo -49.05 -179.01 0.01 OUTLIER 'Trans proline' 0 N--CA 1.501 1.93 0 C-N-CA 123.137 2.558 . . . . 0.0 111.733 179.457 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.604 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 96.2 m -58.22 -50.38 73.75 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 112.321 0.489 . . . . 0.0 112.321 -178.795 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.68 ' HA ' HD22 ' A' ' 23' ' ' ASN . 6.6 pt-20 -56.57 -57.21 13.34 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.771 0.32 . . . . 0.0 111.257 -179.137 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.578 ' O ' HG22 ' A' ' 25' ' ' THR . 18.7 mtmt -62.91 -44.99 94.58 Favored 'General case' 0 CA--C 1.509 -0.604 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.377 -179.718 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.409 ' O ' ' SG ' ' A' ' 26' ' ' CYS . 53.2 t -47.64 -46.43 28.81 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-O 121.233 0.54 . . . . 0.0 111.235 -178.292 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.68 HD22 ' HA ' ' A' ' 20' ' ' GLU . 13.6 p30 -78.92 -53.11 7.39 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 120.483 -0.487 . . . . 0.0 110.39 179.305 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.584 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 29.7 mttp -50.71 -45.04 58.28 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.646 -0.422 . . . . 0.0 110.734 -178.004 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' THR . . . . . 0.578 HG22 ' O ' ' A' ' 21' ' ' LYS . 11.6 t -64.81 -37.86 89.04 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 121.391 0.615 . . . . 0.0 109.845 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.409 ' SG ' ' O ' ' A' ' 22' ' ' CYS . 54.8 m -63.61 -33.75 76.3 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.32 179.299 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.454 HG12 ' O ' ' A' ' 23' ' ' ASN . 3.3 mm -63.26 -36.86 77.75 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.054 179.728 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 29.0 mt-10 -66.1 -34.6 78.42 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.809 -178.639 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.411 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 7.1 m -72.59 -2.37 19.66 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.446 -179.173 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.411 ' CB ' ' O ' ' A' ' 29' ' ' SER . 2.9 m120 78.31 33.68 0.3 Allowed 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.732 -179.88 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.581 ' C ' ' H ' ' A' ' 33' ' ' GLY . 8.0 m-85 -109.35 162.34 14.42 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.114 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.63 26.75 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.745 179.619 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.581 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 87.0 -174.92 46.23 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 110.739 -0.944 . . . . 0.0 110.739 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.425 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -151.67 172.04 31.12 Favored Glycine 0 CA--C 1.52 0.348 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 -179.313 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 20.0 pttt -156.27 -179.28 8.01 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.037 0.446 . . . . 0.0 110.63 -179.535 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 4.0 m -107.76 125.71 51.73 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.12 179.158 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 20.2 m -141.13 174.19 7.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.325 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.64 ' NE2' ' CE1' ' A' ' 45' ' ' PHE . 38.2 m80 -105.67 152.42 23.16 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.477 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 96.7 mt -129.8 125.58 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.477 179.497 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 66.46 21.66 70.74 Favored Glycine 0 CA--C 1.52 0.39 0 N-CA-C 111.339 -0.705 . . . . 0.0 111.339 179.126 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 58.24 38.08 26.14 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.933 0.396 . . . . 0.0 110.586 -179.818 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 44.1 m -82.26 -11.23 58.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.015 -179.847 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' LEU . . . . . 0.409 ' O ' ' CD2' ' A' ' 43' ' ' LEU . 0.8 OUTLIER 68.24 27.99 6.52 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.258 -179.607 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -111.7 135.49 52.23 Favored 'General case' 0 N--CA 1.463 0.188 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 179.262 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.64 ' CE1' ' NE2' ' A' ' 38' ' ' HIS . 52.6 m-85 -91.71 116.15 28.64 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.419 ' O ' HG23 ' A' ' 46' ' ' VAL . 13.2 m -112.9 133.7 57.88 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.272 0 CA-C-N 115.964 -0.562 . . . . 0.0 109.807 -179.824 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.961 ' SG ' HD11 ' A' ' 11' ' ' ILE . 34.6 t -92.48 115.35 28.02 Favored 'General case' 0 CA--C 1.511 -0.536 0 CA-C-N 116.167 -0.47 . . . . 0.0 109.842 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.2 p -134.36 148.58 29.75 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.412 0 CA-C-O 121.118 0.485 . . . . 0.0 110.861 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 6.6 m -97.59 161.66 13.66 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.505 179.729 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 53.0 m-85 -116.84 147.96 41.09 Favored Pre-proline 0 N--CA 1.464 0.259 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.028 -179.326 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -65.92 154.42 74.04 Favored 'Trans proline' 0 N--CA 1.492 1.42 0 C-N-CA 122.405 2.07 . . . . 0.0 111.895 179.298 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 56.8 mtpt -63.76 -21.51 66.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.046 0.451 . . . . 0.0 110.302 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -108.95 40.58 1.78 Allowed 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.56 -179.763 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 46.3 p90 -65.3 134.93 54.67 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.195 179.777 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.2 pt . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 118.06 -0.971 . . . . 0.0 109.983 -179.883 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 72.3 mmtt . . . . . 0 N--CA 1.492 1.663 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ASP . . . . . 0.432 ' OD1' ' O ' ' A' ' 2' ' ' ASP . 47.9 t0 58.33 37.19 25.94 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.258 -179.552 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.602 ' O ' HD12 ' A' ' 3' ' ' ILE . 1.3 pp -123.53 163.37 22.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.006 -179.198 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ASP . . . . . 0.482 ' OD1' ' N ' ' A' ' 5' ' ' GLY . 42.0 p-10 -74.93 -34.72 62.15 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.537 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.482 ' N ' ' OD1' ' A' ' 4' ' ' ASP . . . -77.91 71.75 2.35 Favored Glycine 0 CA--C 1.52 0.369 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 -179.609 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.21 31.04 4.15 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.879 0.371 . . . . 0.0 110.181 -178.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.506 ' CB ' ' NZ ' ' A' ' 7' ' ' LYS . 0.0 OUTLIER -105.12 147.15 34.03 Favored Pre-proline 0 CA--C 1.533 0.31 0 C-N-CA 120.597 -0.441 . . . . 0.0 110.645 179.577 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -68.35 166.48 25.28 Favored 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 122.865 2.377 . . . . 0.0 111.947 179.403 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.65 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.9 tt -136.67 117.31 13.91 Favored 'General case' 0 CA--C 1.52 -0.196 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.543 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.65 ' N ' HD23 ' A' ' 9' ' ' LEU . 8.8 tt -92.8 131.95 37.4 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 179.21 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 10.2 pt -104.18 -36.9 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.281 -179.285 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -177.31 -127.62 1.07 Allowed Glycine 0 CA--C 1.517 0.163 0 N-CA-C 110.674 -0.971 . . . . 0.0 110.674 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.496 ' C ' ' H ' ' A' ' 15' ' ' ILE . 71.5 p -127.77 154.42 45.4 Favored 'General case' 0 CA--C 1.52 -0.189 0 CA-C-O 120.861 0.363 . . . . 0.0 110.479 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 6.6 t -66.3 6.67 0.39 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.521 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.496 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.7 mt -86.58 -40.97 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.138 0 CA-C-O 120.86 0.362 . . . . 0.0 110.143 -179.858 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -102.41 -5.48 24.07 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.978 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 51.2 m-85 -123.5 79.87 54.38 Favored Pre-proline 0 N--CA 1.465 0.293 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.847 179.57 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -47.77 168.01 0.09 OUTLIER 'Trans proline' 0 N--CA 1.495 1.572 0 C-N-CA 122.963 2.442 . . . . 0.0 111.866 179.164 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.436 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 10.0 m -49.78 -52.85 28.93 Favored 'General case' 0 C--N 1.326 -0.425 0 C-N-CA 120.642 -0.423 . . . . 0.0 111.62 -178.806 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.648 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 1.3 pm0 -61.91 -56.96 13.85 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.081 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -56.6 -45.13 81.6 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 121.046 0.451 . . . . 0.0 110.69 -178.201 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 12.4 t -47.75 -65.46 0.56 Allowed 'General case' 0 C--N 1.314 -0.978 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.011 -178.923 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.656 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 2.4 p-10 -62.51 -54.43 40.09 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.339 -179.756 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.656 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 43.8 mtpt -44.53 -43.91 8.31 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 120.546 -0.462 . . . . 0.0 110.853 -179.698 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 99.3 m -64.13 -39.62 94.42 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-O 121.495 0.664 . . . . 0.0 109.875 -179.651 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 58.5 m -67.42 -32.59 73.58 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.698 -179.681 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.3 mm -63.14 -43.63 98.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.518 -179.396 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -65.31 -35.63 81.59 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.42 -178.888 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.445 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 84.0 p -67.12 -3.41 7.43 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.459 -179.325 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.445 ' CB ' ' O ' ' A' ' 29' ' ' SER . 3.2 t-20 80.52 37.14 0.1 Allowed 'General case' 0 N--CA 1.466 0.358 0 O-C-N 123.478 0.486 . . . . 0.0 110.783 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.585 ' C ' ' H ' ' A' ' 33' ' ' GLY . 13.9 m-85 -119.54 160.7 21.91 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 120.993 0.425 . . . . 0.0 110.084 -179.843 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -68.96 27.99 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.584 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.585 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 87.06 -172.92 44.24 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 179.829 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -154.04 174.48 32.52 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.731 -0.947 . . . . 0.0 110.731 -179.437 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 11.6 ptmt -155.89 -178.7 7.49 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.806 0.336 . . . . 0.0 110.507 -179.459 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 69.0 m -105.28 127.72 53.09 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.23 179.359 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 32.5 m -135.59 161.34 39.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.101 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 3.3 p80 -108.9 157.23 18.82 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.295 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.414 ' O ' ' N ' ' A' ' 41' ' ' GLN . 32.8 mm -104.59 122.42 57.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.328 -179.748 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 40.56 -96.47 0.01 OUTLIER Glycine 0 CA--C 1.524 0.634 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.85 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.414 ' N ' ' O ' ' A' ' 39' ' ' ILE . 97.5 mt-30 -139.65 30.47 2.1 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 120.675 0.274 . . . . 0.0 110.525 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 16.8 m -80.78 -6.22 58.21 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.138 0.494 . . . . 0.0 110.738 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' LEU . . . . . 0.443 HD22 ' HA ' ' A' ' 43' ' ' LEU . 0.2 OUTLIER 50.07 28.57 3.05 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.549 -179.702 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 38.7 t0 -109.43 120.79 43.59 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.112 179.594 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 70.6 m-85 -88.74 129.03 35.63 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-O 120.962 0.41 . . . . 0.0 109.919 -179.771 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 33.1 m -124.06 142.31 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.42 -179.359 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -95.25 119.84 34.45 Favored 'General case' 0 CA--C 1.518 -0.27 0 N-CA-C 109.211 -0.662 . . . . 0.0 109.211 -179.803 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.1 p -134.38 149.46 29.98 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.358 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.715 -179.195 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 14.1 m -98.69 177.97 5.14 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.79 179.741 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -137.28 121.12 11.95 Favored Pre-proline 0 CA--C 1.537 0.461 0 C-N-CA 120.82 -0.352 . . . . 0.0 111.035 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -66.7 146.86 80.27 Favored 'Trans proline' 0 N--CA 1.495 1.61 0 C-N-CA 122.626 2.217 . . . . 0.0 111.916 -179.744 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -119.28 -58.05 1.95 Allowed 'General case' 0 N--CA 1.465 0.294 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 179.708 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 7.4 p90 -131.81 19.22 4.63 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.589 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 25.8 t80 -64.51 141.26 58.84 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 110.086 -0.339 . . . . 0.0 110.086 -178.951 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.7 mt . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 118.039 -0.981 . . . . 0.0 110.41 -179.695 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 53.9 mtmt . . . . . 0 N--CA 1.489 1.504 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 56.88 35.01 25.73 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.847 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.432 HG22 ' N ' ' A' ' 5' ' ' GLY . 5.2 mm -111.91 130.62 65.21 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 CA-C-O 121.202 0.525 . . . . 0.0 110.488 179.801 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -63.92 -36.81 85.16 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.36 -0.836 . . . . 0.0 110.22 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.432 ' N ' HG22 ' A' ' 3' ' ' ILE . . . 69.17 60.23 5.32 Favored Glycine 0 C--N 1.331 0.254 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.811 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.42 ' H ' ' HD2' ' A' ' 6' ' ' ARG . 0.0 OUTLIER -126.48 29.05 5.83 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.66 0.267 . . . . 0.0 110.534 -179.637 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 23.5 pttt -131.45 146.02 60.12 Favored Pre-proline 0 N--CA 1.462 0.152 0 C-N-CA 120.989 -0.284 . . . . 0.0 111.184 -179.431 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -65.69 149.28 87.27 Favored 'Trans proline' 0 N--CA 1.491 1.325 0 C-N-CA 122.42 2.08 . . . . 0.0 111.642 179.512 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.733 HD13 ' N ' ' A' ' 10' ' ' LEU . 0.4 OUTLIER -125.05 122.78 38.23 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-O 121.258 0.551 . . . . 0.0 110.798 179.781 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.733 ' N ' HD13 ' A' ' 9' ' ' LEU . 5.9 tt -86.01 147.7 26.09 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.45 178.371 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -126.74 -58.96 1.58 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.569 -178.956 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -160.2 -140.1 2.82 Favored Glycine 0 CA--C 1.519 0.294 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.35 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.443 ' C ' ' H ' ' A' ' 15' ' ' ILE . 43.5 p -131.5 160.12 36.15 Favored 'General case' 0 CA--C 1.518 -0.261 0 CA-C-O 121.006 0.431 . . . . 0.0 110.857 -179.79 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -52.63 -11.2 0.19 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.066 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.443 ' H ' ' C ' ' A' ' 13' ' ' THR . 39.0 mm -72.3 -43.12 65.45 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 CA-C-O 121.158 0.504 . . . . 0.0 110.288 -179.398 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 1.9 pt-20 -102.27 -31.36 10.58 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.39 -0.823 . . . . 0.0 110.945 -179.531 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 15.6 m-85 -120.94 82.78 36.44 Favored Pre-proline 0 N--CA 1.466 0.339 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.128 179.73 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo -48.46 -179.14 0.01 OUTLIER 'Trans proline' 0 N--CA 1.493 1.487 0 C-N-CA 122.807 2.338 . . . . 0.0 111.965 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.431 ' OG1' ' OE2' ' A' ' 20' ' ' GLU . 28.6 p -57.27 -52.31 65.84 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 120.942 0.401 . . . . 0.0 111.557 -179.336 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.631 ' CD ' ' H ' ' A' ' 20' ' ' GLU . 0.2 OUTLIER -58.94 -57.84 11.3 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.474 -179.88 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -59.14 -43.94 92.05 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.736 -178.505 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.1 t -48.11 -60.97 2.22 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.881 -179.271 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.73 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.3 p-10 -62.59 -51.56 66.85 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.453 -179.631 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.73 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 31.7 mttp -47.36 -41.21 19.18 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.873 0.368 . . . . 0.0 110.168 -179.403 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 20.1 m -62.11 -43.9 97.81 Favored 'General case' 0 C--N 1.314 -0.939 0 C-N-CA 120.294 -0.563 . . . . 0.0 110.104 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 5.1 t -65.23 -32.68 74.48 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 179.645 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.5 mm -68.27 -31.71 52.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.538 -179.468 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 30.7 mm-40 -67.92 -34.99 77.68 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.762 -179.504 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.417 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 31.2 m -70.73 1.25 5.6 Favored 'General case' 0 CA--C 1.514 -0.408 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.944 -179.647 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.417 ' CB ' ' O ' ' A' ' 29' ' ' SER . 4.1 m-20 78.19 25.95 0.59 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.618 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.554 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 5.4 m-85 -103.29 -168.68 1.54 Allowed 'General case' 0 N--CA 1.452 -0.326 0 CA-C-O 120.952 0.406 . . . . 0.0 110.226 -179.744 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -76.2 -49.3 17.54 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.586 -179.596 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.496 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 160.54 -175.25 37.29 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 -179.478 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.427 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -148.03 170.4 28.67 Favored Glycine 0 C--O 1.226 -0.374 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -179.05 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 11.2 ptmt -158.68 -179.97 8.56 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.775 0.321 . . . . 0.0 110.525 -179.575 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 23.3 m -105.31 127.65 53.06 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.502 179.139 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 17.7 m -137.58 164.55 28.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.499 179.672 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 3.3 p-80 -103.64 155.84 18.25 Favored 'General case' 0 N--CA 1.462 0.153 0 CA-C-O 121.002 0.429 . . . . 0.0 110.223 179.775 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 97.0 mt -131.37 128.59 61.51 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.627 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 60.4 23.36 60.15 Favored Glycine 0 CA--C 1.52 0.35 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 179.343 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 87.5 mt-30 56.43 30.9 17.82 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 120.881 0.372 . . . . 0.0 110.573 -179.874 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 4.0 m -78.64 -7.2 57.41 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.767 -179.701 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' LEU . . . . . 0.422 HD22 ' HA ' ' A' ' 43' ' ' LEU . 0.2 OUTLIER 68.92 27.84 5.43 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.559 -179.641 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 40.3 t0 -107.44 118.49 36.86 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.091 179.65 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 3.3 m-30 -91.07 115.89 28.37 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-O 121.225 0.536 . . . . 0.0 109.705 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 28.3 m -113.95 142.34 26.89 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.301 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.097 -179.471 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 24.2 t -94.33 119.0 32.45 Favored 'General case' 0 CA--C 1.516 -0.333 0 CA-C-N 116.024 -0.535 . . . . 0.0 109.771 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 10.7 p -128.81 151.33 35.44 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.409 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.392 -179.423 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' CYS . . . . . 0.557 ' SG ' ' N ' ' A' ' 50' ' ' PHE . 33.0 t -96.52 164.83 12.45 Favored 'General case' 0 CA--C 1.514 -0.435 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 -179.634 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.557 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 37.2 m-85 -132.25 131.93 22.67 Favored Pre-proline 0 N--CA 1.465 0.284 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.136 -179.068 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.78 155.82 57.81 Favored 'Trans proline' 0 N--CA 1.489 1.237 0 C-N-CA 122.068 1.845 . . . . 0.0 112.122 179.541 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -63.9 -27.92 69.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.631 179.543 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 99.7 m-85 -107.38 41.88 1.42 Allowed 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.751 -179.331 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 92.0 t80 -68.34 131.4 45.26 Favored 'General case' 0 N--CA 1.455 -0.209 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.286 179.694 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.9 pt . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 118.101 -0.952 . . . . 0.0 110.28 -179.93 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 52.6 mtmt . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 54.6 t0 -69.54 -7.43 38.34 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.464 179.897 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 22.5 mm -79.27 96.63 2.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.221 -179.766 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 67.8 t0 -63.09 -43.08 99.51 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.503 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 52.94 71.29 0.71 Allowed Glycine 0 C--O 1.229 -0.18 0 N-CA-C 110.847 -0.901 . . . . 0.0 110.847 179.647 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.06 22.82 4.89 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.814 -0.193 . . . . 0.0 110.737 -179.839 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.35 153.92 53.8 Favored Pre-proline 0 N--CA 1.47 0.571 0 C-N-CA 121.116 -0.233 . . . . 0.0 111.378 -179.29 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_exo -57.81 144.46 93.54 Favored 'Trans proline' 0 N--CA 1.496 1.655 0 C-N-CA 121.527 1.484 . . . . 0.0 111.783 178.683 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.634 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.7 tt -122.87 117.17 24.99 Favored 'General case' 0 N--CA 1.476 0.874 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.294 179.41 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.656 HD23 ' N ' ' A' ' 11' ' ' ILE . 6.6 tt -95.11 127.48 41.19 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 179.187 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.812 HD11 ' SG ' ' A' ' 47' ' ' CYS . 1.3 pt -103.51 -51.42 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-O 120.779 0.323 . . . . 0.0 110.831 -179.014 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.431 ' H ' HG13 ' A' ' 11' ' ' ILE . . . -160.27 -136.45 2.02 Favored Glycine 0 N--CA 1.451 -0.316 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -179.879 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.5 p -132.1 170.96 14.24 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.1 0.476 . . . . 0.0 110.415 -179.416 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -67.9 -1.86 6.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.332 -179.326 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 2.4 pp -78.2 -20.99 13.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.236 -179.731 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -131.91 -28.94 1.72 Allowed 'General case' 0 C--O 1.233 0.214 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.621 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 42.3 m-85 -116.3 81.77 11.06 Favored Pre-proline 0 CA--C 1.534 0.331 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.367 179.239 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.436 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 16.8 Cg_endo -59.35 -176.41 0.11 Allowed 'Trans proline' 0 N--CA 1.5 1.861 0 C-N-CA 122.449 2.099 . . . . 0.0 112.17 -179.644 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.597 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 83.3 m -58.89 -49.55 77.36 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.678 -0.409 . . . . 0.0 111.299 -179.347 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.55 ' HA ' HD22 ' A' ' 23' ' ' ASN . 8.0 pt-20 -55.57 -59.59 4.62 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.616 -179.516 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.493 ' H ' ' CG ' ' A' ' 20' ' ' GLU . 17.3 mtpp -64.68 -48.39 74.92 Favored 'General case' 0 CA--C 1.512 -0.501 0 CA-C-O 121.084 0.468 . . . . 0.0 111.818 -179.43 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.436 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 34.8 t -43.02 -52.51 5.24 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.106 -177.641 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.597 ' ND2' ' O ' ' A' ' 19' ' ' THR . 18.2 p30 -65.05 -44.51 88.78 Favored 'General case' 0 C--O 1.22 -0.474 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.783 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.576 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 89.1 mttt -50.72 -40.79 55.15 Favored 'General case' 0 CA--C 1.509 -0.609 0 C-N-CA 120.294 -0.562 . . . . 0.0 110.321 -179.575 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 70.0 p -63.2 -41.53 99.18 Favored 'General case' 0 C--N 1.313 -1.0 0 C-N-CA 119.179 -1.008 . . . . 0.0 110.376 -179.079 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.524 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 19.5 t -68.09 -34.1 75.76 Favored 'General case' 0 C--N 1.322 -0.587 0 C-N-CA 120.176 -0.61 . . . . 0.0 109.896 179.733 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.3 mm -66.3 -41.55 89.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.72 -179.258 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.418 ' C ' ' H ' ' A' ' 30' ' ' ASN . 40.2 mm-40 -64.13 -34.97 79.27 Favored 'General case' 0 N--CA 1.444 -0.746 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.654 -179.409 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.414 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 78.1 p -68.44 1.92 2.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.221 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.418 ' H ' ' C ' ' A' ' 28' ' ' GLU . 16.4 t-20 78.05 19.67 1.04 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.623 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.552 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 4.5 m-85 -98.32 -168.23 1.62 Allowed 'General case' 0 CA--C 1.53 0.191 0 CA-C-O 120.938 0.399 . . . . 0.0 110.351 -179.833 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -74.93 -53.26 9.32 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.791 -179.01 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.524 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 165.42 -178.51 40.3 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.151 -1.179 . . . . 0.0 110.151 -179.251 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.457 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -141.07 167.85 25.54 Favored Glycine 0 CA--C 1.519 0.293 0 N-CA-C 111.274 -0.73 . . . . 0.0 111.274 -179.219 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 15.0 ptpt -158.09 178.06 10.62 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.095 0.474 . . . . 0.0 110.401 -179.311 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 3.2 m -105.39 120.3 41.24 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.866 179.159 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 33.0 m -132.17 161.22 41.75 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.102 -179.888 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 5.5 p-80 -107.07 157.14 18.06 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.184 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.512 ' O ' ' N ' ' A' ' 41' ' ' GLN . 33.2 mm -106.46 124.79 62.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.049 -179.549 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 43.34 -91.12 0.01 OUTLIER Glycine 0 C--N 1.33 0.205 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.512 ' N ' ' O ' ' A' ' 39' ' ' ILE . 42.0 tp60 -148.46 37.66 0.84 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.812 0.339 . . . . 0.0 110.436 -179.577 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 71.0 m -87.98 -2.39 58.58 Favored 'General case' 0 CA--C 1.519 -0.235 0 CA-C-O 121.042 0.449 . . . . 0.0 110.613 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 45.81 28.99 0.64 Allowed 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.551 179.522 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 68.3 t0 -108.88 119.32 39.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.919 179.455 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 81.3 m-85 -88.56 118.45 28.22 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.721 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 31.1 m -114.88 143.05 25.46 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.35 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.259 -179.406 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.812 ' SG ' HD11 ' A' ' 11' ' ' ILE . 18.4 t -94.07 117.88 30.73 Favored 'General case' 0 CA--C 1.513 -0.455 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.459 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.7 p -129.07 152.96 37.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-O 120.708 0.29 . . . . 0.0 110.306 -179.689 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' CYS . . . . . 0.552 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 17.2 t -96.83 164.94 12.34 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.547 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 38.1 m-85 -132.34 136.31 27.82 Favored Pre-proline 0 N--CA 1.468 0.474 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.842 -179.319 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -67.13 158.1 58.55 Favored 'Trans proline' 0 N--CA 1.495 1.571 0 C-N-CA 121.945 1.763 . . . . 0.0 112.391 179.903 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -51.65 -79.25 0.02 OUTLIER 'General case' 0 C--N 1.333 -0.141 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.655 -179.124 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 58.9 m-85 -130.55 39.2 3.65 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.764 -179.815 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -108.98 127.66 54.26 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 120.922 0.391 . . . . 0.0 110.132 -179.682 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.5 mp . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.268 -179.836 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 18.2 pttp . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 51.3 t0 -63.79 -32.74 74.35 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.903 -0.589 . . . . 0.0 109.955 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 23.4 mm -53.49 100.16 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.59 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 66.8 t0 -63.75 -39.71 94.94 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.397 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 55.05 69.52 1.24 Allowed Glycine 0 C--N 1.329 0.161 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 179.819 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.423 ' HD3' ' H ' ' A' ' 6' ' ' ARG . 0.0 OUTLIER -130.08 18.67 5.49 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.488 0.185 . . . . 0.0 110.629 -179.42 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 2.6 pttm -132.46 147.08 64.22 Favored Pre-proline 0 N--CA 1.465 0.317 0 CA-C-N 116.62 -0.264 . . . . 0.0 110.99 -179.476 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -67.8 164.08 32.87 Favored 'Trans proline' 0 N--CA 1.494 1.539 0 C-N-CA 122.488 2.125 . . . . 0.0 111.885 179.264 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.635 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.8 tt -138.3 118.02 13.14 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.273 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.663 HD23 ' N ' ' A' ' 11' ' ' ILE . 6.8 tt -92.68 130.87 38.18 Favored 'General case' 0 N--CA 1.465 0.305 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 178.893 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.899 HD11 ' SG ' ' A' ' 47' ' ' CYS . 1.5 pt -107.09 -50.18 7.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-O 120.917 0.389 . . . . 0.0 110.294 -178.78 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -163.35 -162.99 15.04 Favored Glycine 0 N--CA 1.449 -0.491 0 N-CA-C 110.754 -0.938 . . . . 0.0 110.754 179.689 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.5 p -83.93 163.07 20.24 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.829 0.347 . . . . 0.0 110.12 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 48.3 t -71.2 2.79 4.18 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.331 179.703 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 86.8 mt -91.08 -52.48 10.26 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.217 0 CA-C-N 116.234 -0.439 . . . . 0.0 109.826 179.717 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLU . . . . . 0.464 ' OE1' ' CE2' ' A' ' 17' ' ' PHE . 7.5 pt-20 -70.82 -35.45 72.5 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.16 179.113 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.464 ' CE2' ' OE1' ' A' ' 16' ' ' GLU . 59.9 m-85 -114.96 104.61 53.94 Favored Pre-proline 0 CA--C 1.544 0.738 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.44 179.92 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.457 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 56.9 Cg_endo -74.23 -179.8 5.08 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 C-N-CA 123.043 2.495 . . . . 0.0 111.752 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 70.8 m -57.38 -49.12 77.18 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.576 -179.613 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -54.63 -58.24 8.27 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.574 -0.285 . . . . 0.0 111.592 -179.477 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 5.7 ttmt -67.44 -56.65 8.74 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.385 0.612 . . . . 0.0 111.606 -179.145 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.457 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 48.1 t -38.64 -61.51 0.7 Allowed 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.241 -0.89 . . . . 0.0 111.4 -178.786 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.474 ' OD1' ' N ' ' A' ' 24' ' ' LYS . 0.3 OUTLIER -63.42 -49.09 75.13 Favored 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.435 -179.874 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.474 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 51.3 mttm -47.46 -37.73 12.26 Favored 'General case' 0 CA--C 1.515 -0.399 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.218 -179.721 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 98.4 m -63.8 -41.74 97.84 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.342 0.591 . . . . 0.0 109.775 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.452 ' SG ' ' C ' ' A' ' 33' ' ' GLY . 40.2 t -72.13 -34.71 68.76 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.585 0.707 . . . . 0.0 109.999 179.311 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.5 mm -65.33 -48.08 84.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.144 -179.282 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.463 ' C ' ' H ' ' A' ' 30' ' ' ASN . 3.0 pp20? -70.31 -29.01 65.63 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.554 -179.656 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.452 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 24.4 m -65.2 0.89 1.17 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.198 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.537 ' O ' ' NZ ' ' A' ' 52' ' ' LYS . 0.2 OUTLIER 81.05 14.53 0.64 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.435 179.804 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.569 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 5.2 m-85 -100.19 -167.72 1.49 Allowed 'General case' 0 C--N 1.339 0.144 0 CA-C-O 120.76 0.314 . . . . 0.0 110.204 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -76.18 -55.38 5.63 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.141 0.496 . . . . 0.0 111.859 -179.196 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.452 ' C ' ' SG ' ' A' ' 26' ' ' CYS . . . 168.56 173.29 36.27 Favored Glycine 0 CA--C 1.519 0.337 0 N-CA-C 110.318 -1.113 . . . . 0.0 110.318 -179.135 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.448 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -134.59 161.02 24.42 Favored Glycine 0 N--CA 1.46 0.237 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 -179.341 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 2.1 ptmm? -160.06 -174.77 4.72 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.966 0.412 . . . . 0.0 110.69 -178.89 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 30.7 m -104.67 120.09 40.52 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.831 179.361 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 2.6 m -137.79 166.29 24.65 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-O 121.113 0.482 . . . . 0.0 110.896 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -108.85 157.29 18.74 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.403 179.291 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 83.9 mt -122.58 128.64 75.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.551 -179.358 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 52.85 -126.1 31.84 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.481 -1.048 . . . . 0.0 110.481 179.766 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -111.33 27.64 9.48 Favored 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 110.381 -0.229 . . . . 0.0 110.381 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' SER . . . . . 0.497 ' O ' ' N ' ' A' ' 44' ' ' ASP . 52.0 m -85.14 -11.26 55.53 Favored 'General case' 0 CA--C 1.52 -0.199 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.914 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' LEU . . . . . 0.433 HD22 ' HA ' ' A' ' 43' ' ' LEU . 0.2 OUTLIER 36.79 28.26 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.063 -179.687 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 44' ' ' ASP . . . . . 0.497 ' N ' ' O ' ' A' ' 42' ' ' SER . 45.1 t0 -99.78 124.47 45.09 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.278 -179.903 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -85.72 124.55 32.36 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 -179.65 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 32.6 m -129.9 153.76 39.35 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.444 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.145 -179.348 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.899 ' SG ' HD11 ' A' ' 11' ' ' ILE . 34.9 t -93.75 116.43 28.91 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.436 -179.77 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.9 p -131.64 154.39 40.32 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.325 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.499 -178.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' CYS . . . . . 0.572 ' SG ' ' N ' ' A' ' 50' ' ' PHE . 16.4 t -97.42 164.49 12.43 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 179.833 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.572 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 29.6 m-85 -130.7 121.79 19.29 Favored Pre-proline 0 N--CA 1.465 0.321 0 C-N-CA 120.931 -0.307 . . . . 0.0 111.247 -178.68 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -72.62 160.2 47.04 Favored 'Trans proline' 0 N--CA 1.491 1.343 0 C-N-CA 121.721 1.614 . . . . 0.0 112.058 179.274 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.537 ' NZ ' ' O ' ' A' ' 30' ' ' ASN . 64.2 mttp -67.93 -16.57 64.12 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.478 179.803 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -109.08 41.45 1.62 Allowed 'General case' 0 N--CA 1.468 0.436 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.777 -179.801 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 88.1 t80 -86.07 96.33 9.83 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.778 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 16.1 mm . . . . . 0 C--O 1.22 -0.465 0 CA-C-O 118.022 -0.99 . . . . 0.0 110.43 -179.597 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 53.1 mtmt . . . . . 0 N--CA 1.491 1.608 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -86.53 9.81 17.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.633 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 29.5 mm -80.44 118.5 28.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.208 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 54.8 t0 -66.03 -41.15 91.28 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.639 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 49.89 69.26 1.1 Allowed Glycine 0 CA--C 1.518 0.235 0 N-CA-C 111.021 -0.832 . . . . 0.0 111.021 179.775 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.491 ' NE ' ' OH ' ' A' ' 54' ' ' TYR . 0.0 OUTLIER -132.46 37.96 3.48 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.758 0.313 . . . . 0.0 110.987 -179.865 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.506 ' N ' ' CD ' ' A' ' 8' ' ' PRO . 2.5 tppp? -125.43 50.41 4.34 Favored Pre-proline 0 N--CA 1.465 0.294 0 CA-C-O 120.855 0.36 . . . . 0.0 110.708 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.506 ' CD ' ' N ' ' A' ' 7' ' ' LYS . 33.9 Cg_endo -64.93 159.0 48.35 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.824 2.349 . . . . 0.0 111.21 178.987 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.65 HD23 ' N ' ' A' ' 10' ' ' LEU . 4.0 tt -132.38 119.23 20.41 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.265 -179.615 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.65 ' N ' HD23 ' A' ' 9' ' ' LEU . 7.7 tt -93.5 127.33 39.1 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 178.959 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.92 HD11 ' SG ' ' A' ' 47' ' ' CYS . 3.1 pt -103.38 -46.14 10.32 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.412 -179.036 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -170.06 -138.01 2.4 Favored Glycine 0 CA--C 1.521 0.451 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.485 ' C ' ' H ' ' A' ' 15' ' ' ILE . 70.0 p -133.21 163.73 28.63 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.843 0.354 . . . . 0.0 110.902 -179.437 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -57.87 -4.79 0.34 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.97 179.674 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.485 ' H ' ' C ' ' A' ' 13' ' ' THR . 95.8 mt -73.24 -24.18 20.43 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 CA-C-O 121.01 0.433 . . . . 0.0 110.136 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -130.55 -32.06 1.75 Allowed 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.741 -179.614 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 53.7 m-85 -114.65 88.88 17.07 Favored Pre-proline 0 CA--C 1.54 0.568 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 179.36 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.455 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 43.4 Cg_endo -70.17 -178.04 2.31 Favored 'Trans proline' 0 N--CA 1.499 1.809 0 C-N-CA 122.91 2.406 . . . . 0.0 111.968 -179.509 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.605 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 7.1 m -45.93 -68.62 0.18 Allowed 'General case' 0 C--N 1.319 -0.757 0 C-N-CA 120.826 -0.35 . . . . 0.0 111.442 -179.275 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.645 ' CD ' ' H ' ' A' ' 20' ' ' GLU . 0.0 OUTLIER -44.36 -68.14 0.22 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.46 -0.337 . . . . 0.0 111.718 -178.794 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 6.9 ttmt -54.66 -51.63 64.86 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.039 0.447 . . . . 0.0 111.562 -178.043 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.455 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 45.3 t -46.03 -64.97 0.62 Allowed 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.368 -179.3 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.605 ' ND2' ' O ' ' A' ' 19' ' ' THR . 16.8 p30 -61.86 -45.16 94.99 Favored 'General case' 0 C--O 1.22 -0.464 0 C-N-CA 120.721 -0.392 . . . . 0.0 110.478 -179.814 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.57 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 86.9 mttt -51.06 -37.08 43.35 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.443 -0.503 . . . . 0.0 109.852 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 13.4 m -64.36 -41.61 96.64 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.354 0.597 . . . . 0.0 110.352 -179.831 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.488 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 37.8 t -72.73 -34.91 67.39 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.029 179.467 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.2 mm -66.14 -47.68 83.94 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.571 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.884 -179.227 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.458 ' C ' ' H ' ' A' ' 30' ' ' ASN . 3.0 pp20? -70.21 -28.35 65.21 Favored 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.285 -179.413 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.465 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 56.1 m -66.25 1.05 1.71 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.051 -179.863 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.465 ' CB ' ' O ' ' A' ' 29' ' ' SER . 0.2 OUTLIER 82.51 11.04 0.61 Allowed 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.406 179.858 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.552 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 23.0 m-85 -99.47 -171.22 2.03 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-O 121.036 0.445 . . . . 0.0 111.188 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -71.33 -59.91 2.51 Favored 'General case' 0 CA--C 1.532 0.254 0 CA-C-N 115.756 -0.657 . . . . 0.0 111.857 -179.03 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.488 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 172.39 176.8 41.4 Favored Glycine 0 CA--C 1.52 0.377 0 N-CA-C 110.345 -1.102 . . . . 0.0 110.345 -179.104 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.423 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -137.0 166.66 24.86 Favored Glycine 0 N--CA 1.462 0.402 0 N-CA-C 111.233 -0.747 . . . . 0.0 111.233 -179.529 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 12.2 ptmt -159.4 178.45 9.92 Favored 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.771 -179.393 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 1.4 m -106.5 127.71 53.52 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.008 178.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 28.8 m -134.41 159.75 41.84 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.247 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.32 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -104.84 154.67 19.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.265 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.495 ' O ' ' N ' ' A' ' 41' ' ' GLN . 31.2 mm -107.01 128.02 62.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.361 -179.347 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 41.78 -91.56 0.01 OUTLIER Glycine 0 CA--C 1.525 0.711 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.495 ' N ' ' O ' ' A' ' 39' ' ' ILE . 40.6 tt0 -143.22 22.69 1.87 Allowed 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 121.039 0.447 . . . . 0.0 110.252 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 58.4 m -78.57 -9.45 59.36 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.079 0.466 . . . . 0.0 110.265 179.559 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' LEU . . . . . 0.416 ' O ' ' CD2' ' A' ' 43' ' ' LEU . 0.9 OUTLIER 47.03 30.42 1.28 Allowed 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.28 -179.715 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 67.8 t0 -98.78 119.91 38.32 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.597 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 58.1 m-85 -84.44 117.5 23.68 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.026 0.441 . . . . 0.0 110.342 -179.33 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 32.6 m -113.38 136.18 50.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.5 -179.454 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.92 ' SG ' HD11 ' A' ' 11' ' ' ILE . 27.4 t -93.03 115.4 28.08 Favored 'General case' 0 CA--C 1.514 -0.434 0 N-CA-C 109.284 -0.635 . . . . 0.0 109.284 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.5 p -130.88 150.41 34.58 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.261 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.8 -178.774 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' CYS . . . . . 0.552 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 23.6 t -96.82 162.9 13.22 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.529 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 33.7 m-85 -120.91 136.82 25.85 Favored Pre-proline 0 N--CA 1.47 0.541 0 C-N-CA 120.906 -0.318 . . . . 0.0 110.99 -178.85 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.43 ' HG3' ' H ' ' A' ' 7' ' ' LYS . 23.1 Cg_endo -62.33 150.03 88.61 Favored 'Trans proline' 0 N--CA 1.492 1.396 0 C-N-CA 121.759 1.64 . . . . 0.0 112.753 179.519 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 8.1 tptp -136.8 -41.14 0.6 Allowed 'General case' 0 CA--C 1.528 0.106 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.002 179.476 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -112.64 18.91 17.95 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-O 120.634 0.254 . . . . 0.0 111.136 -179.49 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' TYR . . . . . 0.491 ' OH ' ' NE ' ' A' ' 6' ' ' ARG . 74.6 t80 -74.78 131.01 40.47 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-O 120.866 0.365 . . . . 0.0 110.377 179.498 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.2 pt . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 117.895 -1.05 . . . . 0.0 109.975 179.977 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 71.0 mmtt . . . . . 0 N--CA 1.492 1.674 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 34.6 p-10 -73.41 0.84 11.08 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 179.338 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.578 ' O ' HD12 ' A' ' 3' ' ' ILE . 1.0 OUTLIER -93.46 143.78 10.82 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.176 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.916 -179.912 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -62.38 -40.89 97.92 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.291 179.567 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -80.78 104.25 2.29 Favored Glycine 0 C--N 1.329 0.156 0 N-CA-C 110.665 -0.974 . . . . 0.0 110.665 -179.821 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.85 38.13 3.4 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.695 -0.252 . . . . 0.0 111.302 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.426 ' H ' ' HG3' ' A' ' 51' ' ' PRO . 14.5 ttmt -125.4 69.69 61.9 Favored Pre-proline 0 N--CA 1.47 0.567 0 CA-C-O 120.455 0.169 . . . . 0.0 111.165 -179.66 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -77.25 161.68 31.89 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 122.68 2.253 . . . . 0.0 111.586 179.007 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.66 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.3 tt -133.67 120.89 21.21 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 120.568 0.223 . . . . 0.0 110.439 -179.008 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.66 ' N ' HD23 ' A' ' 9' ' ' LEU . 5.8 tt -87.68 134.56 33.63 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 178.535 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 13.2 pt -109.04 -35.0 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 120.934 0.397 . . . . 0.0 110.8 -178.702 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 175.69 -150.0 10.49 Favored Glycine 0 N--CA 1.451 -0.358 0 N-CA-C 110.794 -0.923 . . . . 0.0 110.794 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.416 ' C ' ' H ' ' A' ' 15' ' ' ILE . 42.0 p -98.8 160.66 14.12 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.83 0.347 . . . . 0.0 110.235 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 9.2 t -72.04 6.99 1.81 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.171 179.818 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.416 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.8 mt -91.42 -44.39 14.4 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.199 0 CA-C-N 116.053 -0.522 . . . . 0.0 109.949 179.785 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -87.46 -20.59 26.37 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.735 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 60.1 m-85 -120.69 99.08 47.66 Favored Pre-proline 0 CA--C 1.546 0.796 0 CA-C-N 116.732 -0.213 . . . . 0.0 110.595 179.515 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.409 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 36.4 Cg_endo -71.68 173.23 12.92 Favored 'Trans proline' 0 N--CA 1.493 1.495 0 C-N-CA 122.579 2.186 . . . . 0.0 111.288 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.631 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 10.0 m -47.67 -50.56 24.41 Favored 'General case' 0 C--N 1.319 -0.736 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.712 -179.242 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.603 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 0.5 OUTLIER -56.34 -68.33 0.22 Allowed 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 112.293 0.479 . . . . 0.0 112.293 -179.13 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 6.9 ttmt -57.95 -46.37 85.18 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 121.362 0.601 . . . . 0.0 111.551 -178.126 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.409 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 49.0 t -47.58 -65.03 0.63 Allowed 'General case' 0 C--N 1.308 -1.231 0 CA-C-N 115.311 -0.859 . . . . 0.0 111.465 -178.64 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.631 ' ND2' ' O ' ' A' ' 19' ' ' THR . 15.3 p30 -65.39 -43.73 89.75 Favored 'General case' 0 C--O 1.222 -0.375 0 C-N-CA 120.4 -0.52 . . . . 0.0 110.893 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.577 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 48.8 mttp -52.5 -39.68 61.54 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 120.19 -0.604 . . . . 0.0 109.909 179.826 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 91.6 m -62.62 -43.69 98.18 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.741 -179.438 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.521 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 16.6 t -66.14 -34.93 79.17 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.017 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.3 mm -66.17 -37.77 80.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.717 0 CA-C-N 114.937 -1.029 . . . . 0.0 110.113 179.674 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.41 ' C ' ' H ' ' A' ' 30' ' ' ASN . 34.3 mm-40 -64.09 -37.54 87.8 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.973 -1.012 . . . . 0.0 110.155 -179.369 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 35.9 m -69.46 0.59 4.98 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.834 179.638 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.41 ' H ' ' C ' ' A' ' 28' ' ' GLU . 18.2 t-20 76.7 21.15 1.28 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.508 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.532 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 3.8 m-85 -96.16 -166.93 1.5 Allowed 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 120.811 0.339 . . . . 0.0 110.493 -179.88 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.61 -51.42 16.89 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 116.076 -0.511 . . . . 0.0 112.113 -178.68 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.521 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 161.59 -179.87 36.71 Favored Glycine 0 CA--C 1.519 0.323 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 -179.036 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.424 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -132.49 157.42 22.53 Favored Glycine 0 CA--C 1.52 0.351 0 N-CA-C 111.417 -0.673 . . . . 0.0 111.417 -179.181 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 16.2 ptpt -154.27 168.78 25.44 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.41 -0.395 . . . . 0.0 110.506 -179.319 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 37.8 m -103.86 124.29 48.68 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.042 179.609 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 36.0 m -136.6 161.39 36.69 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-O 120.758 0.313 . . . . 0.0 110.9 -179.904 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.511 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 2.3 p80 -90.07 155.04 19.34 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.326 179.55 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 40.4 mm -110.66 121.6 63.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.816 -179.672 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 46.63 27.74 3.24 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 179.074 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 12.6 mm100 62.72 35.69 13.82 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.943 0.401 . . . . 0.0 110.242 -179.546 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' SER . . . . . 0.422 ' O ' ' CB ' ' A' ' 43' ' ' LEU . 63.6 m -83.39 -7.93 59.48 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.883 -179.901 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' LEU . . . . . 0.422 ' CB ' ' O ' ' A' ' 42' ' ' SER . 0.9 OUTLIER 73.82 27.33 1.7 Allowed 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.239 0.542 . . . . 0.0 109.782 -179.523 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 36.0 t0 -111.74 117.05 31.79 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 178.547 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -91.42 120.61 32.42 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.241 0.543 . . . . 0.0 109.915 -179.819 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 33.5 m -123.5 140.13 47.99 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.449 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.079 -179.573 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -94.47 121.35 35.93 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.19 -179.727 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.2 p -134.35 151.87 32.82 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.312 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.844 -178.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' CYS . . . . . 0.532 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 28.4 t -93.9 161.89 14.13 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 -179.421 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.445 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 51.3 m-85 -127.93 142.52 44.64 Favored Pre-proline 0 N--CA 1.47 0.538 0 C-N-CA 120.619 -0.432 . . . . 0.0 111.359 -178.356 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.426 ' HG3' ' H ' ' A' ' 7' ' ' LYS . 29.6 Cg_endo -62.73 148.36 93.5 Favored 'Trans proline' 0 N--CA 1.494 1.528 0 C-N-CA 122.016 1.811 . . . . 0.0 112.219 179.636 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 38.8 ttpt -121.75 -53.34 1.98 Allowed 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.654 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 45.5 p90 -117.25 20.94 13.45 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.876 -179.538 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 51.4 t80 -81.36 129.28 34.56 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 179.908 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 10.7 mt . . . . . 0 C--O 1.219 -0.544 0 CA-C-O 117.934 -1.031 . . . . 0.0 110.391 -179.756 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 25.3 mtpp . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -84.36 3.01 37.82 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.421 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.438 HG22 ' N ' ' A' ' 5' ' ' GLY . 37.8 mm -68.94 130.87 34.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 121.051 0.453 . . . . 0.0 110.745 179.888 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ASP . . . . . 0.489 ' N ' ' OD1' ' A' ' 4' ' ' ASP . 18.2 p-10 -65.14 -36.35 83.99 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.55 179.669 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.438 ' N ' HG22 ' A' ' 3' ' ' ILE . . . -29.86 96.12 0.01 OUTLIER Glycine 0 N--CA 1.465 0.58 0 O-C-N 123.704 0.628 . . . . 0.0 111.685 -179.725 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.99 40.12 3.82 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.334 -0.433 . . . . 0.0 110.878 -178.679 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.96 155.14 64.38 Favored Pre-proline 0 N--CA 1.467 0.402 0 C-N-CA 121.192 -0.203 . . . . 0.0 110.581 -179.241 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -57.92 149.05 72.65 Favored 'Trans proline' 0 N--CA 1.496 1.63 0 C-N-CA 121.725 1.617 . . . . 0.0 111.416 178.291 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.619 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.8 tt -120.33 118.21 29.79 Favored 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.713 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.682 HD13 ' C ' ' A' ' 10' ' ' LEU . 2.7 tm? -89.04 124.99 34.81 Favored 'General case' 0 CA--C 1.522 -0.132 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.547 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.41 ' N ' HD13 ' A' ' 10' ' ' LEU . 14.9 pt -105.59 -35.58 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.159 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.811 -179.131 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.405 ' O ' HD21 ' A' ' 10' ' ' LEU . . . 176.92 -135.46 2.83 Favored Glycine 0 CA--C 1.522 0.5 0 N-CA-C 111.146 -0.781 . . . . 0.0 111.146 -179.873 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 68.0 p -132.92 161.73 33.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.94 0.4 . . . . 0.0 110.512 -179.629 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -55.91 -9.35 0.57 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.764 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 6.2 mm -71.94 -43.13 68.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 C-N-CA 120.5 -0.48 . . . . 0.0 110.59 -179.313 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -99.75 -23.51 14.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.106 -179.429 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -119.54 83.09 26.53 Favored Pre-proline 0 N--CA 1.463 0.189 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.033 179.583 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -53.29 165.89 1.3 Allowed 'Trans proline' 0 N--CA 1.491 1.367 0 C-N-CA 122.495 2.13 . . . . 0.0 110.582 178.553 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.598 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 36.0 p -45.61 -58.94 3.04 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-O 120.852 0.358 . . . . 0.0 111.701 -178.601 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.497 ' HA ' HD22 ' A' ' 23' ' ' ASN . 6.6 pt-20 -46.01 -60.04 2.49 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.934 -179.385 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.47 ' H ' ' HG3' ' A' ' 20' ' ' GLU . 17.8 mtmt -63.73 -45.79 88.31 Favored 'General case' 0 CA--C 1.51 -0.583 0 CA-C-O 121.105 0.478 . . . . 0.0 111.299 -179.784 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 17.9 t -44.47 -62.61 1.12 Allowed 'General case' 0 C--N 1.31 -1.138 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.351 -178.396 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.598 ' ND2' ' O ' ' A' ' 19' ' ' THR . 12.6 p30 -64.1 -50.48 68.12 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.866 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.543 ' N ' ' OD1' ' A' ' 23' ' ' ASN . 41.2 mttm -48.99 -35.94 16.45 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -179.586 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 19.4 m -63.52 -42.26 98.47 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.192 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.491 ' SG ' ' C ' ' A' ' 33' ' ' GLY . 32.9 t -73.42 -36.9 66.03 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.537 0.684 . . . . 0.0 110.016 178.975 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.3 mm -64.65 -47.42 88.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.996 -178.92 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.433 ' C ' ' H ' ' A' ' 30' ' ' ASN . 2.9 pp20? -71.22 -23.26 61.98 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.756 -179.485 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 39.5 m -71.6 3.71 3.74 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.52 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.433 ' H ' ' C ' ' A' ' 28' ' ' GLU . 2.2 m120 77.59 22.26 0.92 Allowed 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.913 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.554 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 31.1 m-85 -111.25 -167.91 1.24 Allowed 'General case' 0 N--CA 1.455 -0.178 0 CA-C-O 120.82 0.343 . . . . 0.0 111.006 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -74.1 -58.36 3.35 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.94 -0.573 . . . . 0.0 112.239 -178.417 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.491 ' C ' ' SG ' ' A' ' 26' ' ' CYS . . . 172.8 170.63 36.74 Favored Glycine 0 CA--C 1.521 0.465 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -178.85 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.496 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -122.42 159.97 16.94 Favored Glycine 0 N--CA 1.463 0.458 0 N-CA-C 111.186 -0.765 . . . . 0.0 111.186 -178.812 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 16.2 ptpt -155.34 166.38 33.72 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.05 0.452 . . . . 0.0 110.695 -179.558 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.504 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 4.5 m -106.35 123.69 48.44 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.354 179.522 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 32.9 m -137.08 160.77 36.16 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.464 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.689 179.796 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 34.6 p-80 -89.64 157.15 18.14 Favored 'General case' 0 CA--C 1.521 -0.153 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.295 179.488 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.4 ' C ' ' N ' ' A' ' 41' ' ' GLN . 5.7 mm -117.97 129.25 74.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.778 -179.467 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 46.01 22.18 0.79 Allowed Glycine 0 C--O 1.228 -0.233 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 179.328 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.4 ' N ' ' C ' ' A' ' 39' ' ' ILE . 39.6 tt0 69.78 36.75 1.99 Allowed 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.062 0.458 . . . . 0.0 110.175 -179.753 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 5.1 m -86.45 1.46 51.32 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.155 179.79 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER 57.16 26.89 12.69 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.526 -179.379 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 55.0 t0 -106.39 119.13 38.45 Favored 'General case' 0 N--CA 1.466 0.361 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 178.916 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 -85.12 115.68 23.06 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 121.181 0.515 . . . . 0.0 110.325 -179.112 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 11.6 m -111.18 134.57 53.08 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.262 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.19 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 0.8 OUTLIER -94.38 112.8 24.59 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.172 -179.792 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 4.8 p -129.58 155.0 41.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.306 -179.289 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' CYS . . . . . 0.587 ' SG ' ' N ' ' A' ' 50' ' ' PHE . 19.5 t -96.56 166.48 11.66 Favored 'General case' 0 N--CA 1.465 0.312 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.587 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 29.1 m-85 -126.92 117.88 22.25 Favored Pre-proline 0 N--CA 1.469 0.483 0 C-N-CA 121.028 -0.269 . . . . 0.0 110.745 -178.903 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_exo -51.8 137.28 51.48 Favored 'Trans proline' 0 N--CA 1.486 1.083 0 C-N-CA 121.491 1.46 . . . . 0.0 112.27 179.218 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 26.4 tptp -65.8 -18.08 65.08 Favored 'General case' 0 N--CA 1.453 -0.316 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.651 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -106.93 40.9 1.56 Allowed 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.558 -179.471 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 75.4 t80 -113.75 126.22 54.98 Favored 'General case' 0 C--O 1.231 0.115 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.833 179.416 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 83.5 mt . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.277 179.841 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_exo . . . . . 0 N--CA 1.495 1.61 0 N-CA-C 111.406 -0.267 . . . . 0.0 111.406 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.623 HD23 ' N ' ' A' ' 10' ' ' LEU . 2.9 tt -116.68 118.66 33.18 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-O 120.626 0.25 . . . . 0.0 110.493 -179.393 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.623 ' N ' HD23 ' A' ' 9' ' ' LEU . 8.4 tt -90.08 131.18 36.09 Favored 'General case' 0 N--CA 1.464 0.275 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 178.769 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.904 HD11 ' SG ' ' A' ' 47' ' ' CYS . 1.9 pt -108.67 -45.17 6.85 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 120.964 0.412 . . . . 0.0 110.415 -178.669 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -163.68 -176.38 35.55 Favored Glycine 0 N--CA 1.45 -0.421 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.515 ' O ' ' N ' ' A' ' 15' ' ' ILE . 13.6 m -86.65 137.3 32.58 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 8.7 t -46.93 -12.29 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 120.832 -0.347 . . . . 0.0 110.794 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.515 ' N ' ' O ' ' A' ' 13' ' ' THR . 96.6 mt -69.86 -44.3 78.95 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.287 0 CA-C-O 121.364 0.602 . . . . 0.0 110.487 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -88.09 -29.69 20.44 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-N 115.223 -0.899 . . . . 0.0 110.514 -179.599 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 53.0 m-85 -124.85 84.05 58.84 Favored Pre-proline 0 N--CA 1.465 0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.815 179.564 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -53.08 -177.0 0.03 OUTLIER 'Trans proline' 0 N--CA 1.498 1.743 0 C-N-CA 122.959 2.44 . . . . 0.0 111.609 179.26 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.454 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 97.8 m -58.22 -49.71 76.12 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 112.547 0.573 . . . . 0.0 112.547 -178.275 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.499 ' CG ' ' H ' ' A' ' 21' ' ' LYS . 9.0 pt-20 -56.14 -58.18 9.04 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 111.767 0.284 . . . . 0.0 111.767 -178.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.499 ' H ' ' CG ' ' A' ' 20' ' ' GLU . 15.4 mtmt -64.11 -44.72 91.39 Favored 'General case' 0 CA--C 1.51 -0.569 0 CA-C-O 121.221 0.534 . . . . 0.0 111.522 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 28.9 t -44.7 -57.67 3.54 Favored 'General case' 0 C--N 1.312 -1.058 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.757 -177.778 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.693 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.7 p-10 -64.22 -50.73 66.89 Favored 'General case' 0 C--O 1.218 -0.587 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.375 -179.559 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.693 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 70.7 mttt -50.18 -42.12 50.66 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 -179.656 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 15.5 m -64.51 -39.16 93.26 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.645 0.736 . . . . 0.0 109.607 179.115 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 73.0 m -68.76 -31.51 70.6 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.149 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.438 HG12 ' O ' ' A' ' 23' ' ' ASN . 3.0 mm -64.39 -47.03 91.25 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.506 0 CA-C-O 121.087 0.47 . . . . 0.0 110.914 -179.512 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.405 ' HG2' ' H ' ' A' ' 28' ' ' GLU . 9.1 pt-20 -70.14 -22.25 63.01 Favored 'General case' 0 N--CA 1.447 -0.622 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.872 -179.246 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 59.8 p -74.81 -2.07 25.0 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 179.55 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 77.66 27.92 0.58 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.168 -0.923 . . . . 0.0 110.725 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.552 ' C ' ' H ' ' A' ' 33' ' ' GLY . 5.5 m-85 -110.96 162.32 14.95 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.74 -179.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.65 32.85 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.664 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.552 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 81.43 -173.96 54.24 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 -179.743 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -153.65 177.25 31.28 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 -179.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 17.0 ptpt -154.06 177.65 10.84 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.942 0.401 . . . . 0.0 110.784 -179.352 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 67.3 m -104.69 117.76 34.9 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.011 179.123 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 27.1 m -136.31 159.5 38.37 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-O 120.902 0.382 . . . . 0.0 110.865 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.777 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 0.1 OUTLIER -91.07 157.76 17.05 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.47 179.626 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 39.2 mm -105.85 126.92 61.23 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.18 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.451 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 41.02 -98.47 0.01 OUTLIER Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 179.651 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 40.3 tt0 -135.83 21.49 3.3 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 120.986 0.422 . . . . 0.0 109.957 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 58.1 m -79.65 -8.71 59.38 Favored 'General case' 0 CA--C 1.515 -0.397 0 CA-C-O 121.127 0.489 . . . . 0.0 110.418 179.564 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' LEU . . . . . 0.405 ' CD2' ' O ' ' A' ' 43' ' ' LEU . 0.9 OUTLIER 47.12 29.62 1.17 Allowed 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.246 -179.651 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -102.79 119.54 39.02 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 178.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -81.13 132.77 35.38 Favored 'General case' 0 CA--C 1.517 -0.326 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 -179.349 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 35.2 m -134.96 152.39 32.71 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.404 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.547 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.904 ' SG ' HD11 ' A' ' 11' ' ' ILE . 41.0 t -94.34 113.76 25.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.626 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.1 p -126.05 137.9 56.28 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.19 0 CA-C-O 121.001 0.429 . . . . 0.0 110.604 -179.388 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 8.3 m -97.44 165.05 12.19 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.784 -179.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 42.5 m-85 -117.39 145.79 36.92 Favored Pre-proline 0 N--CA 1.47 0.537 0 CA-C-N 116.742 -0.208 . . . . 0.0 111.256 -179.11 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo . . . . . 0 N--CA 1.496 1.658 0 C-N-CA 122.57 2.18 . . . . 0.0 112.077 179.553 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo . . . . . 0 N--CA 1.491 1.354 0 CA-C-O 120.964 0.318 . . . . 0.0 111.691 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.668 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.6 tt -121.53 119.68 32.67 Favored 'General case' 0 N--CA 1.474 0.748 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.562 -179.676 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.668 ' N ' HD23 ' A' ' 9' ' ' LEU . 6.8 tt -92.29 125.54 36.99 Favored 'General case' 0 N--CA 1.464 0.269 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 178.879 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.904 HD11 ' SG ' ' A' ' 47' ' ' CYS . 2.6 pt -102.54 -48.3 10.86 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.667 -179.056 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.411 ' H ' HG13 ' A' ' 11' ' ' ILE . . . -167.72 -138.29 2.42 Favored Glycine 0 N--CA 1.45 -0.398 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.487 ' C ' ' H ' ' A' ' 15' ' ' ILE . 43.1 p -132.62 159.01 40.79 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.085 0.469 . . . . 0.0 110.847 -179.697 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -56.12 -5.56 0.19 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.051 179.786 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.487 ' H ' ' C ' ' A' ' 13' ' ' THR . 84.6 mt -75.94 -26.5 17.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.883 0.373 . . . . 0.0 110.723 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -124.47 -27.69 3.71 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.063 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -122.62 80.57 47.75 Favored Pre-proline 0 C--O 1.233 0.187 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.335 179.206 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_exo -53.0 179.33 0.04 OUTLIER 'Trans proline' 0 N--CA 1.495 1.563 0 C-N-CA 122.787 2.325 . . . . 0.0 111.141 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.467 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 30.5 p -53.74 -61.28 2.4 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 121.074 0.464 . . . . 0.0 111.995 -179.802 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.479 ' HG3' ' H ' ' A' ' 21' ' ' LYS . 5.4 pt-20 -43.8 -59.41 2.25 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.387 -178.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.479 ' H ' ' HG3' ' A' ' 20' ' ' GLU . 19.8 mtmt -64.43 -46.15 84.42 Favored 'General case' 0 CA--C 1.509 -0.608 0 CA-C-O 121.201 0.524 . . . . 0.0 111.269 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 41.2 t -45.07 -60.56 2.03 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-N 115.549 -0.75 . . . . 0.0 111.124 -178.475 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.693 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 2.1 p-10 -65.63 -54.86 21.8 Favored 'General case' 0 C--O 1.22 -0.466 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.517 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.693 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 80.3 mttt -44.91 -44.5 9.75 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 120.691 -0.403 . . . . 0.0 110.575 -179.602 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 17.5 m -63.64 -39.9 95.52 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.164 0.506 . . . . 0.0 110.02 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 51.4 m -66.46 -31.4 72.12 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.573 -0.74 . . . . 0.0 111.042 -179.882 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.4 mm -63.94 -41.33 92.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-O 121.323 0.582 . . . . 0.0 110.141 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.415 ' C ' ' H ' ' A' ' 30' ' ' ASN . 52.9 mm-40 -67.06 -37.7 84.49 Favored 'General case' 0 N--CA 1.445 -0.725 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.527 -178.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 33.7 m -69.07 5.8 1.1 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.029 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.415 ' H ' ' C ' ' A' ' 28' ' ' GLU . 48.4 t30 71.47 50.89 0.26 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.067 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.581 ' C ' ' H ' ' A' ' 33' ' ' GLY . 57.0 m-85 -133.81 162.78 31.08 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.733 179.887 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.17 23.06 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.053 -0.522 . . . . 0.0 110.719 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.581 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 89.78 -175.8 42.22 Favored Glycine 0 CA--C 1.52 0.374 0 N-CA-C 110.533 -1.027 . . . . 0.0 110.533 -179.893 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -147.83 174.01 27.7 Favored Glycine 0 CA--C 1.522 0.482 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 -179.379 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 13.2 ptmt -155.44 178.57 10.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.885 0.374 . . . . 0.0 110.578 -179.377 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 1.8 m -105.17 128.07 53.21 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.144 179.227 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 19.3 m -134.47 158.62 41.93 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.047 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.683 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 0.9 OUTLIER -101.36 156.41 17.47 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.023 179.943 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 35.9 mm -112.67 127.27 70.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.98 -179.755 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.495 ' O ' ' NE2' ' A' ' 41' ' ' GLN . . . 40.11 -97.82 0.01 OUTLIER Glycine 0 CA--C 1.527 0.795 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.495 ' NE2' ' O ' ' A' ' 40' ' ' GLY . 99.2 mm-40 -137.45 28.38 2.75 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.838 0.351 . . . . 0.0 110.477 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . 0.774 ' C ' HD23 ' A' ' 43' ' ' LEU . 73.5 m -87.29 4.73 41.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.917 179.883 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' LEU . . . . . 0.774 HD23 ' C ' ' A' ' 42' ' ' SER . 1.2 pt? 34.65 27.99 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.27 0 O-C-N 123.788 0.68 . . . . 0.0 111.496 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . 0.543 ' N ' ' O ' ' A' ' 42' ' ' SER . 43.4 t0 -99.98 121.1 40.84 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.572 -179.466 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -87.65 117.75 26.68 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.087 0.47 . . . . 0.0 109.963 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 30.6 m -111.86 136.05 49.24 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.255 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.116 -179.623 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.904 ' SG ' HD11 ' A' ' 11' ' ' ILE . 14.0 t -93.39 115.84 28.39 Favored 'General case' 0 CA--C 1.518 -0.286 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.628 -179.575 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.8 p -131.89 152.03 36.19 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.507 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.762 -179.036 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 6.4 m -97.47 172.51 7.7 Favored 'General case' 0 CA--C 1.515 -0.376 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.636 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 56.4 m-85 -138.23 142.57 35.8 Favored Pre-proline 0 C--N 1.331 -0.225 0 C-N-CA 120.882 -0.327 . . . . 0.0 111.359 -179.487 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo . . . . . 0 N--CA 1.494 1.547 0 C-N-CA 122.408 2.072 . . . . 0.0 112.297 178.516 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_exo . . . . . 0 N--CA 1.494 1.51 0 CA-C-O 120.647 0.186 . . . . 0.0 111.876 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.695 HD13 ' N ' ' A' ' 10' ' ' LEU . 0.2 OUTLIER -125.7 128.97 48.61 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-O 121.154 0.502 . . . . 0.0 110.708 179.895 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.695 ' N ' HD13 ' A' ' 9' ' ' LEU . 6.1 tt -90.97 136.63 32.94 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.396 178.867 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.467 HD13 ' N ' ' A' ' 11' ' ' ILE . 0.0 OUTLIER -105.88 -47.47 8.93 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.262 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.125 -179.667 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -172.63 -124.74 0.79 Allowed Glycine 0 CA--C 1.519 0.307 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.53 ' C ' ' H ' ' A' ' 15' ' ' ILE . 66.3 p -127.81 150.36 49.86 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.912 0.387 . . . . 0.0 110.264 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 7.4 t -63.63 4.66 0.24 Allowed 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.353 179.714 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.53 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.2 mt -88.48 -40.75 13.69 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.181 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -99.6 -11.9 20.56 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.752 179.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -124.99 81.06 63.12 Favored Pre-proline 0 N--CA 1.464 0.275 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.028 179.602 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -53.44 168.03 0.75 Allowed 'Trans proline' 0 N--CA 1.5 1.9 0 C-N-CA 123.146 2.564 . . . . 0.0 111.507 178.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.447 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 39.9 p -45.71 -60.01 2.45 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 112.003 0.371 . . . . 0.0 112.003 -178.837 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.492 ' HG3' ' H ' ' A' ' 21' ' ' LYS . 6.6 pt-20 -46.37 -61.16 1.92 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.05 -179.27 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.492 ' H ' ' HG3' ' A' ' 20' ' ' GLU . 20.0 mtmt -63.11 -45.77 90.49 Favored 'General case' 0 CA--C 1.508 -0.644 0 CA-C-O 121.292 0.568 . . . . 0.0 111.629 -179.595 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 22.2 t -43.62 -59.35 2.22 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.024 -178.427 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.722 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 2.2 p-10 -67.3 -57.86 5.87 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.578 179.635 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.722 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 72.0 mttt -43.37 -43.62 5.2 Favored 'General case' 0 C--O 1.222 -0.358 0 CA-C-O 120.852 0.358 . . . . 0.0 110.51 -178.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 19.6 m -64.09 -40.61 96.61 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.177 0.513 . . . . 0.0 110.178 179.66 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.421 ' N ' ' O ' ' A' ' 23' ' ' ASN . 25.5 m -66.71 -30.73 71.04 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.795 -179.895 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.8 mm -64.87 -41.28 91.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-O 121.292 0.568 . . . . 0.0 110.009 -179.705 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.418 ' C ' ' H ' ' A' ' 30' ' ' ASN . 31.2 mm-40 -65.84 -38.07 87.89 Favored 'General case' 0 N--CA 1.447 -0.612 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.379 -178.705 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 26.8 m -69.49 5.15 1.46 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.639 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.418 ' H ' ' C ' ' A' ' 28' ' ' GLU . 44.6 t30 70.86 54.85 0.25 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.006 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.563 ' C ' ' H ' ' A' ' 33' ' ' GLY . 60.4 m-85 -137.76 161.98 35.13 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.592 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.47 28.28 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.981 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.563 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 85.07 -175.26 49.98 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 110.7 -0.96 . . . . 0.0 110.7 -179.784 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.418 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -148.63 174.0 28.42 Favored Glycine 0 CA--C 1.522 0.483 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 -179.403 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 4.7 ptmm? -155.86 -178.12 7.07 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.592 0.234 . . . . 0.0 110.384 -179.247 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 31.1 m -104.45 129.69 52.42 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.414 179.228 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 28.5 m -137.78 161.85 32.63 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.261 179.696 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 3.5 p80 -109.06 157.62 18.53 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.217 -0.447 . . . . 0.0 109.998 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 83.6 mt -122.21 125.98 73.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.339 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 42.03 -128.51 4.37 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.891 -0.883 . . . . 0.0 110.891 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 29.0 pt20 -106.82 31.7 5.1 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 120.694 0.283 . . . . 0.0 110.413 179.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 20.1 m -84.39 -9.77 58.13 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 120.983 0.42 . . . . 0.0 110.598 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' LEU . . . . . 0.444 HD22 ' HA ' ' A' ' 43' ' ' LEU . 0.2 OUTLIER 40.02 29.41 0.05 Allowed 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.635 -0.712 . . . . 0.0 110.872 -179.144 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -107.55 126.45 52.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.222 179.691 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -90.65 124.55 35.16 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.638 -0.505 . . . . 0.0 109.638 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 30.5 m -120.47 138.07 52.19 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 CA-C-N 116.068 -0.514 . . . . 0.0 109.997 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -94.31 119.22 32.75 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.1 p -134.18 153.18 35.4 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.448 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.588 -179.069 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 5.9 m -97.28 172.23 7.92 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.898 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 56.4 m-85 -132.6 148.07 68.11 Favored Pre-proline 0 CA--C 1.531 0.214 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.939 -179.163 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo . . . . . 0 N--CA 1.494 1.52 0 C-N-CA 122.74 2.293 . . . . 0.0 112.308 179.356 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 21.3 Cg_exo . . . . . 0 N--CA 1.487 1.129 0 N-CA-C 111.363 -0.284 . . . . 0.0 111.363 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.64 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.8 tt -126.43 116.65 21.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.598 179.858 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.67 HD23 ' N ' ' A' ' 11' ' ' ILE . 7.2 tt -91.71 129.11 37.73 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 179.009 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.907 HD11 ' SG ' ' A' ' 47' ' ' CYS . 1.4 pt -105.61 -50.07 8.65 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-O 120.837 0.351 . . . . 0.0 110.921 -178.496 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -160.43 -164.61 15.75 Favored Glycine 0 N--CA 1.451 -0.308 0 N-CA-C 110.694 -0.963 . . . . 0.0 110.694 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.457 ' C ' ' H ' ' A' ' 15' ' ' ILE . 6.5 m -89.33 158.29 17.86 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.843 0.354 . . . . 0.0 110.423 -179.385 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 9.5 t -69.35 6.6 0.98 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.207 179.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.457 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.5 mt -91.44 -45.62 14.52 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.148 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -90.92 -11.37 39.33 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.925 179.649 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 54.1 m-85 -142.78 82.02 12.7 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.684 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.42 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 15.9 Cg_exo -65.95 -172.72 0.28 Allowed 'Trans proline' 0 N--CA 1.493 1.479 0 C-N-CA 122.904 2.403 . . . . 0.0 111.83 179.279 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.512 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 26.2 p -48.07 -56.68 7.19 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 120.826 -0.35 . . . . 0.0 111.698 -179.054 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.649 ' CD ' ' H ' ' A' ' 20' ' ' GLU . 0.0 OUTLIER -47.91 -72.2 0.06 Allowed 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.121 0.486 . . . . 0.0 111.736 -178.719 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 52.0 mtmt -60.49 -42.94 97.36 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.683 -178.273 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.42 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 44.7 t -44.94 -59.77 2.4 Favored 'General case' 0 C--N 1.313 -1.013 0 C-N-CA 120.215 -0.594 . . . . 0.0 111.089 -178.547 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.746 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.5 p-10 -64.58 -55.64 19.09 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.546 -179.468 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.746 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 69.1 mttt -47.14 -42.79 20.07 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 120.788 -0.365 . . . . 0.0 110.584 -178.742 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 11.4 m -65.8 -37.75 87.13 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.242 179.71 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 37.9 m -67.64 -33.63 75.34 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.877 -0.602 . . . . 0.0 110.287 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.6 mm -61.5 -46.35 96.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.564 -179.536 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -66.34 -31.07 71.64 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.494 -179.035 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 27.1 m -72.87 1.5 8.57 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.405 -179.12 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.3 m-80 74.51 52.98 0.09 Allowed 'General case' 0 C--N 1.329 -0.312 0 O-C-N 123.559 0.537 . . . . 0.0 111.032 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.565 ' C ' ' H ' ' A' ' 33' ' ' GLY . 68.6 m-85 -138.61 162.02 35.66 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.688 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.79 30.24 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.57 179.626 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.565 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 83.6 -176.87 52.53 Favored Glycine 0 CA--C 1.521 0.442 0 N-CA-C 110.568 -1.013 . . . . 0.0 110.568 -179.653 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.428 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -147.3 178.04 25.18 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 -179.595 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 14.7 ptmt -156.87 -176.79 6.17 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 110.237 -0.283 . . . . 0.0 110.237 -179.625 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 66.7 m -108.44 122.2 46.53 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.519 179.573 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 2.8 m -137.89 163.46 29.98 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.837 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.465 ' CD2' ' H ' ' A' ' 38' ' ' HIS . 2.4 p80 -92.97 157.61 16.24 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.341 179.714 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.437 ' O ' ' N ' ' A' ' 41' ' ' GLN . 34.1 mm -110.18 123.44 66.08 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 CA-C-O 121.086 0.47 . . . . 0.0 110.679 -179.741 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 43.99 20.74 0.17 Allowed Glycine 0 C--O 1.227 -0.307 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.575 179.629 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.437 ' N ' ' O ' ' A' ' 39' ' ' ILE . 37.3 tt0 72.61 36.18 1.01 Allowed 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.846 0.355 . . . . 0.0 110.721 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . 0.422 ' N ' ' O ' ' A' ' 39' ' ' ILE . 41.0 m -85.61 -2.66 58.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.206 0.527 . . . . 0.0 110.885 -179.785 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' LEU . . . . . 0.447 HD22 ' HA ' ' A' ' 43' ' ' LEU . 0.2 OUTLIER 69.96 26.4 4.66 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.672 179.86 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 35.2 t70 -111.78 117.36 32.62 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 178.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -89.36 129.33 35.9 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 27.2 m -133.38 154.6 39.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.387 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.907 ' SG ' HD11 ' A' ' 11' ' ' ILE . 37.9 t -95.26 118.42 31.99 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 115.877 -0.601 . . . . 0.0 109.971 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.0 p -130.21 144.14 38.88 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 CA-C-O 120.87 0.366 . . . . 0.0 110.361 -179.466 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 4.9 m -97.93 167.52 10.86 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.889 -179.739 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 46.4 m-85 -122.18 143.05 38.14 Favored Pre-proline 0 CA--C 1.532 0.275 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.668 -179.428 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo . . . . . 0 N--CA 1.495 1.609 0 C-N-CA 122.544 2.163 . . . . 0.0 111.735 179.579 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_exo . . . . . 0 N--CA 1.494 1.554 0 N-CA-C 110.84 -0.485 . . . . 0.0 110.84 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.602 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.5 tt -129.77 116.89 19.4 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 179.607 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.602 ' N ' HD23 ' A' ' 9' ' ' LEU . 6.4 tt -89.27 124.81 34.75 Favored 'General case' 0 N--CA 1.465 0.321 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 179.711 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.909 HD11 ' SG ' ' A' ' 47' ' ' CYS . 3.2 pt -102.59 -46.97 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.842 -179.009 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -164.49 -138.45 2.41 Favored Glycine 0 CA--C 1.519 0.306 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.42 ' C ' ' N ' ' A' ' 15' ' ' ILE . 65.5 p -136.22 159.5 41.56 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.149 -0.526 . . . . 0.0 110.249 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -53.38 -12.27 0.41 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.05 179.54 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.42 ' N ' ' C ' ' A' ' 13' ' ' THR . 78.0 mt -71.78 -43.75 69.25 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.396 0 CA-C-O 121.353 0.597 . . . . 0.0 110.425 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 3.0 pt-20 -100.91 -34.3 9.85 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.094 -179.297 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.475 ' CD2' HD12 ' A' ' 11' ' ' ILE . 9.3 m-85 -116.93 85.0 16.85 Favored Pre-proline 0 N--CA 1.468 0.473 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.572 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -49.64 -178.63 0.01 OUTLIER 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 122.462 2.108 . . . . 0.0 111.508 -179.565 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.436 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 96.9 m -59.14 -51.41 70.12 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.629 -0.428 . . . . 0.0 111.443 -178.818 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.477 ' CG ' ' N ' ' A' ' 21' ' ' LYS . 11.1 pt-20 -60.62 -50.17 74.61 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 112.052 0.389 . . . . 0.0 112.052 -179.706 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.477 ' N ' ' CG ' ' A' ' 20' ' ' GLU . 2.5 ttpp -64.8 -45.9 84.32 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.232 0.539 . . . . 0.0 110.225 -178.327 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 43.3 t -45.7 -61.47 1.7 Allowed 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.25 -0.886 . . . . 0.0 111.433 -179.57 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.685 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.7 p-10 -64.65 -49.31 71.51 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.697 -179.42 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.685 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 82.3 mttt -48.11 -42.56 29.41 Favored 'General case' 0 C--O 1.218 -0.555 0 C-N-CA 120.544 -0.462 . . . . 0.0 109.852 -179.926 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 20.1 m -61.86 -42.4 99.0 Favored 'General case' 0 C--N 1.311 -1.073 0 C-N-CA 120.016 -0.674 . . . . 0.0 110.748 -179.586 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.495 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 10.2 t -65.51 -34.19 77.68 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.743 0.783 . . . . 0.0 109.229 179.363 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.6 mm -65.99 -41.29 89.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 115.008 -0.996 . . . . 0.0 110.289 -179.768 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.41 ' HG2' ' O ' ' A' ' 24' ' ' LYS . 54.4 mm-40 -64.23 -34.38 77.97 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.502 -179.555 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.448 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 36.1 m -67.87 -0.15 3.98 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.994 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.448 ' CB ' ' O ' ' A' ' 29' ' ' SER . 4.3 t-20 80.9 14.81 0.66 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.483 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.556 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 4.0 m-85 -94.89 -168.3 1.79 Allowed 'General case' 0 CA--C 1.533 0.298 0 CA-C-O 120.781 0.324 . . . . 0.0 110.261 -179.671 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -76.59 -51.26 11.96 Favored 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 -178.748 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.495 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 163.3 -179.24 38.56 Favored Glycine 0 CA--C 1.519 0.318 0 N-CA-C 109.734 -1.347 . . . . 0.0 109.734 -178.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.405 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -142.96 170.35 25.31 Favored Glycine 0 N--CA 1.462 0.405 0 N-CA-C 111.36 -0.696 . . . . 0.0 111.36 -179.115 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 23.3 pttt -156.9 178.43 10.37 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.071 0.462 . . . . 0.0 110.891 -179.663 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 3.2 m -104.56 128.4 52.53 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.053 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 35.1 m -136.23 163.38 34.15 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.573 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 2.8 p80 -108.75 156.61 19.41 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.129 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 95.9 mt -122.82 130.07 74.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.606 -179.391 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 48.02 -107.99 0.31 Allowed Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -136.38 32.29 2.83 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 120.596 0.236 . . . . 0.0 110.48 -179.769 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 8.7 m -82.64 -12.03 57.95 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 121.134 0.492 . . . . 0.0 110.282 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' LEU . . . . . 0.419 HD22 ' HA ' ' A' ' 43' ' ' LEU . 0.2 OUTLIER 49.56 29.17 2.84 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.224 179.657 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -105.62 132.71 51.42 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.344 179.778 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -93.5 117.53 30.2 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-O 120.965 0.412 . . . . 0.0 109.95 179.823 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 16.3 m -111.0 137.16 44.65 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.41 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.007 -179.6 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.909 ' SG ' HD11 ' A' ' 11' ' ' ILE . 16.1 t -93.05 118.79 31.59 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.734 -179.837 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.9 p -128.05 150.91 34.22 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.093 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.84 -179.319 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' CYS . . . . . 0.556 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 28.9 t -96.88 165.4 12.12 Favored 'General case' 0 N--CA 1.467 0.419 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.508 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 25.3 m-85 -127.95 124.17 23.07 Favored Pre-proline 0 CA--C 1.544 0.731 0 C-N-CA 121.114 -0.234 . . . . 0.0 111.236 -178.444 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_exo . . . . . 0 N--CA 1.499 1.818 0 C-N-CA 121.999 1.8 . . . . 0.0 113.018 179.092 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo . . . . . 0 N--CA 1.497 1.693 0 CA-C-O 120.745 0.227 . . . . 0.0 111.984 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.659 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.8 tt -131.63 120.91 23.48 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.42 -179.272 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.729 HD23 ' N ' ' A' ' 11' ' ' ILE . 4.4 tt -89.94 128.43 36.23 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 178.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.729 ' N ' HD23 ' A' ' 10' ' ' LEU . 6.4 pt -101.72 -43.03 9.71 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-O 120.786 0.327 . . . . 0.0 110.865 -178.536 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.46 ' O ' HD21 ' A' ' 10' ' ' LEU . . . -173.54 -143.29 4.22 Favored Glycine 0 N--CA 1.451 -0.307 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.744 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.7 p -99.46 163.66 12.42 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.824 0.345 . . . . 0.0 110.275 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 43.4 t -74.1 7.55 2.64 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.331 179.6 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 97.1 mt -93.15 -43.68 13.63 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.12 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.523 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -88.37 -11.71 45.43 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.652 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 53.6 m-85 -122.84 81.22 49.58 Favored Pre-proline 0 N--CA 1.463 0.214 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.853 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_exo -48.88 165.99 0.17 Allowed 'Trans proline' 0 N--CA 1.495 1.599 0 C-N-CA 122.714 2.276 . . . . 0.0 111.33 179.065 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.424 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 17.0 m -48.39 -52.58 21.22 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.85 -0.34 . . . . 0.0 111.627 -178.036 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.627 ' CD ' ' H ' ' A' ' 20' ' ' GLU . 1.3 pm0 -61.92 -55.44 29.58 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.551 -0.295 . . . . 0.0 111.651 -179.722 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -57.57 -45.82 84.71 Favored 'General case' 0 CA--C 1.518 -0.255 0 CA-C-O 121.302 0.572 . . . . 0.0 110.94 -178.208 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 12.7 t -48.02 -65.12 0.62 Allowed 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.402 -178.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.667 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.6 p-10 -63.71 -48.37 77.37 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.755 -179.597 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.667 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 89.5 mttt -47.27 -42.02 19.88 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 120.543 -0.463 . . . . 0.0 110.05 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 18.6 m -61.57 -43.68 98.41 Favored 'General case' 0 C--N 1.314 -0.978 0 C-N-CA 120.456 -0.498 . . . . 0.0 110.909 -179.453 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.503 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 10.7 t -66.2 -32.51 73.99 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.525 0.679 . . . . 0.0 109.745 179.562 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.6 mm -66.54 -39.34 83.68 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.442 -179.623 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.422 ' C ' ' H ' ' A' ' 30' ' ' ASN . 54.9 mm-40 -64.34 -35.72 81.8 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.299 -179.356 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.401 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 58.6 m -67.86 1.65 2.47 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.268 179.797 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.422 ' H ' ' C ' ' A' ' 28' ' ' GLU . 43.8 t30 77.78 18.25 1.27 Allowed 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.705 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.553 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 4.1 m-85 -96.34 -167.83 1.64 Allowed 'General case' 0 CA--C 1.532 0.288 0 CA-C-O 120.945 0.402 . . . . 0.0 110.406 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -75.71 -51.51 12.55 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 115.893 -0.594 . . . . 0.0 112.076 -179.079 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.503 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 162.56 -178.06 38.46 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 -179.025 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.435 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -142.95 169.02 25.82 Favored Glycine 0 N--CA 1.462 0.375 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.136 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 11.4 ptmt -158.48 -176.25 5.78 Favored 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 120.681 -0.408 . . . . 0.0 110.716 -179.3 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 66.2 m -103.73 119.86 39.76 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.932 179.509 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 18.9 m -133.32 163.93 36.41 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.204 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.6 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 0.3 OUTLIER -132.83 157.67 44.44 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 121.02 0.438 . . . . 0.0 110.394 179.879 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.556 ' O ' ' N ' ' A' ' 41' ' ' GLN . 20.2 mm -99.38 135.84 32.99 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.569 179.673 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -61.84 65.1 0.02 OUTLIER Glycine 0 N--CA 1.461 0.346 0 N-CA-C 111.543 -0.623 . . . . 0.0 111.543 -179.418 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.556 ' N ' ' O ' ' A' ' 39' ' ' ILE . 59.7 tp60 -174.63 -57.49 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.884 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 73.4 m -90.88 -13.84 32.88 Favored 'General case' 0 CA--C 1.505 -0.755 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.588 179.719 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' LEU . . . . . 0.54 ' N ' HD12 ' A' ' 43' ' ' LEU . 8.3 mp 46.88 28.28 0.82 Allowed 'General case' 0 N--CA 1.436 -1.171 0 C-N-CA 119.697 -0.801 . . . . 0.0 111.378 178.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 54.4 t0 -96.36 136.63 36.59 Favored 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.571 ' CE1' ' CD2' ' A' ' 38' ' ' HIS . 64.6 m-85 -86.35 124.75 33.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.998 0.428 . . . . 0.0 110.0 -179.596 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 27.8 m -126.13 150.59 31.76 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.377 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.111 -179.713 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -98.55 125.96 43.96 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.582 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.1 p -136.77 155.0 32.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.188 -179.339 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' CYS . . . . . 0.553 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 17.7 t -97.07 164.65 12.42 Favored 'General case' 0 C--O 1.233 0.215 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.538 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 30.7 m-85 -133.98 126.59 18.78 Favored Pre-proline 0 C--N 1.33 -0.24 0 C-N-CA 121.031 -0.268 . . . . 0.0 110.856 -178.363 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 N--CA 1.491 1.339 0 C-N-CA 121.712 1.608 . . . . 0.0 112.218 179.97 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo . . . . . 0 N--CA 1.498 1.78 0 CA-C-O 120.641 0.184 . . . . 0.0 111.929 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.661 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.5 tt -129.65 120.61 25.5 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.126 -178.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.661 ' N ' HD23 ' A' ' 9' ' ' LEU . 7.2 tt -92.49 125.66 37.23 Favored 'General case' 0 N--CA 1.468 0.438 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 178.494 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.906 HD11 ' SG ' ' A' ' 47' ' ' CYS . 2.9 pt -103.56 -47.45 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-O 120.752 0.31 . . . . 0.0 111.0 -179.188 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -165.14 -135.73 1.88 Allowed Glycine 0 CA--C 1.519 0.311 0 C-N-CA 120.705 -0.76 . . . . 0.0 111.307 -179.649 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 71.3 p -136.89 159.6 41.38 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 114.99 -0.605 . . . . 0.0 110.163 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -56.72 -11.07 1.2 Allowed 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.026 179.636 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 97.3 mt -69.41 -43.24 81.05 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.329 0 CA-C-O 121.454 0.645 . . . . 0.0 109.782 179.71 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -104.34 -31.11 9.7 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 114.9 -1.045 . . . . 0.0 111.648 -178.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.427 ' O ' ' O ' ' A' ' 18' ' ' PRO . 12.0 m-85 -119.06 82.99 22.75 Favored Pre-proline 0 N--CA 1.471 0.612 0 N-CA-C 110.103 -0.332 . . . . 0.0 110.103 179.473 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.427 ' O ' ' O ' ' A' ' 17' ' ' PHE . 77.5 Cg_exo -47.61 179.87 0.01 OUTLIER 'Trans proline' 0 N--CA 1.495 1.57 0 C-N-CA 122.645 2.23 . . . . 0.0 111.701 -179.79 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.449 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 99.0 m -59.0 -50.71 73.06 Favored 'General case' 0 C--N 1.326 -0.428 0 C-N-CA 120.89 -0.324 . . . . 0.0 111.845 -178.513 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.628 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 1.1 pm0 -60.03 -52.59 64.73 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.161 -179.688 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.13 -47.29 85.24 Favored 'General case' 0 CA--C 1.519 -0.235 0 CA-C-O 121.297 0.57 . . . . 0.0 110.691 -179.212 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 38.5 t -45.12 -60.38 2.13 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 115.312 -0.858 . . . . 0.0 111.259 -178.792 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.666 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.9 p-10 -64.71 -51.69 61.07 Favored 'General case' 0 C--O 1.221 -0.411 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.734 -179.593 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.666 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 81.2 mttt -47.97 -42.86 28.77 Favored 'General case' 0 C--N 1.323 -0.554 0 C-N-CA 120.405 -0.518 . . . . 0.0 110.584 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 55.5 m -66.35 -33.3 75.41 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.163 0.506 . . . . 0.0 110.085 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 56.9 m -72.0 -34.04 68.56 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.876 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.3 mm -62.07 -48.51 88.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.727 -179.251 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.459 ' C ' ' H ' ' A' ' 30' ' ' ASN . 6.0 pt-20 -70.47 -30.81 67.71 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.799 -179.303 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 39.5 m -68.96 7.15 0.74 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.706 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.459 ' H ' ' C ' ' A' ' 28' ' ' GLU . 49.8 t30 72.73 47.86 0.22 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.366 179.487 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.55 ' C ' ' H ' ' A' ' 33' ' ' GLY . 73.9 m-85 -137.23 160.8 37.97 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.759 179.424 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.32 23.3 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.168 -179.66 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.55 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 91.92 -179.88 41.4 Favored Glycine 0 CA--C 1.519 0.338 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 -179.683 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -148.92 174.45 28.54 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.433 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 8.8 pttm -154.12 -179.08 7.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.035 0.445 . . . . 0.0 110.788 -179.781 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 3.9 m -105.03 124.46 49.56 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 115.718 -0.673 . . . . 0.0 110.308 179.658 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 35.7 m -136.67 165.91 27.38 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.75 -179.679 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 3.3 p80 -106.92 155.85 19.34 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-O 121.025 0.44 . . . . 0.0 110.66 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 96.0 mt -128.96 126.49 64.74 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.217 -179.481 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 61.46 22.48 61.41 Favored Glycine 0 CA--C 1.52 0.387 0 N-CA-C 111.555 -0.618 . . . . 0.0 111.555 178.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 26.7 mt-30 57.3 37.37 28.11 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.026 0.441 . . . . 0.0 110.03 -179.466 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 20.7 m -81.49 -11.09 59.33 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.181 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' LEU . . . . . 0.41 ' CD2' ' O ' ' A' ' 43' ' ' LEU . 0.9 OUTLIER 70.69 28.63 3.43 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.493 0.663 . . . . 0.0 109.659 -179.783 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -110.97 121.34 45.1 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.665 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 64.5 m-85 -90.63 117.1 29.03 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-O 121.163 0.506 . . . . 0.0 110.007 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.5 m -110.97 137.65 42.55 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.33 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.715 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.906 ' SG ' HD11 ' A' ' 11' ' ' ILE . 13.5 t -93.02 113.95 26.36 Favored 'General case' 0 CA--C 1.512 -0.481 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 -179.862 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 8.8 p -130.39 147.78 33.16 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.308 0 CA-C-O 121.143 0.497 . . . . 0.0 111.62 -178.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 4.8 m -97.43 170.82 8.79 Favored 'General case' 0 CA--C 1.518 -0.257 0 CA-C-N 115.258 -0.883 . . . . 0.0 109.793 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -130.15 143.29 48.57 Favored Pre-proline 0 CA--C 1.542 0.644 0 CA-C-N 116.512 -0.313 . . . . 0.0 111.266 -178.804 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_exo . . . . . 0 N--CA 1.498 1.736 0 C-N-CA 122.37 2.047 . . . . 0.0 112.011 177.676 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo . . . . . 0 N--CA 1.495 1.571 0 N-CA-C 111.187 -0.351 . . . . 0.0 111.187 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.69 HD13 ' N ' ' A' ' 10' ' ' LEU . 0.2 OUTLIER -111.32 126.69 55.18 Favored 'General case' 0 N--CA 1.468 0.472 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.685 -179.006 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.69 ' N ' HD13 ' A' ' 9' ' ' LEU . 2.6 tm? -92.05 128.5 37.91 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 178.336 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.47 HD11 ' SG ' ' A' ' 26' ' ' CYS . 0.0 OUTLIER -108.06 -40.09 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -178.63 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -177.94 -140.59 3.84 Favored Glycine 0 CA--C 1.52 0.404 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 179.698 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.496 ' C ' ' H ' ' A' ' 15' ' ' ILE . 80.6 p -135.63 161.08 36.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.017 0.437 . . . . 0.0 111.045 -179.534 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -58.17 -2.96 0.21 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.26 179.54 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.496 ' H ' ' C ' ' A' ' 13' ' ' THR . 23.8 mm -73.45 -22.65 19.18 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 CA-C-O 121.092 0.473 . . . . 0.0 109.948 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . 0.477 ' OE1' ' CZ ' ' A' ' 17' ' ' PHE . 9.5 pt-20 -134.51 -30.76 1.11 Allowed 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.154 -179.515 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.477 ' CZ ' ' OE1' ' A' ' 16' ' ' GLU . 9.9 m-85 -114.88 93.4 34.01 Favored Pre-proline 0 N--CA 1.468 0.426 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.537 -179.619 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.45 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 56.5 Cg_endo -79.25 -179.08 5.1 Favored 'Trans proline' 0 N--CA 1.489 1.235 0 C-N-CA 122.489 2.126 . . . . 0.0 111.23 -179.543 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.411 ' OG1' ' OE2' ' A' ' 20' ' ' GLU . 23.4 p -45.4 -48.68 13.52 Favored 'General case' 0 C--N 1.32 -0.687 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.116 -178.74 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.469 ' CD ' ' H ' ' A' ' 20' ' ' GLU . 0.3 OUTLIER -52.55 -70.72 0.08 Allowed 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.614 -179.316 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 16.2 ttmt -64.59 -47.36 78.95 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-O 121.443 0.64 . . . . 0.0 111.304 -178.008 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.45 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 51.8 t -41.78 -59.8 1.56 Allowed 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.205 -0.907 . . . . 0.0 111.039 -178.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.691 ' ND2' ' H ' ' A' ' 24' ' ' LYS . 0.0 OUTLIER -66.89 -55.13 16.01 Favored 'General case' 0 C--O 1.218 -0.577 0 C-N-CA 120.205 -0.598 . . . . 0.0 110.421 -179.634 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.691 ' H ' ' ND2' ' A' ' 23' ' ' ASN . 71.7 mttt -44.53 -42.6 7.34 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.871 0.367 . . . . 0.0 110.71 -179.231 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . 0.454 ' O ' ' OE2' ' A' ' 28' ' ' GLU . 8.8 m -65.12 -37.14 86.49 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.416 0.627 . . . . 0.0 109.558 179.408 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.47 ' SG ' HD11 ' A' ' 11' ' ' ILE . 67.9 m -72.08 -35.27 69.19 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.162 179.728 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.9 mm -62.67 -48.34 88.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.386 -179.192 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.454 ' OE2' ' O ' ' A' ' 25' ' ' THR . 2.6 pp20? -70.57 -31.09 67.97 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.601 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.434 ' N ' ' CD ' ' A' ' 28' ' ' GLU . 68.6 m -67.57 2.36 1.86 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.934 -179.688 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.411 ' H ' ' C ' ' A' ' 28' ' ' GLU . 41.6 t30 75.14 43.32 0.21 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.983 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.553 ' C ' ' H ' ' A' ' 33' ' ' GLY . 63.0 m-85 -131.92 160.99 34.13 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.459 179.463 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.48 31.19 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.96 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.553 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 84.11 -176.96 51.92 Favored Glycine 0 CA--C 1.52 0.4 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -150.58 172.13 30.35 Favored Glycine 0 CA--C 1.52 0.36 0 N-CA-C 110.715 -0.954 . . . . 0.0 110.715 -179.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 25.2 pttt -155.25 -179.02 7.68 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 120.935 0.398 . . . . 0.0 110.563 -179.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 3.3 m -103.94 127.08 51.48 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 115.866 -0.607 . . . . 0.0 110.172 179.384 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 34.5 m -136.77 159.81 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.419 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.55 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 2.9 p80 -104.6 156.94 17.53 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-O 121.072 0.463 . . . . 0.0 110.086 179.753 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.478 ' O ' ' N ' ' A' ' 41' ' ' GLN . 34.4 mm -109.21 125.13 66.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.243 -179.765 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 42.5 -92.42 0.01 OUTLIER Glycine 0 CA--C 1.526 0.75 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.484 ' N ' ' CD ' ' A' ' 41' ' ' GLN . 2.0 pm0 -143.9 30.44 1.31 Allowed 'General case' 0 N--CA 1.463 0.197 0 CA-C-O 120.702 0.287 . . . . 0.0 110.531 -179.64 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 66.3 m -84.43 -5.4 59.28 Favored 'General case' 0 CA--C 1.52 -0.188 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.689 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 45.14 28.37 0.4 Allowed 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.677 179.813 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -103.04 119.8 39.51 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.396 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 70.8 m-85 -87.75 117.8 26.83 Favored 'General case' 0 C--N 1.332 -0.191 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.725 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 33.4 m -112.82 137.09 47.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.331 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.432 ' O ' HD22 ' A' ' 10' ' ' LEU . 25.2 t -92.25 108.2 19.77 Favored 'General case' 0 CA--C 1.513 -0.445 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 179.838 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.2 p -124.36 150.23 28.96 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.229 0 CA-C-O 120.941 0.4 . . . . 0.0 110.634 -178.809 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 10.6 m -97.26 163.13 13.03 Favored 'General case' 0 CA--C 1.515 -0.386 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 -179.696 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 -119.33 143.29 34.05 Favored Pre-proline 0 CA--C 1.531 0.249 0 C-N-CA 121.141 -0.224 . . . . 0.0 111.227 -178.879 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo . . . . . 0 N--CA 1.494 1.522 0 C-N-CA 122.221 1.947 . . . . 0.0 111.989 178.81 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo . . . . . 0 N--CA 1.486 1.051 0 N-CA-C 110.993 -0.426 . . . . 0.0 110.993 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.611 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.5 tt -117.0 114.79 24.29 Favored 'General case' 0 CA--C 1.511 -0.523 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 -179.777 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.669 HD13 ' C ' ' A' ' 10' ' ' LEU . 3.0 tm? -93.27 124.5 37.29 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.37 -0.532 . . . . 0.0 109.881 179.266 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.962 HD11 ' SG ' ' A' ' 47' ' ' CYS . 5.7 pt -103.37 -41.91 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-O 121.052 0.453 . . . . 0.0 110.588 -179.342 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.453 ' O ' HD21 ' A' ' 10' ' ' LEU . . . -174.8 -139.5 3.03 Favored Glycine 0 CA--C 1.521 0.418 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.444 ' C ' ' H ' ' A' ' 15' ' ' ILE . 72.7 p -134.06 165.99 23.78 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.914 0.388 . . . . 0.0 110.924 -179.524 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -58.6 -5.6 0.58 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.206 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.444 ' H ' ' C ' ' A' ' 13' ' ' THR . 24.0 mm -74.5 -24.48 18.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.538 -179.292 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -128.33 -29.92 2.43 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.84 -179.592 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -117.34 91.96 38.84 Favored Pre-proline 0 CA--C 1.536 0.411 0 CA-C-N 116.486 -0.324 . . . . 0.0 110.474 179.759 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.463 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 52.9 Cg_endo -71.56 -177.33 2.4 Favored 'Trans proline' 0 N--CA 1.498 1.736 0 C-N-CA 123.12 2.547 . . . . 0.0 111.853 -179.25 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.473 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 31.0 m -46.73 -70.61 0.09 Allowed 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 120.568 -0.453 . . . . 0.0 111.358 -179.275 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.648 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 1.3 pm0 -41.39 -70.13 0.11 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.395 -178.865 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 5.3 ttmt -54.44 -53.88 48.23 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.021 0.439 . . . . 0.0 111.499 -177.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.463 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 43.0 t -41.41 -59.44 1.57 Allowed 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.071 -178.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.745 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 0.9 OUTLIER -65.82 -52.1 53.41 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.848 179.611 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.745 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 69.7 mttt -48.42 -42.61 32.65 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 120.839 0.352 . . . . 0.0 110.674 -178.539 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 20.0 m -63.93 -41.08 97.73 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-O 121.331 0.586 . . . . 0.0 109.995 179.789 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 57.5 m -65.23 -31.06 72.03 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.574 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.41 HG12 ' O ' ' A' ' 23' ' ' ASN . 3.1 mm -65.37 -38.83 83.48 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.427 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 30.2 mm-40 -65.74 -33.06 75.0 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.551 -0.749 . . . . 0.0 110.626 -178.739 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 46.2 m -73.27 -2.66 22.8 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.307 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 1.9 m120 77.84 34.5 0.32 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.958 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.573 ' C ' ' H ' ' A' ' 33' ' ' GLY . 8.2 m-85 -110.34 164.7 12.42 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.049 179.892 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.19 21.29 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.57 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.573 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 90.32 -178.7 43.25 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.371 -1.091 . . . . 0.0 110.371 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.421 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -147.01 170.33 27.93 Favored Glycine 0 CA--C 1.52 0.406 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 -179.344 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 10.7 ptmt -156.36 -177.0 6.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.619 0.247 . . . . 0.0 110.601 -179.576 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 1.7 m -104.02 125.76 50.62 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.131 179.489 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 34.0 m -133.92 162.57 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.297 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 3.1 p80 -109.12 157.42 18.76 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.867 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 92.1 mt -123.27 131.59 72.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.716 -179.485 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 49.55 -103.98 0.09 OUTLIER Glycine 0 CA--C 1.519 0.307 0 N-CA-C 110.812 -0.915 . . . . 0.0 110.812 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 41.2 tp60 -141.44 30.98 1.71 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.876 0.37 . . . . 0.0 110.396 -179.757 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 58.2 m -85.93 -5.7 59.19 Favored 'General case' 0 CA--C 1.518 -0.252 0 CA-C-O 120.967 0.413 . . . . 0.0 110.91 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' LEU . . . . . 0.403 ' CD2' ' O ' ' A' ' 43' ' ' LEU . 0.9 OUTLIER 44.42 29.95 0.43 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.398 -179.499 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -99.8 124.88 45.53 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.073 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -89.7 118.01 28.99 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 109.692 -0.485 . . . . 0.0 109.692 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 29.8 m -112.84 136.21 49.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.102 -179.52 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.962 ' SG ' HD11 ' A' ' 11' ' ' ILE . 22.1 t -92.94 105.98 18.01 Favored 'General case' 0 CA--C 1.513 -0.464 0 N-CA-C 109.373 -0.602 . . . . 0.0 109.373 179.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 4.7 p -125.54 154.97 34.6 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.375 0 CA-C-O 120.94 0.4 . . . . 0.0 110.573 -178.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 8.1 m -99.31 173.36 6.81 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.168 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 64.3 m-85 -133.6 117.95 14.44 Favored Pre-proline 0 CA--C 1.536 0.43 0 CA-C-N 116.269 -0.423 . . . . 0.0 109.999 179.224 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo . . . . . 0 N--CA 1.499 1.826 0 C-N-CA 122.186 1.924 . . . . 0.0 112.328 179.666 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo . . . . . 0 N--CA 1.502 1.986 0 CA-C-O 120.8 0.25 . . . . 0.0 112.303 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.657 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.6 tt -128.42 120.79 27.59 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.755 -179.215 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.657 ' N ' HD23 ' A' ' 9' ' ' LEU . 6.6 tt -89.05 133.9 34.19 Favored 'General case' 0 N--CA 1.468 0.46 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 178.128 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 12.8 pt -109.04 -37.02 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-O 120.869 0.366 . . . . 0.0 111.068 -178.775 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 175.32 -153.72 16.09 Favored Glycine 0 N--CA 1.452 -0.255 0 N-CA-C 110.913 -0.875 . . . . 0.0 110.913 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 6.7 p -90.03 164.85 14.35 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 10.4 t -76.07 7.35 4.19 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.214 179.601 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.5 mt -91.46 -42.32 13.65 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.221 0 CA-C-O 121.149 0.499 . . . . 0.0 109.808 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -87.91 -12.63 44.15 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.361 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -124.81 81.2 61.81 Favored Pre-proline 0 N--CA 1.463 0.217 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.954 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -48.64 163.23 0.29 Allowed 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.05 1.833 . . . . 0.0 110.719 178.731 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.406 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 25.5 p -46.5 -53.24 11.63 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.919 0.39 . . . . 0.0 111.721 -177.837 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.656 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 0.0 OUTLIER -59.72 -55.4 34.78 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.573 -179.429 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -58.96 -44.79 91.53 Favored 'General case' 0 CA--C 1.516 -0.336 0 CA-C-O 121.332 0.587 . . . . 0.0 110.388 -178.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 14.7 t -48.28 -65.46 0.56 Allowed 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 115.265 -0.88 . . . . 0.0 111.427 -178.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.659 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.6 p-10 -64.97 -46.97 79.26 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.011 -179.438 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.659 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 92.9 mttt -50.59 -37.55 40.53 Favored 'General case' 0 CA--C 1.5 -0.952 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.23 179.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 86.8 m -63.93 -42.79 97.26 Favored 'General case' 0 C--N 1.319 -0.751 0 O-C-N 124.012 0.82 . . . . 0.0 110.468 -179.342 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.497 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 33.8 t -72.58 -33.4 66.74 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.106 179.68 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.2 mm -66.08 -46.7 87.19 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.616 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.112 -179.192 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.505 ' C ' ' H ' ' A' ' 30' ' ' ASN . 19.0 pt-20 -69.64 -30.46 68.17 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 115.349 -0.841 . . . . 0.0 110.151 -179.698 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.416 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 68.3 m -65.49 1.78 1.09 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.75 179.845 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.505 ' H ' ' C ' ' A' ' 28' ' ' GLU . 16.9 t-20 79.82 12.56 1.1 Allowed 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.966 179.546 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.562 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 4.5 m-85 -98.07 -167.81 1.57 Allowed 'General case' 0 CA--C 1.533 0.322 0 CA-C-O 120.706 0.289 . . . . 0.0 110.27 -179.842 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -75.79 -53.97 7.65 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.582 0.586 . . . . 0.0 112.582 -178.543 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.497 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 166.5 178.9 39.45 Favored Glycine 0 CA--C 1.519 0.321 0 N-CA-C 110.068 -1.213 . . . . 0.0 110.068 -178.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -137.26 160.98 25.19 Favored Glycine 0 C--N 1.331 0.299 0 N-CA-C 111.579 -0.609 . . . . 0.0 111.579 -179.383 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 14.2 ptpt -153.45 170.23 21.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.29 -0.455 . . . . 0.0 110.779 -178.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 56.5 m -104.86 117.7 34.7 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.891 179.493 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 4.8 m -139.65 -178.5 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-O 120.873 0.368 . . . . 0.0 111.129 -179.427 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.619 ' ND1' ' N ' ' A' ' 44' ' ' ASP . 95.3 m-70 -114.0 147.98 37.72 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.802 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 95.6 mt -124.06 127.8 73.7 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.849 -179.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 68.74 21.78 75.09 Favored Glycine 0 CA--C 1.52 0.35 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 179.374 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 57.79 30.8 19.55 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.196 0.522 . . . . 0.0 109.794 -179.215 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 50.6 m -72.22 -10.92 60.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.443 -0.798 . . . . 0.0 110.511 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' LEU . . . . . 0.445 ' C ' ' ND1' ' A' ' 38' ' ' HIS . 0.9 OUTLIER 63.14 29.33 16.14 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.649 -179.636 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . 0.619 ' N ' ' ND1' ' A' ' 38' ' ' HIS . 67.2 t0 -111.05 138.69 47.16 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.714 179.499 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.489 ' N ' ' OD1' ' A' ' 44' ' ' ASP . 50.2 m-85 -92.95 117.38 29.98 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.645 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 25.9 m -124.29 136.81 59.29 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.328 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.052 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -94.46 122.59 37.19 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.352 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.0 p -135.52 152.52 31.71 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.318 0 C-N-CA 120.655 -0.418 . . . . 0.0 111.319 -179.393 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' CYS . . . . . 0.562 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 23.9 t -96.01 164.18 12.81 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.078 -179.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.494 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 37.7 m-85 -130.75 136.55 29.11 Favored Pre-proline 0 N--CA 1.476 0.849 0 C-N-CA 120.788 -0.365 . . . . 0.0 111.352 -178.427 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo . . . . . 0 N--CA 1.491 1.355 0 C-N-CA 121.865 1.71 . . . . 0.0 112.207 179.888 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo . . . . . 0 N--CA 1.501 1.934 0 CA-C-O 120.561 0.15 . . . . 0.0 111.797 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.634 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.5 tt -128.33 119.5 25.2 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.637 HD23 ' N ' ' A' ' 11' ' ' ILE . 6.6 tt -88.65 126.58 35.36 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 108.839 -0.801 . . . . 0.0 108.839 179.199 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.896 HD11 ' SG ' ' A' ' 47' ' ' CYS . 2.2 pt -105.36 -48.12 9.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-O 120.983 0.421 . . . . 0.0 110.852 -178.549 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -159.87 -144.22 3.9 Favored Glycine 0 CA--C 1.52 0.369 0 N-CA-C 110.771 -0.931 . . . . 0.0 110.771 -179.802 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.478 ' C ' ' H ' ' A' ' 15' ' ' ILE . 55.2 p -138.89 161.22 37.83 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.994 0.426 . . . . 0.0 110.809 -179.826 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -59.81 -1.28 0.26 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.221 179.652 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.478 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.2 mt -77.9 -23.65 13.98 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.406 0 CA-C-O 121.164 0.506 . . . . 0.0 109.806 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 2.7 pt-20 -134.24 -34.17 0.98 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.589 -0.732 . . . . 0.0 111.197 -179.381 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.431 ' CZ ' ' NZ ' ' A' ' 21' ' ' LYS . 6.4 m-85 -106.82 88.85 3.84 Favored Pre-proline 0 CA--C 1.538 0.5 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.416 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 19.0 Cg_endo -63.43 -173.6 0.18 Allowed 'Trans proline' 0 N--CA 1.499 1.799 0 C-N-CA 121.832 1.688 . . . . 0.0 112.461 -178.789 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 70.5 m -58.11 -49.81 75.66 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.021 -179.227 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.43 ' CG ' ' N ' ' A' ' 21' ' ' LYS . 8.9 pt-20 -59.06 -56.66 19.42 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.806 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.431 ' NZ ' ' CZ ' ' A' ' 17' ' ' PHE . 0.6 OUTLIER -64.51 -47.22 79.68 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-O 121.235 0.541 . . . . 0.0 111.087 -177.989 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.416 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 32.4 t -45.4 -63.18 1.0 Allowed 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.375 -0.83 . . . . 0.0 111.682 -179.149 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.625 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 0.0 OUTLIER -63.45 -49.6 73.03 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.008 -179.276 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.625 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 47.5 mttp -45.1 -42.37 8.72 Favored 'General case' 0 C--O 1.218 -0.563 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.087 -179.7 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 17.8 m -62.34 -43.49 98.7 Favored 'General case' 0 C--N 1.311 -1.094 0 C-N-CA 119.98 -0.688 . . . . 0.0 110.366 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.492 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 11.4 t -66.99 -32.65 74.03 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 121.574 0.702 . . . . 0.0 109.788 179.615 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.5 mm -65.9 -41.76 90.63 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.213 -179.445 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.447 ' C ' ' H ' ' A' ' 30' ' ' ASN . 25.6 mm-40 -65.43 -34.87 79.31 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.146 -0.933 . . . . 0.0 110.371 -179.477 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.412 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 27.3 m -66.76 2.38 1.41 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.189 -179.742 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.447 ' H ' ' C ' ' A' ' 28' ' ' GLU . 17.5 t-20 78.24 15.28 1.38 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.59 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.553 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 4.1 m-85 -95.79 -168.62 1.8 Allowed 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 120.898 0.38 . . . . 0.0 110.343 -179.764 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -76.05 -50.13 15.62 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.987 -178.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.492 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 160.39 -176.17 37.08 Favored Glycine 0 C--O 1.226 -0.402 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 -179.148 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.449 ' H ' ' HB2' ' A' ' 23' ' ' ASN . . . -146.02 168.14 27.66 Favored Glycine 0 CA--C 1.519 0.331 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 -179.41 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 14.6 ptpt -155.76 178.65 10.02 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.003 0.43 . . . . 0.0 110.81 -179.126 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 4.6 m -103.59 123.52 47.11 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.077 179.506 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 27.6 m -136.4 161.16 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.45 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.582 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 2.1 p80 -109.34 157.09 19.22 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.074 179.818 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.457 ' O ' ' N ' ' A' ' 41' ' ' GLN . 34.5 mm -107.83 125.74 64.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.174 -179.655 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 41.72 -94.4 0.01 OUTLIER Glycine 0 CA--C 1.527 0.782 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 179.694 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.457 ' N ' ' O ' ' A' ' 39' ' ' ILE . 16.6 mp0 -139.67 35.63 2.01 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.796 0.332 . . . . 0.0 110.348 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . 0.759 ' C ' HD23 ' A' ' 43' ' ' LEU . 63.7 m -87.02 2.22 50.29 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.951 -179.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' LEU . . . . . 0.759 HD23 ' C ' ' A' ' 42' ' ' SER . 1.3 pt? 34.64 28.06 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 O-C-N 123.756 0.66 . . . . 0.0 111.618 -179.583 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 42' ' ' SER . 52.5 t0 -107.78 120.42 42.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.478 -179.843 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 -88.79 117.66 27.93 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 32.5 m -115.12 142.85 26.43 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.269 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.177 -179.431 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.896 ' SG ' HD11 ' A' ' 11' ' ' ILE . 17.0 t -94.03 119.15 32.51 Favored 'General case' 0 CA--C 1.515 -0.396 0 CA-C-N 115.894 -0.594 . . . . 0.0 109.462 179.749 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.4 p -126.39 152.46 33.94 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.204 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.398 -179.512 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' CYS . . . . . 0.553 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 33.0 t -96.41 163.31 13.11 Favored 'General case' 0 N--CA 1.466 0.341 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 -179.771 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.484 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 19.0 m-85 -129.86 125.47 22.15 Favored Pre-proline 0 N--CA 1.469 0.497 0 C-N-CA 121.147 -0.221 . . . . 0.0 110.73 -178.738 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_endo . . . . . 0 N--CA 1.488 1.168 0 C-N-CA 121.812 1.674 . . . . 0.0 112.188 179.789 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.435 ' CB ' ' O ' ' A' ' 49' ' ' CYS . 74.2 Cg_endo . . . . . 0 N--CA 1.493 1.494 0 CA-C-O 120.548 0.145 . . . . 0.0 111.909 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.651 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.4 tt -135.55 119.68 17.66 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-O 120.764 0.316 . . . . 0.0 110.725 -179.312 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.651 ' N ' HD23 ' A' ' 9' ' ' LEU . 6.3 tt -88.97 133.43 34.32 Favored 'General case' 0 N--CA 1.464 0.255 0 N-CA-C 109.584 -0.525 . . . . 0.0 109.584 178.238 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.892 HD11 ' SG ' ' A' ' 47' ' ' CYS . 2.3 pt -109.62 -46.17 6.68 Favored 'Isoleucine or valine' 0 C--O 1.231 0.11 0 CA-C-O 120.835 0.35 . . . . 0.0 110.232 -178.716 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 179.46 -159.74 24.59 Favored Glycine 0 N--CA 1.452 -0.26 0 N-CA-C 111.276 -0.73 . . . . 0.0 111.276 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 68.7 p -100.99 164.09 11.98 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.193 -0.503 . . . . 0.0 110.245 179.755 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -59.12 -11.46 3.73 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.455 179.448 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 97.0 mt -70.35 -43.73 78.08 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 CA-C-O 121.159 0.505 . . . . 0.0 110.296 -179.693 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -98.05 -31.2 12.26 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.954 -179.402 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.779 ' CD2' HD12 ' A' ' 11' ' ' ILE . 13.9 m-85 -121.11 80.47 35.33 Favored Pre-proline 0 N--CA 1.469 0.52 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 178.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.433 ' O ' ' O ' ' A' ' 17' ' ' PHE . 75.3 Cg_exo -47.05 -178.9 0.0 OUTLIER 'Trans proline' 0 N--CA 1.495 1.583 0 C-N-CA 122.794 2.329 . . . . 0.0 111.747 -179.667 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 37.4 p -58.77 -54.71 44.04 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.418 0.628 . . . . 0.0 111.536 -179.278 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.404 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 8.9 pt-20 -55.74 -52.24 64.62 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.01 -0.996 . . . . 0.0 111.216 -179.685 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -63.64 -47.36 81.67 Favored 'General case' 0 CA--C 1.519 -0.215 0 CA-C-O 121.312 0.577 . . . . 0.0 110.534 -179.623 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 36.8 t -45.44 -63.18 1.01 Allowed 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 115.12 -0.945 . . . . 0.0 111.229 -179.233 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.609 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 0.0 OUTLIER -64.36 -47.9 77.58 Favored 'General case' 0 C--O 1.221 -0.424 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.867 -178.953 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.609 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 83.4 mttt -48.73 -39.51 25.1 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.22 -179.675 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . 0.434 ' O ' ' OG ' ' A' ' 29' ' ' SER . 16.7 m -64.9 -40.66 95.44 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.207 0.527 . . . . 0.0 110.112 -179.714 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.508 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 41.2 t -72.58 -36.3 68.13 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.409 0.623 . . . . 0.0 110.492 179.54 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.2 mm -64.62 -47.61 88.23 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.928 -179.097 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.411 ' C ' ' H ' ' A' ' 30' ' ' ASN . 2.9 pp20? -70.95 -27.52 63.8 Favored 'General case' 0 N--CA 1.446 -0.645 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.638 -179.504 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.477 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 72.8 m -67.17 0.66 2.55 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.611 -179.639 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.477 ' CB ' ' O ' ' A' ' 29' ' ' SER . 14.6 t-20 85.59 3.42 0.59 Allowed 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.534 179.781 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.578 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 47.5 m-85 -91.47 -167.79 1.88 Allowed 'General case' 0 N--CA 1.456 -0.169 0 CA-C-O 120.871 0.367 . . . . 0.0 110.525 179.608 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -78.34 -59.12 2.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.35 0.595 . . . . 0.0 111.756 -178.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.508 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 175.18 177.64 44.42 Favored Glycine 0 N--CA 1.449 -0.47 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -178.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.44 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -135.27 157.84 23.33 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -179.538 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 17.6 ptpt -149.62 166.96 27.71 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.915 0.388 . . . . 0.0 110.814 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 1.8 m -103.78 122.91 46.08 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.037 179.577 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 33.4 m -136.98 169.57 19.58 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.601 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.514 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 1.8 m-70 -97.45 154.04 17.74 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.116 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.464 ' O ' ' N ' ' A' ' 41' ' ' GLN . 42.2 mm -115.03 128.69 72.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 42.32 -94.41 0.01 OUTLIER Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.933 -0.867 . . . . 0.0 110.933 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.464 ' N ' ' O ' ' A' ' 39' ' ' ILE . 88.4 mt-30 -140.72 27.5 2.03 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.654 0.264 . . . . 0.0 110.672 -179.768 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 58.8 m -80.2 -9.99 59.74 Favored 'General case' 0 CA--C 1.518 -0.254 0 CA-C-O 121.012 0.434 . . . . 0.0 110.665 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' LEU . . . . . 0.403 ' O ' ' CD2' ' A' ' 43' ' ' LEU . 0.9 OUTLIER 41.92 30.85 0.19 Allowed 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.38 -179.355 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' A' ' 45' ' ' PHE . 66.2 t0 -110.24 141.17 43.57 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.139 179.877 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.521 ' N ' ' OD1' ' A' ' 44' ' ' ASP . 56.8 m-85 -88.59 116.43 26.82 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.045 0.45 . . . . 0.0 110.312 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 19.8 m -114.62 133.53 60.45 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.307 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.28 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.892 ' SG ' HD11 ' A' ' 11' ' ' ILE . 27.9 t -93.58 114.67 27.07 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.317 179.859 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.8 p -125.03 139.83 49.93 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.229 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.029 -178.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' CYS . . . . . 0.578 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 39.2 t -97.27 157.33 16.01 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 115.517 -0.765 . . . . 0.0 109.716 -179.687 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.431 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 0.2 OUTLIER -149.93 151.62 32.65 Favored Pre-proline 0 N--CA 1.473 0.688 0 C-N-CA 120.593 -0.443 . . . . 0.0 110.933 179.775 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_endo . . . . . 0 C--N 1.309 -1.514 0 C-N-CA 122.686 2.257 . . . . 0.0 111.956 178.851 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo . . . . . 0 N--CA 1.489 1.246 0 CA-C-O 120.757 0.232 . . . . 0.0 111.647 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.662 HD23 ' N ' ' A' ' 10' ' ' LEU . 4.0 tt -133.74 119.75 19.69 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 120.78 0.324 . . . . 0.0 110.524 -179.751 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.662 ' N ' HD23 ' A' ' 9' ' ' LEU . 5.8 tt -91.03 130.75 36.91 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.978 0.418 . . . . 0.0 109.947 178.326 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.961 HD11 ' SG ' ' A' ' 47' ' ' CYS . 5.8 pt -106.37 -44.59 7.75 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.632 -179.624 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -176.12 -133.74 1.83 Allowed Glycine 0 CA--C 1.519 0.305 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 -179.593 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.436 ' C ' ' H ' ' A' ' 15' ' ' ILE . 80.7 p -131.56 166.19 21.94 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.925 0.393 . . . . 0.0 111.034 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -61.66 -3.85 1.22 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.974 179.5 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.436 ' H ' ' C ' ' A' ' 13' ' ' THR . 34.2 mm -70.85 -42.73 77.36 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 CA-C-O 121.224 0.535 . . . . 0.0 109.92 -179.562 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -108.24 -23.07 12.09 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.628 -0.715 . . . . 0.0 111.072 -179.568 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 44.7 m-85 -124.67 79.17 63.15 Favored Pre-proline 0 C--O 1.223 -0.292 0 CA-C-N 116.577 -0.283 . . . . 0.0 110.553 179.687 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 71.4 Cg_exo -49.05 -179.01 0.01 OUTLIER 'Trans proline' 0 N--CA 1.501 1.93 0 C-N-CA 123.137 2.558 . . . . 0.0 111.733 179.457 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.454 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 96.2 m -58.22 -50.38 73.75 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 112.321 0.489 . . . . 0.0 112.321 -178.795 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.484 ' CG ' ' H ' ' A' ' 21' ' ' LYS . 6.6 pt-20 -56.57 -57.21 13.34 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.771 0.32 . . . . 0.0 111.257 -179.137 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.578 ' O ' HG22 ' A' ' 25' ' ' THR . 18.7 mtmt -62.91 -44.99 94.58 Favored 'General case' 0 CA--C 1.509 -0.604 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.377 -179.718 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.409 ' O ' ' SG ' ' A' ' 26' ' ' CYS . 53.2 t -47.64 -46.43 28.81 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-O 121.233 0.54 . . . . 0.0 111.235 -178.292 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.734 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.6 p-10 -78.92 -53.11 7.39 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 120.483 -0.487 . . . . 0.0 110.39 179.305 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.734 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 29.7 mttp -50.71 -45.04 58.28 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.646 -0.422 . . . . 0.0 110.734 -178.004 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . 0.578 HG22 ' O ' ' A' ' 21' ' ' LYS . 11.6 t -64.81 -37.86 89.04 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 121.391 0.615 . . . . 0.0 109.845 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.409 ' SG ' ' O ' ' A' ' 22' ' ' CYS . 54.8 m -63.61 -33.75 76.3 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.32 179.299 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.454 HG12 ' O ' ' A' ' 23' ' ' ASN . 3.3 mm -63.26 -36.86 77.75 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.054 179.728 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 29.0 mt-10 -66.1 -34.6 78.42 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.809 -178.639 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.411 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 7.1 m -72.59 -2.37 19.66 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.446 -179.173 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.411 ' CB ' ' O ' ' A' ' 29' ' ' SER . 4.5 m-80 78.31 33.68 0.3 Allowed 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.732 -179.88 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.581 ' C ' ' H ' ' A' ' 33' ' ' GLY . 8.0 m-85 -109.35 162.34 14.42 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.114 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.63 26.75 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.745 179.619 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.581 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 87.0 -174.92 46.23 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 110.739 -0.944 . . . . 0.0 110.739 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.425 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -151.67 172.04 31.12 Favored Glycine 0 CA--C 1.52 0.348 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 -179.313 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 20.0 pttt -156.27 -179.28 8.01 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.037 0.446 . . . . 0.0 110.63 -179.535 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 4.0 m -107.76 125.71 51.73 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.12 179.158 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 20.2 m -141.13 174.19 7.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.325 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.64 ' NE2' ' CE1' ' A' ' 45' ' ' PHE . 38.2 m80 -105.67 152.42 23.16 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.477 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 96.7 mt -129.8 125.58 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.477 179.497 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 66.46 21.66 70.74 Favored Glycine 0 CA--C 1.52 0.39 0 N-CA-C 111.339 -0.705 . . . . 0.0 111.339 179.126 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 58.24 38.08 26.14 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.933 0.396 . . . . 0.0 110.586 -179.818 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 44.1 m -82.26 -11.23 58.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.015 -179.847 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' LEU . . . . . 0.409 ' CD2' ' O ' ' A' ' 43' ' ' LEU . 0.8 OUTLIER 68.24 27.99 6.52 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.258 -179.607 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -111.7 135.49 52.23 Favored 'General case' 0 N--CA 1.463 0.188 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 179.262 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.64 ' CE1' ' NE2' ' A' ' 38' ' ' HIS . 52.6 m-85 -91.71 116.15 28.64 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.419 ' O ' HG23 ' A' ' 46' ' ' VAL . 13.2 m -112.9 133.7 57.88 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.272 0 CA-C-N 115.964 -0.562 . . . . 0.0 109.807 -179.824 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.961 ' SG ' HD11 ' A' ' 11' ' ' ILE . 34.6 t -92.48 115.35 28.02 Favored 'General case' 0 CA--C 1.511 -0.536 0 CA-C-N 116.167 -0.47 . . . . 0.0 109.842 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.2 p -134.36 148.58 29.75 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.412 0 CA-C-O 121.118 0.485 . . . . 0.0 110.861 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 6.6 m -97.59 161.66 13.66 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.505 179.729 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 53.0 m-85 -116.84 147.96 41.09 Favored Pre-proline 0 N--CA 1.464 0.259 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.028 -179.326 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo . . . . . 0 N--CA 1.492 1.42 0 C-N-CA 122.405 2.07 . . . . 0.0 111.895 179.298 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo . . . . . 0 N--CA 1.493 1.492 0 CA-C-O 121.023 0.343 . . . . 0.0 111.947 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.65 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.9 tt -136.67 117.31 13.91 Favored 'General case' 0 CA--C 1.52 -0.196 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.543 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.65 ' N ' HD23 ' A' ' 9' ' ' LEU . 8.8 tt -92.8 131.95 37.4 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 179.21 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 10.2 pt -104.18 -36.9 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.281 -179.285 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -177.31 -127.62 1.07 Allowed Glycine 0 CA--C 1.517 0.163 0 N-CA-C 110.674 -0.971 . . . . 0.0 110.674 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.496 ' C ' ' H ' ' A' ' 15' ' ' ILE . 71.5 p -127.77 154.42 45.4 Favored 'General case' 0 CA--C 1.52 -0.189 0 CA-C-O 120.861 0.363 . . . . 0.0 110.479 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 6.6 t -66.3 6.67 0.39 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.521 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.496 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.7 mt -86.58 -40.97 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.138 0 CA-C-O 120.86 0.362 . . . . 0.0 110.143 -179.858 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -102.41 -5.48 24.07 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.978 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 51.2 m-85 -123.5 79.87 54.38 Favored Pre-proline 0 N--CA 1.465 0.293 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.847 179.57 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -47.77 168.01 0.09 OUTLIER 'Trans proline' 0 N--CA 1.495 1.572 0 C-N-CA 122.963 2.442 . . . . 0.0 111.866 179.164 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.436 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 10.0 m -49.78 -52.85 28.93 Favored 'General case' 0 C--N 1.326 -0.425 0 C-N-CA 120.642 -0.423 . . . . 0.0 111.62 -178.806 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.648 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 1.3 pm0 -61.91 -56.96 13.85 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.081 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -56.6 -45.13 81.6 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 121.046 0.451 . . . . 0.0 110.69 -178.201 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 12.4 t -47.75 -65.46 0.56 Allowed 'General case' 0 C--N 1.314 -0.978 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.011 -178.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.656 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 2.4 p-10 -62.51 -54.43 40.09 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.339 -179.756 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.656 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 43.8 mtpt -44.53 -43.91 8.31 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 120.546 -0.462 . . . . 0.0 110.853 -179.698 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 99.3 m -64.13 -39.62 94.42 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-O 121.495 0.664 . . . . 0.0 109.875 -179.651 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 58.5 m -67.42 -32.59 73.58 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.698 -179.681 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.3 mm -63.14 -43.63 98.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.518 -179.396 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -65.31 -35.63 81.59 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.42 -178.888 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.445 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 84.0 p -67.12 -3.41 7.43 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.459 -179.325 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.445 ' CB ' ' O ' ' A' ' 29' ' ' SER . 3.2 t-20 80.52 37.14 0.1 Allowed 'General case' 0 N--CA 1.466 0.358 0 O-C-N 123.478 0.486 . . . . 0.0 110.783 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.585 ' C ' ' H ' ' A' ' 33' ' ' GLY . 13.9 m-85 -119.54 160.7 21.91 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 120.993 0.425 . . . . 0.0 110.084 -179.843 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -68.96 27.99 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.584 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.585 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 87.06 -172.92 44.24 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 179.829 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -154.04 174.48 32.52 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.731 -0.947 . . . . 0.0 110.731 -179.437 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 11.6 ptmt -155.89 -178.7 7.49 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.806 0.336 . . . . 0.0 110.507 -179.459 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 69.0 m -105.28 127.72 53.09 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.23 179.359 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 32.5 m -135.59 161.34 39.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.101 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 3.3 p80 -108.9 157.23 18.82 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.295 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.414 ' O ' ' N ' ' A' ' 41' ' ' GLN . 32.8 mm -104.59 122.42 57.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.328 -179.748 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 40.56 -96.47 0.01 OUTLIER Glycine 0 CA--C 1.524 0.634 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.85 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.414 ' N ' ' O ' ' A' ' 39' ' ' ILE . 97.5 mt-30 -139.65 30.47 2.1 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 120.675 0.274 . . . . 0.0 110.525 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 16.8 m -80.78 -6.22 58.21 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.138 0.494 . . . . 0.0 110.738 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' LEU . . . . . 0.443 HD22 ' HA ' ' A' ' 43' ' ' LEU . 0.2 OUTLIER 50.07 28.57 3.05 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.549 -179.702 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 38.7 t0 -109.43 120.79 43.59 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.112 179.594 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 70.6 m-85 -88.74 129.03 35.63 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-O 120.962 0.41 . . . . 0.0 109.919 -179.771 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 33.1 m -124.06 142.31 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.42 -179.359 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -95.25 119.84 34.45 Favored 'General case' 0 CA--C 1.518 -0.27 0 N-CA-C 109.211 -0.662 . . . . 0.0 109.211 -179.803 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.1 p -134.38 149.46 29.98 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.358 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.715 -179.195 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 14.1 m -98.69 177.97 5.14 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.79 179.741 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -137.28 121.12 11.95 Favored Pre-proline 0 CA--C 1.537 0.461 0 C-N-CA 120.82 -0.352 . . . . 0.0 111.035 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo . . . . . 0 N--CA 1.495 1.61 0 C-N-CA 122.626 2.217 . . . . 0.0 111.916 -179.744 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo . . . . . 0 N--CA 1.491 1.325 0 N-CA-C 111.642 -0.176 . . . . 0.0 111.642 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.733 HD13 ' N ' ' A' ' 10' ' ' LEU . 0.4 OUTLIER -125.05 122.78 38.23 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-O 121.258 0.551 . . . . 0.0 110.798 179.781 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.733 ' N ' HD13 ' A' ' 9' ' ' LEU . 5.9 tt -86.01 147.7 26.09 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.45 178.371 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -126.74 -58.96 1.58 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.569 -178.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -160.2 -140.1 2.82 Favored Glycine 0 CA--C 1.519 0.294 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.35 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.443 ' C ' ' H ' ' A' ' 15' ' ' ILE . 43.5 p -131.5 160.12 36.15 Favored 'General case' 0 CA--C 1.518 -0.261 0 CA-C-O 121.006 0.431 . . . . 0.0 110.857 -179.79 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -52.63 -11.2 0.19 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.066 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.443 ' H ' ' C ' ' A' ' 13' ' ' THR . 39.0 mm -72.3 -43.12 65.45 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 CA-C-O 121.158 0.504 . . . . 0.0 110.288 -179.398 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 1.9 pt-20 -102.27 -31.36 10.58 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.39 -0.823 . . . . 0.0 110.945 -179.531 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 15.6 m-85 -120.94 82.78 36.44 Favored Pre-proline 0 N--CA 1.466 0.339 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.128 179.73 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo -48.46 -179.14 0.01 OUTLIER 'Trans proline' 0 N--CA 1.493 1.487 0 C-N-CA 122.807 2.338 . . . . 0.0 111.965 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.431 ' OG1' ' OE2' ' A' ' 20' ' ' GLU . 28.6 p -57.27 -52.31 65.84 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 120.942 0.401 . . . . 0.0 111.557 -179.336 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.631 ' CD ' ' H ' ' A' ' 20' ' ' GLU . 0.2 OUTLIER -58.94 -57.84 11.3 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.474 -179.88 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -59.14 -43.94 92.05 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.736 -178.505 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.1 t -48.11 -60.97 2.22 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.881 -179.271 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.73 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.3 p-10 -62.59 -51.56 66.85 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.453 -179.631 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.73 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 31.7 mttp -47.36 -41.21 19.18 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.873 0.368 . . . . 0.0 110.168 -179.403 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 20.1 m -62.11 -43.9 97.81 Favored 'General case' 0 C--N 1.314 -0.939 0 C-N-CA 120.294 -0.563 . . . . 0.0 110.104 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 5.1 t -65.23 -32.68 74.48 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 179.645 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.5 mm -68.27 -31.71 52.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.538 -179.468 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 30.7 mm-40 -67.92 -34.99 77.68 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.762 -179.504 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.417 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 31.2 m -70.73 1.25 5.6 Favored 'General case' 0 CA--C 1.514 -0.408 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.944 -179.647 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.417 ' CB ' ' O ' ' A' ' 29' ' ' SER . 4.1 m-20 78.19 25.95 0.59 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.618 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.554 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 5.4 m-85 -103.29 -168.68 1.54 Allowed 'General case' 0 N--CA 1.452 -0.326 0 CA-C-O 120.952 0.406 . . . . 0.0 110.226 -179.744 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -76.2 -49.3 17.54 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.586 -179.596 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.496 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 160.54 -175.25 37.29 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 -179.478 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.427 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -148.03 170.4 28.67 Favored Glycine 0 C--O 1.226 -0.374 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -179.05 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 11.2 ptmt -158.68 -179.97 8.56 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.775 0.321 . . . . 0.0 110.525 -179.575 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 23.3 m -105.31 127.65 53.06 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.502 179.139 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 17.7 m -137.58 164.55 28.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.499 179.672 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.637 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 2.4 p80 -103.64 155.84 18.25 Favored 'General case' 0 N--CA 1.462 0.153 0 CA-C-O 121.002 0.429 . . . . 0.0 110.223 179.775 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 97.0 mt -131.37 128.59 61.51 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.627 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 60.4 23.36 60.15 Favored Glycine 0 CA--C 1.52 0.35 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 179.343 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 87.5 mt-30 56.43 30.9 17.82 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 120.881 0.372 . . . . 0.0 110.573 -179.874 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 4.0 m -78.64 -7.2 57.41 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.767 -179.701 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' LEU . . . . . 0.422 HD22 ' HA ' ' A' ' 43' ' ' LEU . 0.2 OUTLIER 68.92 27.84 5.43 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.559 -179.641 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 40.3 t0 -107.44 118.49 36.86 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.091 179.65 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 3.3 m-30 -91.07 115.89 28.37 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-O 121.225 0.536 . . . . 0.0 109.705 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 28.3 m -113.95 142.34 26.89 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.301 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.097 -179.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 24.2 t -94.33 119.0 32.45 Favored 'General case' 0 CA--C 1.516 -0.333 0 CA-C-N 116.024 -0.535 . . . . 0.0 109.771 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 10.7 p -128.81 151.33 35.44 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.409 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.392 -179.423 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' CYS . . . . . 0.557 ' SG ' ' N ' ' A' ' 50' ' ' PHE . 33.0 t -96.52 164.83 12.45 Favored 'General case' 0 CA--C 1.514 -0.435 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 -179.634 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.557 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 37.2 m-85 -132.25 131.93 22.67 Favored Pre-proline 0 N--CA 1.465 0.284 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.136 -179.068 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo . . . . . 0 N--CA 1.489 1.237 0 C-N-CA 122.068 1.845 . . . . 0.0 112.122 179.541 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_exo . . . . . 0 N--CA 1.496 1.655 0 N-CA-C 111.783 -0.122 . . . . 0.0 111.783 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.634 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.7 tt -122.87 117.17 24.99 Favored 'General case' 0 N--CA 1.476 0.874 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.294 179.41 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.656 HD23 ' N ' ' A' ' 11' ' ' ILE . 6.6 tt -95.11 127.48 41.19 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 179.187 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.812 HD11 ' SG ' ' A' ' 47' ' ' CYS . 1.3 pt -103.51 -51.42 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-O 120.779 0.323 . . . . 0.0 110.831 -179.014 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.431 ' H ' HG13 ' A' ' 11' ' ' ILE . . . -160.27 -136.45 2.02 Favored Glycine 0 N--CA 1.451 -0.316 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -179.879 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.5 p -132.1 170.96 14.24 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.1 0.476 . . . . 0.0 110.415 -179.416 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -67.9 -1.86 6.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.332 -179.326 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 2.4 pp -78.2 -20.99 13.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.236 -179.731 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -131.91 -28.94 1.72 Allowed 'General case' 0 C--O 1.233 0.214 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.621 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 42.3 m-85 -116.3 81.77 11.06 Favored Pre-proline 0 CA--C 1.534 0.331 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.367 179.239 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.436 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 16.8 Cg_endo -59.35 -176.41 0.11 Allowed 'Trans proline' 0 N--CA 1.5 1.861 0 C-N-CA 122.449 2.099 . . . . 0.0 112.17 -179.644 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.444 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 83.3 m -58.89 -49.55 77.36 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.678 -0.409 . . . . 0.0 111.299 -179.347 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.493 ' CG ' ' H ' ' A' ' 21' ' ' LYS . 8.0 pt-20 -55.57 -59.59 4.62 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.616 -179.516 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.493 ' H ' ' CG ' ' A' ' 20' ' ' GLU . 17.3 mtpp -64.68 -48.39 74.92 Favored 'General case' 0 CA--C 1.512 -0.501 0 CA-C-O 121.084 0.468 . . . . 0.0 111.818 -179.43 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.436 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 34.8 t -43.02 -52.51 5.24 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.106 -177.641 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.721 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 0.8 OUTLIER -65.05 -44.51 88.78 Favored 'General case' 0 C--O 1.22 -0.474 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.783 -179.955 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.721 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 89.1 mttt -50.72 -40.79 55.15 Favored 'General case' 0 CA--C 1.509 -0.609 0 C-N-CA 120.294 -0.562 . . . . 0.0 110.321 -179.575 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 70.0 p -63.2 -41.53 99.18 Favored 'General case' 0 C--N 1.313 -1.0 0 C-N-CA 119.179 -1.008 . . . . 0.0 110.376 -179.079 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.524 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 19.5 t -68.09 -34.1 75.76 Favored 'General case' 0 C--N 1.322 -0.587 0 C-N-CA 120.176 -0.61 . . . . 0.0 109.896 179.733 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.3 mm -66.3 -41.55 89.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.72 -179.258 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.418 ' C ' ' H ' ' A' ' 30' ' ' ASN . 40.2 mm-40 -64.13 -34.97 79.27 Favored 'General case' 0 N--CA 1.444 -0.746 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.654 -179.409 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.414 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 78.1 p -68.44 1.92 2.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.221 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.418 ' H ' ' C ' ' A' ' 28' ' ' GLU . 16.4 t-20 78.05 19.67 1.04 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.623 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.552 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 4.5 m-85 -98.32 -168.23 1.62 Allowed 'General case' 0 CA--C 1.53 0.191 0 CA-C-O 120.938 0.399 . . . . 0.0 110.351 -179.833 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -74.93 -53.26 9.32 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.791 -179.01 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.524 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 165.42 -178.51 40.3 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.151 -1.179 . . . . 0.0 110.151 -179.251 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.457 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -141.07 167.85 25.54 Favored Glycine 0 CA--C 1.519 0.293 0 N-CA-C 111.274 -0.73 . . . . 0.0 111.274 -179.219 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 15.0 ptpt -158.09 178.06 10.62 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.095 0.474 . . . . 0.0 110.401 -179.311 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 3.2 m -105.39 120.3 41.24 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.866 179.159 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 33.0 m -132.17 161.22 41.75 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.102 -179.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.556 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 3.2 p80 -107.07 157.14 18.06 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.184 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.512 ' O ' ' N ' ' A' ' 41' ' ' GLN . 33.2 mm -106.46 124.79 62.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.049 -179.549 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 43.34 -91.12 0.01 OUTLIER Glycine 0 C--N 1.33 0.205 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.512 ' N ' ' O ' ' A' ' 39' ' ' ILE . 42.0 tp60 -148.46 37.66 0.84 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.812 0.339 . . . . 0.0 110.436 -179.577 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 71.0 m -87.98 -2.39 58.58 Favored 'General case' 0 CA--C 1.519 -0.235 0 CA-C-O 121.042 0.449 . . . . 0.0 110.613 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 45.81 28.99 0.64 Allowed 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.551 179.522 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 68.3 t0 -108.88 119.32 39.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.919 179.455 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 81.3 m-85 -88.56 118.45 28.22 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.721 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 31.1 m -114.88 143.05 25.46 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.35 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.259 -179.406 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.812 ' SG ' HD11 ' A' ' 11' ' ' ILE . 18.4 t -94.07 117.88 30.73 Favored 'General case' 0 CA--C 1.513 -0.455 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.459 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.7 p -129.07 152.96 37.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-O 120.708 0.29 . . . . 0.0 110.306 -179.689 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' CYS . . . . . 0.552 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 17.2 t -96.83 164.94 12.34 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.547 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 38.1 m-85 -132.34 136.31 27.82 Favored Pre-proline 0 N--CA 1.468 0.474 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.842 -179.319 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo . . . . . 0 N--CA 1.495 1.571 0 C-N-CA 121.945 1.763 . . . . 0.0 112.391 179.903 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo . . . . . 0 N--CA 1.494 1.539 0 CA-C-O 120.699 0.208 . . . . 0.0 111.885 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.635 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.8 tt -138.3 118.02 13.14 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.273 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.663 HD23 ' N ' ' A' ' 11' ' ' ILE . 6.8 tt -92.68 130.87 38.18 Favored 'General case' 0 N--CA 1.465 0.305 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 178.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.899 HD11 ' SG ' ' A' ' 47' ' ' CYS . 1.5 pt -107.09 -50.18 7.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-O 120.917 0.389 . . . . 0.0 110.294 -178.78 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -163.35 -162.99 15.04 Favored Glycine 0 N--CA 1.449 -0.491 0 N-CA-C 110.754 -0.938 . . . . 0.0 110.754 179.689 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.5 p -83.93 163.07 20.24 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.829 0.347 . . . . 0.0 110.12 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 48.3 t -71.2 2.79 4.18 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.331 179.703 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 86.8 mt -91.08 -52.48 10.26 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.217 0 CA-C-N 116.234 -0.439 . . . . 0.0 109.826 179.717 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . 0.464 ' OE1' ' CE2' ' A' ' 17' ' ' PHE . 7.5 pt-20 -70.82 -35.45 72.5 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.16 179.113 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.464 ' CE2' ' OE1' ' A' ' 16' ' ' GLU . 59.9 m-85 -114.96 104.61 53.94 Favored Pre-proline 0 CA--C 1.544 0.738 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.44 179.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.457 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 56.9 Cg_endo -74.23 -179.8 5.08 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 C-N-CA 123.043 2.495 . . . . 0.0 111.752 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 70.8 m -57.38 -49.12 77.18 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.576 -179.613 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.49 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 6.7 pt-20 -54.63 -58.24 8.27 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.574 -0.285 . . . . 0.0 111.592 -179.477 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 5.7 ttmt -67.44 -56.65 8.74 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.385 0.612 . . . . 0.0 111.606 -179.145 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.457 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 48.1 t -38.64 -61.51 0.7 Allowed 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.241 -0.89 . . . . 0.0 111.4 -178.786 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.625 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 0.0 OUTLIER -63.42 -49.09 75.13 Favored 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.435 -179.874 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.625 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 51.3 mttm -47.46 -37.73 12.26 Favored 'General case' 0 CA--C 1.515 -0.399 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.218 -179.721 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 98.4 m -63.8 -41.74 97.84 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.342 0.591 . . . . 0.0 109.775 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.452 ' SG ' ' C ' ' A' ' 33' ' ' GLY . 40.2 t -72.13 -34.71 68.76 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.585 0.707 . . . . 0.0 109.999 179.311 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.5 mm -65.33 -48.08 84.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.144 -179.282 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.463 ' C ' ' H ' ' A' ' 30' ' ' ASN . 3.0 pp20? -70.31 -29.01 65.63 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.554 -179.656 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.452 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 24.4 m -65.2 0.89 1.17 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.198 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.463 ' H ' ' C ' ' A' ' 28' ' ' GLU . 7.4 t-20 81.05 14.53 0.64 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.435 179.804 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.569 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 5.2 m-85 -100.19 -167.72 1.49 Allowed 'General case' 0 C--N 1.339 0.144 0 CA-C-O 120.76 0.314 . . . . 0.0 110.204 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -76.18 -55.38 5.63 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.141 0.496 . . . . 0.0 111.859 -179.196 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.452 ' C ' ' SG ' ' A' ' 26' ' ' CYS . . . 168.56 173.29 36.27 Favored Glycine 0 CA--C 1.519 0.337 0 N-CA-C 110.318 -1.113 . . . . 0.0 110.318 -179.135 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.448 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -134.59 161.02 24.42 Favored Glycine 0 N--CA 1.46 0.237 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 -179.341 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 2.1 ptmm? -160.06 -174.77 4.72 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.966 0.412 . . . . 0.0 110.69 -178.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 30.7 m -104.67 120.09 40.52 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.831 179.361 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 2.6 m -137.79 166.29 24.65 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-O 121.113 0.482 . . . . 0.0 110.896 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.783 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 0.1 OUTLIER -108.85 157.29 18.74 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.403 179.291 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 83.9 mt -122.58 128.64 75.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.551 -179.358 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 52.85 -126.1 31.84 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.481 -1.048 . . . . 0.0 110.481 179.766 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -111.33 27.64 9.48 Favored 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 110.381 -0.229 . . . . 0.0 110.381 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . 0.497 ' O ' ' N ' ' A' ' 44' ' ' ASP . 52.0 m -85.14 -11.26 55.53 Favored 'General case' 0 CA--C 1.52 -0.199 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.914 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' LEU . . . . . 0.433 HD22 ' HA ' ' A' ' 43' ' ' LEU . 0.2 OUTLIER 36.79 28.26 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.063 -179.687 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . 0.497 ' N ' ' O ' ' A' ' 42' ' ' SER . 45.1 t0 -99.78 124.47 45.09 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.278 -179.903 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -85.72 124.55 32.36 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 -179.65 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 32.6 m -129.9 153.76 39.35 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.444 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.145 -179.348 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.899 ' SG ' HD11 ' A' ' 11' ' ' ILE . 34.9 t -93.75 116.43 28.91 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.436 -179.77 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.9 p -131.64 154.39 40.32 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.325 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.499 -178.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' CYS . . . . . 0.572 ' SG ' ' N ' ' A' ' 50' ' ' PHE . 16.4 t -97.42 164.49 12.43 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 179.833 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.572 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 29.6 m-85 -130.7 121.79 19.29 Favored Pre-proline 0 N--CA 1.465 0.321 0 C-N-CA 120.931 -0.307 . . . . 0.0 111.247 -178.68 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo . . . . . 0 N--CA 1.491 1.343 0 C-N-CA 121.721 1.614 . . . . 0.0 112.058 179.274 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo . . . . . 0 N--CA 1.494 1.535 0 N-CA-C 111.21 -0.342 . . . . 0.0 111.21 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.65 HD23 ' N ' ' A' ' 10' ' ' LEU . 4.0 tt -132.38 119.23 20.41 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.265 -179.615 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.65 ' N ' HD23 ' A' ' 9' ' ' LEU . 7.7 tt -93.5 127.33 39.1 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 178.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.92 HD11 ' SG ' ' A' ' 47' ' ' CYS . 3.1 pt -103.38 -46.14 10.32 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.412 -179.036 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -170.06 -138.01 2.4 Favored Glycine 0 CA--C 1.521 0.451 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.485 ' C ' ' H ' ' A' ' 15' ' ' ILE . 70.0 p -133.21 163.73 28.63 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.843 0.354 . . . . 0.0 110.902 -179.437 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -57.87 -4.79 0.34 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.97 179.674 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.485 ' H ' ' C ' ' A' ' 13' ' ' THR . 95.8 mt -73.24 -24.18 20.43 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 CA-C-O 121.01 0.433 . . . . 0.0 110.136 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -130.55 -32.06 1.75 Allowed 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.741 -179.614 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 53.7 m-85 -114.65 88.88 17.07 Favored Pre-proline 0 CA--C 1.54 0.568 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 179.36 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.455 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 43.4 Cg_endo -70.17 -178.04 2.31 Favored 'Trans proline' 0 N--CA 1.499 1.809 0 C-N-CA 122.91 2.406 . . . . 0.0 111.968 -179.509 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.455 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 7.1 m -45.93 -68.62 0.18 Allowed 'General case' 0 C--N 1.319 -0.757 0 C-N-CA 120.826 -0.35 . . . . 0.0 111.442 -179.275 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.645 ' CD ' ' H ' ' A' ' 20' ' ' GLU . 0.0 OUTLIER -44.36 -68.14 0.22 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.46 -0.337 . . . . 0.0 111.718 -178.794 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 6.9 ttmt -54.66 -51.63 64.86 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.039 0.447 . . . . 0.0 111.562 -178.043 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.455 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 45.3 t -46.03 -64.97 0.62 Allowed 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.368 -179.3 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.71 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 0.8 OUTLIER -61.86 -45.16 94.99 Favored 'General case' 0 C--O 1.22 -0.464 0 C-N-CA 120.721 -0.392 . . . . 0.0 110.478 -179.814 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.71 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 86.9 mttt -51.06 -37.08 43.35 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.443 -0.503 . . . . 0.0 109.852 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 13.4 m -64.36 -41.61 96.64 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.354 0.597 . . . . 0.0 110.352 -179.831 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.488 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 37.8 t -72.73 -34.91 67.39 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.029 179.467 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.2 mm -66.14 -47.68 83.94 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.571 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.884 -179.227 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.458 ' C ' ' H ' ' A' ' 30' ' ' ASN . 3.0 pp20? -70.21 -28.35 65.21 Favored 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.285 -179.413 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.465 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 56.1 m -66.25 1.05 1.71 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.051 -179.863 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.465 ' CB ' ' O ' ' A' ' 29' ' ' SER . 8.7 t-20 82.51 11.04 0.61 Allowed 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.406 179.858 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.552 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 23.0 m-85 -99.47 -171.22 2.03 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-O 121.036 0.445 . . . . 0.0 111.188 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -71.33 -59.91 2.51 Favored 'General case' 0 CA--C 1.532 0.254 0 CA-C-N 115.756 -0.657 . . . . 0.0 111.857 -179.03 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.488 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 172.39 176.8 41.4 Favored Glycine 0 CA--C 1.52 0.377 0 N-CA-C 110.345 -1.102 . . . . 0.0 110.345 -179.104 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.423 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -137.0 166.66 24.86 Favored Glycine 0 N--CA 1.462 0.402 0 N-CA-C 111.233 -0.747 . . . . 0.0 111.233 -179.529 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 12.2 ptmt -159.4 178.45 9.92 Favored 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.771 -179.393 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 1.4 m -106.5 127.71 53.52 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.008 178.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 28.8 m -134.41 159.75 41.84 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.247 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.32 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.8 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 0.1 OUTLIER -104.84 154.67 19.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.265 179.89 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.495 ' O ' ' N ' ' A' ' 41' ' ' GLN . 31.2 mm -107.01 128.02 62.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.361 -179.347 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 41.78 -91.56 0.01 OUTLIER Glycine 0 CA--C 1.525 0.711 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.495 ' N ' ' O ' ' A' ' 39' ' ' ILE . 40.6 tt0 -143.22 22.69 1.87 Allowed 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 121.039 0.447 . . . . 0.0 110.252 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 58.4 m -78.57 -9.45 59.36 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.079 0.466 . . . . 0.0 110.265 179.559 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' LEU . . . . . 0.416 ' O ' ' CD2' ' A' ' 43' ' ' LEU . 0.9 OUTLIER 47.03 30.42 1.28 Allowed 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.28 -179.715 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 67.8 t0 -98.78 119.91 38.32 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.597 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 58.1 m-85 -84.44 117.5 23.68 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.026 0.441 . . . . 0.0 110.342 -179.33 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 32.6 m -113.38 136.18 50.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.5 -179.454 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.92 ' SG ' HD11 ' A' ' 11' ' ' ILE . 27.4 t -93.03 115.4 28.08 Favored 'General case' 0 CA--C 1.514 -0.434 0 N-CA-C 109.284 -0.635 . . . . 0.0 109.284 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.5 p -130.88 150.41 34.58 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.261 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.8 -178.774 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' CYS . . . . . 0.552 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 23.6 t -96.82 162.9 13.22 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.529 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 33.7 m-85 -120.91 136.82 25.85 Favored Pre-proline 0 N--CA 1.47 0.541 0 C-N-CA 120.906 -0.318 . . . . 0.0 110.99 -178.85 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.4 ' HA ' ' CD1' ' A' ' 31' ' ' PHE . 23.1 Cg_endo . . . . . 0 N--CA 1.492 1.396 0 C-N-CA 121.759 1.64 . . . . 0.0 112.753 179.519 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo . . . . . 0 N--CA 1.494 1.511 0 N-CA-C 111.586 -0.198 . . . . 0.0 111.586 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.66 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.3 tt -133.67 120.89 21.21 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 120.568 0.223 . . . . 0.0 110.439 -179.008 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.66 ' N ' HD23 ' A' ' 9' ' ' LEU . 5.8 tt -87.68 134.56 33.63 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 178.535 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 13.2 pt -109.04 -35.0 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 120.934 0.397 . . . . 0.0 110.8 -178.702 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 175.69 -150.0 10.49 Favored Glycine 0 N--CA 1.451 -0.358 0 N-CA-C 110.794 -0.923 . . . . 0.0 110.794 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.416 ' C ' ' H ' ' A' ' 15' ' ' ILE . 42.0 p -98.8 160.66 14.12 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.83 0.347 . . . . 0.0 110.235 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 9.2 t -72.04 6.99 1.81 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.171 179.818 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.416 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.8 mt -91.42 -44.39 14.4 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.199 0 CA-C-N 116.053 -0.522 . . . . 0.0 109.949 179.785 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -87.46 -20.59 26.37 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.735 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 60.1 m-85 -120.69 99.08 47.66 Favored Pre-proline 0 CA--C 1.546 0.796 0 CA-C-N 116.732 -0.213 . . . . 0.0 110.595 179.515 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.409 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 36.4 Cg_endo -71.68 173.23 12.92 Favored 'Trans proline' 0 N--CA 1.493 1.495 0 C-N-CA 122.579 2.186 . . . . 0.0 111.288 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.48 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 10.0 m -47.67 -50.56 24.41 Favored 'General case' 0 C--N 1.319 -0.736 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.712 -179.242 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.603 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 0.5 OUTLIER -56.34 -68.33 0.22 Allowed 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 112.293 0.479 . . . . 0.0 112.293 -179.13 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 6.9 ttmt -57.95 -46.37 85.18 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 121.362 0.601 . . . . 0.0 111.551 -178.126 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.409 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 49.0 t -47.58 -65.03 0.63 Allowed 'General case' 0 C--N 1.308 -1.231 0 CA-C-N 115.311 -0.859 . . . . 0.0 111.465 -178.64 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.717 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 0.4 OUTLIER -65.39 -43.73 89.75 Favored 'General case' 0 C--O 1.222 -0.375 0 C-N-CA 120.4 -0.52 . . . . 0.0 110.893 -179.944 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.717 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 48.8 mttp -52.5 -39.68 61.54 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 120.19 -0.604 . . . . 0.0 109.909 179.826 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 91.6 m -62.62 -43.69 98.18 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.741 -179.438 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.521 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 16.6 t -66.14 -34.93 79.17 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.017 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.3 mm -66.17 -37.77 80.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.717 0 CA-C-N 114.937 -1.029 . . . . 0.0 110.113 179.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.41 ' C ' ' H ' ' A' ' 30' ' ' ASN . 34.3 mm-40 -64.09 -37.54 87.8 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.973 -1.012 . . . . 0.0 110.155 -179.369 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 35.9 m -69.46 0.59 4.98 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.834 179.638 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.41 ' H ' ' C ' ' A' ' 28' ' ' GLU . 18.2 t-20 76.7 21.15 1.28 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.508 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.532 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 3.8 m-85 -96.16 -166.93 1.5 Allowed 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 120.811 0.339 . . . . 0.0 110.493 -179.88 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.61 -51.42 16.89 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 116.076 -0.511 . . . . 0.0 112.113 -178.68 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.521 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 161.59 -179.87 36.71 Favored Glycine 0 CA--C 1.519 0.323 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 -179.036 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.424 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -132.49 157.42 22.53 Favored Glycine 0 CA--C 1.52 0.351 0 N-CA-C 111.417 -0.673 . . . . 0.0 111.417 -179.181 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 16.2 ptpt -154.27 168.78 25.44 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.41 -0.395 . . . . 0.0 110.506 -179.319 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 37.8 m -103.86 124.29 48.68 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.042 179.609 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 36.0 m -136.6 161.39 36.69 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-O 120.758 0.313 . . . . 0.0 110.9 -179.904 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.511 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 2.3 p80 -90.07 155.04 19.34 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.326 179.55 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 40.4 mm -110.66 121.6 63.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.816 -179.672 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 46.63 27.74 3.24 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 179.074 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 12.6 mm100 62.72 35.69 13.82 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.943 0.401 . . . . 0.0 110.242 -179.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . 0.422 ' O ' ' CB ' ' A' ' 43' ' ' LEU . 63.6 m -83.39 -7.93 59.48 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.883 -179.901 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' LEU . . . . . 0.422 ' CB ' ' O ' ' A' ' 42' ' ' SER . 0.9 OUTLIER 73.82 27.33 1.7 Allowed 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.239 0.542 . . . . 0.0 109.782 -179.523 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 36.0 t0 -111.74 117.05 31.79 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 178.547 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -91.42 120.61 32.42 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.241 0.543 . . . . 0.0 109.915 -179.819 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 33.5 m -123.5 140.13 47.99 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.449 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.079 -179.573 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -94.47 121.35 35.93 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.19 -179.727 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.2 p -134.35 151.87 32.82 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.312 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.844 -178.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' CYS . . . . . 0.532 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 28.4 t -93.9 161.89 14.13 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 -179.421 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.445 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 51.3 m-85 -127.93 142.52 44.64 Favored Pre-proline 0 N--CA 1.47 0.538 0 C-N-CA 120.619 -0.432 . . . . 0.0 111.359 -178.356 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo . . . . . 0 N--CA 1.494 1.528 0 C-N-CA 122.016 1.811 . . . . 0.0 112.219 179.636 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo . . . . . 0 N--CA 1.496 1.63 0 N-CA-C 111.416 -0.263 . . . . 0.0 111.416 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.619 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.8 tt -120.33 118.21 29.79 Favored 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.713 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.682 HD13 ' C ' ' A' ' 10' ' ' LEU . 2.7 tm? -89.04 124.99 34.81 Favored 'General case' 0 CA--C 1.522 -0.132 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.547 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.41 ' N ' HD13 ' A' ' 10' ' ' LEU . 14.9 pt -105.59 -35.58 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.159 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.811 -179.131 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.405 ' O ' HD21 ' A' ' 10' ' ' LEU . . . 176.92 -135.46 2.83 Favored Glycine 0 CA--C 1.522 0.5 0 N-CA-C 111.146 -0.781 . . . . 0.0 111.146 -179.873 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 68.0 p -132.92 161.73 33.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.94 0.4 . . . . 0.0 110.512 -179.629 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -55.91 -9.35 0.57 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.764 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 6.2 mm -71.94 -43.13 68.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 C-N-CA 120.5 -0.48 . . . . 0.0 110.59 -179.313 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -99.75 -23.51 14.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.106 -179.429 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -119.54 83.09 26.53 Favored Pre-proline 0 N--CA 1.463 0.189 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.033 179.583 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -53.29 165.89 1.3 Allowed 'Trans proline' 0 N--CA 1.491 1.367 0 C-N-CA 122.495 2.13 . . . . 0.0 110.582 178.553 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.448 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 36.0 p -45.61 -58.94 3.04 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-O 120.852 0.358 . . . . 0.0 111.701 -178.601 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.47 ' HG3' ' H ' ' A' ' 21' ' ' LYS . 6.6 pt-20 -46.01 -60.04 2.49 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.934 -179.385 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.47 ' H ' ' HG3' ' A' ' 20' ' ' GLU . 17.8 mtmt -63.73 -45.79 88.31 Favored 'General case' 0 CA--C 1.51 -0.583 0 CA-C-O 121.105 0.478 . . . . 0.0 111.299 -179.784 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 17.9 t -44.47 -62.61 1.12 Allowed 'General case' 0 C--N 1.31 -1.138 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.351 -178.396 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.693 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.8 p-10 -64.1 -50.48 68.12 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.866 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.693 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 41.2 mttm -48.99 -35.94 16.45 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -179.586 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 19.4 m -63.52 -42.26 98.47 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.192 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.491 ' SG ' ' C ' ' A' ' 33' ' ' GLY . 32.9 t -73.42 -36.9 66.03 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.537 0.684 . . . . 0.0 110.016 178.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.3 mm -64.65 -47.42 88.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.996 -178.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.433 ' C ' ' H ' ' A' ' 30' ' ' ASN . 2.9 pp20? -71.22 -23.26 61.98 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.756 -179.485 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 39.5 m -71.6 3.71 3.74 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.52 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.433 ' H ' ' C ' ' A' ' 28' ' ' GLU . 2.2 m120 77.59 22.26 0.92 Allowed 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.913 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.554 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 31.1 m-85 -111.25 -167.91 1.24 Allowed 'General case' 0 N--CA 1.455 -0.178 0 CA-C-O 120.82 0.343 . . . . 0.0 111.006 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -74.1 -58.36 3.35 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.94 -0.573 . . . . 0.0 112.239 -178.417 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.491 ' C ' ' SG ' ' A' ' 26' ' ' CYS . . . 172.8 170.63 36.74 Favored Glycine 0 CA--C 1.521 0.465 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -178.85 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.496 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -122.42 159.97 16.94 Favored Glycine 0 N--CA 1.463 0.458 0 N-CA-C 111.186 -0.765 . . . . 0.0 111.186 -178.812 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 16.2 ptpt -155.34 166.38 33.72 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.05 0.452 . . . . 0.0 110.695 -179.558 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.504 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 4.5 m -106.35 123.69 48.44 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.354 179.522 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 32.9 m -137.08 160.77 36.16 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.464 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.689 179.796 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.608 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 8.8 p80 -89.64 157.15 18.14 Favored 'General case' 0 CA--C 1.521 -0.153 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.295 179.488 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.4 ' C ' ' N ' ' A' ' 41' ' ' GLN . 5.7 mm -117.97 129.25 74.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.778 -179.467 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 46.01 22.18 0.79 Allowed Glycine 0 C--O 1.228 -0.233 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 179.328 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.4 ' N ' ' C ' ' A' ' 39' ' ' ILE . 39.6 tt0 69.78 36.75 1.99 Allowed 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.062 0.458 . . . . 0.0 110.175 -179.753 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 5.1 m -86.45 1.46 51.32 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.155 179.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER 57.16 26.89 12.69 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.526 -179.379 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 55.0 t0 -106.39 119.13 38.45 Favored 'General case' 0 N--CA 1.466 0.361 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 178.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 -85.12 115.68 23.06 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 121.181 0.515 . . . . 0.0 110.325 -179.112 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 11.6 m -111.18 134.57 53.08 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.262 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.19 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 0.8 OUTLIER -94.38 112.8 24.59 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.172 -179.792 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 4.8 p -129.58 155.0 41.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.306 -179.289 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' CYS . . . . . 0.587 ' SG ' ' N ' ' A' ' 50' ' ' PHE . 19.5 t -96.56 166.48 11.66 Favored 'General case' 0 N--CA 1.465 0.312 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.587 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 29.1 m-85 -126.92 117.88 22.25 Favored Pre-proline 0 N--CA 1.469 0.483 0 C-N-CA 121.028 -0.269 . . . . 0.0 110.745 -178.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_exo . . . . . 0 N--CA 1.486 1.083 0 C-N-CA 121.491 1.46 . . . . 0.0 112.27 179.218 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 72.4 mmtt . . . . . 0 N--CA 1.488 1.439 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 29.1 p-10 -91.59 10.59 27.37 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.623 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 27.2 mm -74.55 121.4 25.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.289 -179.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 65.0 t0 -64.06 -45.98 86.39 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.214 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 42.34 80.64 0.04 OUTLIER Glycine 0 CA--C 1.52 0.371 0 N-CA-C 111.15 -0.78 . . . . 0.0 111.15 179.676 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 2.7 ppt_? -133.47 38.13 3.29 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 111.952 0.352 . . . . 0.0 111.952 -179.084 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.497 ' NZ ' ' CE1' ' A' ' 54' ' ' TYR . 12.2 ptmt -128.54 78.74 75.39 Favored Pre-proline 0 N--CA 1.472 0.648 0 CA-C-O 121.173 0.511 . . . . 0.0 111.326 179.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_exo -61.5 145.04 98.26 Favored 'Trans proline' 0 C--N 1.303 -1.829 0 C-N-CA 122.256 1.971 . . . . 0.0 111.406 179.273 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.623 HD23 ' N ' ' A' ' 10' ' ' LEU . 2.9 tt -116.68 118.66 33.18 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-O 120.626 0.25 . . . . 0.0 110.493 -179.393 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.623 ' N ' HD23 ' A' ' 9' ' ' LEU . 8.4 tt -90.08 131.18 36.09 Favored 'General case' 0 N--CA 1.464 0.275 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 178.769 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.904 HD11 ' SG ' ' A' ' 47' ' ' CYS . 1.9 pt -108.67 -45.17 6.85 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 120.964 0.412 . . . . 0.0 110.415 -178.669 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -163.68 -176.38 35.55 Favored Glycine 0 N--CA 1.45 -0.421 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.515 ' O ' ' N ' ' A' ' 15' ' ' ILE . 13.6 m -86.65 137.3 32.58 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 8.7 t -46.93 -12.29 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 120.832 -0.347 . . . . 0.0 110.794 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.515 ' N ' ' O ' ' A' ' 13' ' ' THR . 96.6 mt -69.86 -44.3 78.95 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.287 0 CA-C-O 121.364 0.602 . . . . 0.0 110.487 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -88.09 -29.69 20.44 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-N 115.223 -0.899 . . . . 0.0 110.514 -179.599 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 53.0 m-85 -124.85 84.05 58.84 Favored Pre-proline 0 N--CA 1.465 0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.815 179.564 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -53.08 -177.0 0.03 OUTLIER 'Trans proline' 0 N--CA 1.498 1.743 0 C-N-CA 122.959 2.44 . . . . 0.0 111.609 179.26 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.454 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 97.8 m -58.22 -49.71 76.12 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 112.547 0.573 . . . . 0.0 112.547 -178.275 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.499 ' CG ' ' H ' ' A' ' 21' ' ' LYS . 9.0 pt-20 -56.14 -58.18 9.04 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 111.767 0.284 . . . . 0.0 111.767 -178.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.499 ' H ' ' CG ' ' A' ' 20' ' ' GLU . 15.4 mtmt -64.11 -44.72 91.39 Favored 'General case' 0 CA--C 1.51 -0.569 0 CA-C-O 121.221 0.534 . . . . 0.0 111.522 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 28.9 t -44.7 -57.67 3.54 Favored 'General case' 0 C--N 1.312 -1.058 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.757 -177.778 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.693 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.7 p-10 -64.22 -50.73 66.89 Favored 'General case' 0 C--O 1.218 -0.587 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.375 -179.559 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.693 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 70.7 mttt -50.18 -42.12 50.66 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 -179.656 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 15.5 m -64.51 -39.16 93.26 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.645 0.736 . . . . 0.0 109.607 179.115 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 73.0 m -68.76 -31.51 70.6 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.149 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.438 HG12 ' O ' ' A' ' 23' ' ' ASN . 3.0 mm -64.39 -47.03 91.25 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.506 0 CA-C-O 121.087 0.47 . . . . 0.0 110.914 -179.512 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.405 ' HG2' ' H ' ' A' ' 28' ' ' GLU . 9.1 pt-20 -70.14 -22.25 63.01 Favored 'General case' 0 N--CA 1.447 -0.622 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.872 -179.246 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 59.8 p -74.81 -2.07 25.0 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 179.55 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 77.66 27.92 0.58 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.168 -0.923 . . . . 0.0 110.725 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.552 ' C ' ' H ' ' A' ' 33' ' ' GLY . 5.5 m-85 -110.96 162.32 14.95 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.74 -179.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.65 32.85 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.664 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.552 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 81.43 -173.96 54.24 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 -179.743 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -153.65 177.25 31.28 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 -179.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 17.0 ptpt -154.06 177.65 10.84 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.942 0.401 . . . . 0.0 110.784 -179.352 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 67.3 m -104.69 117.76 34.9 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.011 179.123 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 27.1 m -136.31 159.5 38.37 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-O 120.902 0.382 . . . . 0.0 110.865 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.777 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 0.1 OUTLIER -91.07 157.76 17.05 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.47 179.626 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 39.2 mm -105.85 126.92 61.23 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.18 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.451 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 41.02 -98.47 0.01 OUTLIER Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 179.651 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 40.3 tt0 -135.83 21.49 3.3 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 120.986 0.422 . . . . 0.0 109.957 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 58.1 m -79.65 -8.71 59.38 Favored 'General case' 0 CA--C 1.515 -0.397 0 CA-C-O 121.127 0.489 . . . . 0.0 110.418 179.564 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . 0.405 ' O ' ' CD2' ' A' ' 43' ' ' LEU . 0.9 OUTLIER 47.12 29.62 1.17 Allowed 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.246 -179.651 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -102.79 119.54 39.02 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 178.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -81.13 132.77 35.38 Favored 'General case' 0 CA--C 1.517 -0.326 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 -179.349 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 35.2 m -134.96 152.39 32.71 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.404 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.547 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.904 ' SG ' HD11 ' A' ' 11' ' ' ILE . 41.0 t -94.34 113.76 25.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.626 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.1 p -126.05 137.9 56.28 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.19 0 CA-C-O 121.001 0.429 . . . . 0.0 110.604 -179.388 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 8.3 m -97.44 165.05 12.19 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.784 -179.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 42.5 m-85 -117.39 145.79 36.92 Favored Pre-proline 0 N--CA 1.47 0.537 0 CA-C-N 116.742 -0.208 . . . . 0.0 111.256 -179.11 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.404 ' HG3' ' H ' ' A' ' 7' ' ' LYS . 27.5 Cg_endo -63.75 149.46 90.75 Favored 'Trans proline' 0 N--CA 1.496 1.658 0 C-N-CA 122.57 2.18 . . . . 0.0 112.077 179.553 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 13.5 tppt? -143.52 -43.6 0.28 Allowed 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.284 179.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -110.01 21.63 16.59 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.752 -179.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . 0.497 ' CE1' ' NZ ' ' A' ' 7' ' ' LYS . 62.1 t80 -82.48 98.21 8.8 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.784 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 49.7 mt . . . . . 0 C--O 1.22 -0.459 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.193 -179.73 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . 0.543 ' C ' ' H ' ' A' ' 3' ' ' ILE . 68.7 mttm . . . . . 0 N--CA 1.489 1.5 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -55.92 -2.73 0.06 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.456 179.764 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.543 ' H ' ' C ' ' A' ' 1' ' ' LYS . 4.0 mm -63.63 129.33 27.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 120.991 0.424 . . . . 0.0 109.9 -179.67 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 41.4 t0 -66.78 -27.8 67.87 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.436 179.73 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.464 ' N ' HG22 ' A' ' 3' ' ' ILE . . . -75.13 70.21 1.85 Allowed Glycine 0 C--N 1.332 0.329 0 N-CA-C 111.066 -0.814 . . . . 0.0 111.066 -179.71 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.435 ' H ' ' HD3' ' A' ' 7' ' ' LYS . 3.1 ppt_? -130.85 30.65 4.59 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.58 0.229 . . . . 0.0 110.457 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.435 ' HD3' ' H ' ' A' ' 6' ' ' ARG . 0.2 OUTLIER -126.68 150.03 69.96 Favored Pre-proline 0 N--CA 1.464 0.248 0 CA-C-N 116.662 -0.245 . . . . 0.0 110.866 -179.643 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -57.3 140.67 93.65 Favored 'Trans proline' 0 N--CA 1.491 1.354 0 C-N-CA 121.824 1.683 . . . . 0.0 111.691 179.849 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.668 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.6 tt -121.53 119.68 32.67 Favored 'General case' 0 N--CA 1.474 0.748 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.562 -179.676 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.668 ' N ' HD23 ' A' ' 9' ' ' LEU . 6.8 tt -92.29 125.54 36.99 Favored 'General case' 0 N--CA 1.464 0.269 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 178.879 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.904 HD11 ' SG ' ' A' ' 47' ' ' CYS . 2.6 pt -102.54 -48.3 10.86 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.667 -179.056 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.411 ' H ' HG13 ' A' ' 11' ' ' ILE . . . -167.72 -138.29 2.42 Favored Glycine 0 N--CA 1.45 -0.398 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.487 ' C ' ' H ' ' A' ' 15' ' ' ILE . 43.1 p -132.62 159.01 40.79 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.085 0.469 . . . . 0.0 110.847 -179.697 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -56.12 -5.56 0.19 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.051 179.786 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.487 ' H ' ' C ' ' A' ' 13' ' ' THR . 84.6 mt -75.94 -26.5 17.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.883 0.373 . . . . 0.0 110.723 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -124.47 -27.69 3.71 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.063 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -122.62 80.57 47.75 Favored Pre-proline 0 C--O 1.233 0.187 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.335 179.206 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_exo -53.0 179.33 0.04 OUTLIER 'Trans proline' 0 N--CA 1.495 1.563 0 C-N-CA 122.787 2.325 . . . . 0.0 111.141 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.467 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 30.5 p -53.74 -61.28 2.4 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 121.074 0.464 . . . . 0.0 111.995 -179.802 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.479 ' HG3' ' H ' ' A' ' 21' ' ' LYS . 5.4 pt-20 -43.8 -59.41 2.25 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.387 -178.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.479 ' H ' ' HG3' ' A' ' 20' ' ' GLU . 19.8 mtmt -64.43 -46.15 84.42 Favored 'General case' 0 CA--C 1.509 -0.608 0 CA-C-O 121.201 0.524 . . . . 0.0 111.269 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 41.2 t -45.07 -60.56 2.03 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-N 115.549 -0.75 . . . . 0.0 111.124 -178.475 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.693 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 2.1 p-10 -65.63 -54.86 21.8 Favored 'General case' 0 C--O 1.22 -0.466 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.517 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.693 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 80.3 mttt -44.91 -44.5 9.75 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 120.691 -0.403 . . . . 0.0 110.575 -179.602 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 17.5 m -63.64 -39.9 95.52 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.164 0.506 . . . . 0.0 110.02 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 51.4 m -66.46 -31.4 72.12 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.573 -0.74 . . . . 0.0 111.042 -179.882 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.4 mm -63.94 -41.33 92.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-O 121.323 0.582 . . . . 0.0 110.141 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.415 ' C ' ' H ' ' A' ' 30' ' ' ASN . 52.9 mm-40 -67.06 -37.7 84.49 Favored 'General case' 0 N--CA 1.445 -0.725 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.527 -178.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 33.7 m -69.07 5.8 1.1 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.029 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.415 ' H ' ' C ' ' A' ' 28' ' ' GLU . 48.4 t30 71.47 50.89 0.26 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.067 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.581 ' C ' ' H ' ' A' ' 33' ' ' GLY . 57.0 m-85 -133.81 162.78 31.08 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.733 179.887 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.17 23.06 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.053 -0.522 . . . . 0.0 110.719 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.581 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 89.78 -175.8 42.22 Favored Glycine 0 CA--C 1.52 0.374 0 N-CA-C 110.533 -1.027 . . . . 0.0 110.533 -179.893 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -147.83 174.01 27.7 Favored Glycine 0 CA--C 1.522 0.482 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 -179.379 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 13.2 ptmt -155.44 178.57 10.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.885 0.374 . . . . 0.0 110.578 -179.377 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 1.8 m -105.17 128.07 53.21 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.144 179.227 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 19.3 m -134.47 158.62 41.93 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.047 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.683 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 0.9 OUTLIER -101.36 156.41 17.47 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.023 179.943 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 35.9 mm -112.67 127.27 70.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.98 -179.755 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.495 ' O ' ' NE2' ' A' ' 41' ' ' GLN . . . 40.11 -97.82 0.01 OUTLIER Glycine 0 CA--C 1.527 0.795 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.495 ' NE2' ' O ' ' A' ' 40' ' ' GLY . 99.2 mm-40 -137.45 28.38 2.75 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.838 0.351 . . . . 0.0 110.477 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . 0.774 ' C ' HD23 ' A' ' 43' ' ' LEU . 73.5 m -87.29 4.73 41.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.917 179.883 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . 0.774 HD23 ' C ' ' A' ' 42' ' ' SER . 1.2 pt? 34.65 27.99 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.27 0 O-C-N 123.788 0.68 . . . . 0.0 111.496 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . 0.543 ' N ' ' O ' ' A' ' 42' ' ' SER . 43.4 t0 -99.98 121.1 40.84 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.572 -179.466 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -87.65 117.75 26.68 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.087 0.47 . . . . 0.0 109.963 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 30.6 m -111.86 136.05 49.24 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.255 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.116 -179.623 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.904 ' SG ' HD11 ' A' ' 11' ' ' ILE . 14.0 t -93.39 115.84 28.39 Favored 'General case' 0 CA--C 1.518 -0.286 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.628 -179.575 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.8 p -131.89 152.03 36.19 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.507 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.762 -179.036 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 6.4 m -97.47 172.51 7.7 Favored 'General case' 0 CA--C 1.515 -0.376 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.636 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 56.4 m-85 -138.23 142.57 35.8 Favored Pre-proline 0 C--N 1.331 -0.225 0 C-N-CA 120.882 -0.327 . . . . 0.0 111.359 -179.487 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -67.94 161.49 43.89 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 122.408 2.072 . . . . 0.0 112.297 178.516 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 30.6 mmtp -57.56 -83.51 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.702 -179.794 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 13.6 p90 -130.59 38.18 3.75 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.631 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 59.2 t80 -79.6 97.3 6.44 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.946 0.403 . . . . 0.0 110.217 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 32.6 pt . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.961 -1.019 . . . . 0.0 110.493 -179.875 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 31.5 mtmm . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 43.6 t0 -69.0 -7.03 31.59 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.597 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.412 HG22 ' H ' ' A' ' 5' ' ' GLY . 45.0 mm -70.22 134.33 30.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 121.148 0.499 . . . . 0.0 110.921 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . 0.477 ' OD1' ' N ' ' A' ' 4' ' ' ASP . 16.8 p-10 -63.72 -39.98 95.63 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.608 -0.723 . . . . 0.0 110.675 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.412 ' H ' HG22 ' A' ' 3' ' ' ILE . . . 59.13 65.96 3.11 Favored Glycine 0 CA--C 1.516 0.125 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 179.414 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -130.22 22.53 5.23 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 110.525 -0.176 . . . . 0.0 110.525 -179.621 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 9.2 pttp -132.57 149.14 72.22 Favored Pre-proline 0 CA--C 1.533 0.322 0 C-N-CA 121.051 -0.259 . . . . 0.0 111.146 179.652 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_exo -48.4 135.87 25.92 Favored 'Trans proline' 0 N--CA 1.494 1.51 0 C-N-CA 121.991 1.794 . . . . 0.0 111.876 178.697 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.695 HD13 ' N ' ' A' ' 10' ' ' LEU . 0.2 OUTLIER -125.7 128.97 48.61 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-O 121.154 0.502 . . . . 0.0 110.708 179.895 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.695 ' N ' HD13 ' A' ' 9' ' ' LEU . 6.1 tt -90.97 136.63 32.94 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.396 178.867 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.467 HD13 ' N ' ' A' ' 11' ' ' ILE . 0.0 OUTLIER -105.88 -47.47 8.93 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.262 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.125 -179.667 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -172.63 -124.74 0.79 Allowed Glycine 0 CA--C 1.519 0.307 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.53 ' C ' ' H ' ' A' ' 15' ' ' ILE . 66.3 p -127.81 150.36 49.86 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.912 0.387 . . . . 0.0 110.264 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 7.4 t -63.63 4.66 0.24 Allowed 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.353 179.714 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.53 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.2 mt -88.48 -40.75 13.69 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.181 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -99.6 -11.9 20.56 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.752 179.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -124.99 81.06 63.12 Favored Pre-proline 0 N--CA 1.464 0.275 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.028 179.602 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -53.44 168.03 0.75 Allowed 'Trans proline' 0 N--CA 1.5 1.9 0 C-N-CA 123.146 2.564 . . . . 0.0 111.507 178.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.447 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 39.9 p -45.71 -60.01 2.45 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 112.003 0.371 . . . . 0.0 112.003 -178.837 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.492 ' HG3' ' H ' ' A' ' 21' ' ' LYS . 6.6 pt-20 -46.37 -61.16 1.92 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.05 -179.27 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.492 ' H ' ' HG3' ' A' ' 20' ' ' GLU . 20.0 mtmt -63.11 -45.77 90.49 Favored 'General case' 0 CA--C 1.508 -0.644 0 CA-C-O 121.292 0.568 . . . . 0.0 111.629 -179.595 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 22.2 t -43.62 -59.35 2.22 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.024 -178.427 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.722 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 2.2 p-10 -67.3 -57.86 5.87 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.578 179.635 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.722 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 72.0 mttt -43.37 -43.62 5.2 Favored 'General case' 0 C--O 1.222 -0.358 0 CA-C-O 120.852 0.358 . . . . 0.0 110.51 -178.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 19.6 m -64.09 -40.61 96.61 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.177 0.513 . . . . 0.0 110.178 179.66 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.421 ' N ' ' O ' ' A' ' 23' ' ' ASN . 25.5 m -66.71 -30.73 71.04 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.795 -179.895 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.8 mm -64.87 -41.28 91.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-O 121.292 0.568 . . . . 0.0 110.009 -179.705 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.418 ' C ' ' H ' ' A' ' 30' ' ' ASN . 31.2 mm-40 -65.84 -38.07 87.89 Favored 'General case' 0 N--CA 1.447 -0.612 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.379 -178.705 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 26.8 m -69.49 5.15 1.46 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.639 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.418 ' H ' ' C ' ' A' ' 28' ' ' GLU . 44.6 t30 70.86 54.85 0.25 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.006 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.563 ' C ' ' H ' ' A' ' 33' ' ' GLY . 60.4 m-85 -137.76 161.98 35.13 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.592 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.47 28.28 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.981 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.563 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 85.07 -175.26 49.98 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 110.7 -0.96 . . . . 0.0 110.7 -179.784 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.418 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -148.63 174.0 28.42 Favored Glycine 0 CA--C 1.522 0.483 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 -179.403 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 4.7 ptmm? -155.86 -178.12 7.07 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.592 0.234 . . . . 0.0 110.384 -179.247 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 31.1 m -104.45 129.69 52.42 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.414 179.228 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 28.5 m -137.78 161.85 32.63 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.261 179.696 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 3.5 p80 -109.06 157.62 18.53 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.217 -0.447 . . . . 0.0 109.998 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 83.6 mt -122.21 125.98 73.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.339 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 42.03 -128.51 4.37 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.891 -0.883 . . . . 0.0 110.891 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 29.0 pt20 -106.82 31.7 5.1 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 120.694 0.283 . . . . 0.0 110.413 179.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 20.1 m -84.39 -9.77 58.13 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 120.983 0.42 . . . . 0.0 110.598 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . 0.444 HD22 ' HA ' ' A' ' 43' ' ' LEU . 0.2 OUTLIER 40.02 29.41 0.05 Allowed 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.635 -0.712 . . . . 0.0 110.872 -179.144 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -107.55 126.45 52.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.222 179.691 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -90.65 124.55 35.16 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.638 -0.505 . . . . 0.0 109.638 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 30.5 m -120.47 138.07 52.19 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 CA-C-N 116.068 -0.514 . . . . 0.0 109.997 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -94.31 119.22 32.75 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.1 p -134.18 153.18 35.4 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.448 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.588 -179.069 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 5.9 m -97.28 172.23 7.92 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.898 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 56.4 m-85 -132.6 148.07 68.11 Favored Pre-proline 0 CA--C 1.531 0.214 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.939 -179.163 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -68.0 161.0 46.09 Favored 'Trans proline' 0 N--CA 1.494 1.52 0 C-N-CA 122.74 2.293 . . . . 0.0 112.308 179.356 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -65.54 -81.5 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.761 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.419 ' O ' ' CD2' ' A' ' 53' ' ' TYR . 33.3 p90 -128.95 32.53 4.74 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.827 -179.742 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . 0.47 ' O ' HG23 ' A' ' 55' ' ' ILE . 46.0 t80 -73.86 125.5 28.31 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.784 0.326 . . . . 0.0 110.216 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.47 HG23 ' O ' ' A' ' 54' ' ' TYR . 9.0 pt . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 118.087 -0.959 . . . . 0.0 110.391 -179.837 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 45.7 mmtt . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -99.43 4.61 46.25 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.196 179.602 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 12.9 tt -52.04 140.96 6.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.492 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -63.16 -38.93 93.13 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.109 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -91.05 88.49 1.41 Allowed Glycine 0 C--O 1.228 -0.238 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 3.8 ppt_? -133.49 41.11 3.1 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 120.743 0.306 . . . . 0.0 110.65 -179.55 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.401 ' H ' ' HG3' ' A' ' 51' ' ' PRO . 10.3 tptm -130.41 78.93 73.41 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 120.843 0.354 . . . . 0.0 111.258 -179.79 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 21.3 Cg_exo -65.46 155.92 66.24 Favored 'Trans proline' 0 C--N 1.307 -1.637 0 C-N-CA 122.856 2.37 . . . . 0.0 111.363 178.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.64 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.8 tt -126.43 116.65 21.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.598 179.858 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.67 HD23 ' N ' ' A' ' 11' ' ' ILE . 7.2 tt -91.71 129.11 37.73 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 179.009 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.907 HD11 ' SG ' ' A' ' 47' ' ' CYS . 1.4 pt -105.61 -50.07 8.65 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-O 120.837 0.351 . . . . 0.0 110.921 -178.496 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -160.43 -164.61 15.75 Favored Glycine 0 N--CA 1.451 -0.308 0 N-CA-C 110.694 -0.963 . . . . 0.0 110.694 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.457 ' C ' ' H ' ' A' ' 15' ' ' ILE . 6.5 m -89.33 158.29 17.86 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.843 0.354 . . . . 0.0 110.423 -179.385 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 9.5 t -69.35 6.6 0.98 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.207 179.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.457 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.5 mt -91.44 -45.62 14.52 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.148 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -90.92 -11.37 39.33 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.925 179.649 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 54.1 m-85 -142.78 82.02 12.7 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.684 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.42 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 15.9 Cg_exo -65.95 -172.72 0.28 Allowed 'Trans proline' 0 N--CA 1.493 1.479 0 C-N-CA 122.904 2.403 . . . . 0.0 111.83 179.279 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.512 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 26.2 p -48.07 -56.68 7.19 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 120.826 -0.35 . . . . 0.0 111.698 -179.054 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.649 ' CD ' ' H ' ' A' ' 20' ' ' GLU . 0.0 OUTLIER -47.91 -72.2 0.06 Allowed 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.121 0.486 . . . . 0.0 111.736 -178.719 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 52.0 mtmt -60.49 -42.94 97.36 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.683 -178.273 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.42 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 44.7 t -44.94 -59.77 2.4 Favored 'General case' 0 C--N 1.313 -1.013 0 C-N-CA 120.215 -0.594 . . . . 0.0 111.089 -178.547 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.746 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.5 p-10 -64.58 -55.64 19.09 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.546 -179.468 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.746 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 69.1 mttt -47.14 -42.79 20.07 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 120.788 -0.365 . . . . 0.0 110.584 -178.742 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 11.4 m -65.8 -37.75 87.13 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.242 179.71 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 37.9 m -67.64 -33.63 75.34 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.877 -0.602 . . . . 0.0 110.287 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.6 mm -61.5 -46.35 96.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.564 -179.536 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -66.34 -31.07 71.64 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.494 -179.035 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 27.1 m -72.87 1.5 8.57 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.405 -179.12 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.3 m-80 74.51 52.98 0.09 Allowed 'General case' 0 C--N 1.329 -0.312 0 O-C-N 123.559 0.537 . . . . 0.0 111.032 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.565 ' C ' ' H ' ' A' ' 33' ' ' GLY . 68.6 m-85 -138.61 162.02 35.66 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.688 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.79 30.24 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.57 179.626 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.565 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 83.6 -176.87 52.53 Favored Glycine 0 CA--C 1.521 0.442 0 N-CA-C 110.568 -1.013 . . . . 0.0 110.568 -179.653 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.428 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -147.3 178.04 25.18 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 -179.595 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 14.7 ptmt -156.87 -176.79 6.17 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 110.237 -0.283 . . . . 0.0 110.237 -179.625 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 66.7 m -108.44 122.2 46.53 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.519 179.573 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 2.8 m -137.89 163.46 29.98 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.837 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.465 ' CD2' ' H ' ' A' ' 38' ' ' HIS . 2.4 p80 -92.97 157.61 16.24 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.341 179.714 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.437 ' O ' ' N ' ' A' ' 41' ' ' GLN . 34.1 mm -110.18 123.44 66.08 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 CA-C-O 121.086 0.47 . . . . 0.0 110.679 -179.741 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 43.99 20.74 0.17 Allowed Glycine 0 C--O 1.227 -0.307 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.575 179.629 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.437 ' N ' ' O ' ' A' ' 39' ' ' ILE . 37.3 tt0 72.61 36.18 1.01 Allowed 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.846 0.355 . . . . 0.0 110.721 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . 0.422 ' N ' ' O ' ' A' ' 39' ' ' ILE . 41.0 m -85.61 -2.66 58.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.206 0.527 . . . . 0.0 110.885 -179.785 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . 0.447 HD22 ' HA ' ' A' ' 43' ' ' LEU . 0.2 OUTLIER 69.96 26.4 4.66 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.672 179.86 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 35.2 t70 -111.78 117.36 32.62 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 178.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -89.36 129.33 35.9 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 27.2 m -133.38 154.6 39.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.387 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.907 ' SG ' HD11 ' A' ' 11' ' ' ILE . 37.9 t -95.26 118.42 31.99 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 115.877 -0.601 . . . . 0.0 109.971 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.0 p -130.21 144.14 38.88 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 CA-C-O 120.87 0.366 . . . . 0.0 110.361 -179.466 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 4.9 m -97.93 167.52 10.86 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.889 -179.739 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 46.4 m-85 -122.18 143.05 38.14 Favored Pre-proline 0 CA--C 1.532 0.275 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.668 -179.428 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.401 ' HG3' ' H ' ' A' ' 7' ' ' LYS . 35.4 Cg_endo -66.11 144.33 75.08 Favored 'Trans proline' 0 N--CA 1.495 1.609 0 C-N-CA 122.544 2.163 . . . . 0.0 111.735 179.579 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 46.4 mtmt -93.44 -70.02 0.72 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.166 179.212 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 63.2 m-85 -130.66 34.24 4.15 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.459 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 54.3 t80 -62.23 132.06 51.46 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.49 -0.323 . . . . 0.0 110.426 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.3 pt . . . . . 0 C--O 1.219 -0.511 0 CA-C-O 117.859 -1.067 . . . . 0.0 110.44 -179.916 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . 0.413 ' C ' ' H ' ' A' ' 3' ' ' ILE . 70.5 mmtt . . . . . 0 N--CA 1.493 1.704 0 N-CA-C 108.642 -0.874 . . . . 0.0 108.642 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . 0.51 ' C ' ' H ' ' A' ' 4' ' ' ASP . 58.6 t0 -64.05 -6.2 5.97 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 108.903 -0.776 . . . . 0.0 108.903 179.492 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.413 ' H ' ' C ' ' A' ' 1' ' ' LYS . 2.0 pp -59.11 -0.87 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-N 115.194 -0.912 . . . . 0.0 110.794 179.684 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . 0.51 ' H ' ' C ' ' A' ' 2' ' ' ASP . 41.2 t0 -54.5 -39.2 67.33 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.345 -179.408 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 73.73 85.31 0.26 Allowed Glycine 0 N--CA 1.449 -0.451 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 4.9 ppt_? -129.42 40.32 3.62 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 112.08 0.4 . . . . 0.0 112.08 -178.419 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.434 ' H ' ' HG2' ' A' ' 51' ' ' PRO . 43.3 tttp -132.83 73.12 76.38 Favored Pre-proline 0 CA--C 1.532 0.261 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.752 179.01 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_exo -69.43 153.46 70.41 Favored 'Trans proline' 0 C--N 1.304 -1.8 0 C-N-CA 122.821 2.347 . . . . 0.0 110.84 178.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.602 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.5 tt -129.77 116.89 19.4 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 179.607 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.602 ' N ' HD23 ' A' ' 9' ' ' LEU . 6.4 tt -89.27 124.81 34.75 Favored 'General case' 0 N--CA 1.465 0.321 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 179.711 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.909 HD11 ' SG ' ' A' ' 47' ' ' CYS . 3.2 pt -102.59 -46.97 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.842 -179.009 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -164.49 -138.45 2.41 Favored Glycine 0 CA--C 1.519 0.306 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.42 ' C ' ' N ' ' A' ' 15' ' ' ILE . 65.5 p -136.22 159.5 41.56 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.149 -0.526 . . . . 0.0 110.249 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -53.38 -12.27 0.41 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.05 179.54 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.42 ' N ' ' C ' ' A' ' 13' ' ' THR . 78.0 mt -71.78 -43.75 69.25 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.396 0 CA-C-O 121.353 0.597 . . . . 0.0 110.425 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 3.0 pt-20 -100.91 -34.3 9.85 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.094 -179.297 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.475 ' CD2' HD12 ' A' ' 11' ' ' ILE . 9.3 m-85 -116.93 85.0 16.85 Favored Pre-proline 0 N--CA 1.468 0.473 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.572 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -49.64 -178.63 0.01 OUTLIER 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 122.462 2.108 . . . . 0.0 111.508 -179.565 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.436 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 96.9 m -59.14 -51.41 70.12 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.629 -0.428 . . . . 0.0 111.443 -178.818 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.477 ' CG ' ' N ' ' A' ' 21' ' ' LYS . 11.1 pt-20 -60.62 -50.17 74.61 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 112.052 0.389 . . . . 0.0 112.052 -179.706 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.477 ' N ' ' CG ' ' A' ' 20' ' ' GLU . 2.5 ttpp -64.8 -45.9 84.32 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.232 0.539 . . . . 0.0 110.225 -178.327 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 43.3 t -45.7 -61.47 1.7 Allowed 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.25 -0.886 . . . . 0.0 111.433 -179.57 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.685 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.7 p-10 -64.65 -49.31 71.51 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.697 -179.42 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.685 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 82.3 mttt -48.11 -42.56 29.41 Favored 'General case' 0 C--O 1.218 -0.555 0 C-N-CA 120.544 -0.462 . . . . 0.0 109.852 -179.926 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 20.1 m -61.86 -42.4 99.0 Favored 'General case' 0 C--N 1.311 -1.073 0 C-N-CA 120.016 -0.674 . . . . 0.0 110.748 -179.586 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.495 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 10.2 t -65.51 -34.19 77.68 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.743 0.783 . . . . 0.0 109.229 179.363 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.6 mm -65.99 -41.29 89.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 115.008 -0.996 . . . . 0.0 110.289 -179.768 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.41 ' HG2' ' O ' ' A' ' 24' ' ' LYS . 54.4 mm-40 -64.23 -34.38 77.97 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.502 -179.555 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.448 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 36.1 m -67.87 -0.15 3.98 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.994 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.448 ' CB ' ' O ' ' A' ' 29' ' ' SER . 4.3 t-20 80.9 14.81 0.66 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.483 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.556 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 4.0 m-85 -94.89 -168.3 1.79 Allowed 'General case' 0 CA--C 1.533 0.298 0 CA-C-O 120.781 0.324 . . . . 0.0 110.261 -179.671 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -76.59 -51.26 11.96 Favored 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 -178.748 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.495 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 163.3 -179.24 38.56 Favored Glycine 0 CA--C 1.519 0.318 0 N-CA-C 109.734 -1.347 . . . . 0.0 109.734 -178.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.405 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -142.96 170.35 25.31 Favored Glycine 0 N--CA 1.462 0.405 0 N-CA-C 111.36 -0.696 . . . . 0.0 111.36 -179.115 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 23.3 pttt -156.9 178.43 10.37 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.071 0.462 . . . . 0.0 110.891 -179.663 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 3.2 m -104.56 128.4 52.53 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.053 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 35.1 m -136.23 163.38 34.15 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.573 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 2.8 p80 -108.75 156.61 19.41 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.129 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 95.9 mt -122.82 130.07 74.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.606 -179.391 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 48.02 -107.99 0.31 Allowed Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -136.38 32.29 2.83 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 120.596 0.236 . . . . 0.0 110.48 -179.769 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 8.7 m -82.64 -12.03 57.95 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 121.134 0.492 . . . . 0.0 110.282 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . 0.419 HD22 ' HA ' ' A' ' 43' ' ' LEU . 0.2 OUTLIER 49.56 29.17 2.84 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.224 179.657 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -105.62 132.71 51.42 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.344 179.778 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -93.5 117.53 30.2 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-O 120.965 0.412 . . . . 0.0 109.95 179.823 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 16.3 m -111.0 137.16 44.65 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.41 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.007 -179.6 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.909 ' SG ' HD11 ' A' ' 11' ' ' ILE . 16.1 t -93.05 118.79 31.59 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.734 -179.837 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.9 p -128.05 150.91 34.22 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.093 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.84 -179.319 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' CYS . . . . . 0.556 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 28.9 t -96.88 165.4 12.12 Favored 'General case' 0 N--CA 1.467 0.419 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.508 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 25.3 m-85 -127.95 124.17 23.07 Favored Pre-proline 0 CA--C 1.544 0.731 0 C-N-CA 121.114 -0.234 . . . . 0.0 111.236 -178.444 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.434 ' HG2' ' H ' ' A' ' 7' ' ' LYS . 48.4 Cg_exo -51.29 137.6 46.71 Favored 'Trans proline' 0 N--CA 1.499 1.818 0 C-N-CA 121.999 1.8 . . . . 0.0 113.018 179.092 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 64.2 tttp -112.34 -48.9 2.99 Favored 'General case' 0 CA--C 1.529 0.15 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.298 178.747 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.536 ' CD2' ' O ' ' A' ' 53' ' ' TYR . 24.4 p90 -129.89 40.33 3.58 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.778 -179.483 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 90.3 t80 -83.45 96.86 8.7 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.944 0.402 . . . . 0.0 110.003 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 18.2 mm . . . . . 0 C--O 1.22 -0.463 0 CA-C-O 118.053 -0.975 . . . . 0.0 110.505 -179.348 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 68.4 mttm . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . 0.428 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 34.4 p-10 -87.79 3.94 46.3 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.509 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 35.1 mm -74.07 129.84 36.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.517 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 59.8 t0 -61.68 -42.29 98.73 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.169 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 44.17 75.85 0.14 Allowed Glycine 0 C--N 1.331 0.277 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.706 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.0 31.47 4.68 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.748 0.309 . . . . 0.0 111.02 -179.312 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -121.69 150.07 54.47 Favored Pre-proline 0 N--CA 1.469 0.488 0 CA-C-N 116.438 -0.347 . . . . 0.0 110.746 -179.493 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -61.64 154.82 57.42 Favored 'Trans proline' 0 N--CA 1.497 1.693 0 C-N-CA 122.408 2.072 . . . . 0.0 111.984 179.065 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.659 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.8 tt -131.63 120.91 23.48 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.42 -179.272 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.729 HD23 ' N ' ' A' ' 11' ' ' ILE . 4.4 tt -89.94 128.43 36.23 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 178.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.729 ' N ' HD23 ' A' ' 10' ' ' LEU . 6.4 pt -101.72 -43.03 9.71 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-O 120.786 0.327 . . . . 0.0 110.865 -178.536 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.46 ' O ' HD21 ' A' ' 10' ' ' LEU . . . -173.54 -143.29 4.22 Favored Glycine 0 N--CA 1.451 -0.307 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.744 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.7 p -99.46 163.66 12.42 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.824 0.345 . . . . 0.0 110.275 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 43.4 t -74.1 7.55 2.64 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.331 179.6 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 97.1 mt -93.15 -43.68 13.63 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.12 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.523 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -88.37 -11.71 45.43 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.652 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 53.6 m-85 -122.84 81.22 49.58 Favored Pre-proline 0 N--CA 1.463 0.214 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.853 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_exo -48.88 165.99 0.17 Allowed 'Trans proline' 0 N--CA 1.495 1.599 0 C-N-CA 122.714 2.276 . . . . 0.0 111.33 179.065 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.424 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 17.0 m -48.39 -52.58 21.22 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.85 -0.34 . . . . 0.0 111.627 -178.036 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.627 ' CD ' ' H ' ' A' ' 20' ' ' GLU . 1.3 pm0 -61.92 -55.44 29.58 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.551 -0.295 . . . . 0.0 111.651 -179.722 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -57.57 -45.82 84.71 Favored 'General case' 0 CA--C 1.518 -0.255 0 CA-C-O 121.302 0.572 . . . . 0.0 110.94 -178.208 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 12.7 t -48.02 -65.12 0.62 Allowed 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.402 -178.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.667 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.6 p-10 -63.71 -48.37 77.37 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.755 -179.597 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.667 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 89.5 mttt -47.27 -42.02 19.88 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 120.543 -0.463 . . . . 0.0 110.05 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 18.6 m -61.57 -43.68 98.41 Favored 'General case' 0 C--N 1.314 -0.978 0 C-N-CA 120.456 -0.498 . . . . 0.0 110.909 -179.453 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.503 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 10.7 t -66.2 -32.51 73.99 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.525 0.679 . . . . 0.0 109.745 179.562 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.6 mm -66.54 -39.34 83.68 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.442 -179.623 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.422 ' C ' ' H ' ' A' ' 30' ' ' ASN . 54.9 mm-40 -64.34 -35.72 81.8 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.299 -179.356 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.401 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 58.6 m -67.86 1.65 2.47 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.268 179.797 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.422 ' H ' ' C ' ' A' ' 28' ' ' GLU . 43.8 t30 77.78 18.25 1.27 Allowed 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.705 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.553 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 4.1 m-85 -96.34 -167.83 1.64 Allowed 'General case' 0 CA--C 1.532 0.288 0 CA-C-O 120.945 0.402 . . . . 0.0 110.406 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -75.71 -51.51 12.55 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 115.893 -0.594 . . . . 0.0 112.076 -179.079 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.503 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 162.56 -178.06 38.46 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 -179.025 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.435 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -142.95 169.02 25.82 Favored Glycine 0 N--CA 1.462 0.375 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.136 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 11.4 ptmt -158.48 -176.25 5.78 Favored 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 120.681 -0.408 . . . . 0.0 110.716 -179.3 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 66.2 m -103.73 119.86 39.76 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.932 179.509 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 18.9 m -133.32 163.93 36.41 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.204 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.6 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 0.3 OUTLIER -132.83 157.67 44.44 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 121.02 0.438 . . . . 0.0 110.394 179.879 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.556 ' O ' ' N ' ' A' ' 41' ' ' GLN . 20.2 mm -99.38 135.84 32.99 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.569 179.673 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -61.84 65.1 0.02 OUTLIER Glycine 0 N--CA 1.461 0.346 0 N-CA-C 111.543 -0.623 . . . . 0.0 111.543 -179.418 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.556 ' N ' ' O ' ' A' ' 39' ' ' ILE . 59.7 tp60 -174.63 -57.49 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.884 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 73.4 m -90.88 -13.84 32.88 Favored 'General case' 0 CA--C 1.505 -0.755 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.588 179.719 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . 0.54 ' N ' HD12 ' A' ' 43' ' ' LEU . 8.3 mp 46.88 28.28 0.82 Allowed 'General case' 0 N--CA 1.436 -1.171 0 C-N-CA 119.697 -0.801 . . . . 0.0 111.378 178.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 54.4 t0 -96.36 136.63 36.59 Favored 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.571 ' CE1' ' CD2' ' A' ' 38' ' ' HIS . 64.6 m-85 -86.35 124.75 33.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.998 0.428 . . . . 0.0 110.0 -179.596 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 27.8 m -126.13 150.59 31.76 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.377 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.111 -179.713 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -98.55 125.96 43.96 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.582 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.1 p -136.77 155.0 32.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.188 -179.339 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' CYS . . . . . 0.553 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 17.7 t -97.07 164.65 12.42 Favored 'General case' 0 C--O 1.233 0.215 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.538 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 30.7 m-85 -133.98 126.59 18.78 Favored Pre-proline 0 C--N 1.33 -0.24 0 C-N-CA 121.031 -0.268 . . . . 0.0 110.856 -178.363 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.28 158.09 58.89 Favored 'Trans proline' 0 N--CA 1.491 1.339 0 C-N-CA 121.712 1.608 . . . . 0.0 112.218 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 22.6 mmtp -63.8 -8.84 11.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.779 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 87.7 m-85 -109.33 39.6 2.03 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.397 -179.698 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 82.9 t80 -111.59 121.69 45.82 Favored 'General case' 0 C--O 1.231 0.101 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 86.5 mt . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.244 -179.927 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 53.3 mtpt . . . . . 0 N--CA 1.492 1.651 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . 0.613 ' C ' ' H ' ' A' ' 4' ' ' ASP . 17.0 p-10 -75.23 -58.08 3.5 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.16 -0.473 . . . . 0.0 109.763 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.437 ' H ' ' CG ' ' A' ' 2' ' ' ASP . 0.3 OUTLIER 62.25 -25.99 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.522 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.446 178.554 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . 0.613 ' H ' ' C ' ' A' ' 2' ' ' ASP . 37.4 t0 -58.83 -27.63 65.29 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.18 0.514 . . . . 0.0 110.056 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 93.67 74.14 1.24 Allowed Glycine 0 C--N 1.33 0.239 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.531 ' NE ' ' O ' ' A' ' 6' ' ' ARG . 0.0 OUTLIER -132.16 42.22 3.15 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 112.376 0.51 . . . . 0.0 112.376 -177.985 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.684 ' H ' ' HG3' ' A' ' 51' ' ' PRO . 27.8 tptt -125.64 43.99 1.05 Allowed Pre-proline 0 C--N 1.323 -0.567 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.208 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.547 ' CD ' ' N ' ' A' ' 7' ' ' LYS . 61.1 Cg_endo -69.38 154.35 69.35 Favored 'Trans proline' 0 N--CA 1.498 1.78 0 C-N-CA 122.71 2.273 . . . . 0.0 111.929 179.409 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.661 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.5 tt -129.65 120.61 25.5 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.126 -178.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.661 ' N ' HD23 ' A' ' 9' ' ' LEU . 7.2 tt -92.49 125.66 37.23 Favored 'General case' 0 N--CA 1.468 0.438 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 178.494 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.906 HD11 ' SG ' ' A' ' 47' ' ' CYS . 2.9 pt -103.56 -47.45 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-O 120.752 0.31 . . . . 0.0 111.0 -179.188 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -165.14 -135.73 1.88 Allowed Glycine 0 CA--C 1.519 0.311 0 C-N-CA 120.705 -0.76 . . . . 0.0 111.307 -179.649 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 71.3 p -136.89 159.6 41.38 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 114.99 -0.605 . . . . 0.0 110.163 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -56.72 -11.07 1.2 Allowed 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.026 179.636 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 97.3 mt -69.41 -43.24 81.05 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.329 0 CA-C-O 121.454 0.645 . . . . 0.0 109.782 179.71 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -104.34 -31.11 9.7 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 114.9 -1.045 . . . . 0.0 111.648 -178.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.427 ' O ' ' O ' ' A' ' 18' ' ' PRO . 12.0 m-85 -119.06 82.99 22.75 Favored Pre-proline 0 N--CA 1.471 0.612 0 N-CA-C 110.103 -0.332 . . . . 0.0 110.103 179.473 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.427 ' O ' ' O ' ' A' ' 17' ' ' PHE . 77.5 Cg_exo -47.61 179.87 0.01 OUTLIER 'Trans proline' 0 N--CA 1.495 1.57 0 C-N-CA 122.645 2.23 . . . . 0.0 111.701 -179.79 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.449 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 99.0 m -59.0 -50.71 73.06 Favored 'General case' 0 C--N 1.326 -0.428 0 C-N-CA 120.89 -0.324 . . . . 0.0 111.845 -178.513 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.628 ' CD ' ' H ' ' A' ' 20' ' ' GLU . 1.1 pm0 -60.03 -52.59 64.73 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.161 -179.688 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.13 -47.29 85.24 Favored 'General case' 0 CA--C 1.519 -0.235 0 CA-C-O 121.297 0.57 . . . . 0.0 110.691 -179.212 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 38.5 t -45.12 -60.38 2.13 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 115.312 -0.858 . . . . 0.0 111.259 -178.792 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.666 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.9 p-10 -64.71 -51.69 61.07 Favored 'General case' 0 C--O 1.221 -0.411 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.734 -179.593 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.666 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 81.2 mttt -47.97 -42.86 28.77 Favored 'General case' 0 C--N 1.323 -0.554 0 C-N-CA 120.405 -0.518 . . . . 0.0 110.584 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 55.5 m -66.35 -33.3 75.41 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.163 0.506 . . . . 0.0 110.085 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 56.9 m -72.0 -34.04 68.56 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.876 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.3 mm -62.07 -48.51 88.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.727 -179.251 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.459 ' C ' ' H ' ' A' ' 30' ' ' ASN . 6.0 pt-20 -70.47 -30.81 67.71 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.799 -179.303 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 39.5 m -68.96 7.15 0.74 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.706 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.459 ' H ' ' C ' ' A' ' 28' ' ' GLU . 49.8 t30 72.73 47.86 0.22 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.366 179.487 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.55 ' C ' ' H ' ' A' ' 33' ' ' GLY . 73.9 m-85 -137.23 160.8 37.97 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.759 179.424 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.32 23.3 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.168 -179.66 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.55 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 91.92 -179.88 41.4 Favored Glycine 0 CA--C 1.519 0.338 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 -179.683 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -148.92 174.45 28.54 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.433 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 8.8 pttm -154.12 -179.08 7.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.035 0.445 . . . . 0.0 110.788 -179.781 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 3.9 m -105.03 124.46 49.56 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 115.718 -0.673 . . . . 0.0 110.308 179.658 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 35.7 m -136.67 165.91 27.38 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.75 -179.679 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 3.3 p80 -106.92 155.85 19.34 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-O 121.025 0.44 . . . . 0.0 110.66 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 96.0 mt -128.96 126.49 64.74 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.217 -179.481 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 61.46 22.48 61.41 Favored Glycine 0 CA--C 1.52 0.387 0 N-CA-C 111.555 -0.618 . . . . 0.0 111.555 178.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 26.7 mt-30 57.3 37.37 28.11 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.026 0.441 . . . . 0.0 110.03 -179.466 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 20.7 m -81.49 -11.09 59.33 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.181 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . 0.41 ' O ' ' CD2' ' A' ' 43' ' ' LEU . 0.9 OUTLIER 70.69 28.63 3.43 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.493 0.663 . . . . 0.0 109.659 -179.783 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -110.97 121.34 45.1 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.665 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 64.5 m-85 -90.63 117.1 29.03 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-O 121.163 0.506 . . . . 0.0 110.007 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.5 m -110.97 137.65 42.55 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.33 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.715 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.906 ' SG ' HD11 ' A' ' 11' ' ' ILE . 13.5 t -93.02 113.95 26.36 Favored 'General case' 0 CA--C 1.512 -0.481 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 -179.862 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 8.8 p -130.39 147.78 33.16 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.308 0 CA-C-O 121.143 0.497 . . . . 0.0 111.62 -178.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 4.8 m -97.43 170.82 8.79 Favored 'General case' 0 CA--C 1.518 -0.257 0 CA-C-N 115.258 -0.883 . . . . 0.0 109.793 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -130.15 143.29 48.57 Favored Pre-proline 0 CA--C 1.542 0.644 0 CA-C-N 116.512 -0.313 . . . . 0.0 111.266 -178.804 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.684 ' HG3' ' H ' ' A' ' 7' ' ' LYS . 40.8 Cg_exo -47.52 137.05 20.26 Favored 'Trans proline' 0 N--CA 1.498 1.736 0 C-N-CA 122.37 2.047 . . . . 0.0 112.011 177.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 41.6 mmtt -41.55 -86.0 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 114.97 -1.014 . . . . 0.0 112.695 -178.525 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 6.6 m-85 -116.05 17.41 15.85 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-O 121.208 0.528 . . . . 0.0 110.004 -178.688 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 2.4 m-85 -93.49 101.69 13.89 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.413 -0.812 . . . . 0.0 109.298 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 32.4 pt . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.455 -179.444 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 41.3 pttt . . . . . 0 N--CA 1.492 1.628 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 47.5 t0 58.68 36.68 25.09 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 -179.102 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.608 ' O ' HD12 ' A' ' 3' ' ' ILE . 1.5 pp -122.92 163.18 22.01 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.225 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.816 -179.303 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 64.5 t0 -60.1 -45.66 92.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.25 -179.434 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 78.87 74.59 1.05 Allowed Glycine 0 C--O 1.228 -0.228 0 N-CA-C 110.772 -0.931 . . . . 0.0 110.772 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.539 ' NH2' ' O ' ' A' ' 53' ' ' TYR . 21.0 mmt180 -131.63 40.8 3.36 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 120.759 0.314 . . . . 0.0 110.817 -179.618 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 17.3 pttt -130.66 101.87 16.86 Favored Pre-proline 0 N--CA 1.466 0.334 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -179.438 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -50.79 142.94 31.19 Favored 'Trans proline' 0 N--CA 1.495 1.571 0 C-N-CA 121.588 1.526 . . . . 0.0 111.187 178.016 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.69 HD13 ' N ' ' A' ' 10' ' ' LEU . 0.2 OUTLIER -111.32 126.69 55.18 Favored 'General case' 0 N--CA 1.468 0.472 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.685 -179.006 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.69 ' N ' HD13 ' A' ' 9' ' ' LEU . 2.6 tm? -92.05 128.5 37.91 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 178.336 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.47 HD11 ' SG ' ' A' ' 26' ' ' CYS . 0.0 OUTLIER -108.06 -40.09 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -178.63 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -177.94 -140.59 3.84 Favored Glycine 0 CA--C 1.52 0.404 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 179.698 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.496 ' C ' ' H ' ' A' ' 15' ' ' ILE . 80.6 p -135.63 161.08 36.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.017 0.437 . . . . 0.0 111.045 -179.534 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -58.17 -2.96 0.21 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.26 179.54 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.496 ' H ' ' C ' ' A' ' 13' ' ' THR . 23.8 mm -73.45 -22.65 19.18 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 CA-C-O 121.092 0.473 . . . . 0.0 109.948 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . 0.477 ' OE1' ' CZ ' ' A' ' 17' ' ' PHE . 9.5 pt-20 -134.51 -30.76 1.11 Allowed 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.154 -179.515 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.477 ' CZ ' ' OE1' ' A' ' 16' ' ' GLU . 9.9 m-85 -114.88 93.4 34.01 Favored Pre-proline 0 N--CA 1.468 0.426 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.537 -179.619 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.45 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 56.5 Cg_endo -79.25 -179.08 5.1 Favored 'Trans proline' 0 N--CA 1.489 1.235 0 C-N-CA 122.489 2.126 . . . . 0.0 111.23 -179.543 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.411 ' OG1' ' OE2' ' A' ' 20' ' ' GLU . 23.4 p -45.4 -48.68 13.52 Favored 'General case' 0 C--N 1.32 -0.687 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.116 -178.74 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.469 ' CD ' ' H ' ' A' ' 20' ' ' GLU . 0.3 OUTLIER -52.55 -70.72 0.08 Allowed 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.614 -179.316 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 16.2 ttmt -64.59 -47.36 78.95 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-O 121.443 0.64 . . . . 0.0 111.304 -178.008 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.45 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 51.8 t -41.78 -59.8 1.56 Allowed 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.205 -0.907 . . . . 0.0 111.039 -178.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.691 ' ND2' ' H ' ' A' ' 24' ' ' LYS . 0.0 OUTLIER -66.89 -55.13 16.01 Favored 'General case' 0 C--O 1.218 -0.577 0 C-N-CA 120.205 -0.598 . . . . 0.0 110.421 -179.634 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.691 ' H ' ' ND2' ' A' ' 23' ' ' ASN . 71.7 mttt -44.53 -42.6 7.34 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.871 0.367 . . . . 0.0 110.71 -179.231 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . 0.454 ' O ' ' OE2' ' A' ' 28' ' ' GLU . 8.8 m -65.12 -37.14 86.49 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.416 0.627 . . . . 0.0 109.558 179.408 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.47 ' SG ' HD11 ' A' ' 11' ' ' ILE . 67.9 m -72.08 -35.27 69.19 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.162 179.728 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.9 mm -62.67 -48.34 88.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.386 -179.192 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.454 ' OE2' ' O ' ' A' ' 25' ' ' THR . 2.6 pp20? -70.57 -31.09 67.97 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.601 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.434 ' N ' ' CD ' ' A' ' 28' ' ' GLU . 68.6 m -67.57 2.36 1.86 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.934 -179.688 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.411 ' H ' ' C ' ' A' ' 28' ' ' GLU . 41.6 t30 75.14 43.32 0.21 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.983 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.553 ' C ' ' H ' ' A' ' 33' ' ' GLY . 63.0 m-85 -131.92 160.99 34.13 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.459 179.463 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.48 31.19 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.96 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.553 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 84.11 -176.96 51.92 Favored Glycine 0 CA--C 1.52 0.4 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -150.58 172.13 30.35 Favored Glycine 0 CA--C 1.52 0.36 0 N-CA-C 110.715 -0.954 . . . . 0.0 110.715 -179.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 25.2 pttt -155.25 -179.02 7.68 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 120.935 0.398 . . . . 0.0 110.563 -179.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 3.3 m -103.94 127.08 51.48 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 115.866 -0.607 . . . . 0.0 110.172 179.384 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 34.5 m -136.77 159.81 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.419 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.55 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 2.9 p80 -104.6 156.94 17.53 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-O 121.072 0.463 . . . . 0.0 110.086 179.753 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.478 ' O ' ' N ' ' A' ' 41' ' ' GLN . 34.4 mm -109.21 125.13 66.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.243 -179.765 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 42.5 -92.42 0.01 OUTLIER Glycine 0 CA--C 1.526 0.75 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.484 ' N ' ' CD ' ' A' ' 41' ' ' GLN . 2.0 pm0 -143.9 30.44 1.31 Allowed 'General case' 0 N--CA 1.463 0.197 0 CA-C-O 120.702 0.287 . . . . 0.0 110.531 -179.64 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 66.3 m -84.43 -5.4 59.28 Favored 'General case' 0 CA--C 1.52 -0.188 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.689 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 45.14 28.37 0.4 Allowed 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.677 179.813 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -103.04 119.8 39.51 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.396 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 70.8 m-85 -87.75 117.8 26.83 Favored 'General case' 0 C--N 1.332 -0.191 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.725 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 33.4 m -112.82 137.09 47.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.331 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.432 ' O ' HD22 ' A' ' 10' ' ' LEU . 25.2 t -92.25 108.2 19.77 Favored 'General case' 0 CA--C 1.513 -0.445 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 179.838 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.2 p -124.36 150.23 28.96 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.229 0 CA-C-O 120.941 0.4 . . . . 0.0 110.634 -178.809 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 10.6 m -97.26 163.13 13.03 Favored 'General case' 0 CA--C 1.515 -0.386 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 -179.696 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 -119.33 143.29 34.05 Favored Pre-proline 0 CA--C 1.531 0.249 0 C-N-CA 121.141 -0.224 . . . . 0.0 111.227 -178.879 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.404 ' C ' ' H ' ' A' ' 53' ' ' TYR . 39.4 Cg_endo -64.28 149.62 89.86 Favored 'Trans proline' 0 N--CA 1.494 1.522 0 C-N-CA 122.221 1.947 . . . . 0.0 111.989 178.81 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 68.1 mmtt -64.3 -2.69 2.31 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.534 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.539 ' O ' ' NH2' ' A' ' 6' ' ' ARG . 52.0 m-85 -109.02 18.4 20.68 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.463 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 86.7 t80 -83.4 123.08 29.32 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.089 179.681 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 8.0 pt . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.118 -0.944 . . . . 0.0 110.194 -179.759 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 35.7 tttp . . . . . 0 N--CA 1.49 1.557 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . 0.425 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 34.4 p-10 -74.0 -2.53 24.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.401 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 31.4 mm -88.41 125.63 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 CA-C-O 121.286 0.565 . . . . 0.0 110.762 179.61 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -65.13 -35.43 81.09 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.908 179.424 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -81.91 95.13 1.71 Allowed Glycine 0 CA--C 1.518 0.267 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -179.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 1.3 ppt_? -132.55 40.82 3.25 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.729 0.3 . . . . 0.0 111.048 -179.705 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 3.1 ptmm? -120.5 83.34 34.06 Favored Pre-proline 0 N--CA 1.464 0.226 0 CA-C-O 121.034 0.445 . . . . 0.0 110.955 -179.701 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -59.7 147.29 92.67 Favored 'Trans proline' 0 C--N 1.306 -1.678 0 C-N-CA 122.162 1.908 . . . . 0.0 110.993 179.641 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.611 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.5 tt -117.0 114.79 24.29 Favored 'General case' 0 CA--C 1.511 -0.523 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 -179.777 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.669 HD13 ' C ' ' A' ' 10' ' ' LEU . 3.0 tm? -93.27 124.5 37.29 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.37 -0.532 . . . . 0.0 109.881 179.266 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.962 HD11 ' SG ' ' A' ' 47' ' ' CYS . 5.7 pt -103.37 -41.91 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-O 121.052 0.453 . . . . 0.0 110.588 -179.342 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.453 ' O ' HD21 ' A' ' 10' ' ' LEU . . . -174.8 -139.5 3.03 Favored Glycine 0 CA--C 1.521 0.418 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.444 ' C ' ' H ' ' A' ' 15' ' ' ILE . 72.7 p -134.06 165.99 23.78 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.914 0.388 . . . . 0.0 110.924 -179.524 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -58.6 -5.6 0.58 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.206 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.444 ' H ' ' C ' ' A' ' 13' ' ' THR . 24.0 mm -74.5 -24.48 18.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.538 -179.292 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -128.33 -29.92 2.43 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.84 -179.592 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -117.34 91.96 38.84 Favored Pre-proline 0 CA--C 1.536 0.411 0 CA-C-N 116.486 -0.324 . . . . 0.0 110.474 179.759 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.463 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 52.9 Cg_endo -71.56 -177.33 2.4 Favored 'Trans proline' 0 N--CA 1.498 1.736 0 C-N-CA 123.12 2.547 . . . . 0.0 111.853 -179.25 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.473 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 31.0 m -46.73 -70.61 0.09 Allowed 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 120.568 -0.453 . . . . 0.0 111.358 -179.275 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.648 ' CD ' ' H ' ' A' ' 20' ' ' GLU . 1.3 pm0 -41.39 -70.13 0.11 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.395 -178.865 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 5.3 ttmt -54.44 -53.88 48.23 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.021 0.439 . . . . 0.0 111.499 -177.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.463 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 43.0 t -41.41 -59.44 1.57 Allowed 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.071 -178.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.745 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 0.9 OUTLIER -65.82 -52.1 53.41 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.848 179.611 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.745 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 69.7 mttt -48.42 -42.61 32.65 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 120.839 0.352 . . . . 0.0 110.674 -178.539 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 20.0 m -63.93 -41.08 97.73 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-O 121.331 0.586 . . . . 0.0 109.995 179.789 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 57.5 m -65.23 -31.06 72.03 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.574 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.41 HG12 ' O ' ' A' ' 23' ' ' ASN . 3.1 mm -65.37 -38.83 83.48 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.427 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 30.2 mm-40 -65.74 -33.06 75.0 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.551 -0.749 . . . . 0.0 110.626 -178.739 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 46.2 m -73.27 -2.66 22.8 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.307 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 1.9 m120 77.84 34.5 0.32 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.958 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.573 ' C ' ' H ' ' A' ' 33' ' ' GLY . 8.2 m-85 -110.34 164.7 12.42 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.049 179.892 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.19 21.29 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.57 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.573 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 90.32 -178.7 43.25 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.371 -1.091 . . . . 0.0 110.371 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.421 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -147.01 170.33 27.93 Favored Glycine 0 CA--C 1.52 0.406 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 -179.344 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 10.7 ptmt -156.36 -177.0 6.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.619 0.247 . . . . 0.0 110.601 -179.576 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 1.7 m -104.02 125.76 50.62 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.131 179.489 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 34.0 m -133.92 162.57 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.297 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 3.1 p80 -109.12 157.42 18.76 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.867 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 92.1 mt -123.27 131.59 72.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.716 -179.485 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 49.55 -103.98 0.09 OUTLIER Glycine 0 CA--C 1.519 0.307 0 N-CA-C 110.812 -0.915 . . . . 0.0 110.812 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 41.2 tp60 -141.44 30.98 1.71 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.876 0.37 . . . . 0.0 110.396 -179.757 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 58.2 m -85.93 -5.7 59.19 Favored 'General case' 0 CA--C 1.518 -0.252 0 CA-C-O 120.967 0.413 . . . . 0.0 110.91 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . 0.403 ' O ' ' CD2' ' A' ' 43' ' ' LEU . 0.9 OUTLIER 44.42 29.95 0.43 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.398 -179.499 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -99.8 124.88 45.53 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.073 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -89.7 118.01 28.99 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 109.692 -0.485 . . . . 0.0 109.692 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 29.8 m -112.84 136.21 49.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.102 -179.52 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.962 ' SG ' HD11 ' A' ' 11' ' ' ILE . 22.1 t -92.94 105.98 18.01 Favored 'General case' 0 CA--C 1.513 -0.464 0 N-CA-C 109.373 -0.602 . . . . 0.0 109.373 179.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 4.7 p -125.54 154.97 34.6 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.375 0 CA-C-O 120.94 0.4 . . . . 0.0 110.573 -178.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 8.1 m -99.31 173.36 6.81 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.168 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 64.3 m-85 -133.6 117.95 14.44 Favored Pre-proline 0 CA--C 1.536 0.43 0 CA-C-N 116.269 -0.423 . . . . 0.0 109.999 179.224 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -49.54 127.73 19.07 Favored 'Trans proline' 0 N--CA 1.499 1.826 0 C-N-CA 122.186 1.924 . . . . 0.0 112.328 179.666 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 56.6 tttp -96.33 -60.03 1.71 Allowed 'General case' 0 N--CA 1.451 -0.424 0 CA-C-N 116.249 -0.432 . . . . 0.0 109.877 179.081 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.472 ' CD2' ' O ' ' A' ' 53' ' ' TYR . 32.7 p90 -133.26 31.22 3.82 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.667 -179.794 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 85.0 t80 -60.04 95.45 0.03 OUTLIER 'General case' 0 N--CA 1.449 -0.516 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.184 -179.032 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 117.913 -1.041 . . . . 0.0 109.886 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . 0.634 ' NZ ' HD22 ' A' ' 30' ' ' ASN . 60.9 pttt . . . . . 0 N--CA 1.491 1.621 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 32.1 m-20 -65.49 -8.79 21.11 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.4 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 15.4 pt -58.23 170.18 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.467 179.409 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 64.4 t0 -61.91 -41.84 98.38 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.892 -179.486 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 66.82 62.99 4.11 Favored Glycine 0 N--CA 1.461 0.307 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.63 30.34 4.68 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.718 0.294 . . . . 0.0 111.028 -179.433 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.477 ' NZ ' ' CB ' ' A' ' 7' ' ' LYS . 0.1 OUTLIER -131.35 147.48 66.32 Favored Pre-proline 0 N--CA 1.47 0.574 0 CA-C-N 116.555 -0.293 . . . . 0.0 111.086 -179.568 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -74.02 158.96 45.34 Favored 'Trans proline' 0 N--CA 1.502 1.986 0 C-N-CA 122.908 2.405 . . . . 0.0 112.303 179.474 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.657 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.6 tt -128.42 120.79 27.59 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.755 -179.215 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.657 ' N ' HD23 ' A' ' 9' ' ' LEU . 6.6 tt -89.05 133.9 34.19 Favored 'General case' 0 N--CA 1.468 0.46 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 178.128 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 12.8 pt -109.04 -37.02 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-O 120.869 0.366 . . . . 0.0 111.068 -178.775 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 175.32 -153.72 16.09 Favored Glycine 0 N--CA 1.452 -0.255 0 N-CA-C 110.913 -0.875 . . . . 0.0 110.913 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 6.7 p -90.03 164.85 14.35 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 10.4 t -76.07 7.35 4.19 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.214 179.601 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.5 mt -91.46 -42.32 13.65 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.221 0 CA-C-O 121.149 0.499 . . . . 0.0 109.808 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -87.91 -12.63 44.15 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.361 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -124.81 81.2 61.81 Favored Pre-proline 0 N--CA 1.463 0.217 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.954 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -48.64 163.23 0.29 Allowed 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.05 1.833 . . . . 0.0 110.719 178.731 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.406 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 25.5 p -46.5 -53.24 11.63 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.919 0.39 . . . . 0.0 111.721 -177.837 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.656 ' CD ' ' H ' ' A' ' 20' ' ' GLU . 0.0 OUTLIER -59.72 -55.4 34.78 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.573 -179.429 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -58.96 -44.79 91.53 Favored 'General case' 0 CA--C 1.516 -0.336 0 CA-C-O 121.332 0.587 . . . . 0.0 110.388 -178.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 14.7 t -48.28 -65.46 0.56 Allowed 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 115.265 -0.88 . . . . 0.0 111.427 -178.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.659 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.6 p-10 -64.97 -46.97 79.26 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.011 -179.438 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.659 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 92.9 mttt -50.59 -37.55 40.53 Favored 'General case' 0 CA--C 1.5 -0.952 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.23 179.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 86.8 m -63.93 -42.79 97.26 Favored 'General case' 0 C--N 1.319 -0.751 0 O-C-N 124.012 0.82 . . . . 0.0 110.468 -179.342 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.497 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 33.8 t -72.58 -33.4 66.74 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.106 179.68 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.2 mm -66.08 -46.7 87.19 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.616 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.112 -179.192 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.505 ' C ' ' H ' ' A' ' 30' ' ' ASN . 19.0 pt-20 -69.64 -30.46 68.17 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 115.349 -0.841 . . . . 0.0 110.151 -179.698 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.416 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 68.3 m -65.49 1.78 1.09 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.75 179.845 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.634 HD22 ' NZ ' ' A' ' 1' ' ' LYS . 16.9 t-20 79.82 12.56 1.1 Allowed 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.966 179.546 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.562 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 4.5 m-85 -98.07 -167.81 1.57 Allowed 'General case' 0 CA--C 1.533 0.322 0 CA-C-O 120.706 0.289 . . . . 0.0 110.27 -179.842 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -75.79 -53.97 7.65 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.582 0.586 . . . . 0.0 112.582 -178.543 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.497 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 166.5 178.9 39.45 Favored Glycine 0 CA--C 1.519 0.321 0 N-CA-C 110.068 -1.213 . . . . 0.0 110.068 -178.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -137.26 160.98 25.19 Favored Glycine 0 C--N 1.331 0.299 0 N-CA-C 111.579 -0.609 . . . . 0.0 111.579 -179.383 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 14.2 ptpt -153.45 170.23 21.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.29 -0.455 . . . . 0.0 110.779 -178.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 56.5 m -104.86 117.7 34.7 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.891 179.493 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 4.8 m -139.65 -178.5 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-O 120.873 0.368 . . . . 0.0 111.129 -179.427 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.619 ' ND1' ' N ' ' A' ' 44' ' ' ASP . 95.3 m-70 -114.0 147.98 37.72 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.802 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 95.6 mt -124.06 127.8 73.7 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.849 -179.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 68.74 21.78 75.09 Favored Glycine 0 CA--C 1.52 0.35 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 179.374 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 57.79 30.8 19.55 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.196 0.522 . . . . 0.0 109.794 -179.215 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 50.6 m -72.22 -10.92 60.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.443 -0.798 . . . . 0.0 110.511 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . 0.445 ' C ' ' ND1' ' A' ' 38' ' ' HIS . 0.9 OUTLIER 63.14 29.33 16.14 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.649 -179.636 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . 0.619 ' N ' ' ND1' ' A' ' 38' ' ' HIS . 67.2 t0 -111.05 138.69 47.16 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.714 179.499 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.489 ' N ' ' OD1' ' A' ' 44' ' ' ASP . 50.2 m-85 -92.95 117.38 29.98 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.645 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 25.9 m -124.29 136.81 59.29 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.328 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.052 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -94.46 122.59 37.19 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.352 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.0 p -135.52 152.52 31.71 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.318 0 C-N-CA 120.655 -0.418 . . . . 0.0 111.319 -179.393 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' CYS . . . . . 0.562 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 23.9 t -96.01 164.18 12.81 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.078 -179.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.494 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 37.7 m-85 -130.75 136.55 29.11 Favored Pre-proline 0 N--CA 1.476 0.849 0 C-N-CA 120.788 -0.365 . . . . 0.0 111.352 -178.427 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -70.41 156.35 61.85 Favored 'Trans proline' 0 N--CA 1.491 1.355 0 C-N-CA 121.865 1.71 . . . . 0.0 112.207 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 29.5 mmtp -67.04 -19.92 65.76 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.879 -0.6 . . . . 0.0 109.925 179.379 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 73.2 m-85 -109.53 40.0 1.97 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.493 -179.525 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 90.3 t80 -73.24 126.79 30.9 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.193 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 5.2 pt . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.066 -0.969 . . . . 0.0 110.222 -179.889 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 98.6 mttt . . . . . 0 N--CA 1.489 1.495 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 45.8 t0 -67.42 -9.76 44.81 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.663 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 5.9 mm -81.16 130.29 36.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.476 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 66.6 t0 -62.12 -42.1 98.9 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.502 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 42.4 87.57 0.01 OUTLIER Glycine 0 N--CA 1.46 0.258 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.43 ' HD3' ' H ' ' A' ' 6' ' ' ARG . 0.0 OUTLIER -130.33 25.63 5.15 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.67 -0.265 . . . . 0.0 110.699 -179.339 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.1 153.25 76.65 Favored Pre-proline 0 CA--C 1.54 0.591 0 CA-C-N 116.689 -0.232 . . . . 0.0 111.534 -179.276 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -57.71 145.34 90.32 Favored 'Trans proline' 0 N--CA 1.501 1.934 0 C-N-CA 121.879 1.719 . . . . 0.0 111.797 178.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.634 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.5 tt -128.33 119.5 25.2 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.637 HD23 ' N ' ' A' ' 11' ' ' ILE . 6.6 tt -88.65 126.58 35.36 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 108.839 -0.801 . . . . 0.0 108.839 179.199 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.896 HD11 ' SG ' ' A' ' 47' ' ' CYS . 2.2 pt -105.36 -48.12 9.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-O 120.983 0.421 . . . . 0.0 110.852 -178.549 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -159.87 -144.22 3.9 Favored Glycine 0 CA--C 1.52 0.369 0 N-CA-C 110.771 -0.931 . . . . 0.0 110.771 -179.802 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.478 ' C ' ' H ' ' A' ' 15' ' ' ILE . 55.2 p -138.89 161.22 37.83 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.994 0.426 . . . . 0.0 110.809 -179.826 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -59.81 -1.28 0.26 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.221 179.652 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.478 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.2 mt -77.9 -23.65 13.98 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.406 0 CA-C-O 121.164 0.506 . . . . 0.0 109.806 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 2.7 pt-20 -134.24 -34.17 0.98 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.589 -0.732 . . . . 0.0 111.197 -179.381 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.431 ' CZ ' ' NZ ' ' A' ' 21' ' ' LYS . 6.4 m-85 -106.82 88.85 3.84 Favored Pre-proline 0 CA--C 1.538 0.5 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.416 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 19.0 Cg_endo -63.43 -173.6 0.18 Allowed 'Trans proline' 0 N--CA 1.499 1.799 0 C-N-CA 121.832 1.688 . . . . 0.0 112.461 -178.789 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 70.5 m -58.11 -49.81 75.66 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.021 -179.227 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.43 ' CG ' ' N ' ' A' ' 21' ' ' LYS . 8.9 pt-20 -59.06 -56.66 19.42 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.806 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.431 ' NZ ' ' CZ ' ' A' ' 17' ' ' PHE . 0.6 OUTLIER -64.51 -47.22 79.68 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-O 121.235 0.541 . . . . 0.0 111.087 -177.989 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.416 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 32.4 t -45.4 -63.18 1.0 Allowed 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.375 -0.83 . . . . 0.0 111.682 -179.149 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.625 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 0.0 OUTLIER -63.45 -49.6 73.03 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.008 -179.276 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.625 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 47.5 mttp -45.1 -42.37 8.72 Favored 'General case' 0 C--O 1.218 -0.563 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.087 -179.7 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 17.8 m -62.34 -43.49 98.7 Favored 'General case' 0 C--N 1.311 -1.094 0 C-N-CA 119.98 -0.688 . . . . 0.0 110.366 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.492 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 11.4 t -66.99 -32.65 74.03 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 121.574 0.702 . . . . 0.0 109.788 179.615 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.5 mm -65.9 -41.76 90.63 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.213 -179.445 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.447 ' C ' ' H ' ' A' ' 30' ' ' ASN . 25.6 mm-40 -65.43 -34.87 79.31 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.146 -0.933 . . . . 0.0 110.371 -179.477 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.412 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 27.3 m -66.76 2.38 1.41 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.189 -179.742 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.447 ' H ' ' C ' ' A' ' 28' ' ' GLU . 17.5 t-20 78.24 15.28 1.38 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.59 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.553 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 4.1 m-85 -95.79 -168.62 1.8 Allowed 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 120.898 0.38 . . . . 0.0 110.343 -179.764 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -76.05 -50.13 15.62 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.987 -178.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.492 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 160.39 -176.17 37.08 Favored Glycine 0 C--O 1.226 -0.402 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 -179.148 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.449 ' H ' ' HB2' ' A' ' 23' ' ' ASN . . . -146.02 168.14 27.66 Favored Glycine 0 CA--C 1.519 0.331 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 -179.41 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 14.6 ptpt -155.76 178.65 10.02 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.003 0.43 . . . . 0.0 110.81 -179.126 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 4.6 m -103.59 123.52 47.11 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.077 179.506 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 27.6 m -136.4 161.16 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.45 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.582 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 2.1 p80 -109.34 157.09 19.22 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.074 179.818 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.457 ' O ' ' N ' ' A' ' 41' ' ' GLN . 34.5 mm -107.83 125.74 64.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.174 -179.655 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 41.72 -94.4 0.01 OUTLIER Glycine 0 CA--C 1.527 0.782 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 179.694 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.457 ' N ' ' O ' ' A' ' 39' ' ' ILE . 16.6 mp0 -139.67 35.63 2.01 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.796 0.332 . . . . 0.0 110.348 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . 0.759 ' C ' HD23 ' A' ' 43' ' ' LEU . 63.7 m -87.02 2.22 50.29 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.951 -179.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . 0.759 HD23 ' C ' ' A' ' 42' ' ' SER . 1.3 pt? 34.64 28.06 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 O-C-N 123.756 0.66 . . . . 0.0 111.618 -179.583 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 42' ' ' SER . 52.5 t0 -107.78 120.42 42.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.478 -179.843 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 -88.79 117.66 27.93 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 32.5 m -115.12 142.85 26.43 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.269 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.177 -179.431 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.896 ' SG ' HD11 ' A' ' 11' ' ' ILE . 17.0 t -94.03 119.15 32.51 Favored 'General case' 0 CA--C 1.515 -0.396 0 CA-C-N 115.894 -0.594 . . . . 0.0 109.462 179.749 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.4 p -126.39 152.46 33.94 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.204 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.398 -179.512 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' CYS . . . . . 0.553 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 33.0 t -96.41 163.31 13.11 Favored 'General case' 0 N--CA 1.466 0.341 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 -179.771 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.484 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 19.0 m-85 -129.86 125.47 22.15 Favored Pre-proline 0 N--CA 1.469 0.497 0 C-N-CA 121.147 -0.221 . . . . 0.0 110.73 -178.738 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_endo -74.3 159.81 43.1 Favored 'Trans proline' 0 N--CA 1.488 1.168 0 C-N-CA 121.812 1.674 . . . . 0.0 112.188 179.789 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -62.85 -28.04 69.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.693 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 98.9 m-85 -107.33 41.02 1.56 Allowed 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.71 -179.326 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 41.2 p90 -65.3 134.01 52.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.263 179.762 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 3.1 pt . . . . . 0 C--O 1.22 -0.498 0 CA-C-O 117.982 -1.008 . . . . 0.0 110.071 -179.844 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 64.0 mttp . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 44.8 t0 57.54 35.53 25.89 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.537 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 5.8 mm -98.77 127.87 50.91 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-O 120.955 0.407 . . . . 0.0 110.19 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -62.54 -39.32 93.22 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.773 -179.811 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 52.73 89.04 0.01 OUTLIER Glycine 0 C--O 1.23 -0.14 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.415 ' H ' ' HD2' ' A' ' 6' ' ' ARG . 0.0 OUTLIER -128.54 23.61 5.86 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.581 -0.31 . . . . 0.0 110.617 -179.789 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.694 ' H ' ' CD ' ' A' ' 7' ' ' LYS . 0.0 OUTLIER -109.11 144.97 30.79 Favored Pre-proline 0 N--CA 1.471 0.619 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.825 -179.936 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.435 ' CB ' ' O ' ' A' ' 49' ' ' CYS . 74.2 Cg_endo -71.58 161.67 44.62 Favored 'Trans proline' 0 N--CA 1.493 1.494 0 C-N-CA 122.215 1.943 . . . . 0.0 111.909 179.217 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.651 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.4 tt -135.55 119.68 17.66 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-O 120.764 0.316 . . . . 0.0 110.725 -179.312 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.651 ' N ' HD23 ' A' ' 9' ' ' LEU . 6.3 tt -88.97 133.43 34.32 Favored 'General case' 0 N--CA 1.464 0.255 0 N-CA-C 109.584 -0.525 . . . . 0.0 109.584 178.238 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.892 HD11 ' SG ' ' A' ' 47' ' ' CYS . 2.3 pt -109.62 -46.17 6.68 Favored 'Isoleucine or valine' 0 C--O 1.231 0.11 0 CA-C-O 120.835 0.35 . . . . 0.0 110.232 -178.716 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 179.46 -159.74 24.59 Favored Glycine 0 N--CA 1.452 -0.26 0 N-CA-C 111.276 -0.73 . . . . 0.0 111.276 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 68.7 p -100.99 164.09 11.98 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.193 -0.503 . . . . 0.0 110.245 179.755 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -59.12 -11.46 3.73 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.455 179.448 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 97.0 mt -70.35 -43.73 78.08 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 CA-C-O 121.159 0.505 . . . . 0.0 110.296 -179.693 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -98.05 -31.2 12.26 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.954 -179.402 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.779 ' CD2' HD12 ' A' ' 11' ' ' ILE . 13.9 m-85 -121.11 80.47 35.33 Favored Pre-proline 0 N--CA 1.469 0.52 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 178.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.433 ' O ' ' O ' ' A' ' 17' ' ' PHE . 75.3 Cg_exo -47.05 -178.9 0.0 OUTLIER 'Trans proline' 0 N--CA 1.495 1.583 0 C-N-CA 122.794 2.329 . . . . 0.0 111.747 -179.667 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 37.4 p -58.77 -54.71 44.04 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.418 0.628 . . . . 0.0 111.536 -179.278 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.404 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 8.9 pt-20 -55.74 -52.24 64.62 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.01 -0.996 . . . . 0.0 111.216 -179.685 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -63.64 -47.36 81.67 Favored 'General case' 0 CA--C 1.519 -0.215 0 CA-C-O 121.312 0.577 . . . . 0.0 110.534 -179.623 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 36.8 t -45.44 -63.18 1.01 Allowed 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 115.12 -0.945 . . . . 0.0 111.229 -179.233 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.609 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 0.0 OUTLIER -64.36 -47.9 77.58 Favored 'General case' 0 C--O 1.221 -0.424 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.867 -178.953 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.609 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 83.4 mttt -48.73 -39.51 25.1 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.22 -179.675 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . 0.434 ' O ' ' OG ' ' A' ' 29' ' ' SER . 16.7 m -64.9 -40.66 95.44 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.207 0.527 . . . . 0.0 110.112 -179.714 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.508 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 41.2 t -72.58 -36.3 68.13 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.409 0.623 . . . . 0.0 110.492 179.54 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.2 mm -64.62 -47.61 88.23 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.928 -179.097 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.411 ' C ' ' H ' ' A' ' 30' ' ' ASN . 2.9 pp20? -70.95 -27.52 63.8 Favored 'General case' 0 N--CA 1.446 -0.645 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.638 -179.504 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.477 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 72.8 m -67.17 0.66 2.55 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.611 -179.639 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.477 ' CB ' ' O ' ' A' ' 29' ' ' SER . 14.6 t-20 85.59 3.42 0.59 Allowed 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.534 179.781 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.578 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 47.5 m-85 -91.47 -167.79 1.88 Allowed 'General case' 0 N--CA 1.456 -0.169 0 CA-C-O 120.871 0.367 . . . . 0.0 110.525 179.608 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -78.34 -59.12 2.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.35 0.595 . . . . 0.0 111.756 -178.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.508 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 175.18 177.64 44.42 Favored Glycine 0 N--CA 1.449 -0.47 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -178.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.44 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -135.27 157.84 23.33 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -179.538 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 17.6 ptpt -149.62 166.96 27.71 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.915 0.388 . . . . 0.0 110.814 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 1.8 m -103.78 122.91 46.08 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.037 179.577 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 33.4 m -136.98 169.57 19.58 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.601 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.514 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 1.8 m-70 -97.45 154.04 17.74 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.116 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.464 ' O ' ' N ' ' A' ' 41' ' ' GLN . 42.2 mm -115.03 128.69 72.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 42.32 -94.41 0.01 OUTLIER Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.933 -0.867 . . . . 0.0 110.933 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.464 ' N ' ' O ' ' A' ' 39' ' ' ILE . 88.4 mt-30 -140.72 27.5 2.03 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.654 0.264 . . . . 0.0 110.672 -179.768 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 58.8 m -80.2 -9.99 59.74 Favored 'General case' 0 CA--C 1.518 -0.254 0 CA-C-O 121.012 0.434 . . . . 0.0 110.665 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . 0.403 ' O ' ' CD2' ' A' ' 43' ' ' LEU . 0.9 OUTLIER 41.92 30.85 0.19 Allowed 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.38 -179.355 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' A' ' 45' ' ' PHE . 66.2 t0 -110.24 141.17 43.57 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.139 179.877 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.521 ' N ' ' OD1' ' A' ' 44' ' ' ASP . 56.8 m-85 -88.59 116.43 26.82 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.045 0.45 . . . . 0.0 110.312 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 19.8 m -114.62 133.53 60.45 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.307 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.28 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.892 ' SG ' HD11 ' A' ' 11' ' ' ILE . 27.9 t -93.58 114.67 27.07 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.317 179.859 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.8 p -125.03 139.83 49.93 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.229 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.029 -178.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' CYS . . . . . 0.578 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 39.2 t -97.27 157.33 16.01 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 115.517 -0.765 . . . . 0.0 109.716 -179.687 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.431 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 0.2 OUTLIER -149.93 151.62 32.65 Favored Pre-proline 0 N--CA 1.473 0.688 0 C-N-CA 120.593 -0.443 . . . . 0.0 110.933 179.775 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_endo -70.95 165.33 32.66 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 C-N-CA 122.686 2.257 . . . . 0.0 111.956 178.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -71.79 -20.89 61.79 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.591 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -109.17 40.14 1.9 Allowed 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.676 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . 0.403 ' O ' HG23 ' A' ' 55' ' ' ILE . 89.8 t80 -75.48 100.29 4.47 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.025 179.802 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.403 HG23 ' O ' ' A' ' 54' ' ' TYR . 26.5 pt . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.402 -179.742 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 45.6 mmtt . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -99.22 7.22 45.92 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.388 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.5 tt -58.52 141.36 15.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.511 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . 0.419 ' OD1' ' N ' ' A' ' 5' ' ' GLY . 1.3 p30 -63.29 -39.07 93.55 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 120.888 -0.325 . . . . 0.0 110.533 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.419 ' N ' ' OD1' ' A' ' 4' ' ' ASP . . . 79.97 -94.89 1.48 Allowed Glycine 0 C--N 1.329 0.189 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 179.748 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.425 ' H ' ' HD2' ' A' ' 6' ' ' ARG . 0.8 OUTLIER -126.61 37.89 4.22 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 110.172 -0.307 . . . . 0.0 110.172 -179.58 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 2.8 tppp? -120.17 126.54 26.78 Favored Pre-proline 0 CA--C 1.534 0.351 0 C-N-CA 121.083 -0.247 . . . . 0.0 111.394 -179.463 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -74.5 171.77 17.47 Favored 'Trans proline' 0 N--CA 1.489 1.246 0 C-N-CA 122.055 1.837 . . . . 0.0 111.647 179.142 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.662 HD23 ' N ' ' A' ' 10' ' ' LEU . 4.0 tt -133.74 119.75 19.69 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 120.78 0.324 . . . . 0.0 110.524 -179.751 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.662 ' N ' HD23 ' A' ' 9' ' ' LEU . 5.8 tt -91.03 130.75 36.91 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.978 0.418 . . . . 0.0 109.947 178.326 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.961 HD11 ' SG ' ' A' ' 47' ' ' CYS . 5.8 pt -106.37 -44.59 7.75 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.632 -179.624 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -176.12 -133.74 1.83 Allowed Glycine 0 CA--C 1.519 0.305 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 -179.593 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.436 ' C ' ' H ' ' A' ' 15' ' ' ILE . 80.7 p -131.56 166.19 21.94 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.925 0.393 . . . . 0.0 111.034 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -61.66 -3.85 1.22 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.974 179.5 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.436 ' H ' ' C ' ' A' ' 13' ' ' THR . 34.2 mm -70.85 -42.73 77.36 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 CA-C-O 121.224 0.535 . . . . 0.0 109.92 -179.562 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -108.24 -23.07 12.09 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.628 -0.715 . . . . 0.0 111.072 -179.568 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 44.7 m-85 -124.67 79.17 63.15 Favored Pre-proline 0 C--O 1.223 -0.292 0 CA-C-N 116.577 -0.283 . . . . 0.0 110.553 179.687 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 71.4 Cg_exo -49.05 -179.01 0.01 OUTLIER 'Trans proline' 0 N--CA 1.501 1.93 0 C-N-CA 123.137 2.558 . . . . 0.0 111.733 179.457 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.454 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 96.2 m -58.22 -50.38 73.75 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 112.321 0.489 . . . . 0.0 112.321 -178.795 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.484 ' CG ' ' H ' ' A' ' 21' ' ' LYS . 6.6 pt-20 -56.57 -57.21 13.34 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.771 0.32 . . . . 0.0 111.257 -179.137 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.578 ' O ' HG22 ' A' ' 25' ' ' THR . 18.7 mtmt -62.91 -44.99 94.58 Favored 'General case' 0 CA--C 1.509 -0.604 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.377 -179.718 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.409 ' O ' ' SG ' ' A' ' 26' ' ' CYS . 53.2 t -47.64 -46.43 28.81 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-O 121.233 0.54 . . . . 0.0 111.235 -178.292 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.734 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.6 p-10 -78.92 -53.11 7.39 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 120.483 -0.487 . . . . 0.0 110.39 179.305 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.734 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 29.7 mttp -50.71 -45.04 58.28 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.646 -0.422 . . . . 0.0 110.734 -178.004 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . 0.578 HG22 ' O ' ' A' ' 21' ' ' LYS . 11.6 t -64.81 -37.86 89.04 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 121.391 0.615 . . . . 0.0 109.845 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.409 ' SG ' ' O ' ' A' ' 22' ' ' CYS . 54.8 m -63.61 -33.75 76.3 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.32 179.299 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.454 HG12 ' O ' ' A' ' 23' ' ' ASN . 3.3 mm -63.26 -36.86 77.75 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.054 179.728 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 29.0 mt-10 -66.1 -34.6 78.42 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.809 -178.639 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.411 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 7.1 m -72.59 -2.37 19.66 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.446 -179.173 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.411 ' CB ' ' O ' ' A' ' 29' ' ' SER . 4.5 m-80 78.31 33.68 0.3 Allowed 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.732 -179.88 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.581 ' C ' ' H ' ' A' ' 33' ' ' GLY . 8.0 m-85 -109.35 162.34 14.42 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.114 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.63 26.75 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.745 179.619 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.581 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 87.0 -174.92 46.23 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 110.739 -0.944 . . . . 0.0 110.739 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.425 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -151.67 172.04 31.12 Favored Glycine 0 CA--C 1.52 0.348 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 -179.313 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 20.0 pttt -156.27 -179.28 8.01 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.037 0.446 . . . . 0.0 110.63 -179.535 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 4.0 m -107.76 125.71 51.73 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.12 179.158 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 20.2 m -141.13 174.19 7.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.325 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.64 ' NE2' ' CE1' ' A' ' 45' ' ' PHE . 38.2 m80 -105.67 152.42 23.16 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.477 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 96.7 mt -129.8 125.58 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.477 179.497 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 66.46 21.66 70.74 Favored Glycine 0 CA--C 1.52 0.39 0 N-CA-C 111.339 -0.705 . . . . 0.0 111.339 179.126 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 58.24 38.08 26.14 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.933 0.396 . . . . 0.0 110.586 -179.818 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 44.1 m -82.26 -11.23 58.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.015 -179.847 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . 0.409 ' O ' ' CD2' ' A' ' 43' ' ' LEU . 0.8 OUTLIER 68.24 27.99 6.52 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.258 -179.607 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -111.7 135.49 52.23 Favored 'General case' 0 N--CA 1.463 0.188 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 179.262 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.64 ' CE1' ' NE2' ' A' ' 38' ' ' HIS . 52.6 m-85 -91.71 116.15 28.64 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.419 ' O ' HG23 ' A' ' 46' ' ' VAL . 13.2 m -112.9 133.7 57.88 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.272 0 CA-C-N 115.964 -0.562 . . . . 0.0 109.807 -179.824 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.961 ' SG ' HD11 ' A' ' 11' ' ' ILE . 34.6 t -92.48 115.35 28.02 Favored 'General case' 0 CA--C 1.511 -0.536 0 CA-C-N 116.167 -0.47 . . . . 0.0 109.842 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.2 p -134.36 148.58 29.75 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.412 0 CA-C-O 121.118 0.485 . . . . 0.0 110.861 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 6.6 m -97.59 161.66 13.66 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.505 179.729 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 53.0 m-85 -116.84 147.96 41.09 Favored Pre-proline 0 N--CA 1.464 0.259 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.028 -179.326 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -65.92 154.42 74.04 Favored 'Trans proline' 0 N--CA 1.492 1.42 0 C-N-CA 122.405 2.07 . . . . 0.0 111.895 179.298 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 56.8 mtpt -63.76 -21.51 66.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.046 0.451 . . . . 0.0 110.302 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -108.95 40.58 1.78 Allowed 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.56 -179.763 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 46.3 p90 -65.3 134.93 54.67 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.195 179.777 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.2 pt . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 118.06 -0.971 . . . . 0.0 109.983 -179.883 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 72.3 mmtt . . . . . 0 N--CA 1.492 1.663 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . 0.432 ' OD1' ' O ' ' A' ' 2' ' ' ASP . 47.9 t0 58.33 37.19 25.94 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.258 -179.552 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.602 ' O ' HD12 ' A' ' 3' ' ' ILE . 1.3 pp -123.53 163.37 22.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.006 -179.198 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . 0.482 ' OD1' ' N ' ' A' ' 5' ' ' GLY . 42.0 p-10 -74.93 -34.72 62.15 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.537 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.482 ' N ' ' OD1' ' A' ' 4' ' ' ASP . . . -77.91 71.75 2.35 Favored Glycine 0 CA--C 1.52 0.369 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 -179.609 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.21 31.04 4.15 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.879 0.371 . . . . 0.0 110.181 -178.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.506 ' CB ' ' NZ ' ' A' ' 7' ' ' LYS . 0.0 OUTLIER -105.12 147.15 34.03 Favored Pre-proline 0 CA--C 1.533 0.31 0 C-N-CA 120.597 -0.441 . . . . 0.0 110.645 179.577 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -68.35 166.48 25.28 Favored 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 122.865 2.377 . . . . 0.0 111.947 179.403 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.65 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.9 tt -136.67 117.31 13.91 Favored 'General case' 0 CA--C 1.52 -0.196 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.543 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.65 ' N ' HD23 ' A' ' 9' ' ' LEU . 8.8 tt -92.8 131.95 37.4 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 179.21 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 10.2 pt -104.18 -36.9 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.281 -179.285 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -177.31 -127.62 1.07 Allowed Glycine 0 CA--C 1.517 0.163 0 N-CA-C 110.674 -0.971 . . . . 0.0 110.674 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.496 ' C ' ' H ' ' A' ' 15' ' ' ILE . 71.5 p -127.77 154.42 45.4 Favored 'General case' 0 CA--C 1.52 -0.189 0 CA-C-O 120.861 0.363 . . . . 0.0 110.479 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 6.6 t -66.3 6.67 0.39 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.521 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.496 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.7 mt -86.58 -40.97 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.138 0 CA-C-O 120.86 0.362 . . . . 0.0 110.143 -179.858 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -102.41 -5.48 24.07 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.978 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 51.2 m-85 -123.5 79.87 54.38 Favored Pre-proline 0 N--CA 1.465 0.293 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.847 179.57 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -47.77 168.01 0.09 OUTLIER 'Trans proline' 0 N--CA 1.495 1.572 0 C-N-CA 122.963 2.442 . . . . 0.0 111.866 179.164 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.436 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 10.0 m -49.78 -52.85 28.93 Favored 'General case' 0 C--N 1.326 -0.425 0 C-N-CA 120.642 -0.423 . . . . 0.0 111.62 -178.806 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.648 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 1.3 pm0 -61.91 -56.96 13.85 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.081 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -56.6 -45.13 81.6 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 121.046 0.451 . . . . 0.0 110.69 -178.201 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 12.4 t -47.75 -65.46 0.56 Allowed 'General case' 0 C--N 1.314 -0.978 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.011 -178.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.656 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 2.4 p-10 -62.51 -54.43 40.09 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.339 -179.756 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.656 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 43.8 mtpt -44.53 -43.91 8.31 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 120.546 -0.462 . . . . 0.0 110.853 -179.698 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 99.3 m -64.13 -39.62 94.42 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-O 121.495 0.664 . . . . 0.0 109.875 -179.651 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 58.5 m -67.42 -32.59 73.58 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.698 -179.681 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.3 mm -63.14 -43.63 98.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.518 -179.396 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -65.31 -35.63 81.59 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.42 -178.888 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.445 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 84.0 p -67.12 -3.41 7.43 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.459 -179.325 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.445 ' CB ' ' O ' ' A' ' 29' ' ' SER . 3.2 t-20 80.52 37.14 0.1 Allowed 'General case' 0 N--CA 1.466 0.358 0 O-C-N 123.478 0.486 . . . . 0.0 110.783 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.585 ' C ' ' H ' ' A' ' 33' ' ' GLY . 13.9 m-85 -119.54 160.7 21.91 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 120.993 0.425 . . . . 0.0 110.084 -179.843 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -68.96 27.99 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.584 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.585 ' H ' ' C ' ' A' ' 31' ' ' PHE . . . 87.06 -172.92 44.24 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 179.829 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -154.04 174.48 32.52 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.731 -0.947 . . . . 0.0 110.731 -179.437 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 11.6 ptmt -155.89 -178.7 7.49 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.806 0.336 . . . . 0.0 110.507 -179.459 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 69.0 m -105.28 127.72 53.09 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.23 179.359 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 32.5 m -135.59 161.34 39.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.101 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 3.3 p80 -108.9 157.23 18.82 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.295 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.414 ' O ' ' N ' ' A' ' 41' ' ' GLN . 32.8 mm -104.59 122.42 57.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.328 -179.748 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 40.56 -96.47 0.01 OUTLIER Glycine 0 CA--C 1.524 0.634 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.85 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.414 ' N ' ' O ' ' A' ' 39' ' ' ILE . 97.5 mt-30 -139.65 30.47 2.1 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 120.675 0.274 . . . . 0.0 110.525 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 16.8 m -80.78 -6.22 58.21 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.138 0.494 . . . . 0.0 110.738 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . 0.443 HD22 ' HA ' ' A' ' 43' ' ' LEU . 0.2 OUTLIER 50.07 28.57 3.05 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.549 -179.702 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 38.7 t0 -109.43 120.79 43.59 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.112 179.594 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 70.6 m-85 -88.74 129.03 35.63 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-O 120.962 0.41 . . . . 0.0 109.919 -179.771 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 33.1 m -124.06 142.31 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.42 -179.359 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -95.25 119.84 34.45 Favored 'General case' 0 CA--C 1.518 -0.27 0 N-CA-C 109.211 -0.662 . . . . 0.0 109.211 -179.803 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.1 p -134.38 149.46 29.98 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.358 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.715 -179.195 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' CYS . . . . . . . . . . . . . 14.1 m -98.69 177.97 5.14 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.79 179.741 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -137.28 121.12 11.95 Favored Pre-proline 0 CA--C 1.537 0.461 0 C-N-CA 120.82 -0.352 . . . . 0.0 111.035 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -66.7 146.86 80.27 Favored 'Trans proline' 0 N--CA 1.495 1.61 0 C-N-CA 122.626 2.217 . . . . 0.0 111.916 -179.744 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -119.28 -58.05 1.95 Allowed 'General case' 0 N--CA 1.465 0.294 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 179.708 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 7.4 p90 -131.81 19.22 4.63 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.589 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 25.8 t80 -64.51 141.26 58.84 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 110.086 -0.339 . . . . 0.0 110.086 -178.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.7 mt . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 118.039 -0.981 . . . . 0.0 110.41 -179.695 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 53.9 mtmt . . . . . 0 N--CA 1.489 1.504 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 56.88 35.01 25.73 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.847 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.432 HG22 ' N ' ' A' ' 5' ' ' GLY . 5.2 mm -111.91 130.62 65.21 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 CA-C-O 121.202 0.525 . . . . 0.0 110.488 179.801 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -63.92 -36.81 85.16 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.36 -0.836 . . . . 0.0 110.22 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.432 ' N ' HG22 ' A' ' 3' ' ' ILE . . . 69.17 60.23 5.32 Favored Glycine 0 C--N 1.331 0.254 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.811 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.42 ' H ' ' HD2' ' A' ' 6' ' ' ARG . 0.0 OUTLIER -126.48 29.05 5.83 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.66 0.267 . . . . 0.0 110.534 -179.637 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 23.5 pttt -131.45 146.02 60.12 Favored Pre-proline 0 N--CA 1.462 0.152 0 C-N-CA 120.989 -0.284 . . . . 0.0 111.184 -179.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -65.69 149.28 87.27 Favored 'Trans proline' 0 N--CA 1.491 1.325 0 C-N-CA 122.42 2.08 . . . . 0.0 111.642 179.512 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.733 HD13 ' N ' ' A' ' 10' ' ' LEU . 0.4 OUTLIER -125.05 122.78 38.23 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-O 121.258 0.551 . . . . 0.0 110.798 179.781 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.733 ' N ' HD13 ' A' ' 9' ' ' LEU . 5.9 tt -86.01 147.7 26.09 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.45 178.371 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -126.74 -58.96 1.58 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.569 -178.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -160.2 -140.1 2.82 Favored Glycine 0 CA--C 1.519 0.294 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.35 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.443 ' C ' ' H ' ' A' ' 15' ' ' ILE . 43.5 p -131.5 160.12 36.15 Favored 'General case' 0 CA--C 1.518 -0.261 0 CA-C-O 121.006 0.431 . . . . 0.0 110.857 -179.79 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -52.63 -11.2 0.19 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.066 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.443 ' H ' ' C ' ' A' ' 13' ' ' THR . 39.0 mm -72.3 -43.12 65.45 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 CA-C-O 121.158 0.504 . . . . 0.0 110.288 -179.398 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 1.9 pt-20 -102.27 -31.36 10.58 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.39 -0.823 . . . . 0.0 110.945 -179.531 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 15.6 m-85 -120.94 82.78 36.44 Favored Pre-proline 0 N--CA 1.466 0.339 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.128 179.73 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo -48.46 -179.14 0.01 OUTLIER 'Trans proline' 0 N--CA 1.493 1.487 0 C-N-CA 122.807 2.338 . . . . 0.0 111.965 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.431 ' OG1' ' OE2' ' A' ' 20' ' ' GLU . 28.6 p -57.27 -52.31 65.84 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 120.942 0.401 . . . . 0.0 111.557 -179.336 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.631 ' CD ' ' H ' ' A' ' 20' ' ' GLU . 0.2 OUTLIER -58.94 -57.84 11.3 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.474 -179.88 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -59.14 -43.94 92.05 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.736 -178.505 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.1 t -48.11 -60.97 2.22 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.881 -179.271 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.73 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.3 p-10 -62.59 -51.56 66.85 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.453 -179.631 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.73 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 31.7 mttp -47.36 -41.21 19.18 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.873 0.368 . . . . 0.0 110.168 -179.403 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 20.1 m -62.11 -43.9 97.81 Favored 'General case' 0 C--N 1.314 -0.939 0 C-N-CA 120.294 -0.563 . . . . 0.0 110.104 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 5.1 t -65.23 -32.68 74.48 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 179.645 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.5 mm -68.27 -31.71 52.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.538 -179.468 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 30.7 mm-40 -67.92 -34.99 77.68 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.762 -179.504 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.417 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 31.2 m -70.73 1.25 5.6 Favored 'General case' 0 CA--C 1.514 -0.408 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.944 -179.647 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.417 ' CB ' ' O ' ' A' ' 29' ' ' SER . 4.1 m-20 78.19 25.95 0.59 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.618 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.554 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 5.4 m-85 -103.29 -168.68 1.54 Allowed 'General case' 0 N--CA 1.452 -0.326 0 CA-C-O 120.952 0.406 . . . . 0.0 110.226 -179.744 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -76.2 -49.3 17.54 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.586 -179.596 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.496 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 160.54 -175.25 37.29 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 -179.478 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.427 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -148.03 170.4 28.67 Favored Glycine 0 C--O 1.226 -0.374 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -179.05 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 11.2 ptmt -158.68 -179.97 8.56 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.775 0.321 . . . . 0.0 110.525 -179.575 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 23.3 m -105.31 127.65 53.06 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.502 179.139 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 17.7 m -137.58 164.55 28.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.499 179.672 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.637 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 2.4 p80 -103.64 155.84 18.25 Favored 'General case' 0 N--CA 1.462 0.153 0 CA-C-O 121.002 0.429 . . . . 0.0 110.223 179.775 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 97.0 mt -131.37 128.59 61.51 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.627 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 60.4 23.36 60.15 Favored Glycine 0 CA--C 1.52 0.35 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 179.343 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 87.5 mt-30 56.43 30.9 17.82 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 120.881 0.372 . . . . 0.0 110.573 -179.874 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 4.0 m -78.64 -7.2 57.41 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.767 -179.701 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . 0.422 HD22 ' HA ' ' A' ' 43' ' ' LEU . 0.2 OUTLIER 68.92 27.84 5.43 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.559 -179.641 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 40.3 t0 -107.44 118.49 36.86 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.091 179.65 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 3.3 m-30 -91.07 115.89 28.37 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-O 121.225 0.536 . . . . 0.0 109.705 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 28.3 m -113.95 142.34 26.89 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.301 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.097 -179.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 24.2 t -94.33 119.0 32.45 Favored 'General case' 0 CA--C 1.516 -0.333 0 CA-C-N 116.024 -0.535 . . . . 0.0 109.771 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 10.7 p -128.81 151.33 35.44 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.409 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.392 -179.423 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' CYS . . . . . 0.557 ' SG ' ' N ' ' A' ' 50' ' ' PHE . 33.0 t -96.52 164.83 12.45 Favored 'General case' 0 CA--C 1.514 -0.435 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 -179.634 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.557 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 37.2 m-85 -132.25 131.93 22.67 Favored Pre-proline 0 N--CA 1.465 0.284 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.136 -179.068 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.78 155.82 57.81 Favored 'Trans proline' 0 N--CA 1.489 1.237 0 C-N-CA 122.068 1.845 . . . . 0.0 112.122 179.541 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -63.9 -27.92 69.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.631 179.543 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 99.7 m-85 -107.38 41.88 1.42 Allowed 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.751 -179.331 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 92.0 t80 -68.34 131.4 45.26 Favored 'General case' 0 N--CA 1.455 -0.209 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.286 179.694 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.9 pt . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 118.101 -0.952 . . . . 0.0 110.28 -179.93 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 52.6 mtmt . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 54.6 t0 -69.54 -7.43 38.34 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.464 179.897 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 22.5 mm -79.27 96.63 2.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.221 -179.766 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 67.8 t0 -63.09 -43.08 99.51 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.503 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 52.94 71.29 0.71 Allowed Glycine 0 C--O 1.229 -0.18 0 N-CA-C 110.847 -0.901 . . . . 0.0 110.847 179.647 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.06 22.82 4.89 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.814 -0.193 . . . . 0.0 110.737 -179.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.35 153.92 53.8 Favored Pre-proline 0 N--CA 1.47 0.571 0 C-N-CA 121.116 -0.233 . . . . 0.0 111.378 -179.29 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_exo -57.81 144.46 93.54 Favored 'Trans proline' 0 N--CA 1.496 1.655 0 C-N-CA 121.527 1.484 . . . . 0.0 111.783 178.683 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.634 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.7 tt -122.87 117.17 24.99 Favored 'General case' 0 N--CA 1.476 0.874 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.294 179.41 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.656 HD23 ' N ' ' A' ' 11' ' ' ILE . 6.6 tt -95.11 127.48 41.19 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 179.187 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.812 HD11 ' SG ' ' A' ' 47' ' ' CYS . 1.3 pt -103.51 -51.42 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-O 120.779 0.323 . . . . 0.0 110.831 -179.014 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.431 ' H ' HG13 ' A' ' 11' ' ' ILE . . . -160.27 -136.45 2.02 Favored Glycine 0 N--CA 1.451 -0.316 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -179.879 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.5 p -132.1 170.96 14.24 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.1 0.476 . . . . 0.0 110.415 -179.416 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -67.9 -1.86 6.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.332 -179.326 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 2.4 pp -78.2 -20.99 13.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.236 -179.731 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -131.91 -28.94 1.72 Allowed 'General case' 0 C--O 1.233 0.214 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.621 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 42.3 m-85 -116.3 81.77 11.06 Favored Pre-proline 0 CA--C 1.534 0.331 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.367 179.239 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.436 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 16.8 Cg_endo -59.35 -176.41 0.11 Allowed 'Trans proline' 0 N--CA 1.5 1.861 0 C-N-CA 122.449 2.099 . . . . 0.0 112.17 -179.644 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.444 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 83.3 m -58.89 -49.55 77.36 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.678 -0.409 . . . . 0.0 111.299 -179.347 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.493 ' CG ' ' H ' ' A' ' 21' ' ' LYS . 8.0 pt-20 -55.57 -59.59 4.62 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.616 -179.516 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.493 ' H ' ' CG ' ' A' ' 20' ' ' GLU . 17.3 mtpp -64.68 -48.39 74.92 Favored 'General case' 0 CA--C 1.512 -0.501 0 CA-C-O 121.084 0.468 . . . . 0.0 111.818 -179.43 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.436 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 34.8 t -43.02 -52.51 5.24 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.106 -177.641 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.721 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 0.8 OUTLIER -65.05 -44.51 88.78 Favored 'General case' 0 C--O 1.22 -0.474 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.783 -179.955 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.721 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 89.1 mttt -50.72 -40.79 55.15 Favored 'General case' 0 CA--C 1.509 -0.609 0 C-N-CA 120.294 -0.562 . . . . 0.0 110.321 -179.575 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 70.0 p -63.2 -41.53 99.18 Favored 'General case' 0 C--N 1.313 -1.0 0 C-N-CA 119.179 -1.008 . . . . 0.0 110.376 -179.079 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.524 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 19.5 t -68.09 -34.1 75.76 Favored 'General case' 0 C--N 1.322 -0.587 0 C-N-CA 120.176 -0.61 . . . . 0.0 109.896 179.733 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.3 mm -66.3 -41.55 89.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.72 -179.258 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.418 ' C ' ' H ' ' A' ' 30' ' ' ASN . 40.2 mm-40 -64.13 -34.97 79.27 Favored 'General case' 0 N--CA 1.444 -0.746 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.654 -179.409 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.414 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 78.1 p -68.44 1.92 2.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.221 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.418 ' H ' ' C ' ' A' ' 28' ' ' GLU . 16.4 t-20 78.05 19.67 1.04 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.623 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.552 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 4.5 m-85 -98.32 -168.23 1.62 Allowed 'General case' 0 CA--C 1.53 0.191 0 CA-C-O 120.938 0.399 . . . . 0.0 110.351 -179.833 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -74.93 -53.26 9.32 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.791 -179.01 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.524 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 165.42 -178.51 40.3 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.151 -1.179 . . . . 0.0 110.151 -179.251 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.457 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -141.07 167.85 25.54 Favored Glycine 0 CA--C 1.519 0.293 0 N-CA-C 111.274 -0.73 . . . . 0.0 111.274 -179.219 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 15.0 ptpt -158.09 178.06 10.62 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.095 0.474 . . . . 0.0 110.401 -179.311 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 3.2 m -105.39 120.3 41.24 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.866 179.159 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 33.0 m -132.17 161.22 41.75 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.102 -179.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.556 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 3.2 p80 -107.07 157.14 18.06 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.184 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.512 ' O ' ' N ' ' A' ' 41' ' ' GLN . 33.2 mm -106.46 124.79 62.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.049 -179.549 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 43.34 -91.12 0.01 OUTLIER Glycine 0 C--N 1.33 0.205 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.512 ' N ' ' O ' ' A' ' 39' ' ' ILE . 42.0 tp60 -148.46 37.66 0.84 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.812 0.339 . . . . 0.0 110.436 -179.577 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 71.0 m -87.98 -2.39 58.58 Favored 'General case' 0 CA--C 1.519 -0.235 0 CA-C-O 121.042 0.449 . . . . 0.0 110.613 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 45.81 28.99 0.64 Allowed 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.551 179.522 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 68.3 t0 -108.88 119.32 39.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.919 179.455 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 81.3 m-85 -88.56 118.45 28.22 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.721 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 31.1 m -114.88 143.05 25.46 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.35 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.259 -179.406 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.812 ' SG ' HD11 ' A' ' 11' ' ' ILE . 18.4 t -94.07 117.88 30.73 Favored 'General case' 0 CA--C 1.513 -0.455 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.459 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.7 p -129.07 152.96 37.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-O 120.708 0.29 . . . . 0.0 110.306 -179.689 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' CYS . . . . . 0.552 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 17.2 t -96.83 164.94 12.34 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.547 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 38.1 m-85 -132.34 136.31 27.82 Favored Pre-proline 0 N--CA 1.468 0.474 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.842 -179.319 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -67.13 158.1 58.55 Favored 'Trans proline' 0 N--CA 1.495 1.571 0 C-N-CA 121.945 1.763 . . . . 0.0 112.391 179.903 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -51.65 -79.25 0.02 OUTLIER 'General case' 0 C--N 1.333 -0.141 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.655 -179.124 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 58.9 m-85 -130.55 39.2 3.65 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.764 -179.815 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -108.98 127.66 54.26 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 120.922 0.391 . . . . 0.0 110.132 -179.682 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.5 mp . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.268 -179.836 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 18.2 pttp . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 51.3 t0 -63.79 -32.74 74.35 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.903 -0.589 . . . . 0.0 109.955 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 23.4 mm -53.49 100.16 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.59 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 66.8 t0 -63.75 -39.71 94.94 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.397 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 55.05 69.52 1.24 Allowed Glycine 0 C--N 1.329 0.161 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 179.819 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.423 ' HD3' ' H ' ' A' ' 6' ' ' ARG . 0.0 OUTLIER -130.08 18.67 5.49 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.488 0.185 . . . . 0.0 110.629 -179.42 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 2.6 pttm -132.46 147.08 64.22 Favored Pre-proline 0 N--CA 1.465 0.317 0 CA-C-N 116.62 -0.264 . . . . 0.0 110.99 -179.476 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -67.8 164.08 32.87 Favored 'Trans proline' 0 N--CA 1.494 1.539 0 C-N-CA 122.488 2.125 . . . . 0.0 111.885 179.264 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.635 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.8 tt -138.3 118.02 13.14 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.273 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.663 HD23 ' N ' ' A' ' 11' ' ' ILE . 6.8 tt -92.68 130.87 38.18 Favored 'General case' 0 N--CA 1.465 0.305 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 178.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.899 HD11 ' SG ' ' A' ' 47' ' ' CYS . 1.5 pt -107.09 -50.18 7.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-O 120.917 0.389 . . . . 0.0 110.294 -178.78 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -163.35 -162.99 15.04 Favored Glycine 0 N--CA 1.449 -0.491 0 N-CA-C 110.754 -0.938 . . . . 0.0 110.754 179.689 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.5 p -83.93 163.07 20.24 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.829 0.347 . . . . 0.0 110.12 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 48.3 t -71.2 2.79 4.18 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.331 179.703 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 86.8 mt -91.08 -52.48 10.26 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.217 0 CA-C-N 116.234 -0.439 . . . . 0.0 109.826 179.717 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . 0.464 ' OE1' ' CE2' ' A' ' 17' ' ' PHE . 7.5 pt-20 -70.82 -35.45 72.5 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.16 179.113 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.464 ' CE2' ' OE1' ' A' ' 16' ' ' GLU . 59.9 m-85 -114.96 104.61 53.94 Favored Pre-proline 0 CA--C 1.544 0.738 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.44 179.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.457 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 56.9 Cg_endo -74.23 -179.8 5.08 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 C-N-CA 123.043 2.495 . . . . 0.0 111.752 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 70.8 m -57.38 -49.12 77.18 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.576 -179.613 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.49 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 6.7 pt-20 -54.63 -58.24 8.27 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.574 -0.285 . . . . 0.0 111.592 -179.477 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 5.7 ttmt -67.44 -56.65 8.74 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.385 0.612 . . . . 0.0 111.606 -179.145 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.457 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 48.1 t -38.64 -61.51 0.7 Allowed 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.241 -0.89 . . . . 0.0 111.4 -178.786 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.625 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 0.0 OUTLIER -63.42 -49.09 75.13 Favored 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.435 -179.874 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.625 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 51.3 mttm -47.46 -37.73 12.26 Favored 'General case' 0 CA--C 1.515 -0.399 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.218 -179.721 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 98.4 m -63.8 -41.74 97.84 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.342 0.591 . . . . 0.0 109.775 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.452 ' SG ' ' C ' ' A' ' 33' ' ' GLY . 40.2 t -72.13 -34.71 68.76 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.585 0.707 . . . . 0.0 109.999 179.311 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.5 mm -65.33 -48.08 84.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.144 -179.282 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.463 ' C ' ' H ' ' A' ' 30' ' ' ASN . 3.0 pp20? -70.31 -29.01 65.63 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.554 -179.656 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.452 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 24.4 m -65.2 0.89 1.17 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.198 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.537 ' O ' ' NZ ' ' A' ' 52' ' ' LYS . 7.4 t-20 81.05 14.53 0.64 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.435 179.804 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.569 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 5.2 m-85 -100.19 -167.72 1.49 Allowed 'General case' 0 C--N 1.339 0.144 0 CA-C-O 120.76 0.314 . . . . 0.0 110.204 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -76.18 -55.38 5.63 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.141 0.496 . . . . 0.0 111.859 -179.196 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.452 ' C ' ' SG ' ' A' ' 26' ' ' CYS . . . 168.56 173.29 36.27 Favored Glycine 0 CA--C 1.519 0.337 0 N-CA-C 110.318 -1.113 . . . . 0.0 110.318 -179.135 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.448 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -134.59 161.02 24.42 Favored Glycine 0 N--CA 1.46 0.237 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 -179.341 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 2.1 ptmm? -160.06 -174.77 4.72 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.966 0.412 . . . . 0.0 110.69 -178.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 30.7 m -104.67 120.09 40.52 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.831 179.361 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 2.6 m -137.79 166.29 24.65 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-O 121.113 0.482 . . . . 0.0 110.896 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.783 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 0.1 OUTLIER -108.85 157.29 18.74 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.403 179.291 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 83.9 mt -122.58 128.64 75.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.551 -179.358 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 52.85 -126.1 31.84 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.481 -1.048 . . . . 0.0 110.481 179.766 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -111.33 27.64 9.48 Favored 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 110.381 -0.229 . . . . 0.0 110.381 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . 0.497 ' O ' ' N ' ' A' ' 44' ' ' ASP . 52.0 m -85.14 -11.26 55.53 Favored 'General case' 0 CA--C 1.52 -0.199 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.914 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . 0.433 HD22 ' HA ' ' A' ' 43' ' ' LEU . 0.2 OUTLIER 36.79 28.26 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.063 -179.687 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . 0.497 ' N ' ' O ' ' A' ' 42' ' ' SER . 45.1 t0 -99.78 124.47 45.09 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.278 -179.903 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -85.72 124.55 32.36 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 -179.65 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 32.6 m -129.9 153.76 39.35 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.444 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.145 -179.348 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.899 ' SG ' HD11 ' A' ' 11' ' ' ILE . 34.9 t -93.75 116.43 28.91 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.436 -179.77 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.9 p -131.64 154.39 40.32 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.325 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.499 -178.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' CYS . . . . . 0.572 ' SG ' ' N ' ' A' ' 50' ' ' PHE . 16.4 t -97.42 164.49 12.43 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 179.833 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.572 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 29.6 m-85 -130.7 121.79 19.29 Favored Pre-proline 0 N--CA 1.465 0.321 0 C-N-CA 120.931 -0.307 . . . . 0.0 111.247 -178.68 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -72.62 160.2 47.04 Favored 'Trans proline' 0 N--CA 1.491 1.343 0 C-N-CA 121.721 1.614 . . . . 0.0 112.058 179.274 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.537 ' NZ ' ' O ' ' A' ' 30' ' ' ASN . 64.2 mttp -67.93 -16.57 64.12 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.478 179.803 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -109.08 41.45 1.62 Allowed 'General case' 0 N--CA 1.468 0.436 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.777 -179.801 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 88.1 t80 -86.07 96.33 9.83 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.778 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 16.1 mm . . . . . 0 C--O 1.22 -0.465 0 CA-C-O 118.022 -0.99 . . . . 0.0 110.43 -179.597 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 53.1 mtmt . . . . . 0 N--CA 1.491 1.608 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -86.53 9.81 17.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.633 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 29.5 mm -80.44 118.5 28.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.208 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 54.8 t0 -66.03 -41.15 91.28 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.639 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 49.89 69.26 1.1 Allowed Glycine 0 CA--C 1.518 0.235 0 N-CA-C 111.021 -0.832 . . . . 0.0 111.021 179.775 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.491 ' NE ' ' OH ' ' A' ' 54' ' ' TYR . 0.0 OUTLIER -132.46 37.96 3.48 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.758 0.313 . . . . 0.0 110.987 -179.865 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.506 ' N ' ' CD ' ' A' ' 8' ' ' PRO . 2.5 tppp? -125.43 50.41 4.34 Favored Pre-proline 0 N--CA 1.465 0.294 0 CA-C-O 120.855 0.36 . . . . 0.0 110.708 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.506 ' CD ' ' N ' ' A' ' 7' ' ' LYS . 33.9 Cg_endo -64.93 159.0 48.35 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.824 2.349 . . . . 0.0 111.21 178.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.65 HD23 ' N ' ' A' ' 10' ' ' LEU . 4.0 tt -132.38 119.23 20.41 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.265 -179.615 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.65 ' N ' HD23 ' A' ' 9' ' ' LEU . 7.7 tt -93.5 127.33 39.1 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 178.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.92 HD11 ' SG ' ' A' ' 47' ' ' CYS . 3.1 pt -103.38 -46.14 10.32 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.412 -179.036 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -170.06 -138.01 2.4 Favored Glycine 0 CA--C 1.521 0.451 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.485 ' C ' ' H ' ' A' ' 15' ' ' ILE . 70.0 p -133.21 163.73 28.63 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.843 0.354 . . . . 0.0 110.902 -179.437 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -57.87 -4.79 0.34 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.97 179.674 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.485 ' H ' ' C ' ' A' ' 13' ' ' THR . 95.8 mt -73.24 -24.18 20.43 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 CA-C-O 121.01 0.433 . . . . 0.0 110.136 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -130.55 -32.06 1.75 Allowed 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.741 -179.614 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 53.7 m-85 -114.65 88.88 17.07 Favored Pre-proline 0 CA--C 1.54 0.568 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 179.36 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.455 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 43.4 Cg_endo -70.17 -178.04 2.31 Favored 'Trans proline' 0 N--CA 1.499 1.809 0 C-N-CA 122.91 2.406 . . . . 0.0 111.968 -179.509 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.455 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 7.1 m -45.93 -68.62 0.18 Allowed 'General case' 0 C--N 1.319 -0.757 0 C-N-CA 120.826 -0.35 . . . . 0.0 111.442 -179.275 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.645 ' CD ' ' H ' ' A' ' 20' ' ' GLU . 0.0 OUTLIER -44.36 -68.14 0.22 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.46 -0.337 . . . . 0.0 111.718 -178.794 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 6.9 ttmt -54.66 -51.63 64.86 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.039 0.447 . . . . 0.0 111.562 -178.043 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.455 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 45.3 t -46.03 -64.97 0.62 Allowed 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.368 -179.3 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.71 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 0.8 OUTLIER -61.86 -45.16 94.99 Favored 'General case' 0 C--O 1.22 -0.464 0 C-N-CA 120.721 -0.392 . . . . 0.0 110.478 -179.814 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.71 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 86.9 mttt -51.06 -37.08 43.35 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.443 -0.503 . . . . 0.0 109.852 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 13.4 m -64.36 -41.61 96.64 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.354 0.597 . . . . 0.0 110.352 -179.831 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.488 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 37.8 t -72.73 -34.91 67.39 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.029 179.467 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.2 mm -66.14 -47.68 83.94 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.571 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.884 -179.227 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.458 ' C ' ' H ' ' A' ' 30' ' ' ASN . 3.0 pp20? -70.21 -28.35 65.21 Favored 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.285 -179.413 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.465 ' O ' ' CB ' ' A' ' 30' ' ' ASN . 56.1 m -66.25 1.05 1.71 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.051 -179.863 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.465 ' CB ' ' O ' ' A' ' 29' ' ' SER . 8.7 t-20 82.51 11.04 0.61 Allowed 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.406 179.858 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.552 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 23.0 m-85 -99.47 -171.22 2.03 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-O 121.036 0.445 . . . . 0.0 111.188 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -71.33 -59.91 2.51 Favored 'General case' 0 CA--C 1.532 0.254 0 CA-C-N 115.756 -0.657 . . . . 0.0 111.857 -179.03 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.488 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 172.39 176.8 41.4 Favored Glycine 0 CA--C 1.52 0.377 0 N-CA-C 110.345 -1.102 . . . . 0.0 110.345 -179.104 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.423 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -137.0 166.66 24.86 Favored Glycine 0 N--CA 1.462 0.402 0 N-CA-C 111.233 -0.747 . . . . 0.0 111.233 -179.529 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 12.2 ptmt -159.4 178.45 9.92 Favored 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.771 -179.393 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 1.4 m -106.5 127.71 53.52 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.008 178.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 28.8 m -134.41 159.75 41.84 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.247 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.32 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.8 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 0.1 OUTLIER -104.84 154.67 19.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.265 179.89 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.495 ' O ' ' N ' ' A' ' 41' ' ' GLN . 31.2 mm -107.01 128.02 62.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.361 -179.347 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 41.78 -91.56 0.01 OUTLIER Glycine 0 CA--C 1.525 0.711 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.495 ' N ' ' O ' ' A' ' 39' ' ' ILE . 40.6 tt0 -143.22 22.69 1.87 Allowed 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 121.039 0.447 . . . . 0.0 110.252 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 58.4 m -78.57 -9.45 59.36 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.079 0.466 . . . . 0.0 110.265 179.559 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . 0.416 ' O ' ' CD2' ' A' ' 43' ' ' LEU . 0.9 OUTLIER 47.03 30.42 1.28 Allowed 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.28 -179.715 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 67.8 t0 -98.78 119.91 38.32 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.597 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 58.1 m-85 -84.44 117.5 23.68 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.026 0.441 . . . . 0.0 110.342 -179.33 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 32.6 m -113.38 136.18 50.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.5 -179.454 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.92 ' SG ' HD11 ' A' ' 11' ' ' ILE . 27.4 t -93.03 115.4 28.08 Favored 'General case' 0 CA--C 1.514 -0.434 0 N-CA-C 109.284 -0.635 . . . . 0.0 109.284 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.5 p -130.88 150.41 34.58 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.261 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.8 -178.774 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' CYS . . . . . 0.552 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 23.6 t -96.82 162.9 13.22 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.529 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 33.7 m-85 -120.91 136.82 25.85 Favored Pre-proline 0 N--CA 1.47 0.541 0 C-N-CA 120.906 -0.318 . . . . 0.0 110.99 -178.85 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.43 ' HG3' ' H ' ' A' ' 7' ' ' LYS . 23.1 Cg_endo -62.33 150.03 88.61 Favored 'Trans proline' 0 N--CA 1.492 1.396 0 C-N-CA 121.759 1.64 . . . . 0.0 112.753 179.519 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 8.1 tptp -136.8 -41.14 0.6 Allowed 'General case' 0 CA--C 1.528 0.106 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.002 179.476 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -112.64 18.91 17.95 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-O 120.634 0.254 . . . . 0.0 111.136 -179.49 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . 0.491 ' OH ' ' NE ' ' A' ' 6' ' ' ARG . 74.6 t80 -74.78 131.01 40.47 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-O 120.866 0.365 . . . . 0.0 110.377 179.498 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.2 pt . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 117.895 -1.05 . . . . 0.0 109.975 179.977 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 71.0 mmtt . . . . . 0 N--CA 1.492 1.674 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 34.6 p-10 -73.41 0.84 11.08 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 179.338 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.578 ' O ' HD12 ' A' ' 3' ' ' ILE . 1.0 OUTLIER -93.46 143.78 10.82 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.176 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.916 -179.912 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -62.38 -40.89 97.92 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.291 179.567 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -80.78 104.25 2.29 Favored Glycine 0 C--N 1.329 0.156 0 N-CA-C 110.665 -0.974 . . . . 0.0 110.665 -179.821 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.85 38.13 3.4 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.695 -0.252 . . . . 0.0 111.302 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.426 ' H ' ' HG3' ' A' ' 51' ' ' PRO . 14.5 ttmt -125.4 69.69 61.9 Favored Pre-proline 0 N--CA 1.47 0.567 0 CA-C-O 120.455 0.169 . . . . 0.0 111.165 -179.66 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -77.25 161.68 31.89 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 122.68 2.253 . . . . 0.0 111.586 179.007 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.66 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.3 tt -133.67 120.89 21.21 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 120.568 0.223 . . . . 0.0 110.439 -179.008 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.66 ' N ' HD23 ' A' ' 9' ' ' LEU . 5.8 tt -87.68 134.56 33.63 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 178.535 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 13.2 pt -109.04 -35.0 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 120.934 0.397 . . . . 0.0 110.8 -178.702 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 175.69 -150.0 10.49 Favored Glycine 0 N--CA 1.451 -0.358 0 N-CA-C 110.794 -0.923 . . . . 0.0 110.794 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.416 ' C ' ' H ' ' A' ' 15' ' ' ILE . 42.0 p -98.8 160.66 14.12 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.83 0.347 . . . . 0.0 110.235 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 9.2 t -72.04 6.99 1.81 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.171 179.818 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.416 ' H ' ' C ' ' A' ' 13' ' ' THR . 96.8 mt -91.42 -44.39 14.4 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.199 0 CA-C-N 116.053 -0.522 . . . . 0.0 109.949 179.785 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -87.46 -20.59 26.37 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.735 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 60.1 m-85 -120.69 99.08 47.66 Favored Pre-proline 0 CA--C 1.546 0.796 0 CA-C-N 116.732 -0.213 . . . . 0.0 110.595 179.515 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.409 ' O ' ' CB ' ' A' ' 22' ' ' CYS . 36.4 Cg_endo -71.68 173.23 12.92 Favored 'Trans proline' 0 N--CA 1.493 1.495 0 C-N-CA 122.579 2.186 . . . . 0.0 111.288 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.48 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 10.0 m -47.67 -50.56 24.41 Favored 'General case' 0 C--N 1.319 -0.736 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.712 -179.242 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.603 ' H ' ' CD ' ' A' ' 20' ' ' GLU . 0.5 OUTLIER -56.34 -68.33 0.22 Allowed 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 112.293 0.479 . . . . 0.0 112.293 -179.13 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 6.9 ttmt -57.95 -46.37 85.18 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 121.362 0.601 . . . . 0.0 111.551 -178.126 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.409 ' CB ' ' O ' ' A' ' 18' ' ' PRO . 49.0 t -47.58 -65.03 0.63 Allowed 'General case' 0 C--N 1.308 -1.231 0 CA-C-N 115.311 -0.859 . . . . 0.0 111.465 -178.64 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.717 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 0.4 OUTLIER -65.39 -43.73 89.75 Favored 'General case' 0 C--O 1.222 -0.375 0 C-N-CA 120.4 -0.52 . . . . 0.0 110.893 -179.944 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.717 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 48.8 mttp -52.5 -39.68 61.54 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 120.19 -0.604 . . . . 0.0 109.909 179.826 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 91.6 m -62.62 -43.69 98.18 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.741 -179.438 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.521 ' SG ' ' O ' ' A' ' 33' ' ' GLY . 16.6 t -66.14 -34.93 79.17 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.017 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.3 mm -66.17 -37.77 80.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.717 0 CA-C-N 114.937 -1.029 . . . . 0.0 110.113 179.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.41 ' C ' ' H ' ' A' ' 30' ' ' ASN . 34.3 mm-40 -64.09 -37.54 87.8 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.973 -1.012 . . . . 0.0 110.155 -179.369 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 35.9 m -69.46 0.59 4.98 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.834 179.638 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.41 ' H ' ' C ' ' A' ' 28' ' ' GLU . 18.2 t-20 76.7 21.15 1.28 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.508 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.532 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 3.8 m-85 -96.16 -166.93 1.5 Allowed 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 120.811 0.339 . . . . 0.0 110.493 -179.88 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.61 -51.42 16.89 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 116.076 -0.511 . . . . 0.0 112.113 -178.68 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.521 ' O ' ' SG ' ' A' ' 26' ' ' CYS . . . 161.59 -179.87 36.71 Favored Glycine 0 CA--C 1.519 0.323 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 -179.036 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.424 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -132.49 157.42 22.53 Favored Glycine 0 CA--C 1.52 0.351 0 N-CA-C 111.417 -0.673 . . . . 0.0 111.417 -179.181 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 16.2 ptpt -154.27 168.78 25.44 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.41 -0.395 . . . . 0.0 110.506 -179.319 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 37.8 m -103.86 124.29 48.68 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.042 179.609 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 36.0 m -136.6 161.39 36.69 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-O 120.758 0.313 . . . . 0.0 110.9 -179.904 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.511 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 2.3 p80 -90.07 155.04 19.34 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.326 179.55 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 40.4 mm -110.66 121.6 63.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.816 -179.672 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 46.63 27.74 3.24 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 179.074 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 12.6 mm100 62.72 35.69 13.82 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.943 0.401 . . . . 0.0 110.242 -179.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . 0.422 ' O ' ' CB ' ' A' ' 43' ' ' LEU . 63.6 m -83.39 -7.93 59.48 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.883 -179.901 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . 0.422 ' CB ' ' O ' ' A' ' 42' ' ' SER . 0.9 OUTLIER 73.82 27.33 1.7 Allowed 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.239 0.542 . . . . 0.0 109.782 -179.523 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 36.0 t0 -111.74 117.05 31.79 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 178.547 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -91.42 120.61 32.42 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.241 0.543 . . . . 0.0 109.915 -179.819 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 33.5 m -123.5 140.13 47.99 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.449 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.079 -179.573 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -94.47 121.35 35.93 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.19 -179.727 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.2 p -134.35 151.87 32.82 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.312 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.844 -178.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' CYS . . . . . 0.532 ' SG ' ' CB ' ' A' ' 31' ' ' PHE . 28.4 t -93.9 161.89 14.13 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 -179.421 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.445 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 51.3 m-85 -127.93 142.52 44.64 Favored Pre-proline 0 N--CA 1.47 0.538 0 C-N-CA 120.619 -0.432 . . . . 0.0 111.359 -178.356 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.426 ' HG3' ' H ' ' A' ' 7' ' ' LYS . 29.6 Cg_endo -62.73 148.36 93.5 Favored 'Trans proline' 0 N--CA 1.494 1.528 0 C-N-CA 122.016 1.811 . . . . 0.0 112.219 179.636 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 38.8 ttpt -121.75 -53.34 1.98 Allowed 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.654 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 45.5 p90 -117.25 20.94 13.45 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.876 -179.538 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 51.4 t80 -81.36 129.28 34.56 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 179.908 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 10.7 mt . . . . . 0 C--O 1.219 -0.544 0 CA-C-O 117.934 -1.031 . . . . 0.0 110.391 -179.756 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 25.3 mtpp . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -84.36 3.01 37.82 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.421 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.438 HG22 ' N ' ' A' ' 5' ' ' GLY . 37.8 mm -68.94 130.87 34.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 121.051 0.453 . . . . 0.0 110.745 179.888 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . 0.489 ' N ' ' OD1' ' A' ' 4' ' ' ASP . 18.2 p-10 -65.14 -36.35 83.99 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.55 179.669 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.438 ' N ' HG22 ' A' ' 3' ' ' ILE . . . -29.86 96.12 0.01 OUTLIER Glycine 0 N--CA 1.465 0.58 0 O-C-N 123.704 0.628 . . . . 0.0 111.685 -179.725 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.99 40.12 3.82 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.334 -0.433 . . . . 0.0 110.878 -178.679 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.96 155.14 64.38 Favored Pre-proline 0 N--CA 1.467 0.402 0 C-N-CA 121.192 -0.203 . . . . 0.0 110.581 -179.241 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -57.92 149.05 72.65 Favored 'Trans proline' 0 N--CA 1.496 1.63 0 C-N-CA 121.725 1.617 . . . . 0.0 111.416 178.291 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.619 HD23 ' N ' ' A' ' 10' ' ' LEU . 3.8 tt -120.33 118.21 29.79 Favored 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.713 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.682 HD13 ' C ' ' A' ' 10' ' ' LEU . 2.7 tm? -89.04 124.99 34.81 Favored 'General case' 0 CA--C 1.522 -0.132 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.547 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.41 ' N ' HD13 ' A' ' 10' ' ' LEU . 14.9 pt -105.59 -35.58 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.159 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.811 -179.131 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.405 ' O ' HD21 ' A' ' 10' ' ' LEU . . . 176.92 -135.46 2.83 Favored Glycine 0 CA--C 1.522 0.5 0 N-CA-C 111.146 -0.781 . . . . 0.0 111.146 -179.873 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 68.0 p -132.92 161.73 33.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.94 0.4 . . . . 0.0 110.512 -179.629 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -55.91 -9.35 0.57 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.764 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 6.2 mm -71.94 -43.13 68.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 C-N-CA 120.5 -0.48 . . . . 0.0 110.59 -179.313 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -99.75 -23.51 14.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.106 -179.429 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -119.54 83.09 26.53 Favored Pre-proline 0 N--CA 1.463 0.189 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.033 179.583 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -53.29 165.89 1.3 Allowed 'Trans proline' 0 N--CA 1.491 1.367 0 C-N-CA 122.495 2.13 . . . . 0.0 110.582 178.553 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.448 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 36.0 p -45.61 -58.94 3.04 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-O 120.852 0.358 . . . . 0.0 111.701 -178.601 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.47 ' HG3' ' H ' ' A' ' 21' ' ' LYS . 6.6 pt-20 -46.01 -60.04 2.49 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.934 -179.385 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.47 ' H ' ' HG3' ' A' ' 20' ' ' GLU . 17.8 mtmt -63.73 -45.79 88.31 Favored 'General case' 0 CA--C 1.51 -0.583 0 CA-C-O 121.105 0.478 . . . . 0.0 111.299 -179.784 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 17.9 t -44.47 -62.61 1.12 Allowed 'General case' 0 C--N 1.31 -1.138 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.351 -178.396 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.693 ' ND2' ' N ' ' A' ' 24' ' ' LYS . 1.8 p-10 -64.1 -50.48 68.12 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.866 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.693 ' N ' ' ND2' ' A' ' 23' ' ' ASN . 41.2 mttm -48.99 -35.94 16.45 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -179.586 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 19.4 m -63.52 -42.26 98.47 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.192 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.491 ' SG ' ' C ' ' A' ' 33' ' ' GLY . 32.9 t -73.42 -36.9 66.03 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.537 0.684 . . . . 0.0 110.016 178.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.3 mm -64.65 -47.42 88.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.996 -178.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.433 ' C ' ' H ' ' A' ' 30' ' ' ASN . 2.9 pp20? -71.22 -23.26 61.98 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.756 -179.485 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 39.5 m -71.6 3.71 3.74 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.52 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.433 ' H ' ' C ' ' A' ' 28' ' ' GLU . 2.2 m120 77.59 22.26 0.92 Allowed 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.913 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.554 ' CB ' ' SG ' ' A' ' 49' ' ' CYS . 31.1 m-85 -111.25 -167.91 1.24 Allowed 'General case' 0 N--CA 1.455 -0.178 0 CA-C-O 120.82 0.343 . . . . 0.0 111.006 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -74.1 -58.36 3.35 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.94 -0.573 . . . . 0.0 112.239 -178.417 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.491 ' C ' ' SG ' ' A' ' 26' ' ' CYS . . . 172.8 170.63 36.74 Favored Glycine 0 CA--C 1.521 0.465 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -178.85 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.496 ' H ' ' HA ' ' A' ' 23' ' ' ASN . . . -122.42 159.97 16.94 Favored Glycine 0 N--CA 1.463 0.458 0 N-CA-C 111.186 -0.765 . . . . 0.0 111.186 -178.812 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 16.2 ptpt -155.34 166.38 33.72 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.05 0.452 . . . . 0.0 110.695 -179.558 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.504 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 4.5 m -106.35 123.69 48.44 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.354 179.522 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 32.9 m -137.08 160.77 36.16 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.464 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.689 179.796 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.608 ' H ' ' CD2' ' A' ' 38' ' ' HIS . 8.8 p80 -89.64 157.15 18.14 Favored 'General case' 0 CA--C 1.521 -0.153 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.295 179.488 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.4 ' C ' ' N ' ' A' ' 41' ' ' GLN . 5.7 mm -117.97 129.25 74.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.778 -179.467 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 46.01 22.18 0.79 Allowed Glycine 0 C--O 1.228 -0.233 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 179.328 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.4 ' N ' ' C ' ' A' ' 39' ' ' ILE . 39.6 tt0 69.78 36.75 1.99 Allowed 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.062 0.458 . . . . 0.0 110.175 -179.753 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 5.1 m -86.45 1.46 51.32 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.155 179.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER 57.16 26.89 12.69 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.526 -179.379 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 55.0 t0 -106.39 119.13 38.45 Favored 'General case' 0 N--CA 1.466 0.361 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 178.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 -85.12 115.68 23.06 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 121.181 0.515 . . . . 0.0 110.325 -179.112 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 11.6 m -111.18 134.57 53.08 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.262 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.19 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 0.8 OUTLIER -94.38 112.8 24.59 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.172 -179.792 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 4.8 p -129.58 155.0 41.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.306 -179.289 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' CYS . . . . . 0.587 ' SG ' ' N ' ' A' ' 50' ' ' PHE . 19.5 t -96.56 166.48 11.66 Favored 'General case' 0 N--CA 1.465 0.312 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.587 ' N ' ' SG ' ' A' ' 49' ' ' CYS . 29.1 m-85 -126.92 117.88 22.25 Favored Pre-proline 0 N--CA 1.469 0.483 0 C-N-CA 121.028 -0.269 . . . . 0.0 110.745 -178.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_exo -51.8 137.28 51.48 Favored 'Trans proline' 0 N--CA 1.486 1.083 0 C-N-CA 121.491 1.46 . . . . 0.0 112.27 179.218 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 26.4 tptp -65.8 -18.08 65.08 Favored 'General case' 0 N--CA 1.453 -0.316 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.651 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -106.93 40.9 1.56 Allowed 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.558 -179.471 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 75.4 t80 -113.75 126.22 54.98 Favored 'General case' 0 C--O 1.231 0.115 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.833 179.416 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 83.5 mt . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.277 179.841 . . . . . . . . 0 0 . 1 stop_ save_